{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "65624d3710b949579af864a8e896cbec": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_703744a121a64fe98b949c33253c8195",
              "IPY_MODEL_82d0352b6360415d839cf6d607e7f97c",
              "IPY_MODEL_f9c32ba779dd489bbde9bac47a279641"
            ],
            "layout": "IPY_MODEL_8613d5c6d33343d1975f9c06071ec455"
          }
        },
        "703744a121a64fe98b949c33253c8195": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_87606d2aea174b07b8b982a201f4503c",
            "placeholder": "​",
            "style": "IPY_MODEL_033b34e204cc43bd80e96da3f8648a25",
            "value": "Batches: 100%"
          }
        },
        "82d0352b6360415d839cf6d607e7f97c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_cb5bcc0a16844fd0bf128d5787234313",
            "max": 413,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_43abfe5493c2419f93bdac09689ab924",
            "value": 413
          }
        },
        "f9c32ba779dd489bbde9bac47a279641": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_914e769b63274c9ab136828730ec56bd",
            "placeholder": "​",
            "style": "IPY_MODEL_214d8f0c51da44adb61c411e02ed2b4a",
            "value": " 413/413 [10:30&lt;00:00,  4.46it/s]"
          }
        },
        "8613d5c6d33343d1975f9c06071ec455": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "87606d2aea174b07b8b982a201f4503c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "033b34e204cc43bd80e96da3f8648a25": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "cb5bcc0a16844fd0bf128d5787234313": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "43abfe5493c2419f93bdac09689ab924": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "914e769b63274c9ab136828730ec56bd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "214d8f0c51da44adb61c411e02ed2b4a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "iPdYVfhE-cRW"
      },
      "outputs": [],
      "source": [
        "import re\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "\n",
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "from sklearn.cluster import KMeans, AgglomerativeClustering\n",
        "from sklearn.metrics import silhouette_score\n",
        "\n",
        "\n",
        "try:\n",
        "    from sentence_transformers import SentenceTransformer\n",
        "except ImportError:\n",
        "    !pip install -q sentence-transformers\n",
        "    from sentence_transformers import SentenceTransformer\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n",
        "\n",
        "import os\n",
        "\n",
        "EXCEL_PATH = \"/content/drive/MyDrive/Harvard HW#5/derm.xlsx\"\n",
        "\n",
        "print(\"Using path:\", EXCEL_PATH)\n",
        "print(\"File exists:\", os.path.exists(EXCEL_PATH))\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "dYSKPfv4tNd5",
        "outputId": "49d76ea2-2f5b-42c9-e901-e82c088e46d6"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n",
            "Using path: /content/drive/MyDrive/Harvard HW#5/derm.xlsx\n",
            "File exists: True\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "BJTzl-TCtObI"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Load and expload inclusion criteria\n",
        "\n",
        "def load_and_expand_criteria(\n",
        "    path: str,\n",
        "    id_col: str = \"nctid\",\n",
        "    crit_col: str = \"inclusion\"\n",
        ") -> pd.DataFrame:\n",
        "\n",
        "    df_raw = pd.read_excel(path)\n",
        "\n",
        "    print(\"Columns:\", df_raw.columns.tolist())\n",
        "\n",
        "    df = df_raw[[id_col, crit_col]].copy()\n",
        "\n",
        "    df[crit_col] = df[crit_col].astype(str)\n",
        "\n",
        "    rows = []\n",
        "    splitter = re.compile(r\"(\\n|\\r|\\r\\n|\\*)\")\n",
        "\n",
        "    for _, row in df.iterrows():\n",
        "        nctid = row[id_col]\n",
        "        text = row[crit_col]\n",
        "\n",
        "        raw_parts = [p.strip() for p in splitter.split(text)\n",
        "                     if p.strip() and p.strip() != \"*\"]\n",
        "\n",
        "        cleaned_parts = []\n",
        "        for p in raw_parts:\n",
        "            p = re.sub(r\"^[\\-\\*\\u2022]?\\s*(\\d+[\\.\\)]\\s*)?\", \"\", p).strip()\n",
        "            if len(p) > 0:\n",
        "                cleaned_parts.append(p)\n",
        "\n",
        "        for crit in cleaned_parts:\n",
        "            rows.append({\"nctid\": nctid, \"criterion\": crit})\n",
        "\n",
        "    expanded = pd.DataFrame(rows).drop_duplicates().reset_index(drop=True)\n",
        "    print(\"Expanded to\", len(expanded), \"rows\")\n",
        "    return expanded\n"
      ],
      "metadata": {
        "id": "hZGthv6ZoqJs"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "criteria_df = load_and_expand_criteria(EXCEL_PATH, crit_col=\"inclusion\")\n",
        "criteria_df.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 243
        },
        "id": "6uW_Af9AmDKT",
        "outputId": "e13b33f8-4071-4453-a38e-4667e41c72e1"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Columns: ['nctid', 'inclusion']\n",
            "Expanded to 26369 rows\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         nctid                                          criterion\n",
              "0  NCT00001137                                     HIV-1 infected\n",
              "1  NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...\n",
              "2  NCT00001137  Willing to provide consent for the release and...\n",
              "3  NCT00001137               Life expectancy of at least 24 weeks\n",
              "4  NCT00001137  Parent or guardian willing to provide informed..."
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-52f1cc53-4591-4927-bbe8-0efcd69a3404\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>nctid</th>\n",
              "      <th>criterion</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>HIV-1 infected</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Enrolled in an AIDS Clinical Trial Group (ACTG...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Willing to provide consent for the release and...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Life expectancy of at least 24 weeks</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Parent or guardian willing to provide informed...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-52f1cc53-4591-4927-bbe8-0efcd69a3404')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-52f1cc53-4591-4927-bbe8-0efcd69a3404 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-52f1cc53-4591-4927-bbe8-0efcd69a3404');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-2d0d7a06-5565-4959-85b6-1fbfa67ebad7\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2d0d7a06-5565-4959-85b6-1fbfa67ebad7')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-2d0d7a06-5565-4959-85b6-1fbfa67ebad7 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "criteria_df",
              "summary": "{\n  \"name\": \"criteria_df\",\n  \"rows\": 26369,\n  \"fields\": [\n    {\n      \"column\": \"nctid\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3103,\n        \"samples\": [\n          \"NCT02349828\",\n          \"NCT04265716\",\n          \"NCT00612768\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"criterion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24761,\n        \"samples\": [\n          \"Prior to starting mifepristone subjects must meet the following laboratory criteria; Granulocytes \\\\> 1.5E9/l (grade \\u2264 1); Platelets \\u2265 100E9/l; Hemoglobin \\\\> 10 g/dl (grade \\u2264 1); Creatinine \\\\< 1.5x normal reference range (grade \\u2264 1); SGOT, SGPT, alk phos \\u2264 1x normal reference range; Total bilirubin \\\\< 1x normal reference range; Calcium \\\\< 11.5 mg/dl (grade \\u2264 1); HBsAg = Negative; HCV Ab = Negative; INR \\\\< 1.5;\",\n          \"Part 1F: prostate cancer\",\n          \"Females of childbearing potential must use a reliable method of contraception\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# text normalization\n",
        "def normalize_text(s: str) -> str:\n",
        "    s = s.lower()\n",
        "    s = re.sub(r\"[^a-z0-9\\s]\", \" \", s)\n",
        "    s = re.sub(r\"\\s+\", \" \", s).strip()\n",
        "    return s\n",
        "\n",
        "criteria_df[\"clean_text\"] = criteria_df[\"criterion\"].apply(normalize_text)\n",
        "criteria_df.head()"
      ],
      "metadata": {
        "id": "yCH80FN9orYK",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "outputId": "efa99d42-dfb5-4ec8-94b2-2698dae368c7"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         nctid                                          criterion  \\\n",
              "0  NCT00001137                                     HIV-1 infected   \n",
              "1  NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...   \n",
              "2  NCT00001137  Willing to provide consent for the release and...   \n",
              "3  NCT00001137               Life expectancy of at least 24 weeks   \n",
              "4  NCT00001137  Parent or guardian willing to provide informed...   \n",
              "\n",
              "                                          clean_text  \n",
              "0                                     hiv 1 infected  \n",
              "1  enrolled in an aids clinical trial group actg ...  \n",
              "2  willing to provide consent for the release and...  \n",
              "3               life expectancy of at least 24 weeks  \n",
              "4  parent or guardian willing to provide informed...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-1d9fc119-b91b-4d89-80e8-f7d2a8295200\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>nctid</th>\n",
              "      <th>criterion</th>\n",
              "      <th>clean_text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>HIV-1 infected</td>\n",
              "      <td>hiv 1 infected</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Enrolled in an AIDS Clinical Trial Group (ACTG...</td>\n",
              "      <td>enrolled in an aids clinical trial group actg ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Willing to provide consent for the release and...</td>\n",
              "      <td>willing to provide consent for the release and...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Life expectancy of at least 24 weeks</td>\n",
              "      <td>life expectancy of at least 24 weeks</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Parent or guardian willing to provide informed...</td>\n",
              "      <td>parent or guardian willing to provide informed...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-1d9fc119-b91b-4d89-80e8-f7d2a8295200')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-1d9fc119-b91b-4d89-80e8-f7d2a8295200 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-1d9fc119-b91b-4d89-80e8-f7d2a8295200');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-0fde2091-cfa1-4746-9838-a6ecdc4397dc\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-0fde2091-cfa1-4746-9838-a6ecdc4397dc')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-0fde2091-cfa1-4746-9838-a6ecdc4397dc button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "criteria_df",
              "summary": "{\n  \"name\": \"criteria_df\",\n  \"rows\": 26369,\n  \"fields\": [\n    {\n      \"column\": \"nctid\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3103,\n        \"samples\": [\n          \"NCT02349828\",\n          \"NCT04265716\",\n          \"NCT00612768\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"criterion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24761,\n        \"samples\": [\n          \"Prior to starting mifepristone subjects must meet the following laboratory criteria; Granulocytes \\\\> 1.5E9/l (grade \\u2264 1); Platelets \\u2265 100E9/l; Hemoglobin \\\\> 10 g/dl (grade \\u2264 1); Creatinine \\\\< 1.5x normal reference range (grade \\u2264 1); SGOT, SGPT, alk phos \\u2264 1x normal reference range; Total bilirubin \\\\< 1x normal reference range; Calcium \\\\< 11.5 mg/dl (grade \\u2264 1); HBsAg = Negative; HCV Ab = Negative; INR \\\\< 1.5;\",\n          \"Part 1F: prostate cancer\",\n          \"Females of childbearing potential must use a reliable method of contraception\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"clean_text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 23777,\n        \"samples\": [\n          \"documented progressive disease within 6 months of the last regimen\",\n          \"more than 4 weeks since prior systemic therapy\",\n          \"informed consent to receive protocol treatment to provide biologic specimens and to complete neurotoxicity questionnaires\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# run a tf-idf + Vectorization\n",
        "# KMeans Clustering Algorithm\n",
        "def vectorize_tfidf(texts, max_features=5000, ngram_range=(1, 2)):\n",
        "    vectorizer = TfidfVectorizer(\n",
        "        max_features=max_features,\n",
        "        ngram_range=ngram_range,\n",
        "        stop_words=\"english\"\n",
        "    )\n",
        "    X = vectorizer.fit_transform(texts)\n",
        "    return X, vectorizer\n",
        "\n",
        "def cluster_kmeans(X, n_clusters: int, random_state: int = 42):\n",
        "    model = KMeans(\n",
        "        n_clusters=n_clusters,\n",
        "        n_init=10,\n",
        "        random_state=random_state\n",
        "    )\n",
        "    labels = model.fit_predict(X)\n",
        "    return model, labels\n",
        "\n",
        "\n",
        "K_TFIDF = 25\n",
        "\n",
        "X_tfidf, tfidf_vec = vectorize_tfidf(criteria_df[\"clean_text\"].tolist())\n",
        "kmeans_tfidf, labels_tfidf = cluster_kmeans(X_tfidf, n_clusters=K_TFIDF)\n",
        "\n",
        "criteria_df[\"cluster_tfidf\"] = labels_tfidf\n",
        "# now make DBSCAN\n",
        "criteria_df.head()\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "hN3F3Uomotk8",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "outputId": "9467ccb1-1278-4d3c-ecae-4a2e695a2034"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         nctid                                          criterion  \\\n",
              "0  NCT00001137                                     HIV-1 infected   \n",
              "1  NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...   \n",
              "2  NCT00001137  Willing to provide consent for the release and...   \n",
              "3  NCT00001137               Life expectancy of at least 24 weeks   \n",
              "4  NCT00001137  Parent or guardian willing to provide informed...   \n",
              "\n",
              "                                          clean_text  cluster_tfidf  \n",
              "0                                     hiv 1 infected              3  \n",
              "1  enrolled in an aids clinical trial group actg ...              6  \n",
              "2  willing to provide consent for the release and...              6  \n",
              "3               life expectancy of at least 24 weeks              5  \n",
              "4  parent or guardian willing to provide informed...              7  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-44eac030-a437-46b3-aac0-0cecfbd9fa1a\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>nctid</th>\n",
              "      <th>criterion</th>\n",
              "      <th>clean_text</th>\n",
              "      <th>cluster_tfidf</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>HIV-1 infected</td>\n",
              "      <td>hiv 1 infected</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Enrolled in an AIDS Clinical Trial Group (ACTG...</td>\n",
              "      <td>enrolled in an aids clinical trial group actg ...</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Willing to provide consent for the release and...</td>\n",
              "      <td>willing to provide consent for the release and...</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Life expectancy of at least 24 weeks</td>\n",
              "      <td>life expectancy of at least 24 weeks</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Parent or guardian willing to provide informed...</td>\n",
              "      <td>parent or guardian willing to provide informed...</td>\n",
              "      <td>7</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-44eac030-a437-46b3-aac0-0cecfbd9fa1a')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-44eac030-a437-46b3-aac0-0cecfbd9fa1a button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-44eac030-a437-46b3-aac0-0cecfbd9fa1a');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-27a5c481-f131-4f40-accb-31acda31fdcf\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-27a5c481-f131-4f40-accb-31acda31fdcf')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-27a5c481-f131-4f40-accb-31acda31fdcf button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "criteria_df",
              "summary": "{\n  \"name\": \"criteria_df\",\n  \"rows\": 26369,\n  \"fields\": [\n    {\n      \"column\": \"nctid\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3103,\n        \"samples\": [\n          \"NCT02349828\",\n          \"NCT04265716\",\n          \"NCT00612768\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"criterion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24761,\n        \"samples\": [\n          \"Prior to starting mifepristone subjects must meet the following laboratory criteria; Granulocytes \\\\> 1.5E9/l (grade \\u2264 1); Platelets \\u2265 100E9/l; Hemoglobin \\\\> 10 g/dl (grade \\u2264 1); Creatinine \\\\< 1.5x normal reference range (grade \\u2264 1); SGOT, SGPT, alk phos \\u2264 1x normal reference range; Total bilirubin \\\\< 1x normal reference range; Calcium \\\\< 11.5 mg/dl (grade \\u2264 1); HBsAg = Negative; HCV Ab = Negative; INR \\\\< 1.5;\",\n          \"Part 1F: prostate cancer\",\n          \"Females of childbearing potential must use a reliable method of contraception\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"clean_text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 23777,\n        \"samples\": [\n          \"documented progressive disease within 6 months of the last regimen\",\n          \"more than 4 weeks since prior systemic therapy\",\n          \"informed consent to receive protocol treatment to provide biologic specimens and to complete neurotoxicity questionnaires\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"cluster_tfidf\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 25,\n        \"samples\": [\n          0,\n          22,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "chXvtqzBqz6F"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.cluster import DBSCAN\n",
        "\n",
        "def clusterDBSCAN(X, eps, min_smples):\n",
        "    model = DBSCAN(eps=eps, min_samples=min_smples, metric='euclidean')\n",
        "    labels = model.fit_predict(X)\n",
        "    return model, labels\n",
        "\n",
        "# run dbscan\n",
        "eps = 0.5\n",
        "min_samples = 5\n",
        "dbscan_model, dbscan_labels = clusterDBSCAN(X_tfidf, eps, min_samples)\n",
        "newdf = criteria_df.copy()\n",
        "\n",
        "newdf[\"cluster_dbscan\"] = dbscan_labels\n",
        "\n",
        "newdf.head(20)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 676
        },
        "id": "MXKmtXdpO2qO",
        "outputId": "bf35c555-f1cd-46d1-cff4-1cecb3c948ff"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "          nctid                                          criterion  \\\n",
              "0   NCT00001137                                     HIV-1 infected   \n",
              "1   NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...   \n",
              "2   NCT00001137  Willing to provide consent for the release and...   \n",
              "3   NCT00001137               Life expectancy of at least 24 weeks   \n",
              "4   NCT00001137  Parent or guardian willing to provide informed...   \n",
              "5   NCT00001137  Active alcohol or drug abuse that may interfer...   \n",
              "6   NCT00003199  Patients with inflammatory (stage IIIb) or res...   \n",
              "7   NCT00003199  Patients should have received 4-7 cycles of an...   \n",
              "8   NCT00003199  Patient has received Cytoxan 4 gm/m\\^2 x 1 and...   \n",
              "9   NCT00003199  Stem cells were collected after mobilization w...   \n",
              "10  NCT00003199  The patient must have the capacity to give inf...   \n",
              "11  NCT00003199  Hepatic function: Bilirubin =\\< 2 mg%; SGOT or...   \n",
              "12  NCT00003199  Renal function: Creatinine =\\< 2.0 mg/dl or a ...   \n",
              "13  NCT00003199  Pre-Study tests have been performed as outline...   \n",
              "14  NCT00003199  Patients will begin IL-2/GM-CSF therapy if the...   \n",
              "15  NCT00003199  Can start therapy 30 to 100 days after transplant   \n",
              "16  NCT00003199                 Karnofsky performance status \\> 60   \n",
              "17  NCT00003199  ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,0...   \n",
              "18  NCT00003199    Total bilirubin =\\< 2.5 x upper limit of normal   \n",
              "19  NCT00003199               SGOT =\\< 2.5 x upper limit of normal   \n",
              "\n",
              "                                           clean_text  cluster_tfidf  \\\n",
              "0                                      hiv 1 infected              3   \n",
              "1   enrolled in an aids clinical trial group actg ...              6   \n",
              "2   willing to provide consent for the release and...              6   \n",
              "3                life expectancy of at least 24 weeks              5   \n",
              "4   parent or guardian willing to provide informed...              7   \n",
              "5   active alcohol or drug abuse that may interfer...              3   \n",
              "6   patients with inflammatory stage iiib or respo...              4   \n",
              "7   patients should have received 4 7 cycles of an...              4   \n",
              "8   patient has received cytoxan 4 gm m 2 x 1 and ...             15   \n",
              "9   stem cells were collected after mobilization w...              3   \n",
              "10  the patient must have the capacity to give inf...              7   \n",
              "11  hepatic function bilirubin 2 mg sgot or sgpt 2...             21   \n",
              "12  renal function creatinine 2 0 mg dl or a creat...             21   \n",
              "13  pre study tests have been performed as outline...              6   \n",
              "14  patients will begin il 2 gm csf therapy if the...              4   \n",
              "15  can start therapy 30 to 100 days after transplant             15   \n",
              "16                    karnofsky performance status 60             23   \n",
              "17  anc 1 000 cells mm 3 and platelets 30 000 cell...              0   \n",
              "18        total bilirubin 2 5 x upper limit of normal             20   \n",
              "19                   sgot 2 5 x upper limit of normal             20   \n",
              "\n",
              "    cluster_dbscan  \n",
              "0               -1  \n",
              "1               -1  \n",
              "2               -1  \n",
              "3               -1  \n",
              "4               -1  \n",
              "5               -1  \n",
              "6               -1  \n",
              "7               -1  \n",
              "8               -1  \n",
              "9               -1  \n",
              "10              -1  \n",
              "11              -1  \n",
              "12              -1  \n",
              "13              -1  \n",
              "14              -1  \n",
              "15              -1  \n",
              "16              -1  \n",
              "17              -1  \n",
              "18               0  \n",
              "19              -1  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-29994612-be4e-4943-96d5-cc9dc7b957ad\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>nctid</th>\n",
              "      <th>criterion</th>\n",
              "      <th>clean_text</th>\n",
              "      <th>cluster_tfidf</th>\n",
              "      <th>cluster_dbscan</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>HIV-1 infected</td>\n",
              "      <td>hiv 1 infected</td>\n",
              "      <td>3</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Enrolled in an AIDS Clinical Trial Group (ACTG...</td>\n",
              "      <td>enrolled in an aids clinical trial group actg ...</td>\n",
              "      <td>6</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Willing to provide consent for the release and...</td>\n",
              "      <td>willing to provide consent for the release and...</td>\n",
              "      <td>6</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Life expectancy of at least 24 weeks</td>\n",
              "      <td>life expectancy of at least 24 weeks</td>\n",
              "      <td>5</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Parent or guardian willing to provide informed...</td>\n",
              "      <td>parent or guardian willing to provide informed...</td>\n",
              "      <td>7</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Active alcohol or drug abuse that may interfer...</td>\n",
              "      <td>active alcohol or drug abuse that may interfer...</td>\n",
              "      <td>3</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Patients with inflammatory (stage IIIb) or res...</td>\n",
              "      <td>patients with inflammatory stage iiib or respo...</td>\n",
              "      <td>4</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Patients should have received 4-7 cycles of an...</td>\n",
              "      <td>patients should have received 4 7 cycles of an...</td>\n",
              "      <td>4</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Patient has received Cytoxan 4 gm/m\\^2 x 1 and...</td>\n",
              "      <td>patient has received cytoxan 4 gm m 2 x 1 and ...</td>\n",
              "      <td>15</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Stem cells were collected after mobilization w...</td>\n",
              "      <td>stem cells were collected after mobilization w...</td>\n",
              "      <td>3</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>The patient must have the capacity to give inf...</td>\n",
              "      <td>the patient must have the capacity to give inf...</td>\n",
              "      <td>7</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Hepatic function: Bilirubin =\\&lt; 2 mg%; SGOT or...</td>\n",
              "      <td>hepatic function bilirubin 2 mg sgot or sgpt 2...</td>\n",
              "      <td>21</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Renal function: Creatinine =\\&lt; 2.0 mg/dl or a ...</td>\n",
              "      <td>renal function creatinine 2 0 mg dl or a creat...</td>\n",
              "      <td>21</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Pre-Study tests have been performed as outline...</td>\n",
              "      <td>pre study tests have been performed as outline...</td>\n",
              "      <td>6</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Patients will begin IL-2/GM-CSF therapy if the...</td>\n",
              "      <td>patients will begin il 2 gm csf therapy if the...</td>\n",
              "      <td>4</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Can start therapy 30 to 100 days after transplant</td>\n",
              "      <td>can start therapy 30 to 100 days after transplant</td>\n",
              "      <td>15</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Karnofsky performance status \\&gt; 60</td>\n",
              "      <td>karnofsky performance status 60</td>\n",
              "      <td>23</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>ANC \\&gt; 1,000 cells/mm\\^3 and platelets \\&gt; 30,0...</td>\n",
              "      <td>anc 1 000 cells mm 3 and platelets 30 000 cell...</td>\n",
              "      <td>0</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>Total bilirubin =\\&lt; 2.5 x upper limit of normal</td>\n",
              "      <td>total bilirubin 2 5 x upper limit of normal</td>\n",
              "      <td>20</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>NCT00003199</td>\n",
              "      <td>SGOT =\\&lt; 2.5 x upper limit of normal</td>\n",
              "      <td>sgot 2 5 x upper limit of normal</td>\n",
              "      <td>20</td>\n",
              "      <td>-1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-29994612-be4e-4943-96d5-cc9dc7b957ad')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-29994612-be4e-4943-96d5-cc9dc7b957ad button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-29994612-be4e-4943-96d5-cc9dc7b957ad');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-4bc08beb-a7e5-43aa-8a33-3d6af5c3a4ca\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-4bc08beb-a7e5-43aa-8a33-3d6af5c3a4ca')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-4bc08beb-a7e5-43aa-8a33-3d6af5c3a4ca button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "newdf",
              "summary": "{\n  \"name\": \"newdf\",\n  \"rows\": 26369,\n  \"fields\": [\n    {\n      \"column\": \"nctid\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3103,\n        \"samples\": [\n          \"NCT02349828\",\n          \"NCT04265716\",\n          \"NCT00612768\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"criterion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24761,\n        \"samples\": [\n          \"Prior to starting mifepristone subjects must meet the following laboratory criteria; Granulocytes \\\\> 1.5E9/l (grade \\u2264 1); Platelets \\u2265 100E9/l; Hemoglobin \\\\> 10 g/dl (grade \\u2264 1); Creatinine \\\\< 1.5x normal reference range (grade \\u2264 1); SGOT, SGPT, alk phos \\u2264 1x normal reference range; Total bilirubin \\\\< 1x normal reference range; Calcium \\\\< 11.5 mg/dl (grade \\u2264 1); HBsAg = Negative; HCV Ab = Negative; INR \\\\< 1.5;\",\n          \"Part 1F: prostate cancer\",\n          \"Females of childbearing potential must use a reliable method of contraception\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"clean_text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 23777,\n        \"samples\": [\n          \"documented progressive disease within 6 months of the last regimen\",\n          \"more than 4 weeks since prior systemic therapy\",\n          \"informed consent to receive protocol treatment to provide biologic specimens and to complete neurotoxicity questionnaires\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"cluster_tfidf\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 25,\n        \"samples\": [\n          0,\n          22,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"cluster_dbscan\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 47,\n        \"min\": -1,\n        \"max\": 294,\n        \"num_unique_values\": 296,\n        \"samples\": [\n          269,\n          147,\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(dbscan_labels[0]*5*-1==5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "hFdFNaVnRK6h",
        "outputId": "858f6bfd-034b-494d-fb7e-7df9b8496c17"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "True\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "OiBkcw-IQIyp"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Comoute silhouette score for Kmeans\n",
        "sample_idx = np.random.choice(X_tfidf.shape[0], size=min(5000, X_tfidf.shape[0]), replace=False)\n",
        "sil_tfidf = silhouette_score(X_tfidf[sample_idx], labels_tfidf[sample_idx])\n",
        "print(\"TFIDF KMeans silhouette (sample):\", sil_tfidf)\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "# Compute silhouette score for DBSCAN\n",
        "sample_idx = np.random.choice(\n",
        "    X_tfidf.shape[0],\n",
        "    size=min(5000, X_tfidf.shape[0]),\n",
        "    replace=False\n",
        ")\n",
        "\n",
        "X_sample = X_tfidf[sample_idx]\n",
        "labels_sample = dbscan_labels[sample_idx]\n",
        "\n",
        "# Silhouette requires at least 2 non-noise clusters\n",
        "unique_clusters = [c for c in set(labels_sample) if c != -1]\n",
        "\n",
        "if len(unique_clusters) >= 2:\n",
        "    sil_dbscan = silhouette_score(X_sample, labels_sample)\n",
        "    print(\"DBSCAN silhouette (sample):\", sil_dbscan)\n",
        "else:\n",
        "    print(\"DBSCAN silhouette cannot be computed — fewer than 2 clusters found.\")\n",
        "\n",
        "# in this case  DBSCAN is worse than random assignment, so we ignore it\n",
        "# This means that we have to optimize it"
      ],
      "metadata": {
        "id": "T0cHv17bou2B",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "7bf35237-1bfa-4f56-88a5-13fa5e346a0a"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TFIDF KMeans silhouette (sample): 0.03811533251679994\n",
            "DBSCAN silhouette (sample): -0.1776735279698304\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# run sentence embedding to breakdown words into roots\n",
        "def build_embeddings(texts, model_name: str = \"all-MiniLM-L6-v2\", batch_size: int = 64):\n",
        "    model = SentenceTransformer(model_name)\n",
        "    embeddings = model.encode(\n",
        "        texts,\n",
        "        batch_size=batch_size,\n",
        "        show_progress_bar=True,\n",
        "        convert_to_numpy=True,\n",
        "        normalize_embeddings=True\n",
        "    )\n",
        "    return embeddings, model\n",
        "\n",
        "embeddings, sbert_model = build_embeddings(criteria_df[\"criterion\"].tolist())\n",
        "print(\"Embedding shape:\", embeddings.shape)\n",
        "\n",
        "\n",
        "# run hierarchial clustering in bottom up (algglomertive clustering)\n",
        "def cluster_agglomerative(X, n_clusters: int):\n",
        "    model = AgglomerativeClustering(\n",
        "        n_clusters=n_clusters,\n",
        "        linkage=\"ward\"\n",
        "    )\n",
        "    labels = model.fit_predict(X)\n",
        "    return model, labels\n",
        "\n",
        "K_EMB = 30  # 20,30\n",
        "\n",
        "agg_model, labels_emb = cluster_agglomerative(embeddings, n_clusters=K_EMB)\n",
        "criteria_df[\"cluster_emb\"] = labels_emb\n",
        "sample_idx = np.random.choice(embeddings.shape[0], size=min(5000, embeddings.shape[0]), replace=False)\n",
        "sil_emb = silhouette_score(embeddings[sample_idx], labels_emb[sample_idx])\n",
        "print(\"Embedding Agglomerative silhouette (sample):\", sil_emb)\n"
      ],
      "metadata": {
        "id": "wbdMsfRPovwo",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 197,
          "referenced_widgets": [
            "65624d3710b949579af864a8e896cbec",
            "703744a121a64fe98b949c33253c8195",
            "82d0352b6360415d839cf6d607e7f97c",
            "f9c32ba779dd489bbde9bac47a279641",
            "8613d5c6d33343d1975f9c06071ec455",
            "87606d2aea174b07b8b982a201f4503c",
            "033b34e204cc43bd80e96da3f8648a25",
            "cb5bcc0a16844fd0bf128d5787234313",
            "43abfe5493c2419f93bdac09689ab924",
            "914e769b63274c9ab136828730ec56bd",
            "214d8f0c51da44adb61c411e02ed2b4a"
          ]
        },
        "outputId": "f2331c89-645b-449a-981f-629e8e88b076"
      },
      "execution_count": 10,
      "outputs": [
        {
          "metadata": {
            "tags": null
          },
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "65624d3710b949579af864a8e896cbec",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "Batches:   0%|          | 0/413 [00:00<?, ?it/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Embedding shape: (26369, 384)\n",
            "Embedding Agglomerative silhouette (sample): 0.062006738\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import umap\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# Optimizing UMAP\n",
        "# Tighter clusters often come from lower n_neighbors and lower min_dist\n",
        "reducer = umap.UMAP(\n",
        "    n_neighbors=15,\n",
        "    n_components=5,\n",
        "    min_dist=0.0,\n",
        "    metric='cosine',\n",
        "    random_state=42\n",
        ")\n",
        "\n",
        "X_umap_optimized = reducer.fit_transform(embeddings)\n",
        "print(\"UMAP reduced shape:\", X_umap_optimized.shape)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "6cka8p0JzxBs",
        "outputId": "8be9be6a-fd54-462e-999e-9ae3850f7b17"
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/umap/umap_.py:1952: UserWarning: n_jobs value 1 overridden to 1 by setting random_state. Use no seed for parallelism.\n",
            "  warn(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "UMAP reduced shape: (26369, 5)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# 2. Optimize hyperparameter based on n_clusters\n",
        "range_n_clusters = [10, 20, 30, 40, 50, 60, 80, 100] # Adjust range based on dataset size\n",
        "best_k = 0\n",
        "best_score = -1\n",
        "inertias = []\n",
        "sil_scores = []\n",
        "\n",
        "print(\"Optimizing KMeans...\")\n",
        "for n_clusters in range_n_clusters:\n",
        "    # Use the UMAP reduced data, it usually clusters better than raw SBERT\n",
        "    clusterer = KMeans(n_clusters=n_clusters, random_state=42, n_init=10)\n",
        "    cluster_labels = clusterer.fit_predict(X_umap_optimized)\n",
        "\n",
        "    silhouette_avg = silhouette_score(X_umap_optimized, cluster_labels)\n",
        "    inertias.append(clusterer.inertia_)\n",
        "    sil_scores.append(silhouette_avg)\n",
        "\n",
        "    print(f\"For n_clusters = {n_clusters}, Silhouette Score = {silhouette_avg:.4f}\")\n",
        "\n",
        "    if silhouette_avg > best_score:\n",
        "        best_score = silhouette_avg\n",
        "        best_k = n_clusters\n",
        "\n",
        "# Plotting the Elbow and Silhouette\n",
        "fig, (ax1, ax2) = plt.subplots(1, 2, figsize=(15, 5))\n",
        "\n",
        "# Elbow Plot\n",
        "ax1.plot(range_n_clusters, inertias, 'bx-')\n",
        "ax1.set_xlabel('k')\n",
        "ax1.set_ylabel('Inertia (Sum of squared distances)')\n",
        "ax1.set_title('Elbow Method For Optimal k')\n",
        "\n",
        "# Silhouette Plot\n",
        "ax2.plot(range_n_clusters, sil_scores, 'rx-')\n",
        "ax2.set_xlabel('k')\n",
        "ax2.set_ylabel('Silhouette Score')\n",
        "ax2.set_title('Silhouette Score per k')\n",
        "plt.show()\n",
        "\n",
        "print(f\"Best K found: {best_k}\")"
      ],
      "metadata": {
        "id": "WHwfhWDnPoGi",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 672
        },
        "outputId": "620d63a3-9093-4a58-ddab-d2aa9f4e4dd3"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Optimizing KMeans...\n",
            "For n_clusters = 10, Silhouette Score = 0.4690\n",
            "For n_clusters = 20, Silhouette Score = 0.4638\n",
            "For n_clusters = 30, Silhouette Score = 0.4997\n",
            "For n_clusters = 40, Silhouette Score = 0.5250\n",
            "For n_clusters = 50, Silhouette Score = 0.5049\n",
            "For n_clusters = 60, Silhouette Score = 0.5118\n",
            "For n_clusters = 80, Silhouette Score = 0.5088\n",
            "For n_clusters = 100, Silhouette Score = 0.5155\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1500x500 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Best K found: 40\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.neighbors import NearestNeighbors\n",
        "\n",
        "# 3. FIND OPTIMAL EPS FOR DBSCAN\n",
        "# We look at the distance to the k-th nearest neighbor (k = 2 * n_components usually works)\n",
        "k = 10 # Since we have 5 components in UMAP\n",
        "nbrs = NearestNeighbors(n_neighbors=k).fit(X_umap_optimized)\n",
        "distances, indices = nbrs.kneighbors(X_umap_optimized)\n",
        "\n",
        "# Sort distance values by ascending value and plot\n",
        "distance_desc = sorted(distances[:, k-1], reverse=False)\n",
        "\n",
        "plt.figure(figsize=(10, 5))\n",
        "plt.plot(distance_desc)\n",
        "plt.title('K-Distance Graph (Look for the \"Elbow\" or \"Knee\")')\n",
        "plt.ylabel(f'{k}-NN Distance')\n",
        "plt.xlabel('Points sorted by distance')\n",
        "plt.grid(True)\n",
        "plt.show()\n",
        "\n",
        "# INSTRUCTION: Look at the Y-axis value where the curve shoots up.\n",
        "# That Y-value is your optimal 'eps'."
      ],
      "metadata": {
        "id": "jORBIgQyPrXo",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 487
        },
        "outputId": "3decaf6e-ce09-4c26-c2bd-3e7d5c113aa6"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# --- FINAL CLUSTERING WITH OPTIMIZED PARAMS ---\n",
        "\n",
        "# 1. Final KMeans\n",
        "final_kmeans = KMeans(n_clusters=best_k, random_state=42, n_init=10)\n",
        "criteria_df['cluster_kmeans_opt'] = final_kmeans.fit_predict(X_umap_optimized)\n",
        "\n",
        "# 2. Final DBSCAN (Replace 0.3 with the value from your K-distance plot)\n",
        "# min_samples is usually good around 5 to 10 for this data size\n",
        "final_dbscan = DBSCAN(eps=0.3, min_samples=10, metric='euclidean')\n",
        "criteria_df['cluster_dbscan_opt'] = final_dbscan.fit_predict(X_umap_optimized)\n",
        "\n",
        "# Calculate final score (Filtering out noise -1 for DBSCAN)\n",
        "mask = criteria_df['cluster_dbscan_opt'] != -1\n",
        "if mask.sum() > 0:\n",
        "    score = silhouette_score(X_umap_optimized[mask], criteria_df.loc[mask, 'cluster_dbscan_opt'])\n",
        "    print(f\"Final Optimized DBSCAN Silhouette (excluding noise): {score:.4f}\")"
      ],
      "metadata": {
        "id": "CF5zfA-FPuTq",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "cb42fe26-91d1-4f92-8303-2a830dea4daf"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Final Optimized DBSCAN Silhouette (excluding noise): 0.0533\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Optimized DBSCAN application\n",
        "# Look at the K-Distance graph above.\n",
        "# Set 'best_eps' to the Y-value where the curve bends sharply (the \"elbow\").\n",
        "best_eps = 0.15   # <--- CHANGE THIS based on your graph!\n",
        "\n",
        "print(f\"Running Final DBSCAN with eps={best_eps}...\")\n",
        "final_dbscan = DBSCAN(\n",
        "    eps=best_eps,\n",
        "    min_samples=10,\n",
        "    metric='euclidean'\n",
        ")\n",
        "\n",
        "dbscan_umap_labels = final_dbscan.fit_predict(X_umap_optimized)\n",
        "criteria_df[\"cluster_dbscan_opt\"] = dbscan_umap_labels\n",
        "\n",
        "print(\"Clustering complete.\")"
      ],
      "metadata": {
        "id": "vEsBg96Ozq5n",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "c262e416-0166-4b42-86ac-603bf9c6456c"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Running Final DBSCAN with eps=0.15...\n",
            "Clustering complete.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "mask = dbscan_labels != -1\n",
        "X_non_noise = X_umap_optimized[mask]\n",
        "labels_non_noise = dbscan_labels[mask]\n",
        "\n",
        "if len(np.unique(labels_non_noise)) >= 2 and len(labels_non_noise) > 50:\n",
        "    sample_idx = np.random.choice(\n",
        "        X_non_noise.shape[0],\n",
        "        size=min(5000, X_non_noise.shape[0]),\n",
        "        replace=False\n",
        "    )\n",
        "    sil_dbscan_umap = silhouette_score(\n",
        "        X_non_noise[sample_idx],\n",
        "        labels_non_noise[sample_idx]\n",
        "    )\n",
        "    print(\"DBSCAN+UMAP silhouette (sample non-noise):\", sil_dbscan_umap)\n",
        "else:\n",
        "    print(\"DBSCAN+UMAP silhouette cannot be computed (not enough clusters).\")"
      ],
      "metadata": {
        "id": "68bEyRmr0K4H",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "12869b4f-477d-493c-8e50-ae0e3f8552a6"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "DBSCAN+UMAP silhouette (sample non-noise): 0.070811\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.cluster import DBSCAN\n",
        "best_eps = 0.15\n",
        "best_min_samples = 10\n",
        "print(f\"Generating labels with eps={best_eps}...\")\n",
        "final_dbscan = DBSCAN(\n",
        "    eps=best_eps,\n",
        "    min_samples=best_min_samples,\n",
        "    metric='euclidean'\n",
        ")\n",
        "labels = final_dbscan.fit_predict(X_umap_optimized)\n",
        "\n",
        "criteria_df['cluster_dbscan_umap'] = labels\n",
        "\n",
        "print(\"Column 'cluster_dbscan_umap' created successfully.\")\n",
        "print(f\"Clusters found: {len(set(labels)) - (1 if -1 in labels else 0)}\")\n",
        "\n",
        "inspect_dbscan_umap(criteria_df, n_examples=5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "q3EhnNoVZa-p",
        "outputId": "2bdf5775-e3cc-4097-8eab-2c23701eb5cd"
      },
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Generating labels with eps=0.15...\n",
            "Column 'cluster_dbscan_umap' created successfully.\n",
            "Clusters found: 275\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 0\n",
            "- [NCT00001137] HIV-1 infected\n",
            "- [NCT00003895] Patients must be negative for human immunodeficiency virus (HIV) antibody by enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is positive) if they are considered to be at high risk; others do not require serologic testing if there are no symptoms or risk factors for HIV disease\n",
            "- [NCT00005764] Are HIV-positive.\n",
            "- [NCT00005764] Have had HIV-1 RNA levels less than 400 copies/ml on the 2 most recent measurements.\n",
            "- [NCT00005764] Have had an HIV vaccine within 3 months of the screening visit.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 1\n",
            "- [NCT00001137] Willing to provide consent for the release and use of clinical data from the parent study\n",
            "- [NCT00003199] The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines\n",
            "- [NCT00003895] Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy\n",
            "- [NCT00004067] Psychiatric or addictive disorders that would preclude obtaining informed consent.\n",
            "- [NCT00004074] Written signed informed consent; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 2\n",
            "- [NCT00001137] Life expectancy of at least 24 weeks\n",
            "- [NCT00004067] The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)\n",
            "- [NCT00004074] Life expectancy of at least 6 months\n",
            "- [NCT00028405] Minimum life expectancy of 12 weeks.\n",
            "- [NCT00044291] Predicted life expectancy of 12 weeks or more\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 3\n",
            "- [NCT00001137] Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria\n",
            "- [NCT00035958] Patient and/or parent or legal guardian must be willing to sign consent and assent forms Exclusion criteria at the time of enrollment:\n",
            "- [NCT00106184] Parent willing to provide informed consent, if applicable\n",
            "- [NCT00315393] Parent or guardian willing to provide informed consent, if applicable\n",
            "- [NCT00346398] Parent or guardian willing to provide informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 4\n",
            "- [NCT00003199] Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (\\>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions\n",
            "- [NCT00004067] The tumor must be invasive adenocarcinoma on histologic examination.\n",
            "- [NCT00004067] Prior history of breast cancer, including DCIS (patients with a history of lobular carcinoma in situ \\[LCIS\\] are eligible).\n",
            "- [NCT00024154] Histologically confirmed metastatic adenocarcinoma of the breast\n",
            "- [NCT00034918] Histological and/or cytological confirmation of metastatic breast cancer which is refractory to anthracycline, taxane, with or without capecitabine therapies;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 5\n",
            "- [NCT00003199] Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol\n",
            "- [NCT00004067] Prior anthracycline or taxane therapy for any malignancy.\n",
            "- [NCT00048633] Histologically proven breast cancer with primary resistance to anthracyclines (doxorubicin, epirubicin) or taxane (paclitaxel, docetaxel) or both. Primary chemotherapy resistance is defined for the purpose of this protocol as any of the following: 1. Progression after a minimum of 1 cycles of therapy, or 2. Stable disease after a minimum of 2 cycles of therapy or, 3. Relapse within 6 months after completion of an anthracycline or/and taxane containing chemotherapy regimen.\n",
            "- [NCT00051103] No more than two prior regimens for metastatic breast cancer. Each regimen must have contained Herceptin.\n",
            "- [NCT00063570] Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 6\n",
            "- [NCT00003199] Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (\\>= 2.5 x 10\\^6 CD34+ cells/kg)\n",
            "- [NCT00003895] Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic techniques, flow cytometry, or molecular techniques\n",
            "- [NCT00005617] HLA-A2.1 positive and express MART-1, as assessed by either RT-PCR or by immunohistochemistry\n",
            "- [NCT00005949] HLA-A2\\\n",
            "- [NCT00024154] No prior organ allograft\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 7\n",
            "- [NCT00003199] Hepatic function: Bilirubin =\\< 2 mg%; SGOT or SGPT =\\< 2.5 x institutional normal\n",
            "- [NCT00048633] Normal renal function: creatinine less than or equal to 2.0 mg/dl. Adequate liver function: bilirubin less than or equal to 1.5 mg/dl. Transaminase (SGOT) and alkaline phosphatase must be less than or equal to 1.5 x of the upper limit of normal in the absence of bone or liver metastasis, or less than or equal to 2.5 x of the upper limit of normal in the presence of radiologically apparent liver metastasis or bone metastasis, respectively.\n",
            "- [NCT00087477] Adequate liver function with alkaline phosphatase \\<= 2.5 X upper limit of normal, SGOT and SGPT \\<= 1.5 X upper limit of normal and total bilirubin \\<= 1.5 X upper limit of normal.\n",
            "- [NCT00129376] Hepatic function: total bilirubin \\<= 1 x upper normal limit (UNL); Aspartate aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) \\<= 2.5 x UNL; alkaline phosphatase \\<= 5 x UNL.\n",
            "- [NCT00155259] Adequate liver and kidney function: total bilirubin ≦ 2.0 mg/dl, serum alanine transaminases (ALT) and aspartate transaminase (AST) ≦ 3 times upper normal limit, serum creatinine ≦ 1.5 mg/dl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 8\n",
            "- [NCT00003199] Renal function: Creatinine =\\< 2.0 mg/dl or a creatinine clearance \\>= 50 mg/min\n",
            "- [NCT00003199] Creatinine =\\< 2.0 mg/dl\n",
            "- [NCT00003895] Serum creatinine =\\< 2 mg/dl\n",
            "- [NCT00004067] There must be postoperative evidence of adequate renal function (serum creatinine within or less than the institution's normal range).\n",
            "- [NCT00004074] Calculated creatinine clearance will be used to assess renal function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 9\n",
            "- [NCT00003199] Pre-Study tests have been performed as outlined in the Study Calendar\n",
            "- [NCT00254592] In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28. This allows for efficient patient scheduling without exceeding the guidelines. If Day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day.\n",
            "- [NCT00479674] Laboratory tests performed within 14 days of study entry:\n",
            "- [NCT00491816] Pretreatment lab values must be performed within 14 days of patient registration, and other baseline studies within 30 days\n",
            "- [NCT00544765] Laboratory requirements (within 14 days prior to registration):\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 10\n",
            "- [NCT00003199] Karnofsky performance status \\> 60\n",
            "- [NCT00003895] Patients must be ambulatory with good performance status (Karnofsky performance status \\[PS\\] 80-100)\n",
            "- [NCT00004074] Karnofsky Performance Status index \\>= 70%\n",
            "- [NCT00005617] Karnofsky Performance Status greater than or equal to 70 percent\n",
            "- [NCT00087373] Performance status - Karnofsky 70-100%\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 11\n",
            "- [NCT00003199] Total bilirubin =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003895] Total bilirubin =\\< 2.0 mg/dl\n",
            "- [NCT00005949] Bilirubin normal\n",
            "- [NCT00024154] Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
            "- [NCT00036621] Total bilirubin \\< 1.5 x ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 12\n",
            "- [NCT00003199] SGOT =\\< 2.5 x upper limit of normal\n",
            "- [NCT00005949] AST no greater than 2.5 times upper limit of normal\n",
            "- [NCT00024154] INR no greater than 1.5 times ULN\n",
            "- [NCT00074308] AST and ALT no greater than 2.5 times ULN\n",
            "- [NCT00087373] AST and ALT ≤ 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 13\n",
            "- [NCT00003895] Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision\n",
            "- [NCT00003895] Patients whose melanoma is \\> 4.0 mm thick who have positive or negative regional lymph nodes are also eligible\n",
            "- [NCT00005617] Adults over the age of 18 with malignant melanoma.\n",
            "- [NCT00005617] Tumor stages T3N0M0 or greater are eligible for this trial according to the following: 1. I (\\<.75 to 1.5 mm or Clark level III-T1-2N0M0-)-not eligible 2. II (1.5 to 4 mm or level IV-T3N0M0-)-eligible 3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)-eligible 4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)-eligible 5. Relapsed melanoma-eligible\n",
            "- [NCT00005617] Patients previously treated with any form of therapy for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous treatment was completed \\>30 days prior to enrollment\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 14\n",
            "- [NCT00003895] After accrual to the original 26 patient goal, all patients must be enrolled prior to sentinel lymph node dissection; patients with previous lymph node dissection will not be eligible\n",
            "- [NCT00004067] Ipsilateral nodes must be cN0-1 by clinical evaluation.\n",
            "- [NCT00004067] Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.\n",
            "- [NCT00004067] Patients must have undergone either a total mastectomy and an axillary dissection or a lumpectomy and an axillary dissection. Sentinel node biopsy is permitted, but must be followed by an axillary dissection.\n",
            "- [NCT00004067] Patients treated by lumpectomy and axillary node dissection to be followed by breast radiation therapy must meet all the eligibility criteria in addition to the following: Generally, lumpectomy should be reserved for tumors \\<5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are eligible. The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients in whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary dissection has been performed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. Whole breast irradiation is required. Irradiation of regional lymph nodes is optional, but partial breast irradiation and irradiation of any internal mammary nodes are prohibited in this trial. Intent to irradiate the axilla or other regional node groups must be declared by the investigator prior to randomization for stratification purposes.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 15\n",
            "- [NCT00003895] White blood cell (WBC) \\>= 3500/mm\\^3\n",
            "- [NCT00071981] White blood cell (WBC) at least 4,000/mm\\^3\n",
            "- [NCT00071981] Lymphocyte count at least 700/mm\\^3\n",
            "- [NCT00074308] WBC at least 3,000/mm\\^3\n",
            "- [NCT00087373] WBC ≥ 3,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 16\n",
            "- [NCT00003199] ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,000/cells/mm\\^3 (transfusion independent) for at least 5 days before starting therapy\n",
            "- [NCT00003895] Platelets (Plt) \\>= 100,000/mm\\^3\n",
            "- [NCT00004067] Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.\n",
            "- [NCT00005949] Platelet count at least 100,000/mm\\^3\n",
            "- [NCT00024154] Platelet count at least 100,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 17\n",
            "- [NCT00003895] Hemoglobin \\>= 9 gm/100 ml\n",
            "- [NCT00005949] Hemoglobin at least 10 g/dL\n",
            "- [NCT00094003] Hemoglobin ≥9.0 g/dL\n",
            "- [NCT00146562] Hemoglobin \\> 9 g/dL\n",
            "- [NCT00217672] Hemoglobin ≥ 9.0 g/dL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 18\n",
            "- [NCT00003895] Patients must have recovered from any effects of major surgery and be free of significant systemic infection\n",
            "- [NCT00006412] Had surgery to remove their gallbladder within 3 months prior to study entry.\n",
            "- [NCT00028405] Patient has recovered from all previous surgery in the judgment of the Principal Investigator.\n",
            "- [NCT00071981] Recovered from prior major surgery\n",
            "- [NCT00087373] More than 2 weeks since prior surgery and recovered\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 19\n",
            "- [NCT00003895] Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment\n",
            "- [NCT00004074] Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; a woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant\n",
            "- [NCT00005617] Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment\n",
            "- [NCT00005764] Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.\n",
            "- [NCT00005949] Fertile patients must use effective contraception\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 20\n",
            "- [NCT00004067] The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins) and randomization must be less than or equal to 84 days.\n",
            "- [NCT00004067] Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.\n",
            "- [NCT00513136] At least 3 months since last breast cancer treatment (excluding hormonal therapy or Herceptin).\n",
            "- [NCT00546156] Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer\n",
            "- [NCT01095848] Patients with stage IV breast cancer who have received at least 1 course of hormonal or cytotoxic therapy for metastatic cancer. Patients must be off cytotoxic therapy with stable disease or better for 3 months or greater duration. Patients may have stable disease and still be on hormonal therapy.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 21\n",
            "- [NCT00004067] All of the following staging criteria must be met:\n",
            "- [NCT00004067] Primary tumor must be T1-3 by clinical and pathologic evaluation.\n",
            "- [NCT00004067] Primary tumor staged as T4 for any reason.\n",
            "- [NCT00087373] Stage IV disease\n",
            "- [NCT00087373] Detectable intratumoral T cells measured in the index lesion that is to be injected with rF-TRICOMTM by immunohistochemistry (IHC) for CD4, CD8 or another T cell marker, or by real time RT-PCR for CD8a, CD4, or other T cell transcripts\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 22\n",
            "- [NCT00004067] M0\n",
            "- [NCT00394251] T1-3, N1-3, M0, regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative\n",
            "- [NCT00402519] M0.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 23\n",
            "- [NCT00004067] The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.\n",
            "- [NCT00004067] Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. \"Marginal,\" \"borderline,\" etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.\n",
            "- [NCT00004074] Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use\n",
            "- [NCT00024154] Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)\n",
            "- [NCT00024154] Hormone receptor status:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 24\n",
            "- [NCT00004067] At the time of randomization, the patient must have had the following: history and physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam (for women who have a uterus and who will be taking tamoxifen) within the past year.\n",
            "- [NCT00004067] Bilateral malignancy or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant.\n",
            "- [NCT00123253] Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.\n",
            "- [NCT00129376] Negative extension study, including bilateral mammography, thoracic x-ray, computed tomography (CT)-scan or abdominal echography and bone scintigraphy.\n",
            "- [NCT00161291] Patients must have measurable disease by mammogram and/or breast ultrasound. The target lesion must not have been previously irradiated.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 25\n",
            "- [NCT00004067] Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is \\> 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)\n",
            "- [NCT00004074] Normal cardiac ejection fraction by echocardiogram or MUGA (i.e., greater than OSU lower limit of normal)\n",
            "- [NCT00024154] LVEF ≥ 50% by MUGA scan\n",
            "- [NCT00051103] Cardiac ejection fraction within the institutional range of normal as measured by MUGA (Multiple Gated Acquisition Scan).\n",
            "- [NCT00104884] Left ventricular ejection fraction (LVEF) \\> 40% by Multi Gated Acquisition Scan (MUGA)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 26\n",
            "- [NCT00004067] At the time of randomization:\n",
            "- [NCT00031486] Patient is expected to be available for follow-up visits of study drug administration and through the 24 month study visit.\n",
            "- [NCT00074308] More than 3 months\n",
            "- [NCT00074308] None of the following within the past 6 months:\n",
            "- [NCT00087373] More than 12 weeks\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 27\n",
            "- [NCT00004067] The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or \\<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).\n",
            "- [NCT00094003] Absolute neutrophil count (ANC) ≥1,500/mm3, without growth factor support\n",
            "- [NCT00206492] total neutrophil count must be \\>1.5 x 10\\^9/L, and\n",
            "- [NCT00217672] Absolute neutrophil count ≥ 1,500/mm\\^3\n",
            "- [NCT00258349] Absolute neutrophil count \\>= 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 28\n",
            "- [NCT00004067] Patients must have no clinical or radiologic evidence of metastatic disease. Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A patient with skeletal pain is eligible for inclusion in the study if bone scan and/or roentgenological examination fails to disclose metastatic disease.\n",
            "- [NCT00044291] Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease\n",
            "- [NCT00221221] no known or active metastatic disease.\n",
            "- [NCT00255762] Evidence of metastatic disease\n",
            "- [NCT00258349] Metastatic or chest wall recurrent disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 29\n",
            "- [NCT00004067] Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible only if this therapy is discontinued prior to randomization.)\n",
            "- [NCT00005617] A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy\n",
            "- [NCT00005764] Have had chemotherapy or radiation therapy within 4 weeks prior to screening visit (except for local treatment for Kaposi's sarcoma) or plan to have such treatment during the study.\n",
            "- [NCT00005764] Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical steroids) in the last 4 months or plan to take these drugs during the study.\n",
            "- [NCT00005949] At least 4 weeks since prior chemotherapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 30\n",
            "- [NCT00004067] Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. (Patients are eligible only if these medications are discontinued prior to randomization. These medications are not permitted while on the study except for the use of tamoxifen as described in the protocol)\n",
            "- [NCT00024154] No concurrent hormonal therapy, including tamoxifen\n",
            "- [NCT00036621] Tamoxifen (20mg) given orally once per day\n",
            "- [NCT00201929] Chemotherapy alone or in addition to tamoxifen as an appropriate treatment option Surgery Group:\n",
            "- [NCT00287534] continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 31\n",
            "- [NCT00004067] Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude a patient from being subjected to any of the treatment options or would prevent prolonged follow-up.\n",
            "- [NCT00004074] The patient must have failed standard curative and/or palliative therapies for their disease\n",
            "- [NCT00006412] Have failed previous statin or fibrate therapy (after 24 weeks of treatment) or have had side effects from these drugs.\n",
            "- [NCT00021463] Have had treatment with ABC.\n",
            "- [NCT00024154] No prior gefitinib\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 32\n",
            "- [NCT00004067] Cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin. This includes:\n",
            "- [NCT00004067] Active cardiac disease:\n",
            "- [NCT00004067] angina pectoris that requires the use of antianginal medication;\n",
            "- [NCT00004067] cardiac arrhythmia requiring medication;\n",
            "- [NCT00004067] severe conduction abnormality;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 33\n",
            "- [NCT00004067] patients with poorly controlled hypertension, i.e., diastolic greater than 100 mm/Hg. (Patients with hypertension who are well controlled on medication are eligible for entry.)\n",
            "- [NCT00005949] No antihypertensive medications from 1 day prior until 2 days after first course\n",
            "- [NCT00006412] Have uncontrolled high blood pressure within 4 weeks of study entry.\n",
            "- [NCT00074308] No uncontrolled hypertension within the past 6 months\n",
            "- [NCT00074308] Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 34\n",
            "- [NCT00004067] Sensory/motor neuropathy ≥ grade 2, as defined by the NCI's Common Toxicity Criteria version 2.0.\n",
            "- [NCT00077363] Patients with CTC v 3.0 grade 2-4 neuropathy are not eligible\n",
            "- [NCT00217672] Presence of neuropathy \\> grade 2 (NCI- Common Toxicity Criteria (CTC) version 3.0) at baseline\n",
            "- [NCT00225056] peripheral neuropathy less than or equal to grade 1\n",
            "- [NCT00255762] No peripheral neuropathy ≥ grade 2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 35\n",
            "- [NCT00004067] Contraindications to corticosteroid use which, in the opinion of the investigator, would preclude participation in this study.\n",
            "- [NCT00006290] Have a mental disability that, in the opinion of the researcher, could interfere with study participation.\n",
            "- [NCT00006412] Abuse drugs or alcohol, and the doctor thinks this may interfere with the study.\n",
            "- [NCT00024154] No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation\n",
            "- [NCT00074308] No psychiatric illness or social situation that would preclude study compliance\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 36\n",
            "- [NCT00004067] Concurrent treatment with other investigational agents.\n",
            "- [NCT00024154] No other concurrent investigational agents\n",
            "- [NCT00074308] No other concurrent investigational agents\n",
            "- [NCT00087373] No other concurrent investigational agents\n",
            "- [NCT00258349] No other concurrent investigational agents\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 37\n",
            "- [NCT00004067] Patients in whom the margins of the resected specimen are involved with invasive tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to obtain free margins are allowed. Patients in whom tumor is still present after the additional resection(s) must undergo mastectomy to be eligible.\n",
            "- [NCT00121134] Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.\n",
            "- [NCT00325598] Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.\n",
            "- [NCT00325598] Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.\n",
            "- [NCT00337064] Pathologically negative margins\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 38\n",
            "- [NCT00004074] Patients must have measurable or evaluable disease\n",
            "- [NCT00048633] Patients must have measurable disease as defined by the RECIST criteria in their breast/nodal regions or at a distant organ site(s).\n",
            "- [NCT00063570] Must have disease that can be measured.\n",
            "- [NCT00191243] measurable and/or non-measurable disease\n",
            "- [NCT00225056] must have measurable or evaluable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 39\n",
            "- [NCT00004067] Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.\n",
            "- [NCT00004074] No concurrent malignancy other than non-melanoma skin carcinoma\n",
            "- [NCT00005949] No currently active second malignancy (e.g., patient has completed therapy and is considered unlikely to have recurrence within 1 year) other than nonmelanoma skin cancer\n",
            "- [NCT00024154] No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n",
            "- [NCT00039793] Have a primary oncologist\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 40\n",
            "- [NCT00004074] Adequate hematopoietic, cardiac, renal, and hepatic function\n",
            "- [NCT00006412] Have liver disease.\n",
            "- [NCT00051103] Adequate kidney and liver function\n",
            "- [NCT00087776] Patients must have adequate renal and liver function\n",
            "- [NCT00191243] adequate liver / renal functions defined\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 41\n",
            "- [NCT00005617] No previous evidence of opportunistic infection\n",
            "- [NCT00074308] No ongoing or active infection requiring parenteral antibiotics\n",
            "- [NCT00087373] No uncontrolled active or chronic infection\n",
            "- [NCT00091819] Patients must be expected to require at least 7 days of intravenous antibiotic treatment\n",
            "- [NCT00107978] Patients must be expected to require at least 7 days of intravenous antibiotic treatment.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 42\n",
            "- [NCT00005617] Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): 1. Hemoglobin \\>9.0 g/dl 2. Platelets \\> 100000/mm3 3. WBC \\> 3000/mm3 4. Absolute Neutrophil Count \\> 1000/mm3\n",
            "- [NCT00048633] Adequate bone marrow function: platelets greater than or equal to 100,000/mm3, ANC greater than or equal to 1500 cells/mm3, hemoglobin greater than or equal to 8g/dl.\n",
            "- [NCT00087477] Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and absolute neutrophil count (ANC)≥ 1,500 cells/mm3.\n",
            "- [NCT00129376] Haematology: neutrophils \\>= 2.0 x10\\^9/l; platelets \\>= 100 x10\\^9/l; hemoglobin \\>=10 g/dl.\n",
            "- [NCT00155259] Adequate bone marrow reserve, defined as white blood cell (WBC)≧ 3,500/ mm3, absolute neutrophil count (ANC)≧ 1,500/mm3, platelets ≧ 100,000/mm3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 43\n",
            "- [NCT00005617] Positive skin test to common antigens (tetanus and candida)\n",
            "- [NCT00317980] Presence of 1 to 9 cutaneous lesions clinically compatible with leishmaniasis\n",
            "- [NCT00317980] Positive leishmanin skin test\n",
            "- [NCT00317980] Parasitological diagnosis confirmed through culture or genus-specific polymerase chain reaction (PCR) for Leishmania spp\n",
            "- [NCT01011309] Must have a clinical diagnosis of cutaneous leishmaniasis confirmed by positive identification of Leishmania parasite and identification of L. peruviana by PCR.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 44\n",
            "- [NCT00005617] Ability to give informed consent\n",
            "- [NCT00028405] Ability to provide informed consent.\n",
            "- [NCT00044291] Written informed consent obtained\n",
            "- [NCT00048633] Written informed consent.\n",
            "- [NCT00083239] Written informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 45\n",
            "- [NCT00005764] Patients may be eligible for this study if they:\n",
            "- [NCT00005764] Have taken d4T consistently for the 6 months before entering study. Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "- [NCT00005764] Are enrolled in other clinical studies.\n",
            "- [NCT00006290] Patients may be eligible for this study if they:\n",
            "- [NCT00006290] Are either female or heterosexual male (if enrolling in the University of Pennsylvania or Johns Hopkins University focus groups). Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 46\n",
            "- [NCT00005764] Are at least 18 years old.\n",
            "- [NCT00006412] Are at least 18 years old.\n",
            "- [NCT00650910] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT00821054] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT01473680] Is at least 18 years old, but not older than 61 years old;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 47\n",
            "- [NCT00005764] Have at least 1 of the following situations:\n",
            "- [NCT00006412] (This reflects a change in exclusion requirements.)\n",
            "- [NCT00024154] Not specified\n",
            "- [NCT00087373] Must have 1 of the following criteria:\n",
            "- [NCT00245960] Inclusion Criteria:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 48\n",
            "- [NCT00005764] (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in buttocks area; or\n",
            "- [NCT00005764] (b) an increase in lactate level greater than 2.2 mmol/L at the screening visit plus at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in the buttocks area; or\n",
            "- [NCT00006290] Are experiencing at least 1 of the following symptoms associated with fat changes due to HIV: 1) increase in belt or waist size; 2) increase in size of back of neck; 3) increase in bra, shirt, or blouse size to fit increasing breast size; 4) fat increase in other areas of the body; 5) loss of facial fat; 6) loss of fat in arms or legs; 7) loss of fat in buttocks.\n",
            "- [NCT00006290] Have diabetes or Cushing's disease or have had surgery that might otherwise explain changes in body fat.\n",
            "- [NCT00006290] Have changes in diet or physical activity that might explain changes in body fat.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 49\n",
            "- [NCT00005764] (c) an increase in lactate level greater than 2.2 mmol/L at screening visit plus at least 2 of the following: (1) shortness of breath, (2) weakness, (3) fast heartbeat, (4) recent weight loss (10 lbs. within the past 2 months), (5) pain and/or bloating in the abdomen, (6) nausea and/or vomiting and/or lack of appetite; or\n",
            "- [NCT00005764] Have serious medical conditions, such as congestive heart failure or other heart disease, which would affect the safety of the patient.\n",
            "- [NCT00074308] No other concurrent uncontrolled illness\n",
            "- [NCT00077363] Patients must not have any uncontrolled intercurrent illness including, but not limited to, chronic nausea/vomiting, complete or partial bowel obstruction, dysphagia/odynophagia with inability to swallow pills, ongoing or active infection, symptomatic cardiovascular disease, or other chronic medical or psychiatric conditions that would impair compliance or would substantially increase the risk of participating in this study\n",
            "- [NCT00255762] No other uncontrolled illness\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 50\n",
            "- [NCT00005764] Are able to read at a sixth-grade level.\n",
            "- [NCT00006290] Are able to speak and read English.\n",
            "- [NCT00106184] Able and willing to complete self-report questionnaires. Parents of pediatric participants will be required to complete the questionnaires on behalf of their children.\n",
            "- [NCT00179634] Working knowledge of English\n",
            "- [NCT00198250] able to read, write and speak English\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 51\n",
            "- [NCT00005764] Have diabetes or kidney failure.\n",
            "- [NCT00006412] Have diabetes requiring drug treatment or diabetes not controlled by diet.\n",
            "- [NCT00024154] Random blood sugar less than 2.5 times ULN\n",
            "- [NCT00025883] Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient. Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period. Presence of at least one of the following metabolic abnormalities: 1. Presence of diabetes as defined by the 2007 ADA criteria 1. Fasting plasma glucose greater than or equal to 126 mg/dL, or 2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or 3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl 2. Fasting insulin greater than 30 micro units/ml. 3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants) -Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.\n",
            "- [NCT00065663] Adequately controlled diabetes mellitus (type I or II) as defined by HbA1c \\< 10.0%\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 52\n",
            "- [NCT00005764] Are unable to take medications by mouth.\n",
            "- [NCT00034918] No Gastrointestinal pathology which could affect the bioavailability of ZD6474.\n",
            "- [NCT00051103] Able to swallow and retain oral medication\n",
            "- [NCT00359190] Ability to swallow and retain oral medication.\n",
            "- [NCT00383851] History of malabsorption syndromes or other gastrointestinal disorders that may affect ATN-224 or temozolomide absorption, including bowel obstruction, celiac disease, sprue, cystic fibrosis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 53\n",
            "- [NCT00005764] Are pregnant or breast-feeding.\n",
            "- [NCT00006290] Are pregnant.\n",
            "- [NCT00006412] Are pregnant or breast-feeding.\n",
            "- [NCT00021463] Are pregnant or breast-feeding.\n",
            "- [NCT00087373] Pregnant women\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 54\n",
            "- [NCT00005764] Have taken hydroxyurea within the past 3 days or plan to take this drug during the study.\n",
            "- [NCT00005949] At least 1 month since prior systemic corticosteroids\n",
            "- [NCT00005949] No concurrent systemic, inhaled, or topical corticosteroids\n",
            "- [NCT00006290] Have been on glucocorticoid therapy for a long time.\n",
            "- [NCT00006412] Have taken any prescription or non-prescription lipid-lowering drug within 14 days prior to study entry or for over 24 weeks in the past.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 55\n",
            "- [NCT00005949] 0201 positive by genotyping\n",
            "- [NCT00306553] 0201 haplotype\n",
            "- [NCT00700167] 0201 positive.\n",
            "- [NCT01026051] 0201 as assessed by DNA typing\n",
            "- [NCT01273181] 0201 positive Serology:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 56\n",
            "- [NCT00005949] Measurable disease as defined by the following:\n",
            "- [NCT00024154] Measurable disease\n",
            "- [NCT00050141] Measurable disease\n",
            "- [NCT00074308] Measurable disease (phase II)\n",
            "- [NCT00087373] Measurable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 57\n",
            "- [NCT00005949] At least 1 lesion accurately measured in at least 1 dimension\n",
            "- [NCT00005949] At least 20 mm by conventional techniques\n",
            "- [NCT00005949] Lesions considered intrinsically nonmeasurable include:\n",
            "- [NCT00083239] Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins\n",
            "- [NCT00087373] At least 1 cutaneous or lymph node mass ≥ 1 cm AND amenable to biopsy and percutaneous injection AND can be accurately measured with standard calipers\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 58\n",
            "- [NCT00005949] Bone lesions\n",
            "- [NCT00005949] Abdominal masses not confirmed and followed by imaging techniques\n",
            "- [NCT00051779] A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases.\n",
            "- [NCT00051779] Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention.\n",
            "- [NCT00077363] Patients must have at least one objective measurable disease parameter as defined by RECIST criteria; tumor measurements and evaluation of non-measurable sites must be performed within 4 weeks prior to registration\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 59\n",
            "- [NCT00005949] Leptomeningeal disease\n",
            "- [NCT00005949] No prior or concurrent liver or brain metastases\n",
            "- [NCT00024154] No untreated brain metastases or brain metastases undergoing radiotherapy\n",
            "- [NCT00024154] Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease\n",
            "- [NCT00048633] Patients with brain metastases whose disease remained stable for more than 3 months after completing therapy to the brain are eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 60\n",
            "- [NCT00005949] Ascites\n",
            "- [NCT00369655] Ascites\n",
            "- [NCT01005472] Terfenadine\n",
            "- [NCT01005472] Quinidine\n",
            "- [NCT01005472] Procainamide\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 61\n",
            "- [NCT00005949] Pleural/pericardial effusion\n",
            "- [NCT00369655] Pleural/pericardial effusion\n",
            "- [NCT00436605] No large pleural effusions\n",
            "- [NCT01283789] Pleural/pericardial effusion\n",
            "- [NCT01543126] Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 62\n",
            "- [NCT00005949] Lymphangitis cutis/pulmonis\n",
            "- [NCT00194363] Women without lymphedema must be 1-5 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must be 1-15 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must have stable lymphedema. ONE of the following:\n",
            "- [NCT00194363] A prior clinical diagnosis of lymphedema and having had any prior intensive lymphedema therapy on the affected arm As well as ALL of the following four conditions:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 63\n",
            "- [NCT00005949] At least 10 mm by spiral CT scan\n",
            "- [NCT00005949] Lesions situated in a previously irradiated area\n",
            "- [NCT00071981] Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST criteria)\n",
            "- [NCT00073528] Subjects with either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).\n",
            "- [NCT00077363] Previously irradiated tumors cannot be used to assess a clinical response; patients will not be eligible for this study if the previously irradiated tumors constitute the only site of measurable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 64\n",
            "- [NCT00005949] No severe chronic pulmonary disease\n",
            "- [NCT00035958] JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)\n",
            "- [NCT00333437] Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.\n",
            "- [NCT00377949] Diagnosis of \"pre\" pulmonary arterial hypertension defined as:\n",
            "- [NCT00377949] Pulmonary function test with FVC \\>70% and a DLCO \\<55% of predicted or a FVC/DLco ratio \\>1.6. or\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 65\n",
            "- [NCT00005949] Not pregnant or nursing\n",
            "- [NCT00024154] Not pregnant or nursing\n",
            "- [NCT00035958] Pregnant or nursing female\n",
            "- [NCT00074308] Not pregnant or nursing\n",
            "- [NCT00087373] Not pregnant or nursing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 66\n",
            "- [NCT00003199] Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:\n",
            "- [NCT00005764] Have taken drugs that affect the immune system, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to the screening visit.\n",
            "- [NCT00005949] At least 4 weeks since prior immunotherapy\n",
            "- [NCT00005949] No prior interleukin-2\n",
            "- [NCT00005949] No other concurrent cytokines or growth factors\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 67\n",
            "- [NCT00006290] Are 18 years or older.\n",
            "- [NCT00028405] Age 18 or older.\n",
            "- [NCT00071981] Age: 18 and over\n",
            "- [NCT00107991] Age 18 or older.\n",
            "- [NCT00119158] Age 2 to 65 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 68\n",
            "- [NCT00006412] Are on a lipid-lowering diet based on the patient's statement and have been exercising for at least 30 days before being screened for the study. Patients will be asked if they were counseled by their health care provider. The lipid-lowering diet and exercise program do not have to be prescribed by a physician.\n",
            "- [NCT00006412] Take prescription lipid-lowering agents, other than those given by the study, and non-prescription lipid-lowering agents such as garlic supplements.\n",
            "- [NCT00178126] use wheelchair \\> 6 hours per day\n",
            "- [NCT00193037] Able to perform activities of daily living with minimal assistance\n",
            "- [NCT00235196] Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 69\n",
            "- [NCT00006412] Have a triglyceride (TG) level of at least 200 mg/dl and low-density lipoprotein (LDL) level of at least 130 mg/dl after fasting for 8 to 12 hours.\n",
            "- [NCT00811824] LDL cholesterol \\< 150\n",
            "- [NCT01283789] Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, patient may be included after initiation of appropriate lipid lowering medication with approval from the principal investigator.\n",
            "- [NCT01513356] Cholesterol \\< ULN - 7.75 mmol/L and Triglycerides \\< ULN - 2.5 x ULN (with lipid-lowering drugs permitted)\n",
            "- [NCT01997255] Acceptable fasting serum cholesterol and fasting triglycerides levels.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 70\n",
            "- [NCT00006412] Have hypothyroidism (low thyroid activity).\n",
            "- [NCT00006412] Take or have taken levothyroxine and liothyronine for hypothyroidism.\n",
            "- [NCT00336102] No diagnosis of hypothyroidism or hyperthyroidism.\n",
            "- [NCT00459771] Thyroid stimulating hormone between 0.5-3.9 MU/l\n",
            "- [NCT00777335] Clinically euthyroid function (thyroid-stimulating hormone (TSH) and free T4). (Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 71\n",
            "- [NCT00006412] Are allergic or sensitive to the study drug(s) or to other lipid-lowering drugs.\n",
            "- [NCT00021463] Are allergic to study drugs or any ingredient in them.\n",
            "- [NCT00074308] No prior allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biological composition to imatinib mesylate\n",
            "- [NCT00087373] No prior significant allergic reaction or hypersensitivity to eggs or egg products\n",
            "- [NCT00217672] A history of a severe hypersensitivity reaction to Bevacizumab, or Docetaxel or other drugs formulated with polysorbate 80.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 72\n",
            "- [NCT00006412] Were given radiation therapy within 30 days of study entry.\n",
            "- [NCT00024154] At least 2 weeks since prior radiotherapy\n",
            "- [NCT00024154] No prior radiotherapy to target lesions or only site of measurable disease\n",
            "- [NCT00024154] No concurrent radiotherapy\n",
            "- [NCT00028405] If patients have received radiotherapy to sites of disease other than the one planned for insertion of the light delivery catheter, then the patient must have no current local or systemic toxicity from the prior radiation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 73\n",
            "- [NCT00007280] Men or women at least 18 years old\n",
            "- [NCT00034918] Females, aged \\>= 18 years;\n",
            "- [NCT00044291] Women age 18 years or older\n",
            "- [NCT00087477] Males and females, age ≥ 18 years.\n",
            "- [NCT00094003] Male and female at least 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 74\n",
            "- [NCT00007280] At least one ulcer (wound) greater than or equal to 2 centimeters\n",
            "- [NCT00007280] Ulcer (wound) present for at least 3 months or greater\n",
            "- [NCT00035958] Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis\n",
            "- [NCT00065663] Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement\n",
            "- [NCT00065663] Ulcer present for \\> 6 weeks prior to study entry\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 75\n",
            "- [NCT00007280] Ankle/brachial index \\> 0.7\n",
            "- [NCT00065663] Affected limb transcutaneous oxygen pressure (TcpO2) \\> 30 mmHg at screening or a palpable dorsal pedal or posterior tibial pulse\n",
            "- [NCT00366132] Palpable pedal pulse in the affected leg OR peripheral vascular disease evaluation demonstrating acceptable blood supply to affected foot;\n",
            "- [NCT00446472] Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.\n",
            "- [NCT00448903] Ankle-brachial index (ABI) \\> or = 0,7\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 76\n",
            "- [NCT00021463] Are at least 13 years old and have signed consent of parent or guardian if under 18 years of age.\n",
            "- [NCT00175344] Age 18 years or older with ability to provide written informed consent.\n",
            "- [NCT00245960] 18 years of age or older at time of consent\n",
            "- [NCT00387062] Age 21 or older at the time of consent.\n",
            "- [NCT00403559] Must be 18 or older and sign written informed consent.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 77\n",
            "- [NCT00001137] Active alcohol or drug abuse that may interfere with the study\n",
            "- [NCT00021463] Abuse drugs or alcohol.\n",
            "- [NCT00424749] History of drug, alcohol, or chemical abuse within 6 months prior to screening\n",
            "- [NCT00438815] Narcotic addiction\n",
            "- [NCT00519246] No alcohol drinking.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 78\n",
            "- [NCT00024154] Male or female\n",
            "- [NCT00025883] All ethnic groups. Males and females.\n",
            "- [NCT00270972] Male or female\n",
            "- [NCT00324259] Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.\n",
            "- [NCT00365599] Both men and women of all races and ethnic groups are eligible for this trial.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 79\n",
            "- [NCT00024154] Granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00074308] Absolute granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00077363] Granulocytes \\> 1500/mm\\^3\n",
            "- [NCT00109005] Granulocyte count greater than 1,500/mm\\^3\n",
            "- [NCT00255762] Absolute granulocyte count ≥ 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 80\n",
            "- [NCT00024154] AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases is present)\n",
            "- [NCT00071981] Alkaline phosphatase no greater than 2 times ULN\n",
            "- [NCT00206492] alkaline phosphatase within 5 x ULN. 7. Performance status (WHO scale) \\<2. 8. Age \\> 18 years.\n",
            "- [NCT00255762] Alkaline phosphatase ≤ 3 times ULN\n",
            "- [NCT00349934] Serum ASAT and ALAT \\< 3 times the upper limit of normal or \\< 5 times upper limit of normal if liver metastases are present.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 81\n",
            "- [NCT00024154] PT and PTT no greater than 1.5 times ULN\n",
            "- [NCT00074308] INR no greater than 1.5\n",
            "- [NCT00074308] APTT normal\n",
            "- [NCT00087373] PT/PTT ≤ 1.25 times upper limit of normal (ULN)\n",
            "- [NCT00094003] PT and PTT \\< 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 82\n",
            "- [NCT00024154] No prior trastuzumab (Herceptin)\n",
            "- [NCT00153218] must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy\n",
            "- [NCT00153218] must not have received trastuzumab in the adjuvant or neoadjuvant setting\n",
            "- [NCT00153218] must have started trastuzumab treatment for metastatic disease any time between January 1996 to June 2003\n",
            "- [NCT00258349] More than 4 weeks since prior lapatinib ditosylate\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 83\n",
            "- [NCT00024154] See Disease Characteristics\n",
            "- [NCT00035958] Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter\n",
            "- [NCT00074308] Histologically or cytologically confirmed diagnosis of 1 of the following:\n",
            "- [NCT00087373] See Disease Characteristics\n",
            "- [NCT00257530] CL diagnosis confirmed\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 84\n",
            "- [NCT00024154] No concurrent topical eye agents\n",
            "- [NCT00121511] Patients must have clinical photoaging judged by rhytides, dyspigmentation, poikiloderma, lentigines, skin thinning, and/or telangiectases.\n",
            "- [NCT00176969] Not be taking any medications including topical medications\n",
            "- [NCT00253331] agree to apply gel as per protocol\n",
            "- [NCT00335179] Discontinuation of moisturizers\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 85\n",
            "- [NCT00024154] Concurrent bisphosphonates allowed for hypercalcemia and/or prophylaxis of bone metastases\n",
            "- [NCT00048633] Patients may receive concomitant bisphosphonate therapy for bone metastasis.\n",
            "- [NCT00051779] Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug\n",
            "- [NCT00258349] Concurrent bisphosphonates allowed provided therapy was initiated prior to study treatment\n",
            "- [NCT00324259] For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 86\n",
            "- [NCT00025883] Age greater than or equal to 6 months.\n",
            "- [NCT00104884] Age greater than or equal to 18\n",
            "- [NCT00133341] Age more or equal to 18 years.\n",
            "- [NCT00204529] ≥ 18 years of age and \\< 75 years of age\n",
            "- [NCT00304460] Age greater than or equal to18 years old.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 87\n",
            "- [NCT00028405] Tumor mass is not immediately adjacent to, or directly invading a major vessel or hollow viscus such that tumor necrosis could result in hemorrhage or perforation.\n",
            "- [NCT00044291] At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques)\n",
            "- [NCT00255762] No tumor invasion of major blood vessels\n",
            "- [NCT00388115] Tumor less than or equal to 2.0 cm in diameter.\n",
            "- [NCT00802932] Pathologic tumor size \\< 5.0 cm (Microscopic multifocality is allowed if total pathologic tumor size is within 5 cm)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 88\n",
            "- [NCT00028405] Patient has an ECOG performance status of 0-3 (Karnofsky 30 or higher).\n",
            "- [NCT00161291] Be ambulatory (outpatient) and have an ECOG PS \\<2 (Appendix F).\n",
            "- [NCT00251472] Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I).\n",
            "- [NCT00323206] Patients must have ECOG performance status 0-2\n",
            "- [NCT00324259] The patient must have an ECOG performance status of 0-2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 89\n",
            "- [NCT00031460] Less than or equal to 28 days of age at the time of initial presentation with CNS disease.\n",
            "- [NCT00031486] Patients who are 12 years of age or older.\n",
            "- [NCT00087620] Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama\n",
            "- [NCT00087776] Patients must be \\>= 18 years of age.\n",
            "- [NCT00155259] Patients must be ≦ 65 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 90\n",
            "- [NCT00031460] Birth weight greater than or equal to 800 grams.\n",
            "- [NCT00031486] Patients who weigh greater than or equal to 45.5kg (100 pounds).\n",
            "- [NCT00123253] For males: waist circumference \\> 95 cm and waist to hip ratio \\> 0.94;\n",
            "- [NCT00123253] For females: waist circumference \\> 94 cm and waist to hip ratio \\> 0.88.\n",
            "- [NCT00211133] Weight \\> = 40 kg (88 lbs)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 91\n",
            "- [NCT00034918] WHO performance status 0, 1 or 2 on the day of registration;\n",
            "- [NCT00048633] Zubrod performance status less than or equal to 2.\n",
            "- [NCT00191243] performance status 0-2 (WHO, Zubrod)\n",
            "- [NCT00197912] WHO-Performance Status 0-1\n",
            "- [NCT00237198] Patients whose performance status (PS) is 0～2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 92\n",
            "- [NCT00035958] Prior treatment with specific TNF-blocking agents\n",
            "- [NCT01511315] Subjects must not have received TNF-α inhibitors (such as infliximab, etanercept, adalimumab) within the 12 week period prior to Week 0 or during the study\n",
            "- [NCT02147600] adalimumab (40mg) subcutaneously every other week\n",
            "- [NCT02147600] at least 24 weeks of adalimumab treatment\n",
            "- [NCT02922192] TNF -α antagonists (including adalimumab, certolizumab, etanercept \\[not included for IBD\\], golimumab, infliximab, and natalizumab \\[IBD only\\])\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 93\n",
            "- [NCT00035958] Any of the following laboratory abnormalities at baseline: platelet count \\< 100,000/cmm, total white cell count of \\< 3000 cells/cmm, neutrophils \\< 1000 cells/cmm, serum bilirubin \\> 2 times upper limit of normal, estimated creatinine clearance of \\< 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to \\<13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)\n",
            "- [NCT00161291] Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \\> 1,500/mm3, hemoglobin \\> 8.0 g/dl, platelets \\> 75,000/mm3, total bilirubin \\< 2 mg/dl, serum creatinine \\< 2 mg/dl, Transaminases (AST, ALT) may be up to 2.0 x institutional upper limit of normal. In addition \\< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \\< 1.0.\n",
            "- [NCT00192517] Prior to randomization (must be within 21 days of the first administration of the study drug), all of the following: WBC less than or equal to 3,800/mm3; hematocrit above 32%, platelet count less than or equal to 140,000/mm3; AST, ALT, BUN, or creatinine\\<1.5 x ULN; and stool negative for occult blood\n",
            "- [NCT00197912] Acceptable CBC and blood chemistry results\n",
            "- [NCT00237185] Performance status ≤3 as defined by the Eastern Cooperative Oncology Group (ECOG) criteria, as well as a life expectancy ≥6 months and adequate end organ function defined as follows: Total bilirubin \\<1.5 times upper limit of normal (ULN), aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) \\<2.5 x ULN (or \\<5 x ULN if hepatic metastases were present), creatinine \\<1.5 x ULN, absolute neutrophil count (ANC) \\>1.5 x 10\\^9/L, platelet count \\>100 x 10\\^9/L\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 94\n",
            "- [NCT00035958] Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)\n",
            "- [NCT00071981] This extremity may still be considered for vaccination\n",
            "- [NCT00106184] Willing to forgo immunization with a live vaccine for the duration of the study\n",
            "- [NCT00356460] Documentation of flu vaccination if enrolled during flu season (as defined by the availability of vaccine). Otherwise, patient should receive the current flu vaccine \\> or = 1 wk before beginning GC1008 therapy.\n",
            "- [NCT00723528] Participants must agree not to receive Bacillus Calmette-Guérin (BCG) vaccination and live vaccine inoculation for 1 year after final treatment with the investigational product\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 95\n",
            "- [NCT00036621] ANC \\> 1500/mm3\n",
            "- [NCT00094003] Afebrile (≤37.5C or 99.5F)\n",
            "- [NCT00146562] ANC \\> 1,500/uL\n",
            "- [NCT00407888] ANC \\>= 1,500\n",
            "- [NCT00470301] FEV1 \\>= 1 L\\\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 96\n",
            "- [NCT00043472] To be considered at increased genetic risk of OC, subjects must have: Age greater than or equal to 30; No prior history of OC, including low malignant potential cancers (LMP), or primary papillary serous carcinoma of the peritoneum; At least one intact ovary: Satisfied one of the following additional criteria: The family of the subject has a documented deleterious BRCA1 or BRCA2 mutation - either:\n",
            "- [NCT00043472] the subject herself has tested positive for a deleterious BRCA1 or BRCA2 mutation; OR\n",
            "- [NCT00494234] Advanced breast cancer with positive BRCA1 or BRCA2 status\n",
            "- [NCT00526617] BRCA deficient tumor status\\\n",
            "- [NCT00526617] Patients must have histologically or cytologically confirmed solid tumors with a positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be considered eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 97\n",
            "- [NCT00043472] the subject has a first- or second-degree relative with a deleterious BRCA1 or BRCA2 mutation OR The family contains at least two ovarian and/or breast cancers among the subject or first- or second-degree relatives of the subject within the same lineage. This condition is satisfied by multiple primary cancers in the same person. Where breast cancer is required to meet this criterion, at least one breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown); OR The subject is of Ashkenazi Jewish ethnicity with one first-degree or two second-degree relatives with breast and/or OC. Where breast cancer is required to meet this criterion, at least one case must have been diagnosed prior to menopause (or at age less than or equal to 50, if age at menopause is unknown). OR The subject is of Ashkenazi ancestry and has had breast cancer herself. To meet this criterion, her breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown). OR The probability of carrying a BRCA1/2 mutation given the family pedigree of breast and OCs exceeds 20% as calculated by BRCAPRO. Note: BRCAPRO does NOT need to be calculated on everyone who enters the study. Patients are eligible based on a family history which meets one of the specific patterns described in this protocol, regardless of BRCAPRO results. BRCAPRO assessment is valuable in families where genetic testing has not been done, and the family history does not fit one of the specific patterns described, but the pattern of cancers leads you to believe that the family might still be considered high-risk. At that point, if the BRCAPRO estimate of being a mutation carrier is greater than 20 percent, then the patient IS eligible. Signed an approved informed consent and authorization permitting release of personal health information.\n",
            "- [NCT00150917] at least one 1st-degree relative with Breast Cancer\n",
            "- [NCT00329017] at high risk of developing breast cancer determined by family or personal history\n",
            "- [NCT00996710] Cancer at any age in 2 or more siblings suggestive of a genetic etiology, such as brothers with testicular germ cell tumor or sisters with breast cancer and ovarian cancer\n",
            "- [NCT01004666] High-risk for breast cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 98\n",
            "- [NCT00044291] ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher\n",
            "- [NCT00262834] ECOG 0-2 OR Karnofsky 60-100%\n",
            "- [NCT00436605] ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%\n",
            "- [NCT00659568] ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%\n",
            "- [NCT00720031] General state with Karnowsky greater than 80, ECOG = 0, 1 or 2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 99\n",
            "- [NCT00044291] Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago\n",
            "- [NCT00050141] Postmenopausal\n",
            "- [NCT00065325] Postmenopausal women defined as a women who has stopped having menstrual periods\n",
            "- [NCT00143052] Regular menses\n",
            "- [NCT00146601] Patients must be premenopausal.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 100\n",
            "- [NCT00048633] Patients much have recovered from acute toxic effects of any prior therapy.\n",
            "- [NCT00306553] All AEs form prior anticancer therapy have resolved to ≤ Grade 1.\n",
            "- [NCT00349934] Resolution of toxicity of prior therapy to grade \\< 2 (except alopecia).\n",
            "- [NCT00356460] At the time of enrollment, patients must be \\>4 wks since major surgery, radiotherapy, chemotherapy (\\> or =6 wks if they were treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab), immunotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to\\< or = Grade 1, exclusive of alopecia. Concurrent cancer therapy is not permitted. (In patients who received long acting agents, a treatment-free interval of 2 half-lives should be considered.)\n",
            "- [NCT00431275] Recovered from all prior surgical or adjuvant treatment-related toxicities\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 101\n",
            "- [NCT00050141] Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n",
            "- [NCT00071981] Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n",
            "- [NCT00087477] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "- [NCT00104884] Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n",
            "- [NCT00281697] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 102\n",
            "- [NCT00051103] Signed informed consent\n",
            "- [NCT00123253] Signed informed consent\n",
            "- [NCT00155259] Signed informed consent\n",
            "- [NCT00202241] signed informed consent\n",
            "- [NCT00211133] Must have signed an informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 103\n",
            "- [NCT00051103] Tumor tissue available for testing.\n",
            "- [NCT00198237] Pre-treatment core or incisional bx w/ adequate tissue for histology \\& genomic/proteomic analysis.\n",
            "- [NCT00235235] Disease amenable to pre-treatment core or incisional biopsy with adequate tissue for histology and genomic/proteomic analysis.\n",
            "- [NCT00293865] Previous conservative surgical biopsy\n",
            "- [NCT00323206] Patients must have a minimum of two eligible tumors and may have up to four eligible tumors treated with electroporation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 104\n",
            "- [NCT00051103] Adequate bone marrow function\n",
            "- [NCT00087776] Patients must have adequate bone marrow function.\n",
            "- [NCT00191243] adequate bone marrow reserve defined\n",
            "- [NCT00430105] red cell casts.\n",
            "- [NCT00650910] Adequate bone marrow function.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 105\n",
            "- [NCT00071981] No disease progression in the brain for the past 3 months\n",
            "- [NCT00257530] \\>4 weeks time disease\n",
            "- [NCT00317980] Disease duration of 2 to 20 weeks\n",
            "- [NCT00321178] Disease duration no longer than six months\n",
            "- [NCT00379431] Disease duration less than 4 years (from the appearance of skin changes (oedema, fibrosis)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 106\n",
            "- [NCT00071981] Adequate organ function measured within 4 weeks before randomization:\n",
            "- [NCT00455312] Requirement for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or erythropoietin, or\n",
            "- [NCT00471887] Adequate bone marrow and hepatic function determined within 30 days prior to enrollment, defined as:\n",
            "- [NCT00483223] Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol\n",
            "- [NCT00618826] Patients must have adequate bone marrow reserve as evidenced by the following: ANC \\> 1500/mcL, platelets \\> 100, 000/mcL, and hemoglobin \\> 9.0 gm/dL. These results must be obtained within 28 days prior to registration.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 107\n",
            "- [NCT00071981] Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) no greater than 2 times upper limit of normal (ULN)\n",
            "- [NCT00206492] liver transaminases within 2.5 x ULN,\n",
            "- [NCT00217672] Alkaline phosphatase (AP) normal AND Angiotensin Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN) or AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN or AP ≤ 5 times ULN AND AST or ALT normal. Exclusion Criteria\n",
            "- [NCT00254592] Patients must have a serum creatinine and bilirubin ≤ the institutional upper limit of normal, and an serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.\n",
            "- [NCT00404066] Aspartate aminotransferase (AST); alanine aminotransferase (ALT); and alkaline phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 108\n",
            "- [NCT00071981] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00074308] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00087373] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n",
            "- [NCT00087477] Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity. Localized palliative radiation therapy to non-target lesions is permitted within the four weeks prior to randomization.\n",
            "- [NCT00109005] Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate aminotransferase (AST) less than 10 x upper limit of normal. 6. Patients must have recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified above. 7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation therapy, or biological therapy, for at least 4 weeks prior to starting study medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy. 8. Patients must not have an acute, critical illness, including a serious untreated infection. 9. Patients must be willing to return to the National Institutes of Health (NIH) for follow-up visits. 10. All patients who are sexually active and able to conceive will be required to use contraception during treatment with lenalidomide. Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women of child bearing potential will be required to use two methods of birth control, one highly effective method and one additional method, at the same time during treatment and for one month after the completion of lenalidomide treatment. These methods must be used for at least four weeks before starting lenalidomide, during treatment, and for at least four weeks following the last dose of lenalidomide. Acceptable forms of birth control include: Intrauterine device (IUD) Latex condom Hormonal (Birth control pills, injections, implants) Diaphragm Tubal Ligation Cervical cap Partner's vasectomy Two barrier methods may be used if the physician agrees that the highly effective methods are medically contraindicated. Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the start of lenalidomide. Men who are sexually active must agree to use latex condoms. Patients must be able to understand and sign informed consent form. Patients must be greater than or equal to 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 109\n",
            "- [NCT00074308] Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)\n",
            "- [NCT00155259] Women with histological proven LABC, without metastasis, and no prior therapy. LABC is defined as follows： 1. Tumor more than 5 cm in diameter 2. Tumor involvement of chest wall (ribs or intercostals or serratus anterior muscles) or skin (ipsilateral cutaneous edema, ulceration, or satellite nodules) 3. Clinical evident inflammatory carcinoma 4. Ipsilateral fixed axillary adenopathy\n",
            "- [NCT00237185] Men and non-pregnant women ≥18 years of age with the histopathologically documented diagnosis of malignant GIST that was unresectable and/or metastatic. Confirmation of KIT (CD117) expression via immunohistochemical analysis of tumor sample was also required\n",
            "- [NCT00240682] Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression.\n",
            "- [NCT00526617] Evaluable disease, histologically confirmed malignancy (metastatic or unresectable) and standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 110\n",
            "- [NCT00074308] No history of bleeding diathesis or coagulopathy\n",
            "- [NCT00074308] No recent or concurrent full-dose anticoagulants (except as required to maintain patency of preexisting permanent indwelling IV catheters) or thrombolytic agent\n",
            "- [NCT00077363] Because of the potential for a drug interaction between warfarin and both tipifarnib and capecitabine, patients taking warfarin adjusted to an elevated INR are not eligible; patients taking prophylactic low-dose warfarin (i.e., 1 mg daily) are eligible, but a PT and INR are required within 2 weeks of registration and must be normal\n",
            "- [NCT00087373] No uncontrolled bleeding disorder that would increase the risk of bleeding from the injected lesion\n",
            "- [NCT00087373] No active thrombotic thrombocytopenic purpura within the past 2 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 111\n",
            "- [NCT00074308] Grade II or greater peripheral vascular disease\n",
            "- [NCT00074308] Other arterial thromboembolic event\n",
            "- [NCT00161291] No history of thrombosis during the previous year.\n",
            "- [NCT00217672] Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (\\> grade 2) peripheral vascular disease\n",
            "- [NCT00255762] No clinically significant peripheral vascular disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 112\n",
            "- [NCT00074308] Transient ischemic attack\n",
            "- [NCT00074308] Cerebrovascular accident\n",
            "- [NCT00255762] No clinically significant stroke within the past 6 months\n",
            "- [NCT00369655] Cerebrovascular accident or stroke within the past 6 months\n",
            "- [NCT01005472] Cerebrovascular accident or transient ischemic attack\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 113\n",
            "- [NCT00074308] No seizures not controlled with standard medical therapy\n",
            "- [NCT00087373] No active seizure disorder\n",
            "- [NCT00255762] No uncontrolled seizures\n",
            "- [NCT00436605] Uncontrolled seizure disorder\n",
            "- [NCT01233505] Patients who have active seizures or history of seizures are ineligible\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 114\n",
            "- [NCT00074308] No serious, nonhealing wound, ulcer, or bone fracture\n",
            "- [NCT00087373] No skin disease and/or open unhealing wounds\n",
            "- [NCT00091819] infected burn (see exclusion criteria for important qualifications)\n",
            "- [NCT00091819] wound infections\n",
            "- [NCT00107978] infected burn (see exclusion criteria for important qualifications);\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 115\n",
            "- [NCT00074308] No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)\n",
            "- [NCT00436605] More than 7 days since prior and no concurrent CYP3A4 inhibitors\n",
            "- [NCT00436605] No concurrent CYP3A4 inducers\n",
            "- [NCT00667121] Willing to avoid known inhibitors of the CYP2D6 system for duration of study\n",
            "- [NCT01005472] treatment with potent CYP3A4 inhibitors 7 days before study dosing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 116\n",
            "- [NCT00077363] ECOG performance status 0-2\n",
            "- [NCT00083239] ECOG Performance Status of 0, 1, or 2\n",
            "- [NCT00146562] ECOG performance status 0 or 1\n",
            "- [NCT00146601] ECOG performance status 0-2\n",
            "- [NCT00225056] ECOG of 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 117\n",
            "- [NCT00077363] No prior radiotherapy other than to the conserved breast, to the postmastectomy chest wall or to a limited field involving less than 25% of marrow - containing bone\n",
            "- [NCT00171340] Recent surgery for breast cancer\n",
            "- [NCT00262834] No prior radiotherapy to the ipsilateral breast\n",
            "- [NCT00262834] No prior or concurrent radiotherapy for breast cancer\n",
            "- [NCT00894712] Patients must not have received prior radiation therapy to the breast.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 118\n",
            "- [NCT00083239] Expected survival ≥12 weeks\n",
            "- [NCT00304460] Expected survival greater than three months.\n",
            "- [NCT00306553] Expected survival of at least 6 months.\n",
            "- [NCT00349934] Expected survival longer than three months.\n",
            "- [NCT00356460] Expected survival ≥5 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 119\n",
            "- [NCT00087373] No active autoimmune disorders or disease\n",
            "- [NCT00610857] Patients must not have autoimmune disorders (except vitiligo). Patients with positive titers for autoimmune antibodies are allowed on the study in the absence of history of clinical manifestations of autoimmune disease.\n",
            "- [NCT00753415] Participant has undergone splenectomy or has any history of autoimmune disorder.\n",
            "- [NCT00753415] Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.\n",
            "- [NCT01543126] There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 120\n",
            "- [NCT00087373] Children \\< 3 years of age\n",
            "- [NCT00123253] Ages 18 to 65 years inclusive\n",
            "- [NCT00191815] You are female in the age of 18 to 75 years old.\n",
            "- [NCT00795951] Children and adolescents 6 to 18 years of age, and in general good health.\n",
            "- [NCT00979745] Aged 18 - 70 years (inclusive)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 121\n",
            "- [NCT00087776] Patients must have Eastern Cooperative Oncology Group performance status of 0 - 2.\n",
            "- [NCT00574145] Eastern Cooperative Oncology Group performance status of 0, 1 or 2\n",
            "- [NCT01052142] Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n",
            "- [NCT01220128] Eastern Cooperative Oncology Group (performance status of 0 or 1 at the time of study treatment allocation.\n",
            "- [NCT01344109] Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at initiation of study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 122\n",
            "- [NCT00094003] Life expectancy \\> 3 months\n",
            "- [NCT00240682] Life expectancy \\> 3 months.\n",
            "- [NCT00369655] Life expectancy \\> 3 months\n",
            "- [NCT00431704] Life expectancy \\>3 months\n",
            "- [NCT00436605] Life expectancy \\> 3 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 123\n",
            "- [NCT00094003] ECOG performance status: 0-1\n",
            "- [NCT00121134] ECOG performance status 0-1\n",
            "- [NCT00198237] ECOG performance status 0-1\n",
            "- [NCT00217672] ECOG performance status 0-1\n",
            "- [NCT00369655] ECOG performance status 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 124\n",
            "- [NCT00094003] Serum calcium \\<11 mg/dL\n",
            "- [NCT00324259] Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.\n",
            "- [NCT00526617] Normal sodium, calcium and magnesium levels\n",
            "- [NCT00650910] Potassium and magnesium within the normal range of institutional values. \\[Serum potassium or magnesium values that fall outside the normal range may be repeated once at the discretion of the investigator, provided they are considered to be clinically insignificant.\\]\n",
            "- [NCT00777335] Biochemistry\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 125\n",
            "- [NCT00094003] Amylase and lipase ≤ ULN\n",
            "- [NCT01782508] Amylase and lipase \\< 1.5 x ULN\n",
            "- [NCT02272998] Serum lipase and amylase =\\< 1.5 x ULN\n",
            "- [NCT02303951] Amylase and lipase ≤ 1.5 x ULN\n",
            "- [NCT02519322] Lipase \\< 1.5 X ULN (within 28 days of first study treatment)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 126\n",
            "- [NCT00098358] Moderate to severe facial acne vulgaris\n",
            "- [NCT00098358] 20 to 60 facial inflammatory lesions\n",
            "- [NCT00098358] 10 to 200 facial non-inflammatory lesions\n",
            "- [NCT00098358] No more than 3 facial nodular cystic lesions\n",
            "- [NCT00126399] 10 to 40 papules and pustules and ≤2 nodules\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 127\n",
            "- [NCT00104884] Normal organ and marrow function\n",
            "- [NCT00470301] Normal organ function including:\n",
            "- [NCT00546156] Normal organ function as outlined in the protocol\n",
            "- [NCT00580333] Normal organ function as described in the protocol\n",
            "- [NCT00627978] Patients must have normal organ and marrow function as defined below:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 128\n",
            "- [NCT00106184] Adults with definite or probable dermatomyositis or polymyositis and pediatric patients five years of age and over with definite or probable juvenile dermatomyositis (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e., first symptom of myositis or dermatomyositis rash) is less 18 years of age\n",
            "- [NCT00106184] Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test) score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the following criteria: 1. An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. OR 2. If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at least 3 abnormal core set measures.\n",
            "- [NCT01734369] for myositis subjects are: -Diagnosis of PM, DM or IBM during military service. Subjects may be active duty or no longer active duty personnel. A matrix diagnosis of myositis will be based on ICD-9 codes, laboratory tests and medical records in an attempt to match criteria for probable or definite PM, DM or IBM The inclusion criteria for matched control subjects are: -The same gender, race, age within 10 years, and service in the military within 10 years as the myositis subject. The exclusion criteria for control subjects are: -A matrix diagnosis of autoimmune or chronic muscle disease based on ICD-9 codes and medical records. For Aims 2 and 3 of the study: The inclusion criteria for enrollment of myositis subjects are:\n",
            "- [NCT01734369] Diagnosis of myositis during military service or service as a military contractor or civilian working for the military, based on criteria for probable or definite PM or DM, or clinically or pathologically defined or possible IBM. Subjects may be active duty or no longer active duty personnel. Military contractors or civilians working for the military include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998 and developed myositis will be eligible for this study.\n",
            "- [NCT01734369] Persons with military experience or having served as a military contractor or civilian working for the military attending the same clinic or hospital as the myositis subject to which they are matched, or if not available, volunteers from the general community (such as other participating military or VA hospitals, private HCPs, or the NIH healthy volunteer program), gender- race- and age- (within 10 years) and military service period (within 10 years) matched to the myositis subject. Military contractors include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 129\n",
            "- [NCT00119158] Clinical diagnosis of (Atopic Dermatitis) AD according to the American Academy of Dermatology (AAD) Consensus Conference (2001)\n",
            "- [NCT00257582] Eczema \\& dermatitis group\n",
            "- [NCT00257582] Atopic dermatitis\n",
            "- [NCT00267826] Must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin and Rajka and having active inflammation.\n",
            "- [NCT00346398] Diagnosed with eczema (atopic dermatitis)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 130\n",
            "- [NCT00119158] Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or\n",
            "- [NCT00462280] For women of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she:\n",
            "- [NCT00479674] No reproductive potential:\n",
            "- [NCT00563524] Men and Women of nonchildbearing potential 18 years or older.\n",
            "- [NCT00583739] Women of childbearing potential are eligible for this study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 131\n",
            "- [NCT00119405] Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI\n",
            "- [NCT01033552] UCB\n",
            "- [NCT01889238] Advanced AR+ TNBC;\n",
            "- [NCT01957514] Subjects have metastatic TNBC\n",
            "- [NCT02214381] All TN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 132\n",
            "- [NCT00121511] Patients must have actinic keratoses\n",
            "- [NCT00308854] Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on head and/or face (hairless areas)\n",
            "- [NCT00335179] Have actinic keratoses on balding scalp\n",
            "- [NCT00601640] No more than 10 actinic keratoses on the left forearm, and no actinic keratoses in the treatment area\n",
            "- [NCT00991861] At least 4-10 clinically assessed actinic keratosis grade I to II (according to Olsen et al, 1991) in the face/forehead and/or on the bald scalp\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 133\n",
            "- [NCT00126399] Healthy patients with rosacea\n",
            "- [NCT00989014] Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea.\n",
            "- [NCT01016782] Clinical diagnosis of rosacea\n",
            "- [NCT01016782] Good health with the exception of rosacea\n",
            "- [NCT01359228] \\> 18 years of age with rosacea defined as:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 134\n",
            "- [NCT00126399] Score of 2 to 4 on the IGA\n",
            "- [NCT00143052] Hirsute score: \\>7\n",
            "- [NCT00143052] Hirsute score: 0 (without razing)\n",
            "- [NCT00177840] Average to above average fatigue\n",
            "- [NCT00192517] PASI score greater than 12\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 135\n",
            "- [NCT00126724] Rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) diagnosed according to established criteria.\n",
            "- [NCT00265096] Psoriatic arthritis (PsA) diagnosed \\> 6months prior\n",
            "- [NCT00265096] Active PsA at the time of screening and at baseline visits, with \\>= 3 swollen joints and \\>= 3 tender joints\n",
            "- [NCT00265096] Have at least 1 of the PsA subsets (DIP joint arthritis, polyarticular arthritis without rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis)\n",
            "- [NCT00456092] Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or asymmetrical peripheral joint involvement for at least 6 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 136\n",
            "- [NCT00126724] Persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory arthritis in at least one peripheral joint eligible for injection.\n",
            "- [NCT01169844] The number of tender joints was the same or more than the core study baseline; or,\n",
            "- [NCT01169844] The number of swollen joints was the same or more than the core study baseline; or,\n",
            "- [NCT01877668] Must have 3 or more swollen joints AND 3 or more tender joints\n",
            "- [NCT02047851] Pain from at least two peripheral joints and/or inflammatory back pain\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 137\n",
            "- [NCT00126724] For subjects with RA, an adequate trial of at least one disease-modifying drug (DMARD) prior to screening.\n",
            "- [NCT00126724] For subjects currently on DMARD(s), a stable regimen of inflammatory arthritis for the previous three months, with no changes in doses four weeks prior to screening.\n",
            "- [NCT00265096] Active arthritis despite current disease modifying anti-rheumatic drug (DMARD) or nonsteroidal anti-inflammatory drug (NSAID) therapy\n",
            "- [NCT01877668] Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).\n",
            "- [NCT02181673] Have active PsA despite current or previous disease-modifying antirheumatic drugs (DMARD) and/or nonsteroidal anti-inflammatory drug (NSAID) therapy. DMARD therapy is defined as taking a DMARD for at least 3 months, or evidence of DMARD intolerance. NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of NSAID intolerance\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 138\n",
            "- [NCT00126724] Age greater than 18 years and less than 75 years at the time of screening.\n",
            "- [NCT01026051] 18 years of age or older at screening evaluation\n",
            "- [NCT01220128] The patient is ≥ 18 years of age at the time the informed consent to screening has been obtained.\n",
            "- [NCT01689285] Subject is at least 18 and not older than 55 years of age at screening.\n",
            "- [NCT01971346] At least 18 years of age at screening.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 139\n",
            "- [NCT00133315] Age\\>18 years old\n",
            "- [NCT00197912] Age: \\> 18\n",
            "- [NCT00268125] Age \\> 18 years\n",
            "- [NCT00293865] Age \\> 18 years\n",
            "- [NCT00323206] Age \\> 18 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 140\n",
            "- [NCT00133315] No signs of tuberculosis (TB)\n",
            "- [NCT00134368] Subjects must have a negative tuberculin (TB) skin test at entry into the study\n",
            "- [NCT00307437] Have no history of latent or active tuberculosis (TB)\n",
            "- [NCT00640393] Patient with negative purified protein derivative (PPD) within 3 months of Day 0;\n",
            "- [NCT00687401] Eligible according to tuberculosis (TB) eligibility assessment, screening and early detection of reactivation rules.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 141\n",
            "- [NCT00133341] Signed informed consent.\n",
            "- [NCT00548184] Signed informed consent.\n",
            "- [NCT00691678] Signed informed consent.\n",
            "- [NCT00717015] Signed informed consent.\n",
            "- [NCT00941330] Signed informed consent.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 142\n",
            "- [NCT00134368] Vitiligo patients aged 18 years and older\n",
            "- [NCT00134368] Vitiligo patients with evaluable lesions; duration of 3 months to 10 years.\n",
            "- [NCT00631865] Stable form of vitiligo (no increase in the size of the lesion for at least one year)\n",
            "- [NCT00907062] self selected candidates identifying themselves to suffer with vitiligo vulgaris of any duration\n",
            "- [NCT00907062] stable or progressing vitiligo\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 143\n",
            "- [NCT00134368] Disease interferes significantly with quality of life and/or involving 3% or more body surface area\n",
            "- [NCT00707070] PASI \\> 10 e/o BSA (Body Surface Area) \\> 10\n",
            "- [NCT00927212] Diseased Body surface area (BSA) ≤ 20%.\n",
            "- [NCT01049243] Percentage of overall body surface are of involvement (BSA) must be ≥2%\n",
            "- [NCT01093469] Percentage of overall body surface area of involvement (BSA) must be \\> 1% and may include facial and intertriginous skin.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 144\n",
            "- [NCT00135720] Have a clinical diagnosis of pemphigus vulgaris\n",
            "- [NCT00135720] Have at least 6 active pemphigus lesions (blisters or erosions)\n",
            "- [NCT00135720] Have no adverse effects due to combining etanercept with concurrent pemphigus medications\n",
            "- [NCT00135720] Be on stable dose of current pemphigus medications for at least one month\n",
            "- [NCT00431119] clinical lesions suggestive of bullous pemphigoid\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 145\n",
            "- [NCT00143052] Hirsute subjects:\n",
            "- [NCT00355485] Subjects must be in generally good health.\n",
            "- [NCT00839280] Healthy subjects\n",
            "- [NCT01422538] Subject in good health.\n",
            "- [NCT01519206] Subject in good health\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 146\n",
            "- [NCT00146562] 18 years of age or older\n",
            "- [NCT00202241] 18 years of age or older\n",
            "- [NCT00483223] 18 years of age or older\n",
            "- [NCT00546156] 18 year of age or older\n",
            "- [NCT00580333] 18 years of age or older\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 147\n",
            "- [NCT00150917] live within one hour of downtown Toronto\n",
            "- [NCT00198250] living within 60 miles of Indianapolis\n",
            "- [NCT00286598] Residence within 50 miles of Columbia, MO\n",
            "- [NCT00601640] Resident of Pima or an adjoining Southern Arizona county\n",
            "- [NCT01174875] Singapore citizens or Singapore Permanent Residents\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 148\n",
            "- [NCT00157079] Subjects \\> 24 months of age\n",
            "- [NCT00256230] Subjects must be between the ages of 18 and 80.\n",
            "- [NCT00346606] The subject ≥ 12 years old.\n",
            "- [NCT00366132] Subjects age \\> 18 years;\n",
            "- [NCT00385502] Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 149\n",
            "- [NCT00175344] Patients must be able to provide informed consent and be physically able to perform daily self-administered breast scar massage\n",
            "- [NCT00179634] Skin sparing mastectomy with transverse rectus abdominal muscle (TRAM) or deep inferior epigastric perforator (DIEP) flap reconstruction planned\n",
            "- [NCT00201929] Candidate for breast conserving surgery\n",
            "- [NCT00455533] Unfit for breast and/or axillary surgery\n",
            "- [NCT00499681] Scheduled to undergo surgical treatment with either segmental resection or total mastectomy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 150\n",
            "- [NCT00176969] Must have alopecia totalis or universalis.\n",
            "- [NCT00176969] Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.\n",
            "- [NCT00746980] clinical diagnosis of alopecia totalis, alopecia universalis, or severe ophiasis variant of alopecia areata.\n",
            "- [NCT01008774] Absence of alopecia at inclusion\n",
            "- [NCT01203189] Practice less than or equal to once weekly hair washing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 151\n",
            "- [NCT00176969] Be in good health.\n",
            "- [NCT00427609] With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.\n",
            "- [NCT00467233] Good health.\n",
            "- [NCT00509977] Good health.\n",
            "- [NCT00540917] apparent good health\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 152\n",
            "- [NCT00178126] Braden score of 18 or less\n",
            "- [NCT00178126] combined activity and mobility Braden sub-score of 5 or less\n",
            "- [NCT01333670] Braden index at baseline\\>=10\n",
            "- [NCT02363842] Deemed at risk for tissue breakdown by clinical staff via an institutional assessment protocol such as the Braden Scale, the Waterlow Scale or the Norton Scale.\n",
            "- [NCT03351049] total Braden Score \\<= 18\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 153\n",
            "- [NCT00190697] Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia).\n",
            "- [NCT00193037] Adequate bone marrow, liver and kidney function\n",
            "- [NCT00378313] Evidence of adequate organ function (liver, bone marrow, kidney)\n",
            "- [NCT00383851] Patients must have adequate organ and marrow function as defined below:\n",
            "- [NCT00704158] Adequate bone marrow, renal and liver function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 154\n",
            "- [NCT00192517] Plaque psoriasis involving at least 10% of body surface area (Appendix A)\n",
            "- [NCT00192517] Currently receiving no therapy for psoriasis except emollients\n",
            "- [NCT00245960] Clinically stable, plaque psoriasis involving more than 10% of the body surface area\n",
            "- [NCT00265096] Active plaque psoriasis with a lesion \\>= 2cm in diameter\n",
            "- [NCT00307437] Plaque-type psoriasis diagnosed \\>= 6 months prior\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 155\n",
            "- [NCT00201929] Female\n",
            "- [NCT00268125] Woman\n",
            "- [NCT00404066] Female\n",
            "- [NCT00513058] Female\n",
            "- [NCT00653718] Female\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 156\n",
            "- [NCT00204529] Informed consent\n",
            "- [NCT00204581] Informed consent\n",
            "- [NCT00257582] Giving informed consent\n",
            "- [NCT00388115] Informed consent given.\n",
            "- [NCT00689832] Informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 157\n",
            "- [NCT00206492] Hematocrit \\>30%,\n",
            "- [NCT00456092] Hematocrit ≥ 27%\n",
            "- [NCT00544765] Hematology:\n",
            "- [NCT00712621] Not specified Hematopoietic:\n",
            "- [NCT00777335] Hematology\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 158\n",
            "- [NCT00213460] patients with systemic sclerosis, who had an upper intestinal tract manometry 5 years before, with:\n",
            "- [NCT00213525] patients with scleroderma with:\n",
            "- [NCT00251238] Primary Raynaud´s phenomenon\n",
            "- [NCT00251238] Duration of Raynaud´s phenomenon at least 2 years\n",
            "- [NCT00253331] clinical diagnosis of Raynaud's phenomenon\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 159\n",
            "- [NCT00217672] Required laboratory values\n",
            "- [NCT00359190] Clinical labs are within acceptable ranges.\n",
            "- [NCT00442260] Normal laboratory values as explained below.\n",
            "- [NCT00456092] Must meet the following laboratory criteria:\n",
            "- [NCT00650910] Clinical lab results with ranges as stated per protocol.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 160\n",
            "- [NCT00217672] Total bilirubin \\< 1.0 x upper limit of normal (ULN) (patients with documents Gilbert's syndrome are eligible).\n",
            "- [NCT00258349] Bilirubin =\\< 1.5 mg/dL (3 mg/dL in the presence of Gilbert's disease provided direct bilirubin is normal)\n",
            "- [NCT00304460] Serum creatinine less than or equal to 1.4 mg/dl or creatinine clearance greater than or equal to 90 mL/min, and total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.\n",
            "- [NCT00349934] Total bilirubin \\< 20 mmol/L, except for familial cholemia (Gilbert's disease).\n",
            "- [NCT00471887] Total bilirubin \\< 2 x ULN (except patients with documented Gilbert's syndrome)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 161\n",
            "- [NCT00221221] willing to accept random assignment.\n",
            "- [NCT00513136] Willing to be randomized\n",
            "- [NCT00945607] Willingness to complete CSES, PSS-14 and FACIT-F scales\n",
            "- [NCT01275872] Willing to participate\n",
            "- [NCT01751893] Willing to participate\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 162\n",
            "- [NCT00221221] not currently participating in another QoL intervention.\n",
            "- [NCT01613482] Inclusion in an other clinical trial or in the 4 weeks before th inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT02799121] The patient agrees to abstain from enrolment in any other interventional clinical trial for the duration of the study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 163\n",
            "- [NCT00225056] must have adequate organ function\n",
            "- [NCT00237198] Patients with sufficient organ function to evaluate the safety\n",
            "- [NCT00320541] Must have adequate organ function as seen in blood test results. Exclusion Criteria:\n",
            "- [NCT00386685] Adequate organs functions\n",
            "- [NCT00496366] Adequate end organ function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 164\n",
            "- [NCT00225056] must be at least 19 years of age\n",
            "- [NCT00267826] Must be at least 18 years of age.\n",
            "- [NCT00270569] Age must be older than 18 and younger than 75 year-old.\n",
            "- [NCT00673829] Must be 18 years of age or older\n",
            "- [NCT00791557] Must Be ages 18-75\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 165\n",
            "- [NCT00226174] Patients presenting to the UCSF oral medicine clinic with oral lichen planus confirmed by biopsy. Patients with either the atrophic or the erosive form of oral lichen planus were eligible.\n",
            "- [NCT00297037] With a diagnosis of oral lichen planus previously proven on biopsy.\n",
            "- [NCT00455312] A triad of mucocutaneous features: oral leukoplakia, nail dystrophy, abnormal reticular skin hyperpigmentation.\n",
            "- [NCT00542373] Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)\n",
            "- [NCT00542373] Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 166\n",
            "- [NCT00240682] ECOG Performance status \\< 2.\n",
            "- [NCT00277160] ECOG performance status \\</=2\n",
            "- [NCT00304460] ECOG less than 2.\n",
            "- [NCT00518895] ECOG performance status ≤ 1\n",
            "- [NCT00661531] Ecog performance status \\</= 2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 167\n",
            "- [NCT00240682] Age \\> 18 years.\n",
            "- [NCT00284180] Age \\>18 years.\n",
            "- [NCT00544765] Age \\> 18 years.\n",
            "- [NCT00691678] Age \\>21 years.\n",
            "- [NCT00991978] Age \\> 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 168\n",
            "- [NCT00255762] No known esophageal varices\n",
            "- [NCT01522820] Esophageal: resected patients with any nodal (i.e., thoracic or abdominal) disease; and patients with residual disease on imaging after definitive chemoradiation therapy\n",
            "- [NCT03475953] or esophageal or gastric carcinoma (cohort C),\n",
            "- [NCT03924466] adenocarcinoma of the gastric body or gastro-esophageal junction\n",
            "- [NCT04032704] Cohort 5: esophageal-squamous (Parts A and B)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 169\n",
            "- [NCT00006412] Have gall bladder disease or symptoms within 3 months prior to study entry or symptoms of gallstones.\n",
            "- [NCT00091819] major abscess requiring surgical incision and drainage\n",
            "- [NCT00107978] major abscess requiring surgical incision and drainage;\n",
            "- [NCT00217672] Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning therapy\n",
            "- [NCT00255762] No history of abdominal fistula\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 170\n",
            "- [NCT00021463] Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).\n",
            "- [NCT00255762] VEGF Trap\n",
            "- [NCT00255762] Anti-VEGF receptor monoclonal antibody\n",
            "- [NCT00255762] Small molecular tyrosine kinase inhibitors of VEGF receptors\n",
            "- [NCT00369655] No history of lung carcinoma of squamous cell type\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 171\n",
            "- [NCT00257582] Chronic urticaria\n",
            "- [NCT00346606] The subject with documented signs and symptoms of CIU for 6 weeks or more.\n",
            "- [NCT00346606] The subject has to have a CIU flare for 3 weeks or more before screening, with urticarial lesions visible 3 days or more per week.\n",
            "- [NCT00346606] The overall severities of CIU have to be at least mild to moderate at screening and baseline, subjects have to have at least mild to moderate pruritus, hives have to be apparent at screening, and subjects have intention to treatment.\n",
            "- [NCT00385372] chronic urticaria (duration: at least 6 weeks)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 172\n",
            "- [NCT00257582] Prurigo group: Acute prurigo, Prurigo subacuta, Chronic prurigo\n",
            "- [NCT00257582] Pruritus cutaneous: Systemic pruritus cutaneous, Topical pruritus cutaneous\n",
            "- [NCT00257582] Children who have 2 grades or more pruritus score when assessed by the investigator or sub-investigator with the criteria for the diurnal or nocturnal pruritus score in the patient diary.\n",
            "- [NCT00257582] Children with a pruritus severity of \"2.Mild\" or severer on the first day of the treatment period.\n",
            "- [NCT00715260] Patients who have \"mild\", \"moderate\" or \"severe\" pruritus;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 173\n",
            "- [NCT00262301] Clear clinical and laboratory diagnosis of HAE\n",
            "- [NCT00262301] Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack\n",
            "- [NCT00438815] Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or\n",
            "- [NCT00438815] Had a known HAE-causing C1INH mutation, or\n",
            "- [NCT00438815] Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 174\n",
            "- [NCT00268125] Patient affiliated at a welfare or beneficiary from it\n",
            "- [NCT00513058] Patients must be affiliated with a Social Security system\n",
            "- [NCT00555061] French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category\n",
            "- [NCT00905281] Patient affiliated with social security\n",
            "- [NCT01262469] Patients must be affiliated to a Social Security System\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 175\n",
            "- [NCT00277160] \\>/= 65 years old\n",
            "- [NCT00448305] Age \\>= 18 years old\n",
            "- [NCT00713154] is \\>/= 18 years of age\n",
            "- [NCT01344109] Age \\>/= 18 years old\n",
            "- [NCT01583426] Age \\>= 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 176\n",
            "- [NCT00281697] ≥ 18 years of age.\n",
            "- [NCT00450762] Age ≥ 18 years\n",
            "- [NCT00496366] Age ³ 18 years of age\n",
            "- [NCT00683670] Age ≥ 18 years\n",
            "- [NCT00704158] Age ≥ 18 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 177\n",
            "- [NCT00286598] Functioning telephone service\n",
            "- [NCT00945607] Access to a CD player\n",
            "- [NCT01108315] Has access to either a phone or the internet\n",
            "- [NCT01450020] Owns an operational vehicle\n",
            "- [NCT01450020] Has access to a personal computer with internet access\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 178\n",
            "- [NCT00121511] Subjects must be willing and able to comply with the requirements of the protocol.\n",
            "- [NCT00306553] Able and willing to complete all protocol requirements.\n",
            "- [NCT00403559] Must be wiling and able to comply with protocol.\n",
            "- [NCT00688272] The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria\n",
            "- [NCT00991978] Able to comply with the protocol.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 179\n",
            "- [NCT00306553] Wash-out period of 4 weeks after chemotherapy\n",
            "- [NCT00356642] 14 day washout of current therapy.\n",
            "- [NCT01375101] two weeks wash out periods after the last treatment\n",
            "- [NCT01511315] Washout Period :\n",
            "- [NCT01941537] A washout period from any systemic investigational therapy of at least 90 days.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 180\n",
            "- [NCT00308204] adults 18 to 70 years of age.\n",
            "- [NCT00815282] And who are in the following age groups:\n",
            "- [NCT01045772] Adult (18 years or older)\n",
            "- [NCT01111695] Adult\n",
            "- [NCT01228656] Adults of both sexes, regardless of color or social class;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 181\n",
            "- [NCT00308854] Selected AK study lesions have clearly defined margins and are mild to moderate\n",
            "- [NCT00603798] Have 5 to 20 AKs on the face or balding scalp.\n",
            "- [NCT00859105] Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp\n",
            "- [NCT00942604] 4 to 8 AK lesions on non-head locations.\n",
            "- [NCT00991861] The diameter of each AK target lesion is not less than 0.5 cm and not greater than 1.5 cm\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 182\n",
            "- [NCT00308854] Skin sun sensitivity type I to IV according to Fitzpatrick\n",
            "- [NCT00523588] Fitzpatrick I-III skin type (very fair, fair, or medium skin)\n",
            "- [NCT00688272] Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).\n",
            "- [NCT00719121] Subjects with a phototype III or IV (according to Fitzpatrick classification)\n",
            "- [NCT00839280] Phototype: I to IV according to Fitzpatrick scale\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 183\n",
            "- [NCT00315393] Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA and MPA.\n",
            "- [NCT00315393] For diagnosis of GPA, meets at least 2 of the following 5 modified American College of Rheumatology (ACR) criteria: 1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood 2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities 3. Urinary sediment with microhematuria or red cell casts 4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy 5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA\n",
            "- [NCT00315393] For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA: 1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles) 2. Necrotizing arteritis involving small- and medium-sized arteries may be present 3. Necrotizing glomerulonephritis is very common 4. Pulmonary capillaritis often occurs\n",
            "- [NCT00430105] A new diagnosis of WG, MP or renal-limited vasculitis (RLV) (appendix 5). Patients not previously treated with cytotoxic drugs will be permitted. 2. Renal involvement attributable to active WG, MP or RLV with at least one of the following:\n",
            "- [NCT00430105] haematuria with \\>30 red blood cells/high powered field and proteinuria \\> 1g/24hr. 3. ANCA positivity or confirmatory histology or both (appendix 5). ANCA positivity requires a typical CANCA pattern by indirect immunofluorescence (IIF), (preferably confirmed by anti-PR3 ELISA), or the presence of PR3-ANCA or MPO-ANCA determined by ELISA, PANCA requires confirmation by anti-MPO ELISA \\[6\\]. (Central review of ANCA serology and histology will be performed). 4. Age 18-80 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 184\n",
            "- [NCT00321178] At least 5 years of age\n",
            "- [NCT00359190] At least 18 years of age.\n",
            "- [NCT00389402] At least 18 years of age.\n",
            "- [NCT00548184] Age at least 18 years.\n",
            "- [NCT00612742] at least 50 years of age\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 185\n",
            "- [NCT00121511] Subjects must be in generally good health and willing to undergo skin biopsies from the face.\n",
            "- [NCT00335179] Discontinuation of tanning bed use\n",
            "- [NCT00420173] photoprovocation-test performed in advance\n",
            "- [NCT00469183] Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits.\n",
            "- [NCT00601640] Visible sun-induced damage to the skin as assessed by the study dermatologists\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 186\n",
            "- [NCT00356460] In Part 1, Dose Escalation: Patients with histologically confirmed, locally advanced \\& surgically inoperable or metastatic renal cell carcinoma or malignant melanoma are eligible.\n",
            "- [NCT01263145] For the dose escalation cohorts, patients must have received front-line, cytotoxic, systemic therapy (combination or single agent, with or without the addition of targeted agents) for advanced cancer\n",
            "- [NCT02857270] Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal adenocarcinoma (dose escalation and dose expansion).\n",
            "- [NCT03475953] Dose escalation part: histologically confirmed non MSI-H or deficient-MMR colorectal cancer, or GIST, or esophageal or gastric carcinoma or hepatobiliary cancers,\n",
            "- [NCT04424641] Dose-escalation part: • Patient with locally advanced or metastatic solid tumor(s) (excluding patients with primary central nervous system \\[CNS\\] tumors), who has experienced disease progression while on standard therapy or is intolerant of, or not eligible for, standard therapy. Expansion part: • Must have an advanced or metastatic, pathologically confirmed diagnosis of one of the following tumors: Uterine Cancer, Prostate Cancer, Esophageal Cancer, TNBC, SCCHN, NSCLC (both adenocarcinoma \\[ACC\\] and squamous cell carcinoma \\[SCC\\], Bladder Cancer. Both parts:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 187\n",
            "- [NCT00359190] Females must meet certain criteria specified in protocol.\n",
            "- [NCT00581256] Both men and women are eligible.\n",
            "- [NCT01081106] Participants must be 18 years old or older\n",
            "- [NCT01081106] Participants must be female\n",
            "- [NCT01120184] Adult participants \\>/=18 years of age\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 188\n",
            "- [NCT00091819] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00107978] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00368537] Clinical diagnosis of complicated skin or skin structure infection\n",
            "- [NCT00463801] Subjects with a diagnosis of complicated skin and skin-structure infections (cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalization and intravenous antimicrobial treatment\n",
            "- [NCT00514527] Complicated skin and skin structure infection, presumed or proven to be caused by gram-positive pathogen(s).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 189\n",
            "- [NCT00379431] Severe disease defined by either one of the following: a modified Rodnan skin score (TSS° \\>= 14 ), disease activity score \\>= 3\n",
            "- [NCT00704665] A baseline modified Rodnan skin score (MRSS) of 20 or greater, or at least 16 if truncal involvement was present.\n",
            "- [NCT00962923] Rapidly progressive disease \\<2 years duration with a modified Rodnan skin score(mRSS) above 20, plus ESR \\>25 mm/first h and/or Hb \\<11 g/dL, not explained by other causes than active SSc\n",
            "- [NCT01532869] \\>/= 15 and \\</= 40 mRSS units at screening\n",
            "- [NCT01538719] Must have a MRSS of ≥ 15.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 190\n",
            "- [NCT00379678] Active AD of any severity will be defined according to Hanifin and Rajka clinical criteria (Hanifin, J.M., Rajka, G. 1980)\n",
            "- [NCT00379678] Chronic AD for more than one year duration\n",
            "- [NCT00546000] Subjects meet protocol specific AD signs and symptom severity score\n",
            "- [NCT00753805] A clear and definite diagnosis of AD\n",
            "- [NCT02031445] History of AD for at least 3 months prior to Baseline\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 191\n",
            "- [NCT00383851] Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥50%; see Appendix A)\n",
            "- [NCT00404066] Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 / Karnofsky ≥ 60% at screening and on the first day of treatment.\n",
            "- [NCT00462280] Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky \\> 70%)\n",
            "- [NCT00576654] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2 (Karnofsky \\>= 60%)\n",
            "- [NCT01042535] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1 (Karnofsky \\>= 70%)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 192\n",
            "- [NCT00383851] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00429299] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00576654] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00802932] Ability to understand and the willingness to sign written informed consent document\n",
            "- [NCT01042535] Ability to understand and the willingness to sign a written informed consent document\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 193\n",
            "- [NCT00385502] Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails (\"target toenails\"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum\n",
            "- [NCT00385502] Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.\n",
            "- [NCT00385502] Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 194\n",
            "- [NCT00388115] Core biopsy proven low or intermediate grade DCIS.\n",
            "- [NCT00402519] For DCIS only: lesions must be classified as low or intermediate risk group (Van Nuys Prognostic Index \\<8).\n",
            "- [NCT00455312] Disease Characteristics for DC (both of the following):\n",
            "- [NCT00455312] Diagnosis of DC:\n",
            "- [NCT00669747] Pathological diagnosis of DCIS requiring surgical resection\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 195\n",
            "- [NCT00388115] Multifocal invasive breast cancer patients are eligible. All tumors that are palpable or visualized by USS can be treated.\n",
            "- [NCT01185145] Multifocal findings (define as 2 or more breast quadrants) on MRI scanning should be further evaluated by ultrasound and, if necessary biopsy, to exclude multiquadrant disease.\n",
            "- [NCT01208441] Multifocal disease allowed provided that ≥ 1 of the tumors is \\> 2 cm\n",
            "- [NCT01417286] Multifocal/multicentric disease is allowed\n",
            "- [NCT01583426] In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 196\n",
            "- [NCT00389636] Patients\n",
            "- [NCT00553618] Patients must fulfill one of the following criteria:\n",
            "- [NCT00758862] Patients suffering from SITL must have:\n",
            "- [NCT01068483] All patients:\n",
            "- [NCT01361035] Physician\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 197\n",
            "- [NCT00424749] Renal involvement (\\>25% dysmorphic red cell, red blood cell casts, or pauci-immune glomerulonephritis on biopsy)\n",
            "- [NCT00430105] biopsy demonstrating necrotizing glomerulonephritis.\n",
            "- [NCT00474604] The protocol nurse will check with the patient that there is no h/o kidney disease\n",
            "- [NCT00544765] Renal function:\n",
            "- [NCT00712621] Protein (Albumin, Globulin) Renal:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 198\n",
            "- [NCT00442260] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00583739] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00627978] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00656019] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT01010854] Ability to understand and the willingness to sign a written informed consent document.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 199\n",
            "- [NCT00448305] Histologically proven triple-receptor-negative metastatic or relapsed breast cancer\n",
            "- [NCT00528567] primary tumor centrally confirmed as triple negative.\n",
            "- [NCT01150513] Triple-negative breast cancer\n",
            "- [NCT01467310] Histologically confirmed TNBC (i.e., ER negative, PR negative (each \\<10% staining by immunohistochemistry) and Her2 negative (0-1+ or FISH non-amplified; by clinical assay on primary tumor)\n",
            "- [NCT01617915] if tumor is triple-negative, treatment with DNA-damaging chemotherapy as per standard of care in the first-line setting for advanced/metastatic disease.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 200\n",
            "- [NCT00455312] Patients with early myelodysplastic features.\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) requiring a 2nd transplant\n",
            "- [NCT02162420] Early myelodysplastic features\n",
            "- [NCT02706392] CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody, or who have failed tyrosine kinase or phosphatidylinositol 3 (PI3) kinase inhibitors, or who were not eligible for or declined such therapy; patients with fludarabine refractory disease are eligible\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 201\n",
            "- [NCT00456092] If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for at least 14 days prior to screening and throughout the study\n",
            "- [NCT00601640] No concurrent NSAIDs for more than 14 days per month for arthritic and other pain conditions\n",
            "- [NCT00944918] Relapsed or progressed during prior treatment with single-agent NSAI, meeting either of the following criteria:\n",
            "- [NCT00944918] NSAI given as adjuvant therapy that lasted ≥ 12 months OR\n",
            "- [NCT01752907] Chronic use of oral non-steroidal anti-inflammatory drugs (NSAIDs) or oral antihistamines with the following exception: \\- Chronic oral aspirin use for cardiovascular-related indications\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 202\n",
            "- [NCT00467233] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00467233] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "- [NCT00469183] Subjects must have a clinical diagnosis of moderate to severe melasma\n",
            "- [NCT00509977] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00509977] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 203\n",
            "- [NCT00470301] \\[Note: \\\n",
            "- [NCT00474604] \\\n",
            "- [NCT00526617] \\\n",
            "- [NCT00630032] NOTE: \\\n",
            "- [NCT01689935] \\\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 204\n",
            "- [NCT00491816] Patients must have a serum albumin ≥ 3.0 g/dL\n",
            "- [NCT00777335] Serum albumin ≥ Lower Limit of Normal(LLN) or 30g/L\n",
            "- [NCT00896298] Serum leptin levels less than the 7th percentile of normal values reported by the 3rd National Health and Nutrition Examination survey (less than 7.0 ng/mL in females and less than 3/0 ng/mL in males)\n",
            "- [NCT00962923] digestive tract involvement: with serum albumin ,25 g/L or weight loss exceeding 10% body weight in the preceding year\n",
            "- [NCT01050322] Albumin \\> 2.5 gr /dl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 205\n",
            "- [NCT00492323] Experienced postherpetic neuralgia pain on a daily basis for the past 3 months\n",
            "- [NCT00540969] Worst pain in the last 24 hours must be ≥ 4 on a 0-10 numeric scale\n",
            "- [NCT00588640] Chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical scale from 0-10 during the 24 hours prior to study entry.\n",
            "- [NCT01375101] having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score\n",
            "- [NCT01720602] Patient is willing to continue on same AI therapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 206\n",
            "- [NCT00496795] \"Limited\" distant metastases allowed, but patients with massive distant metastases should be excluded\n",
            "- [NCT01064635] Patients with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastases.\n",
            "- [NCT01264731] No metastasis greater than 2 cm at the time of protocol entry\n",
            "- [NCT01394575] No evidence of distant metastasis\n",
            "- [NCT01503034] No known metastasis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 207\n",
            "- [NCT00502684] ASA score of 1-2\n",
            "- [NCT00519246] ASA I-II\n",
            "- [NCT01055236] ASA classification 1-2\n",
            "- [NCT01185145] Be a Tis, T1, N0, M0 AJC Classification\n",
            "- [NCT01392248] ASA 1-2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 208\n",
            "- [NCT00005949] LDH normal\n",
            "- [NCT00518895] Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal\n",
            "- [NCT00610857] Serum LDH less than or equal to 2.0 x ULN\n",
            "- [NCT01005472] LDH ≤ 5 times ULN\n",
            "- [NCT01055522] LDH \\< 2.0 x ULN for Phase IIa patients and normal LDH for the Phase IIb ones.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 209\n",
            "- [NCT00525096] surgical ovariectomy\n",
            "- [NCT00530868] Bilateral oophorectomy\n",
            "- [NCT00650910] Has had a hysterectomy\n",
            "- [NCT00650910] Has had a bilateral oophorectomy (ovariectomy)\n",
            "- [NCT00650910] Has had a bilateral tubal ligation, or\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 210\n",
            "- [NCT00525096] ovarian suppression by radiotherapy\n",
            "- [NCT00982631] Patients with proven advanced breast cancer, endometrial cancer or ovarian cancer, who are refractory to standard therapies or for whom no standard therapy exists.\n",
            "- [NCT01035099] Ovarian stimulation will not affect cancer treatment plan\n",
            "- [NCT01095848] Patients with stage III or IV ovarian cancer who have completed a course of platinin-based cytotoxic therapy after debulking surgery with evidence of a complete or partial response by radiological imaging. Patients with metastatic ovarian cancer who have stable disease for greater than 3 months after completion of first-line therapy.\n",
            "- [NCT01233505] Any-line metastatic mucinous ovarian cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 211\n",
            "- [NCT00542373] Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease\n",
            "- [NCT01727076] Patients must have histological or cytological confirmed malignancy in the following disease groups: melanoma, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which no standard effective or curative options are available\n",
            "- [NCT02069158] Histological or cytological diagnosis of advanced/metastatic breast, NSCLC, ovarian and endometrial, small cell lung cancer (SCLC) and Head and Neck (HNSCC) cancer for which there is an indication to the use of paclitaxel and carboplatin.\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx is allowed, but these participants will not be included as response-evaluable participants for efficacy analysis of HNSCC.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 212\n",
            "- [NCT00555061] Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy: The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion. The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area. Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.\n",
            "- [NCT00646958] Acceptable clinical diagnoses of uSSSI include, but are not limited to: Simple abscess, Impetiginous lesions, Folliculitis, Furunculosis, Carbuncles, Cellulitis\n",
            "- [NCT01789229] Just one current known malignant disease or just one current inflammatory disease\n",
            "- [NCT01815450] Qualifying number of non-inflammatory lesions\n",
            "- [NCT01815450] Qualifying number of inflammatory lesions\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 213\n",
            "- [NCT00555061] Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must demonstrate their willingness to participate in the study and comply with its procedures by signing an informed consent.\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must understand and be able to adhere to the dosing and visit schedule, and agree to report concomitant medications and adverse events to the Investigator or designee.\n",
            "- [NCT01035099] Willingness to provide follow-up information on herself and babies born as part of this study\n",
            "- [NCT01760850] Children may be present with parents, but will not be included in any research activities, unless they are emancipated minors (under 18 and married)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 214\n",
            "- [NCT00576654] Patients must have histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT00576654] Patients enrolled on the dose escalation for intermittent ABT-888 portion of the study must histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT01111201] Age \\>18 years and current or past history of lymphoma\n",
            "- [NCT01188915] treated for Hodgkin disease\n",
            "- [NCT01929941] Aged 18 years or older, with histologically or cytologically confirmed solid tumor, Hodgkin's lymphoma, aggressive or indolent non-Hodgkin's lymphoma. (NOTE: Patients with acute and chronic leukemia, Burkitt's lymphoma, precursor B lymphoblastic leukemia/lymphoma, and myeloma are excluded)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 215\n",
            "- [NCT00588640] Responsible companion living with patient during study. Phase II only:\n",
            "- [NCT00709176] Family caregivers must be 18 years old or older, physically and mentally able to participate, and speak and understand English.\n",
            "- [NCT02954900] Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital\n",
            "- [NCT03130569] Registered at a University of New Mexico primary care clinic for ≥6 months\n",
            "- [NCT03130569] Assigned to a primary care provider\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 216\n",
            "- [NCT00610857] History of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, or any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to CT-scan only.\n",
            "- [NCT02796352] For patients who have received prior anti-CTLA4 monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL-2 therapy. Therefore, for these patients if they have a history of colitis or diarrhea during anti-CTLA4 monoclonal antibody therapy, it is recommended that they have a formal evaluation by a gastroenterologist and a colonoscopy/endoscopy should be considered to demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on this protocol.\n",
            "- [NCT03598790] Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)\n",
            "- [NCT03768219] Moderately to severely active ulcerative colitis as defined by:\n",
            "- [NCT03971643] Personal history of inflammatory bowel disease or inflammatory arthritis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 217\n",
            "- [NCT00612742] with a clinical diagnosis of HSDD.\n",
            "- [NCT00949546] Chronic HS for \\> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS\n",
            "- [NCT02157090] duration of HSL symptoms not more than three days\n",
            "- [NCT03569371] Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.\n",
            "- [NCT03569371] Stable course of HS for at least 90 days before screening, as determined by the investigator.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 218\n",
            "- [NCT00650910] Double-barrier contraception (condom with spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male condom and diaphragm).\n",
            "- [NCT00688272] Diaphragm with spermicide\n",
            "- [NCT00688272] Cervical cap or female condoms.\n",
            "- [NCT00761371] Condoms (with spermicide)\n",
            "- [NCT00761371] Diaphragm/cervical cap (with spermicide)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 219\n",
            "- [NCT00650910] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT00821054] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT01358240] Be willing and able to give informed consent/assent or have their parent/guardian do so, if applicable.\n",
            "- [NCT01386775] Conform to one of the following requirements for providing informed consent/assent:\n",
            "- [NCT01638052] informed consent and assent obtained\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 220\n",
            "- [NCT00665782] Smoking cigarettes for the 24-hour period of saliva-sample collection\n",
            "- [NCT00688272] Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.\n",
            "- [NCT00811824] Non-smoker\n",
            "- [NCT01019603] Nonsmoker or smoker with at least 30 days abstinence from smoking or using nicotine-containing products prior to study entry and willing not to smoke or to use nicotine-containing products throughout the study.\n",
            "- [NCT01140282] Nonsmokers (i.e., not smoking during previous 12 months)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 221\n",
            "- [NCT00688272] Healthy Caucasian male or females with no clinically significant abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead ECG.\n",
            "- [NCT00773734] In good health as judged by the investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), serum chemistry, hematology, immunology, and urinalysis\n",
            "- [NCT01694381] Be without clinical significant abnormalities according to the investigator's judgment, based on a detailed medical history, a complete physical examination (including vital signs), a standard 12-lead electrocardiogram, urinalysis, and routine clinical laboratory tests.\n",
            "- [NCT02505568] Participant must be medically stable on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at Screening. If there are abnormalities, they must be consistent with the underlying illness in the study population, or the participant may be included only if the investigator judge the abnormalities from normal to be not clinically significant or to be appropriate. This determination must be recorded in the participant's source documents by the investigator\n",
            "- [NCT02690142] In good health, as determined by medical history, physical examination, vital signs assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 222\n",
            "- [NCT00688272] Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.\n",
            "- [NCT00761371] Oral, injectable, or implantable contraceptives\n",
            "- [NCT01838655] Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring),\n",
            "- [NCT02231879] Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive,\n",
            "- [NCT02950922] Oral Contraceptive, either combined or progestogen alone \\[Hatcher, 2007a\\] Injectable progestogen \\[Hatcher, 2007a\\]\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 223\n",
            "- [NCT00688272] An intrauterine device (a coil micro-insert).\n",
            "- [NCT00688272] Intrauterine system (IUS) e-g Mirena coil\n",
            "- [NCT00761371] Intrauterine devices (IUDs)\n",
            "- [NCT01300533] Use an intrauterine device (IUD) with a documented failure rate of less than 1% per year.\n",
            "- [NCT01838655] Intrauterine device,\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 224\n",
            "- [NCT00708851] able and willing to attend phototherapy sessions and apply LCD at home\n",
            "- [NCT00773734] Candidate for photo/systemic therapy\n",
            "- [NCT01094717] No systemic or phototherapy in the 4 wks prior to entering the study\n",
            "- [NCT01228409] Stabilized on a phototherapy regimen for 4 weeks.\n",
            "- [NCT01291940] Are receiving phototherapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 225\n",
            "- [NCT00251472] Patients must have signed an IRB-approved informed consent.\n",
            "- [NCT00713154] Can understand and sign the IRB/IEC approved informed consent, can communicate with the Investigator, and can understand with the requirements of the protocol\n",
            "- [NCT00991978] Signed written informed consent (approved by the Institutional Review Board \\[IRB\\]/ Independent Ethics Committee \\[IEC\\]) obtained prior to any study specific screening procedures.\n",
            "- [NCT01047072] If the donor has reached the age of assent, then they must have completed the local institutional review board (IRB) assent process.\n",
            "- [NCT01450176] Sign and date the informed consent form approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 226\n",
            "- [NCT00735293] Have axillary hyperhidrosis/bromidrosis that does not respond to conventional, non-invasive treatment\n",
            "- [NCT02058264] Primary axillary hyperhidrosis of at least 6 months duration.\n",
            "- [NCT02058264] Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.\n",
            "- [NCT02058264] Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.\n",
            "- [NCT02100072] Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 227\n",
            "- [NCT00741260] PART 1:\n",
            "- [NCT00753415] Part A\n",
            "- [NCT01228656] Clarified (appendix);\n",
            "- [NCT01229085] Clarified (appendix);\n",
            "- [NCT02217891] Part 1:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 228\n",
            "- [NCT00743496] Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.\n",
            "- [NCT01104298] Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.\n",
            "- [NCT01104298] Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)\n",
            "- [NCT01104298] Angiosarcoma\n",
            "- [NCT01104298] Synovial sarcoma\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 229\n",
            "- [NCT00802672] Male or female at least 10 years of age, and otherwise healthy\n",
            "- [NCT00850811] healthy males or females;\n",
            "- [NCT01019603] Male or female 12 years of age or older who is in good general health.\n",
            "- [NCT01208298] Females or males subjects, at least 18 to 70 years of age, in good general health\n",
            "- [NCT01243450] Normal, healthy male and female children and adults.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 230\n",
            "- [NCT00814125] No previous endometrial ablation\n",
            "- [NCT01522820] Uterine cancer: patients with advanced (stages II-IV) or recurrent disease who have completed standard therapy, currently no evidence of disease (NED) or with minimal residual disease; patients with stage I uterine serous carcinomas or sarcomas are also eligible after completion of standard therapy\n",
            "- [NCT02996825] Endometrial \\>= 50% of tumor staining \\>= 2+ intensity\n",
            "- [NCT02996825] Cohort B: Patients with recurrent endometrial cancer may have received up to 2 lines of cytotoxic chemotherapy (adjuvant and one line for recurrent disease, or 2 lines of chemotherapy for recurrent uterine cancer in patients who did not receive adjuvant chemotherapy); patients must have received and failed, or have been intolerant to platinum agents, taxanes, liposomal doxorubicin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigator's opinion, patients would benefit from treatment on current protocol\n",
            "- [NCT03924466] endometrial cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 231\n",
            "- [NCT00824889] Age ≥ 18 years.\n",
            "- [NCT01138384] Age ≥ 18 years of age.\n",
            "- [NCT01191528] Age greater than 18\n",
            "- [NCT01291420] Age: ≥ 18 years old\n",
            "- [NCT01308294] Age ≥ 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 232\n",
            "- [NCT00087373] Individuals with extensive skin disease\n",
            "- [NCT00574613] Symmetric lesions in forearms. The extension of the selected symmetric lesions must be at least 15 cm2.\n",
            "- [NCT00601640] No inflammation of the skin on the lateral forearms\n",
            "- [NCT00839280] Subjects with dry skin on their forearms\n",
            "- [NCT01051960] Diffuse\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 233\n",
            "- [NCT00996710] In certain clinical situations, parent(s) with cancer may be included at the discretion of the Principal Investigator, if the Principal Investigator deems that the etiology of cancer in the parent(s) and proband are biologically unrelated.\n",
            "- [NCT04514484] Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04704661] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04996823] Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n",
            "- [NCT05111561] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 234\n",
            "- [NCT01001728] Age ≥18\n",
            "- [NCT01138553] Age ≥18\n",
            "- [NCT01342497] Aged ≥18\n",
            "- [NCT02794324] Age ≥18\n",
            "- [NCT02847728] Age ≥18\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 235\n",
            "- [NCT01010854] Because no dosing or adverse event data are currently available on the use of VPA in combination with FEC100 in patients \\<18 years of age, children are excluded from this study\n",
            "- [NCT01111825] Age ≥ 18, as no dosing or adverse event data are currently available on the use of neratinib or temsirolimus in patients \\<18 years of age, children are excluded from this study.\n",
            "- [NCT01149083] Female, age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of ABT-888 in patients \\< 18 years of age, children are excluded from this study\n",
            "- [NCT01246102] Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of AT13387 in patients \\< 18 years of age, children are excluded from this study.\n",
            "- [NCT01894451] Age ≥ 21 years. Because no dosing or adverse event data are currently available on the use of 89Zr-bevacizumab in participants \\<21 years of age, children are excluded from this study but will be eligible for future pediatric trials.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 236\n",
            "- [NCT01010854] absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01029925] Absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01575522] Absolute neutrophil count \\>= 1,500/mcL\n",
            "- [NCT01705340] Absolute neutrophil count \\>= 1,000/mcL\n",
            "- [NCT01727076] Absolute neutrophil count \\> 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 237\n",
            "- [NCT00324259] Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.\n",
            "- [NCT00526045] Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or lapatinib in combination with other agents) for metastatic disease\n",
            "- [NCT00526045] Patients who develop metastases while receiving adjuvant or neo-adjuvant trastuzumab are eligible. HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on either:\n",
            "- [NCT00704158] Subjects with HER2/neu overexpressing tumors must have been treated with trastuzumab except in situations where the subject was intolerant to or not a candidate for trastuzumab\n",
            "- [NCT01029925] HER-2 positive breast cancer should have received Trastuzumab, in either the adjuvant or metastatic setting.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 238\n",
            "- [NCT01029925] Non-small cell lung cancer patients should have received at least platinum based chemotherapy in the adjuvant, neoadjuvant or metastatic setting.\n",
            "- [NCT01910844] Patient non previously treated by platinum salts,\n",
            "- [NCT02210663] Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; \\\n",
            "- [NCT02365662] Expanded Safety Cohort participants must have confirmed metastatic lung cancer and progressed after receiving prior platinum-containing chemotherapy.\n",
            "- [NCT02561832] Prior use of platinum compound in the advanced or metastatic setting. Previous exposure to platinum compounds is allowed only if they were used in early adjuvant or neoadjuvant setting with relapse occurring \\>6 months after the last platinum administration and if there is no residual toxicity\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 239\n",
            "- [NCT01095848] Patients with prostate cancer who have failed at least 1 course of an accepted hormonal therapy. Specifically prostate cancer patients must have castrate testosterone levels (\\< 50 ng/dl) and 2 PSA values higher than the previously documented baseline at least 3 weeks apart or evidence of increases in measurable disease. These patients may have received previous courses of cytotoxic chemotherapy although chemotherapy naïve patients who are deemed not good candidates or who have refused cytotoxic therapy will be eligible. These patients may remain on anti-androgen therapy during the trial. Patients with evidence of progressive bone or other metastases are acceptable.\n",
            "- [NCT01522820] Prostate cancer: patients with metastatic, castrate refractory prostate cancer; the use of luteinizing hormone-releasing hormone (LHRH) agonist is allowed\n",
            "- [NCT02704832] Prostate cancer : metastatic and refractory to hormonal castration,\n",
            "- [NCT03218826] DISEASE SPECIFIC EXPANSION COHORTS: Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have:\n",
            "- [NCT03310541] Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 240\n",
            "- [NCT01164891] Positive BRAF V600E mutation result (by Roche CoDx test)\n",
            "- [NCT01705392] Known BRAF mutation\n",
            "- [NCT01820364] confirmed BRAF V600 mutation\n",
            "- [NCT01910181] Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test\n",
            "- [NCT02133222] Known genotype BRAF V600\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 241\n",
            "- [NCT01233505] First- or second-line metastatic colorectal cancer\n",
            "- [NCT01291420] Colorectal tumors\n",
            "- [NCT01315990] Histologically-confirmed metastatic colorectal cancer (primary tumor or metastasis)\n",
            "- [NCT01372527] Colorectal cancer: Women and men 52-75 years old\n",
            "- [NCT02704832] Colon and rectum : metastatic (unresectable metastasis),\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 242\n",
            "- [NCT01240213] No menopausal HRT use of any type including vaginal X 6 months and willing to avoid use for study duration\n",
            "- [NCT01381445] A female subject is eligible to participate if she is of: • Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the protocol contraception methods if they wish to continue their HRT during the study.\n",
            "- [NCT01899703] A female subject is eligible to participate if she is not pregnant, as confirmed by a negative serum human chorionic gonadotrophin (hCG) test or at least one of the following conditions applies: Non-reproductive potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \\>40 milli-international units per milliliter and estradiol \\<40 picograms per milliliter (\\<147 picomole per liter) is confirmatory\\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods along with either a second form of highly effective contraception or barrier protection (condoms with spermicide) if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the contraception options methods for the specified duration of time.\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab or dabrafenib + trametinib on the developing human fetus are unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to Step 2 crossover to rule out pregnancy; a female of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\n",
            "- [NCT02466152] A woman is eligible to participate if she is of non-reproductive potential, defined as: 1. Postmenopausal (including all women over 60 years of age). 2. Females with one of the following procedures documented and no plans to utilize assisted reproductive techniques (e.g., in vitro fertilization or donor embryo transfer): Bilateral tubal ligation or salpingectomy; Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Bilateral oophorectomy (surgical menopause) Note: A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile (e.g., age appropriate, \\>45 years, in the absence of hormone replacement therapy \\[HRT\\] or medical suppression of the menstrual cycle). In questionable cases for women \\<60 years of age, a blood sample with simultaneous follicle stimulating hormone and estradiol falling into the central laboratory's postmenopausal reference range is confirmatory. Women \\<60 years of age who are on HRT, wish to continue, and whose menopausal status is in doubt are required to use a highly-effective method to avoid pregnancy. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of postmenopausal status, HRT may be resumed during the study without use of a highly-effective method to avoid pregnancy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 243\n",
            "- [NCT01256489] Bilateral legal blindness (\\<20/200 in better eye)\n",
            "- [NCT01256489] Able to administer eye medications or have a care giver able and willing to do same\n",
            "- [NCT01467310] History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):\n",
            "- [NCT01838655] Bilateral visual acuity E-ETDRS EVA letter score of less than or equal to 83 (i.e., Snellen equivalent of 20/25 or worse) that is not attributable to any other pathology.\n",
            "- [NCT01838655] Bilateral iris transillumination that can be seen in clinical photographs. 2. Predominant contralateral decussation of ganglion cell axons, as determined by pattern visual evoked potential (VEP). 3. Participant has at least one definitive mutation in the OCA1 gene (tyrosinase). 4. Participant has no definitive mutations in the OCA2 gene.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 244\n",
            "- [NCT01276704] Ki-67 ≥2% positivity (≥500 cells).\n",
            "- [NCT01583426] \\- cT1c and Ki67 \\> 20%\n",
            "- [NCT01669265] Ki67 index\n",
            "- [NCT04065321] proliferation index Ki-67 \\< 20%;\n",
            "- [NCT04134598] Ki67 ≤20% by IHC staining;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 245\n",
            "- [NCT01419184] Less than 24 hours post hospital admission\n",
            "- [NCT01965444] Subject is admitted to an intensive Care Unit (ICU) and has an anticipated ICU course of 48 hours or greater.\n",
            "- [NCT01965444] Subject is anticipated to be bedridden for ore than 6 hours per day.\n",
            "- [NCT02152358] mechanical ventilation \\> 96 hrs and expected duration of mechanical ventilation of at least 2 days\n",
            "- [NCT02325388] Expected to have a length of stay on the unit of at least three days.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 246\n",
            "- [NCT00802672] Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed.\n",
            "- [NCT01543126] Got ICF before enrollment;\n",
            "- [NCT01679197] If ≥ 18 years of age, is able to read, understand and sign the U of M IRBMED approved informed consent form (ICF), communicate with study physician and study team, understand and comply with protocol requirements.\n",
            "- [NCT02209662] Prior to the first clinical intervention, a signed Informed Consent Form (ICF) and Data Consent Form (DCF) must be obtained from the subject or legal representative\n",
            "- [NCT02363842] Subject, or their legal representative, is able and willing to sign an informed consent form (ICF) and willing to undergo all study related procedures.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 247\n",
            "- [NCT01689519] Adequate hematologic and end organ function\n",
            "- [NCT01765556] Adequate hematologic and end organ function\n",
            "- [NCT01849666] Adequate hematologic and end organ function\n",
            "- [NCT01973309] Adequate hematologic and end-organ function\n",
            "- [NCT02338245] Patients with acceptable organ and hematological function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 248\n",
            "- [NCT01722812] Age 18 years or above\n",
            "- [NCT02285049] Age 18 years old or above\n",
            "- [NCT02889458] aged 18 or above\n",
            "- [NCT03725722] Age 18 years and above.\n",
            "- [NCT05098821] Age 18 and above\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 249\n",
            "- [NCT01723072] Angioedema at least 4x in the last 6 months\n",
            "- [NCT02966314] Adults or adolescents who are 18 years or older at the time of screening with physician diagnosis of idiopathic angioedema\n",
            "- [NCT02966314] Minimum of two episodes of idiopathic angioedema in the past 6 months at the time of screening\n",
            "- [NCT02966314] Management of idiopathic angioedema with a stable controller treatment plan for the prior 6 months\n",
            "- [NCT03029728] The diagnosis of Hereditary Angioedema is confirmed by CENTOGENE EXCLUSION CRITERIA\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 250\n",
            "- [NCT01727076] At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-programmed cell death 1 (PD1)\n",
            "- [NCT01740297] Subjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.\n",
            "- [NCT01986426] Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment). Arm D:\n",
            "- [NCT02224781] NOTE: Patients should (if possible) be at least 1 week from documented PD on Step 1 of current study. All sites of disease must be evaluated within 4 weeks prior to registration\n",
            "- [NCT02676869] Currently receiving anti-PD-1 therapy with pembrolizumab and after 3 cycles achieved asymptomatic irPD (slowly progressive, not requiring urgent intervention, and stable performance status) or sub-optimal response (irSD, irPR) as demonstrated in imaging assessments performed within 6 weeks prior to study start\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 251\n",
            "- [NCT01820234] Able to provide a brief medical history and have/allow an examination of their skin including photographs.\n",
            "- [NCT02385994] Willing to have digital photographs taken of the treatment area.\n",
            "- [NCT02667288] Have a clinically typical appearance\n",
            "- [NCT03374995] Able and willing to have photographs of the affected area taken regularly\n",
            "- [NCT03910543] Patients must be willing to undergo skin biopsies, blood collection, and total body photography and comply with clinic visits\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 252\n",
            "- [NCT00221221] must be in the post treatment phase of their cancer trajectory.\n",
            "- [NCT01333735] Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)\n",
            "- [NCT01977053] Patient surgically-treated or no for non inflammatory breast cancer or for colon cancer or rectal cancer.\n",
            "- [NCT01999062] Patients with prior treatment such as surgery or chemotherapy for any type of cancer.\n",
            "- [NCT03028584] Patients: Have been treated with curative intent (e.g. surgery, chemotherapy and/or radiation therapy) for a Stage 1-3 cancer diagnosis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 253\n",
            "- [NCT01984255] absolute neutrophil count ≥ 1,500/mcL\n",
            "- [NCT03007979] Absolute neutrophil count ≥ 1,500/mcl\n",
            "- [NCT03225547] absolute neutrophil count ≥ 1,000/mcL\n",
            "- [NCT03691493] Absolute neutrophil count ≥ 1000/mcl (obtained within 14 days prior to registration on study)\n",
            "- [NCT03709446] Absolute neutrophil count ≥ 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 254\n",
            "- [NCT01984255] platelets ≥ 100,000/mcl\n",
            "- [NCT02318771] Platelets ≥100,000 / mcL\n",
            "- [NCT03007979] Platelets ≥ 100,000/mcl\n",
            "- [NCT03225547] platelets ≥ 80,000/mcL\n",
            "- [NCT03709446] platelets ≥ 100,000/mcl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 255\n",
            "- [NCT02023008] Participants must be:\n",
            "- [NCT02425306] All participants must have:\n",
            "- [NCT03139513] Participants included in the TAU from 26 February 2015\n",
            "- [NCT05672992] Participants must meet at least one of the following:\n",
            "- [NCT06007677] Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 256\n",
            "- [NCT02035813] Both cohorts:\n",
            "- [NCT02035813] Ribociclib cohort:\n",
            "- [NCT02035813] INR ≤ 1,5 (ribocilclib cohort)\n",
            "- [NCT02279004] Cohort 1B:\n",
            "- [NCT02279004] Cohort 2B:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 257\n",
            "- [NCT02061085] Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n",
            "- [NCT02115204] Eastern Cooperative Oncology Group (ECOG) status \\< 2\n",
            "- [NCT02657889] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03055312] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03423199] Eastern Cooperative Oncology Group (ECOG) PS 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 258\n",
            "- [NCT02083484] Failed or progressed on standard of care systemic therapy including ipilimumab (with the exception of a participant with progressive disease while on the ipilimumab arm of MK-3475-006, regardless of prior treatment with a BRAF/MEK inhibitor, as long as all other eligibility criteria for this study are met)\n",
            "- [NCT02224781] Malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib, or history of retinal vein occlusion are acceptable for patients crossing over to Arm D (ipilimumab + nivolumab) treatment\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Patients must have recovered from adverse events (toxicities resolved to grade 1 or less) of prior therapy; patients with immune related toxicities from ipilimumab + nivolumab may continue onto Step 2 even if still on steroids to control side effects, so long as toxicity has resolved to grade 1 or less\n",
            "- [NCT02260531] Patients must have normal organ and marrow function and laboratory values as follows within 14 days before the first dose of cabozantinib\n",
            "- [NCT02260531] The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 259\n",
            "- [NCT02127970] Male or female participants 18 - 85 years of age.\n",
            "- [NCT02286583] The perfect sample should be 2000 females or more.\n",
            "- [NCT02694640] Women aged 21 years or over will be eligible if they:\n",
            "- [NCT02836795] Male and Female aged 18 to 70 years are eligible;\n",
            "- [NCT03151447] Female aged 18 to 75 years old are eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 260\n",
            "- [NCT02157090] at least 18 years old\n",
            "- [NCT02205736] At least 18 years old\n",
            "- [NCT02272881] At least 18 years old;\n",
            "- [NCT03398538] At least 18 years old.\n",
            "- [NCT03966924] At least 30 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 261\n",
            "- [NCT02158208] recent onset localised headache\n",
            "- [NCT02531633] Diagnosis of GCA defined by the following Revised GCA Diagnosis Criteria: Age \\>=50 years. History of ESR \\>=50 millimeter/hour (mm/hour) or CRP \\>=2.45 milligram/deciliter(mg/dL). Presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of polymyalgia rheumatic (PMR). Presence of at least one of the following: Temporal artery biopsy revealing features of GCA; Evidence of large-vessel vasculitis by angiography or cross-sectional imaging.\n",
            "- [NCT02531633] Active GCA within 6 weeks of Randomization (Baseline) where active disease is defined by an ESR \\>=30 mm/hr or CRP \\>=1 mg/dL AND the presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of PMR; Other features judged by the clinician investigator to be consistent with GCA or PMR flares.\n",
            "- [NCT02703922] Suspected of GCA according to clinician expertise and / or aortitis arteritis or of one or more arteries from the aorta imaging (CT angiography, magnetic resonance angiography or positron emission tomography TDM18FDG)\n",
            "- [NCT02771483] Rheumatologist, neurologist or ophthalmologist suspect diagnosis of GCA\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 262\n",
            "- [NCT02180412] Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes.\n",
            "- [NCT02180412] Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG).\n",
            "- [NCT02180412] Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples:\n",
            "- [NCT02180412] For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins. Most (\\~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (\\>95 percent) will have a demonstrable disease-causing PBGD mutation.\n",
            "- [NCT02180412] For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins. Almost all (\\>95 percent) will have a demonstrable disease-causing coproporphyrinogen oxidase (CPO) mutation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 263\n",
            "- [NCT01730833] No prior chemotherapy or trastuzumab for treatment of metastatic breast cancer\n",
            "- [NCT02260531] Discontinued prior therapy (with the exception of trastuzumab for patients with HER2+ breast cancer)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 264\n",
            "- [NCT02362594] Tumor tissue available for evaluation of PD-L1 expression\n",
            "- [NCT02519322] All patients must undergo a baseline tumor biopsy; in Arms A and B, tumor biopsy for PD-L1 testing (PD-L1 positivity is determined by greater than or equal to 1% of cells staining in the membrane by immunohistochemistry) is required for stratification; PD-L1 status is not required for enrollment on Arm C; the 28-8 clone for PD-L1 testing is required for assessment of PD-L1 status; for patients with stage IV disease, site of tumor biopsy will preferably be from non-lymph node disease site; for PD-L1 testing, the biopsy should contain sufficient tumor content (\\> 100 tumor cells/4-micron tissue section); if a sample contains insufficient tumor content, a re-biopsy will be required to obtain a sample with sufficient tumor content prior to treatment\n",
            "- [NCT02523313] Tumor tissue from the resected site of disease must be provided for biomarker analyses. In order to be randomized a subject must have a PD-L 1 expression classification (positive (≥ 5% tumor cells expressing PD-L1) or negative (\\< 5% tumor cells expressing PD-L1)). If an insufficient amount of tumor tissue from the resected site is provided for analysis, acquisition of additional archived tumor tissue (block and/or slides) for the biomarker analyses is required.\n",
            "- [NCT02555657] Central determination of programmed cell death ligand 1 (PD-L1) tumor status\n",
            "- [NCT02836795] Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 265\n",
            "- [NCT02540083] Have signed and dated the informed consent form;\n",
            "- [NCT02671513] Signed and dated informed consent\n",
            "- [NCT03055312] Signed and dated an informed consent form\n",
            "- [NCT03330977] Patient who have dated and signed a consent form\n",
            "- [NCT03893019] Signed and dated informed consent before conduct of any trial-specific procedure.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 266\n",
            "- [NCT01935531] Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel\n",
            "- [NCT02612454] Participated in a prior dupilumab study in pediatric participants with AD and adequately completed the visits and assessments required for both the treatment and follow-up periods, as defined in the prior study protocol\n",
            "- [NCT02612454] Must have received the same dupilumab dose regimen to be used in the PFP sub-study during the previous 12 weeks in the main OLE study using the prefilled syringe, as defined in the protocol Key\n",
            "- [NCT04066998] treated with Dupilumab\n",
            "- [NCT04718870] Participants with moderate to severe AD those were eligible to be treated with dupilumab according to product label.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 267\n",
            "- [NCT00036621] Adriamycin (60 mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery)\n",
            "- [NCT00036621] Adriamycin (60mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses, followed by Taxol (175mg/m2 IV on Day 85) repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery). 3. ECOG performance status 0 or 1. 4. Adequate organ function as evidenced by:\n",
            "- [NCT01306825] Patient under treatment with daptomycin for more than 3 days with dosage at 6 mg/kg\n",
            "- [NCT01986140] Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Doxorubicin 50mg/m2 with 5-Fluroruacil 500mg/m2 and Cyclophosphamide 500mg/m2 - Paclitaxel 80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3 weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2-100mg/m2 with pertuzumab and traztuzumab at standard doses - Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and trastuzumab at standard doses\n",
            "- [NCT02614794] Doxorubicin \\> 360 mg/m\\^2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 268\n",
            "- [NCT01105884] Patients with or without PVD\n",
            "- [NCT01334125] Can be antibody positive or negative\n",
            "- [NCT02704429] Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:\n",
            "- [NCT04422912] Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n",
            "- [NCT04422912] mPV inadequately managed by at least one standard immunosuppressive therapies\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 269\n",
            "- [NCT00526617] Dose escalation and expanded safety cohorts\n",
            "- [NCT00722293] There must be measurable disease or evaluable disease for subjects to be included in the cohort expansion phase. Measurable disease is not a criterion for subjects enrolling in the dose escalation phase.\n",
            "- [NCT01001728] For all patients, the following absolute dose constraints should be met: ≤5% of heart volume to receive 18Gy and ≤10% of ipsilateral lung volume to receive ≥20Gy\n",
            "- [NCT01138384] During the dose escalation phase patients are not required to have measurable disease, but if they do, it will be recorded and followed. Patients at the expanded RP2D must have measurable disease defined by the RECIST 1.1.\n",
            "- [NCT03170960] Dose-Escalation Stage:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 270\n",
            "- [NCT00508274] Willing to complete all screening assessments as outlined in the protocol;\n",
            "- [NCT02672475] Patients must complete all screening assessments as outlined in the protocol\n",
            "- [NCT03328897] Patients must have documented current use on the day of the initial screening visit Main Exclusion Criteria\n",
            "- [NCT03569371] Total AN count of at least 3 at screening and baseline.\n",
            "- [NCT03607487] Total AN count of at least 3 at screening and baseline.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 271\n",
            "- [NCT03331003] Always burns, never tans\n",
            "- [NCT03331003] Usually burns, tans minimally\n",
            "- [NCT03331003] Frequently burns and tans (light brown)\n",
            "- [NCT03331003] Rarely burns, tans easily (brown)\n",
            "- [NCT03331003] Very rarely burns, tans very easily (brown)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 272\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Absolute neutrophil count (ANC) \\>= 1500/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Platelet count \\>= 75,000/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Hemoglobin \\>= 9.0 g/dL (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Direct bilirubin \\< 1.5 x upper limit of normal (ULN) (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Aspartate transaminase (AST) =\\< 3 x ULN (obtained =\\< 28 days prior to randomization)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 273\n",
            "- [NCT00073528] Signed informed consent; 2. Subjects with histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery;\n",
            "- [NCT01050322] Signed informed consent must be obtained according to local ethical committee requirements. 2. Subjects must be older than 18 years old. 3. Histologically confirmed invasive adenocarcinoma of the breast which is stage IIIb, stage IIIc with T4 lesion, or stage IV disease \\[according to AJCC 6th edition\\] 4. Documented progression after taxane based treatment for ErbB2 positive patients for 1st line metastatic breast cancer or documented progression after taxane based regimens as adjuvant or neo-adjuvant therapy. Patients may have had a maximum of one prior treatment with a chemotherapy regimen for metastatic disease. 5. Patients must have at least 1 measurable lesion defined by RECIST as follows:\n",
            "- [NCT01300533] Signed informed consent form. (ICF) 2. At least 18 years old. 3. Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists. 4. Measurable or evaluable disease per RECIST version 1.1. 5. Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1. 6. Life expectancy of greater than 12 weeks. 7. Female subjects are eligible to enter and participate in the study if they are of: 1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who:\n",
            "- [NCT01617915] Women or men \\> age 18. Ability to give informed consent Archived tumor tissue must be available for genetic analysis. Patients with early-stage breast cancer Histologic documentation of invasive breast cancer by core needle or incisional biopsy. The invasive cancer must be either:\n",
            "- [NCT02971748] Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \\>/= 18 years of age 3. Has histological confirmation of breast carcinoma. 4. Has confirmed inflammatory breast cancer by using international consensus criteria:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 274\n",
            "- [NCT00601640] No evidence of serious underlying medical conditions as demonstrated by abnormal values on baseline laboratory assessment\n",
            "- [NCT00907062] normal on physical examination at the pre-study intake, and in the case of abnormalities the health care practitioner considers them to be clinically insignificant\n",
            "- [NCT01119313] the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;\n",
            "- [NCT02346760] With no clinically relevant abnormalities in vital signs, and clinical laboratory tests at screening visit judged by investigator.\n",
            "- [NCT02801435] In good health, with no history of diseases of major organs and no abnormality found on physical examination and vital signs\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def inspect_dbscan_umap(df, label_col=\"cluster_dbscan_umap\", n_examples=5):\n",
        "    for label in sorted(df[label_col].unique()):\n",
        "        if label == -1:   # skip noise\n",
        "            continue\n",
        "        subset = df[df[label_col] == label].head(n_examples)\n",
        "        print(\"=\"*80)\n",
        "        print(f\"DBSCAN+UMAP Cluster = {label}\")\n",
        "        for _, row in subset.iterrows():\n",
        "            print(f\"- [{row['nctid']}] {row['criterion']}\")\n",
        "        print()\n",
        "\n",
        "inspect_dbscan_umap(criteria_df, n_examples=5)\n"
      ],
      "metadata": {
        "id": "6Sh8gm8rJ7ok",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "fd2a6e1d-3a0c-48f6-bdbf-a642873c2cf6"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 0\n",
            "- [NCT00001137] HIV-1 infected\n",
            "- [NCT00003895] Patients must be negative for human immunodeficiency virus (HIV) antibody by enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is positive) if they are considered to be at high risk; others do not require serologic testing if there are no symptoms or risk factors for HIV disease\n",
            "- [NCT00005764] Are HIV-positive.\n",
            "- [NCT00005764] Have had HIV-1 RNA levels less than 400 copies/ml on the 2 most recent measurements.\n",
            "- [NCT00005764] Have had an HIV vaccine within 3 months of the screening visit.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 1\n",
            "- [NCT00001137] Willing to provide consent for the release and use of clinical data from the parent study\n",
            "- [NCT00003199] The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines\n",
            "- [NCT00003895] Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy\n",
            "- [NCT00004067] Psychiatric or addictive disorders that would preclude obtaining informed consent.\n",
            "- [NCT00004074] Written signed informed consent; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 2\n",
            "- [NCT00001137] Life expectancy of at least 24 weeks\n",
            "- [NCT00004067] The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)\n",
            "- [NCT00004074] Life expectancy of at least 6 months\n",
            "- [NCT00028405] Minimum life expectancy of 12 weeks.\n",
            "- [NCT00044291] Predicted life expectancy of 12 weeks or more\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 3\n",
            "- [NCT00001137] Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria\n",
            "- [NCT00035958] Patient and/or parent or legal guardian must be willing to sign consent and assent forms Exclusion criteria at the time of enrollment:\n",
            "- [NCT00106184] Parent willing to provide informed consent, if applicable\n",
            "- [NCT00315393] Parent or guardian willing to provide informed consent, if applicable\n",
            "- [NCT00346398] Parent or guardian willing to provide informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 4\n",
            "- [NCT00003199] Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (\\>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions\n",
            "- [NCT00004067] The tumor must be invasive adenocarcinoma on histologic examination.\n",
            "- [NCT00004067] Prior history of breast cancer, including DCIS (patients with a history of lobular carcinoma in situ \\[LCIS\\] are eligible).\n",
            "- [NCT00024154] Histologically confirmed metastatic adenocarcinoma of the breast\n",
            "- [NCT00034918] Histological and/or cytological confirmation of metastatic breast cancer which is refractory to anthracycline, taxane, with or without capecitabine therapies;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 5\n",
            "- [NCT00003199] Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol\n",
            "- [NCT00004067] Prior anthracycline or taxane therapy for any malignancy.\n",
            "- [NCT00048633] Histologically proven breast cancer with primary resistance to anthracyclines (doxorubicin, epirubicin) or taxane (paclitaxel, docetaxel) or both. Primary chemotherapy resistance is defined for the purpose of this protocol as any of the following: 1. Progression after a minimum of 1 cycles of therapy, or 2. Stable disease after a minimum of 2 cycles of therapy or, 3. Relapse within 6 months after completion of an anthracycline or/and taxane containing chemotherapy regimen.\n",
            "- [NCT00051103] No more than two prior regimens for metastatic breast cancer. Each regimen must have contained Herceptin.\n",
            "- [NCT00063570] Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 6\n",
            "- [NCT00003199] Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (\\>= 2.5 x 10\\^6 CD34+ cells/kg)\n",
            "- [NCT00003895] Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic techniques, flow cytometry, or molecular techniques\n",
            "- [NCT00005617] HLA-A2.1 positive and express MART-1, as assessed by either RT-PCR or by immunohistochemistry\n",
            "- [NCT00005949] HLA-A2\\\n",
            "- [NCT00024154] No prior organ allograft\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 7\n",
            "- [NCT00003199] Hepatic function: Bilirubin =\\< 2 mg%; SGOT or SGPT =\\< 2.5 x institutional normal\n",
            "- [NCT00048633] Normal renal function: creatinine less than or equal to 2.0 mg/dl. Adequate liver function: bilirubin less than or equal to 1.5 mg/dl. Transaminase (SGOT) and alkaline phosphatase must be less than or equal to 1.5 x of the upper limit of normal in the absence of bone or liver metastasis, or less than or equal to 2.5 x of the upper limit of normal in the presence of radiologically apparent liver metastasis or bone metastasis, respectively.\n",
            "- [NCT00087477] Adequate liver function with alkaline phosphatase \\<= 2.5 X upper limit of normal, SGOT and SGPT \\<= 1.5 X upper limit of normal and total bilirubin \\<= 1.5 X upper limit of normal.\n",
            "- [NCT00129376] Hepatic function: total bilirubin \\<= 1 x upper normal limit (UNL); Aspartate aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) \\<= 2.5 x UNL; alkaline phosphatase \\<= 5 x UNL.\n",
            "- [NCT00155259] Adequate liver and kidney function: total bilirubin ≦ 2.0 mg/dl, serum alanine transaminases (ALT) and aspartate transaminase (AST) ≦ 3 times upper normal limit, serum creatinine ≦ 1.5 mg/dl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 8\n",
            "- [NCT00003199] Renal function: Creatinine =\\< 2.0 mg/dl or a creatinine clearance \\>= 50 mg/min\n",
            "- [NCT00003199] Creatinine =\\< 2.0 mg/dl\n",
            "- [NCT00003895] Serum creatinine =\\< 2 mg/dl\n",
            "- [NCT00004067] There must be postoperative evidence of adequate renal function (serum creatinine within or less than the institution's normal range).\n",
            "- [NCT00004074] Calculated creatinine clearance will be used to assess renal function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 9\n",
            "- [NCT00003199] Pre-Study tests have been performed as outlined in the Study Calendar\n",
            "- [NCT00254592] In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28. This allows for efficient patient scheduling without exceeding the guidelines. If Day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day.\n",
            "- [NCT00479674] Laboratory tests performed within 14 days of study entry:\n",
            "- [NCT00491816] Pretreatment lab values must be performed within 14 days of patient registration, and other baseline studies within 30 days\n",
            "- [NCT00544765] Laboratory requirements (within 14 days prior to registration):\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 10\n",
            "- [NCT00003199] Karnofsky performance status \\> 60\n",
            "- [NCT00003895] Patients must be ambulatory with good performance status (Karnofsky performance status \\[PS\\] 80-100)\n",
            "- [NCT00004074] Karnofsky Performance Status index \\>= 70%\n",
            "- [NCT00005617] Karnofsky Performance Status greater than or equal to 70 percent\n",
            "- [NCT00087373] Performance status - Karnofsky 70-100%\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 11\n",
            "- [NCT00003199] Total bilirubin =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003895] Total bilirubin =\\< 2.0 mg/dl\n",
            "- [NCT00005949] Bilirubin normal\n",
            "- [NCT00024154] Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
            "- [NCT00036621] Total bilirubin \\< 1.5 x ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 12\n",
            "- [NCT00003199] SGOT =\\< 2.5 x upper limit of normal\n",
            "- [NCT00005949] AST no greater than 2.5 times upper limit of normal\n",
            "- [NCT00024154] INR no greater than 1.5 times ULN\n",
            "- [NCT00074308] AST and ALT no greater than 2.5 times ULN\n",
            "- [NCT00087373] AST and ALT ≤ 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 13\n",
            "- [NCT00003895] Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision\n",
            "- [NCT00003895] Patients whose melanoma is \\> 4.0 mm thick who have positive or negative regional lymph nodes are also eligible\n",
            "- [NCT00005617] Adults over the age of 18 with malignant melanoma.\n",
            "- [NCT00005617] Tumor stages T3N0M0 or greater are eligible for this trial according to the following: 1. I (\\<.75 to 1.5 mm or Clark level III-T1-2N0M0-)-not eligible 2. II (1.5 to 4 mm or level IV-T3N0M0-)-eligible 3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)-eligible 4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)-eligible 5. Relapsed melanoma-eligible\n",
            "- [NCT00005617] Patients previously treated with any form of therapy for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous treatment was completed \\>30 days prior to enrollment\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 14\n",
            "- [NCT00003895] After accrual to the original 26 patient goal, all patients must be enrolled prior to sentinel lymph node dissection; patients with previous lymph node dissection will not be eligible\n",
            "- [NCT00004067] Ipsilateral nodes must be cN0-1 by clinical evaluation.\n",
            "- [NCT00004067] Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.\n",
            "- [NCT00004067] Patients must have undergone either a total mastectomy and an axillary dissection or a lumpectomy and an axillary dissection. Sentinel node biopsy is permitted, but must be followed by an axillary dissection.\n",
            "- [NCT00004067] Patients treated by lumpectomy and axillary node dissection to be followed by breast radiation therapy must meet all the eligibility criteria in addition to the following: Generally, lumpectomy should be reserved for tumors \\<5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are eligible. The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients in whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary dissection has been performed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. Whole breast irradiation is required. Irradiation of regional lymph nodes is optional, but partial breast irradiation and irradiation of any internal mammary nodes are prohibited in this trial. Intent to irradiate the axilla or other regional node groups must be declared by the investigator prior to randomization for stratification purposes.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 15\n",
            "- [NCT00003895] White blood cell (WBC) \\>= 3500/mm\\^3\n",
            "- [NCT00071981] White blood cell (WBC) at least 4,000/mm\\^3\n",
            "- [NCT00071981] Lymphocyte count at least 700/mm\\^3\n",
            "- [NCT00074308] WBC at least 3,000/mm\\^3\n",
            "- [NCT00087373] WBC ≥ 3,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 16\n",
            "- [NCT00003199] ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,000/cells/mm\\^3 (transfusion independent) for at least 5 days before starting therapy\n",
            "- [NCT00003895] Platelets (Plt) \\>= 100,000/mm\\^3\n",
            "- [NCT00004067] Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.\n",
            "- [NCT00005949] Platelet count at least 100,000/mm\\^3\n",
            "- [NCT00024154] Platelet count at least 100,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 17\n",
            "- [NCT00003895] Hemoglobin \\>= 9 gm/100 ml\n",
            "- [NCT00005949] Hemoglobin at least 10 g/dL\n",
            "- [NCT00094003] Hemoglobin ≥9.0 g/dL\n",
            "- [NCT00146562] Hemoglobin \\> 9 g/dL\n",
            "- [NCT00217672] Hemoglobin ≥ 9.0 g/dL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 18\n",
            "- [NCT00003895] Patients must have recovered from any effects of major surgery and be free of significant systemic infection\n",
            "- [NCT00006412] Had surgery to remove their gallbladder within 3 months prior to study entry.\n",
            "- [NCT00028405] Patient has recovered from all previous surgery in the judgment of the Principal Investigator.\n",
            "- [NCT00071981] Recovered from prior major surgery\n",
            "- [NCT00087373] More than 2 weeks since prior surgery and recovered\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 19\n",
            "- [NCT00003895] Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment\n",
            "- [NCT00004074] Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; a woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant\n",
            "- [NCT00005617] Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment\n",
            "- [NCT00005764] Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.\n",
            "- [NCT00005949] Fertile patients must use effective contraception\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 20\n",
            "- [NCT00004067] The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins) and randomization must be less than or equal to 84 days.\n",
            "- [NCT00004067] Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.\n",
            "- [NCT00513136] At least 3 months since last breast cancer treatment (excluding hormonal therapy or Herceptin).\n",
            "- [NCT00546156] Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer\n",
            "- [NCT01095848] Patients with stage IV breast cancer who have received at least 1 course of hormonal or cytotoxic therapy for metastatic cancer. Patients must be off cytotoxic therapy with stable disease or better for 3 months or greater duration. Patients may have stable disease and still be on hormonal therapy.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 21\n",
            "- [NCT00004067] All of the following staging criteria must be met:\n",
            "- [NCT00004067] Primary tumor must be T1-3 by clinical and pathologic evaluation.\n",
            "- [NCT00004067] Primary tumor staged as T4 for any reason.\n",
            "- [NCT00087373] Stage IV disease\n",
            "- [NCT00087373] Detectable intratumoral T cells measured in the index lesion that is to be injected with rF-TRICOMTM by immunohistochemistry (IHC) for CD4, CD8 or another T cell marker, or by real time RT-PCR for CD8a, CD4, or other T cell transcripts\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 22\n",
            "- [NCT00004067] M0\n",
            "- [NCT00394251] T1-3, N1-3, M0, regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative\n",
            "- [NCT00402519] M0.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 23\n",
            "- [NCT00004067] The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.\n",
            "- [NCT00004067] Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. \"Marginal,\" \"borderline,\" etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.\n",
            "- [NCT00004074] Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use\n",
            "- [NCT00024154] Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)\n",
            "- [NCT00024154] Hormone receptor status:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 24\n",
            "- [NCT00004067] At the time of randomization, the patient must have had the following: history and physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam (for women who have a uterus and who will be taking tamoxifen) within the past year.\n",
            "- [NCT00004067] Bilateral malignancy or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant.\n",
            "- [NCT00123253] Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.\n",
            "- [NCT00129376] Negative extension study, including bilateral mammography, thoracic x-ray, computed tomography (CT)-scan or abdominal echography and bone scintigraphy.\n",
            "- [NCT00161291] Patients must have measurable disease by mammogram and/or breast ultrasound. The target lesion must not have been previously irradiated.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 25\n",
            "- [NCT00004067] Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is \\> 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)\n",
            "- [NCT00004074] Normal cardiac ejection fraction by echocardiogram or MUGA (i.e., greater than OSU lower limit of normal)\n",
            "- [NCT00024154] LVEF ≥ 50% by MUGA scan\n",
            "- [NCT00051103] Cardiac ejection fraction within the institutional range of normal as measured by MUGA (Multiple Gated Acquisition Scan).\n",
            "- [NCT00104884] Left ventricular ejection fraction (LVEF) \\> 40% by Multi Gated Acquisition Scan (MUGA)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 26\n",
            "- [NCT00004067] At the time of randomization:\n",
            "- [NCT00031486] Patient is expected to be available for follow-up visits of study drug administration and through the 24 month study visit.\n",
            "- [NCT00074308] More than 3 months\n",
            "- [NCT00074308] None of the following within the past 6 months:\n",
            "- [NCT00087373] More than 12 weeks\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 27\n",
            "- [NCT00004067] The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or \\<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).\n",
            "- [NCT00094003] Absolute neutrophil count (ANC) ≥1,500/mm3, without growth factor support\n",
            "- [NCT00206492] total neutrophil count must be \\>1.5 x 10\\^9/L, and\n",
            "- [NCT00217672] Absolute neutrophil count ≥ 1,500/mm\\^3\n",
            "- [NCT00258349] Absolute neutrophil count \\>= 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 28\n",
            "- [NCT00004067] Patients must have no clinical or radiologic evidence of metastatic disease. Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A patient with skeletal pain is eligible for inclusion in the study if bone scan and/or roentgenological examination fails to disclose metastatic disease.\n",
            "- [NCT00044291] Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease\n",
            "- [NCT00221221] no known or active metastatic disease.\n",
            "- [NCT00255762] Evidence of metastatic disease\n",
            "- [NCT00258349] Metastatic or chest wall recurrent disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 29\n",
            "- [NCT00004067] Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible only if this therapy is discontinued prior to randomization.)\n",
            "- [NCT00005617] A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy\n",
            "- [NCT00005764] Have had chemotherapy or radiation therapy within 4 weeks prior to screening visit (except for local treatment for Kaposi's sarcoma) or plan to have such treatment during the study.\n",
            "- [NCT00005764] Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical steroids) in the last 4 months or plan to take these drugs during the study.\n",
            "- [NCT00005949] At least 4 weeks since prior chemotherapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 30\n",
            "- [NCT00004067] Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. (Patients are eligible only if these medications are discontinued prior to randomization. These medications are not permitted while on the study except for the use of tamoxifen as described in the protocol)\n",
            "- [NCT00024154] No concurrent hormonal therapy, including tamoxifen\n",
            "- [NCT00036621] Tamoxifen (20mg) given orally once per day\n",
            "- [NCT00201929] Chemotherapy alone or in addition to tamoxifen as an appropriate treatment option Surgery Group:\n",
            "- [NCT00287534] continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 31\n",
            "- [NCT00004067] Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude a patient from being subjected to any of the treatment options or would prevent prolonged follow-up.\n",
            "- [NCT00004074] The patient must have failed standard curative and/or palliative therapies for their disease\n",
            "- [NCT00006412] Have failed previous statin or fibrate therapy (after 24 weeks of treatment) or have had side effects from these drugs.\n",
            "- [NCT00021463] Have had treatment with ABC.\n",
            "- [NCT00024154] No prior gefitinib\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 32\n",
            "- [NCT00004067] Cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin. This includes:\n",
            "- [NCT00004067] Active cardiac disease:\n",
            "- [NCT00004067] angina pectoris that requires the use of antianginal medication;\n",
            "- [NCT00004067] cardiac arrhythmia requiring medication;\n",
            "- [NCT00004067] severe conduction abnormality;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 33\n",
            "- [NCT00004067] patients with poorly controlled hypertension, i.e., diastolic greater than 100 mm/Hg. (Patients with hypertension who are well controlled on medication are eligible for entry.)\n",
            "- [NCT00005949] No antihypertensive medications from 1 day prior until 2 days after first course\n",
            "- [NCT00006412] Have uncontrolled high blood pressure within 4 weeks of study entry.\n",
            "- [NCT00074308] No uncontrolled hypertension within the past 6 months\n",
            "- [NCT00074308] Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 34\n",
            "- [NCT00004067] Sensory/motor neuropathy ≥ grade 2, as defined by the NCI's Common Toxicity Criteria version 2.0.\n",
            "- [NCT00077363] Patients with CTC v 3.0 grade 2-4 neuropathy are not eligible\n",
            "- [NCT00217672] Presence of neuropathy \\> grade 2 (NCI- Common Toxicity Criteria (CTC) version 3.0) at baseline\n",
            "- [NCT00225056] peripheral neuropathy less than or equal to grade 1\n",
            "- [NCT00255762] No peripheral neuropathy ≥ grade 2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 35\n",
            "- [NCT00004067] Contraindications to corticosteroid use which, in the opinion of the investigator, would preclude participation in this study.\n",
            "- [NCT00006290] Have a mental disability that, in the opinion of the researcher, could interfere with study participation.\n",
            "- [NCT00006412] Abuse drugs or alcohol, and the doctor thinks this may interfere with the study.\n",
            "- [NCT00024154] No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation\n",
            "- [NCT00074308] No psychiatric illness or social situation that would preclude study compliance\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 36\n",
            "- [NCT00004067] Concurrent treatment with other investigational agents.\n",
            "- [NCT00024154] No other concurrent investigational agents\n",
            "- [NCT00074308] No other concurrent investigational agents\n",
            "- [NCT00087373] No other concurrent investigational agents\n",
            "- [NCT00258349] No other concurrent investigational agents\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 37\n",
            "- [NCT00004067] Patients in whom the margins of the resected specimen are involved with invasive tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to obtain free margins are allowed. Patients in whom tumor is still present after the additional resection(s) must undergo mastectomy to be eligible.\n",
            "- [NCT00121134] Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.\n",
            "- [NCT00325598] Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.\n",
            "- [NCT00325598] Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.\n",
            "- [NCT00337064] Pathologically negative margins\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 38\n",
            "- [NCT00004074] Patients must have measurable or evaluable disease\n",
            "- [NCT00048633] Patients must have measurable disease as defined by the RECIST criteria in their breast/nodal regions or at a distant organ site(s).\n",
            "- [NCT00063570] Must have disease that can be measured.\n",
            "- [NCT00191243] measurable and/or non-measurable disease\n",
            "- [NCT00225056] must have measurable or evaluable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 39\n",
            "- [NCT00004067] Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.\n",
            "- [NCT00004074] No concurrent malignancy other than non-melanoma skin carcinoma\n",
            "- [NCT00005949] No currently active second malignancy (e.g., patient has completed therapy and is considered unlikely to have recurrence within 1 year) other than nonmelanoma skin cancer\n",
            "- [NCT00024154] No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n",
            "- [NCT00039793] Have a primary oncologist\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 40\n",
            "- [NCT00004074] Adequate hematopoietic, cardiac, renal, and hepatic function\n",
            "- [NCT00006412] Have liver disease.\n",
            "- [NCT00051103] Adequate kidney and liver function\n",
            "- [NCT00087776] Patients must have adequate renal and liver function\n",
            "- [NCT00191243] adequate liver / renal functions defined\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 41\n",
            "- [NCT00005617] No previous evidence of opportunistic infection\n",
            "- [NCT00074308] No ongoing or active infection requiring parenteral antibiotics\n",
            "- [NCT00087373] No uncontrolled active or chronic infection\n",
            "- [NCT00091819] Patients must be expected to require at least 7 days of intravenous antibiotic treatment\n",
            "- [NCT00107978] Patients must be expected to require at least 7 days of intravenous antibiotic treatment.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 42\n",
            "- [NCT00005617] Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): 1. Hemoglobin \\>9.0 g/dl 2. Platelets \\> 100000/mm3 3. WBC \\> 3000/mm3 4. Absolute Neutrophil Count \\> 1000/mm3\n",
            "- [NCT00048633] Adequate bone marrow function: platelets greater than or equal to 100,000/mm3, ANC greater than or equal to 1500 cells/mm3, hemoglobin greater than or equal to 8g/dl.\n",
            "- [NCT00087477] Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and absolute neutrophil count (ANC)≥ 1,500 cells/mm3.\n",
            "- [NCT00129376] Haematology: neutrophils \\>= 2.0 x10\\^9/l; platelets \\>= 100 x10\\^9/l; hemoglobin \\>=10 g/dl.\n",
            "- [NCT00155259] Adequate bone marrow reserve, defined as white blood cell (WBC)≧ 3,500/ mm3, absolute neutrophil count (ANC)≧ 1,500/mm3, platelets ≧ 100,000/mm3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 43\n",
            "- [NCT00005617] Positive skin test to common antigens (tetanus and candida)\n",
            "- [NCT00317980] Presence of 1 to 9 cutaneous lesions clinically compatible with leishmaniasis\n",
            "- [NCT00317980] Positive leishmanin skin test\n",
            "- [NCT00317980] Parasitological diagnosis confirmed through culture or genus-specific polymerase chain reaction (PCR) for Leishmania spp\n",
            "- [NCT01011309] Must have a clinical diagnosis of cutaneous leishmaniasis confirmed by positive identification of Leishmania parasite and identification of L. peruviana by PCR.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 44\n",
            "- [NCT00005617] Ability to give informed consent\n",
            "- [NCT00028405] Ability to provide informed consent.\n",
            "- [NCT00044291] Written informed consent obtained\n",
            "- [NCT00048633] Written informed consent.\n",
            "- [NCT00083239] Written informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 45\n",
            "- [NCT00005764] Patients may be eligible for this study if they:\n",
            "- [NCT00005764] Have taken d4T consistently for the 6 months before entering study. Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "- [NCT00005764] Are enrolled in other clinical studies.\n",
            "- [NCT00006290] Patients may be eligible for this study if they:\n",
            "- [NCT00006290] Are either female or heterosexual male (if enrolling in the University of Pennsylvania or Johns Hopkins University focus groups). Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 46\n",
            "- [NCT00005764] Are at least 18 years old.\n",
            "- [NCT00006412] Are at least 18 years old.\n",
            "- [NCT00650910] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT00821054] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT01473680] Is at least 18 years old, but not older than 61 years old;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 47\n",
            "- [NCT00005764] Have at least 1 of the following situations:\n",
            "- [NCT00006412] (This reflects a change in exclusion requirements.)\n",
            "- [NCT00024154] Not specified\n",
            "- [NCT00087373] Must have 1 of the following criteria:\n",
            "- [NCT00245960] Inclusion Criteria:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 48\n",
            "- [NCT00005764] (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in buttocks area; or\n",
            "- [NCT00005764] (b) an increase in lactate level greater than 2.2 mmol/L at the screening visit plus at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in the buttocks area; or\n",
            "- [NCT00006290] Are experiencing at least 1 of the following symptoms associated with fat changes due to HIV: 1) increase in belt or waist size; 2) increase in size of back of neck; 3) increase in bra, shirt, or blouse size to fit increasing breast size; 4) fat increase in other areas of the body; 5) loss of facial fat; 6) loss of fat in arms or legs; 7) loss of fat in buttocks.\n",
            "- [NCT00006290] Have diabetes or Cushing's disease or have had surgery that might otherwise explain changes in body fat.\n",
            "- [NCT00006290] Have changes in diet or physical activity that might explain changes in body fat.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 49\n",
            "- [NCT00005764] (c) an increase in lactate level greater than 2.2 mmol/L at screening visit plus at least 2 of the following: (1) shortness of breath, (2) weakness, (3) fast heartbeat, (4) recent weight loss (10 lbs. within the past 2 months), (5) pain and/or bloating in the abdomen, (6) nausea and/or vomiting and/or lack of appetite; or\n",
            "- [NCT00005764] Have serious medical conditions, such as congestive heart failure or other heart disease, which would affect the safety of the patient.\n",
            "- [NCT00074308] No other concurrent uncontrolled illness\n",
            "- [NCT00077363] Patients must not have any uncontrolled intercurrent illness including, but not limited to, chronic nausea/vomiting, complete or partial bowel obstruction, dysphagia/odynophagia with inability to swallow pills, ongoing or active infection, symptomatic cardiovascular disease, or other chronic medical or psychiatric conditions that would impair compliance or would substantially increase the risk of participating in this study\n",
            "- [NCT00255762] No other uncontrolled illness\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 50\n",
            "- [NCT00005764] Are able to read at a sixth-grade level.\n",
            "- [NCT00006290] Are able to speak and read English.\n",
            "- [NCT00106184] Able and willing to complete self-report questionnaires. Parents of pediatric participants will be required to complete the questionnaires on behalf of their children.\n",
            "- [NCT00179634] Working knowledge of English\n",
            "- [NCT00198250] able to read, write and speak English\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 51\n",
            "- [NCT00005764] Have diabetes or kidney failure.\n",
            "- [NCT00006412] Have diabetes requiring drug treatment or diabetes not controlled by diet.\n",
            "- [NCT00024154] Random blood sugar less than 2.5 times ULN\n",
            "- [NCT00025883] Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient. Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period. Presence of at least one of the following metabolic abnormalities: 1. Presence of diabetes as defined by the 2007 ADA criteria 1. Fasting plasma glucose greater than or equal to 126 mg/dL, or 2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or 3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl 2. Fasting insulin greater than 30 micro units/ml. 3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants) -Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.\n",
            "- [NCT00065663] Adequately controlled diabetes mellitus (type I or II) as defined by HbA1c \\< 10.0%\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 52\n",
            "- [NCT00005764] Are unable to take medications by mouth.\n",
            "- [NCT00034918] No Gastrointestinal pathology which could affect the bioavailability of ZD6474.\n",
            "- [NCT00051103] Able to swallow and retain oral medication\n",
            "- [NCT00359190] Ability to swallow and retain oral medication.\n",
            "- [NCT00383851] History of malabsorption syndromes or other gastrointestinal disorders that may affect ATN-224 or temozolomide absorption, including bowel obstruction, celiac disease, sprue, cystic fibrosis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 53\n",
            "- [NCT00005764] Are pregnant or breast-feeding.\n",
            "- [NCT00006290] Are pregnant.\n",
            "- [NCT00006412] Are pregnant or breast-feeding.\n",
            "- [NCT00021463] Are pregnant or breast-feeding.\n",
            "- [NCT00087373] Pregnant women\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 54\n",
            "- [NCT00005764] Have taken hydroxyurea within the past 3 days or plan to take this drug during the study.\n",
            "- [NCT00005949] At least 1 month since prior systemic corticosteroids\n",
            "- [NCT00005949] No concurrent systemic, inhaled, or topical corticosteroids\n",
            "- [NCT00006290] Have been on glucocorticoid therapy for a long time.\n",
            "- [NCT00006412] Have taken any prescription or non-prescription lipid-lowering drug within 14 days prior to study entry or for over 24 weeks in the past.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 55\n",
            "- [NCT00005949] 0201 positive by genotyping\n",
            "- [NCT00306553] 0201 haplotype\n",
            "- [NCT00700167] 0201 positive.\n",
            "- [NCT01026051] 0201 as assessed by DNA typing\n",
            "- [NCT01273181] 0201 positive Serology:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 56\n",
            "- [NCT00005949] Measurable disease as defined by the following:\n",
            "- [NCT00024154] Measurable disease\n",
            "- [NCT00050141] Measurable disease\n",
            "- [NCT00074308] Measurable disease (phase II)\n",
            "- [NCT00087373] Measurable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 57\n",
            "- [NCT00005949] At least 1 lesion accurately measured in at least 1 dimension\n",
            "- [NCT00005949] At least 20 mm by conventional techniques\n",
            "- [NCT00005949] Lesions considered intrinsically nonmeasurable include:\n",
            "- [NCT00083239] Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins\n",
            "- [NCT00087373] At least 1 cutaneous or lymph node mass ≥ 1 cm AND amenable to biopsy and percutaneous injection AND can be accurately measured with standard calipers\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 58\n",
            "- [NCT00005949] Bone lesions\n",
            "- [NCT00005949] Abdominal masses not confirmed and followed by imaging techniques\n",
            "- [NCT00051779] A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases.\n",
            "- [NCT00051779] Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention.\n",
            "- [NCT00077363] Patients must have at least one objective measurable disease parameter as defined by RECIST criteria; tumor measurements and evaluation of non-measurable sites must be performed within 4 weeks prior to registration\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 59\n",
            "- [NCT00005949] Leptomeningeal disease\n",
            "- [NCT00005949] No prior or concurrent liver or brain metastases\n",
            "- [NCT00024154] No untreated brain metastases or brain metastases undergoing radiotherapy\n",
            "- [NCT00024154] Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease\n",
            "- [NCT00048633] Patients with brain metastases whose disease remained stable for more than 3 months after completing therapy to the brain are eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 60\n",
            "- [NCT00005949] Ascites\n",
            "- [NCT00369655] Ascites\n",
            "- [NCT01005472] Terfenadine\n",
            "- [NCT01005472] Quinidine\n",
            "- [NCT01005472] Procainamide\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 61\n",
            "- [NCT00005949] Pleural/pericardial effusion\n",
            "- [NCT00369655] Pleural/pericardial effusion\n",
            "- [NCT00436605] No large pleural effusions\n",
            "- [NCT01283789] Pleural/pericardial effusion\n",
            "- [NCT01543126] Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 62\n",
            "- [NCT00005949] Lymphangitis cutis/pulmonis\n",
            "- [NCT00194363] Women without lymphedema must be 1-5 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must be 1-15 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must have stable lymphedema. ONE of the following:\n",
            "- [NCT00194363] A prior clinical diagnosis of lymphedema and having had any prior intensive lymphedema therapy on the affected arm As well as ALL of the following four conditions:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 63\n",
            "- [NCT00005949] At least 10 mm by spiral CT scan\n",
            "- [NCT00005949] Lesions situated in a previously irradiated area\n",
            "- [NCT00071981] Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST criteria)\n",
            "- [NCT00073528] Subjects with either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).\n",
            "- [NCT00077363] Previously irradiated tumors cannot be used to assess a clinical response; patients will not be eligible for this study if the previously irradiated tumors constitute the only site of measurable disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 64\n",
            "- [NCT00005949] No severe chronic pulmonary disease\n",
            "- [NCT00035958] JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)\n",
            "- [NCT00333437] Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.\n",
            "- [NCT00377949] Diagnosis of \"pre\" pulmonary arterial hypertension defined as:\n",
            "- [NCT00377949] Pulmonary function test with FVC \\>70% and a DLCO \\<55% of predicted or a FVC/DLco ratio \\>1.6. or\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 65\n",
            "- [NCT00005949] Not pregnant or nursing\n",
            "- [NCT00024154] Not pregnant or nursing\n",
            "- [NCT00035958] Pregnant or nursing female\n",
            "- [NCT00074308] Not pregnant or nursing\n",
            "- [NCT00087373] Not pregnant or nursing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 66\n",
            "- [NCT00003199] Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:\n",
            "- [NCT00005764] Have taken drugs that affect the immune system, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to the screening visit.\n",
            "- [NCT00005949] At least 4 weeks since prior immunotherapy\n",
            "- [NCT00005949] No prior interleukin-2\n",
            "- [NCT00005949] No other concurrent cytokines or growth factors\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 67\n",
            "- [NCT00006290] Are 18 years or older.\n",
            "- [NCT00028405] Age 18 or older.\n",
            "- [NCT00071981] Age: 18 and over\n",
            "- [NCT00107991] Age 18 or older.\n",
            "- [NCT00119158] Age 2 to 65 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 68\n",
            "- [NCT00006412] Are on a lipid-lowering diet based on the patient's statement and have been exercising for at least 30 days before being screened for the study. Patients will be asked if they were counseled by their health care provider. The lipid-lowering diet and exercise program do not have to be prescribed by a physician.\n",
            "- [NCT00006412] Take prescription lipid-lowering agents, other than those given by the study, and non-prescription lipid-lowering agents such as garlic supplements.\n",
            "- [NCT00178126] use wheelchair \\> 6 hours per day\n",
            "- [NCT00193037] Able to perform activities of daily living with minimal assistance\n",
            "- [NCT00235196] Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 69\n",
            "- [NCT00006412] Have a triglyceride (TG) level of at least 200 mg/dl and low-density lipoprotein (LDL) level of at least 130 mg/dl after fasting for 8 to 12 hours.\n",
            "- [NCT00811824] LDL cholesterol \\< 150\n",
            "- [NCT01283789] Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, patient may be included after initiation of appropriate lipid lowering medication with approval from the principal investigator.\n",
            "- [NCT01513356] Cholesterol \\< ULN - 7.75 mmol/L and Triglycerides \\< ULN - 2.5 x ULN (with lipid-lowering drugs permitted)\n",
            "- [NCT01997255] Acceptable fasting serum cholesterol and fasting triglycerides levels.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 70\n",
            "- [NCT00006412] Have hypothyroidism (low thyroid activity).\n",
            "- [NCT00006412] Take or have taken levothyroxine and liothyronine for hypothyroidism.\n",
            "- [NCT00336102] No diagnosis of hypothyroidism or hyperthyroidism.\n",
            "- [NCT00459771] Thyroid stimulating hormone between 0.5-3.9 MU/l\n",
            "- [NCT00777335] Clinically euthyroid function (thyroid-stimulating hormone (TSH) and free T4). (Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 71\n",
            "- [NCT00006412] Are allergic or sensitive to the study drug(s) or to other lipid-lowering drugs.\n",
            "- [NCT00021463] Are allergic to study drugs or any ingredient in them.\n",
            "- [NCT00074308] No prior allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biological composition to imatinib mesylate\n",
            "- [NCT00087373] No prior significant allergic reaction or hypersensitivity to eggs or egg products\n",
            "- [NCT00217672] A history of a severe hypersensitivity reaction to Bevacizumab, or Docetaxel or other drugs formulated with polysorbate 80.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 72\n",
            "- [NCT00006412] Were given radiation therapy within 30 days of study entry.\n",
            "- [NCT00024154] At least 2 weeks since prior radiotherapy\n",
            "- [NCT00024154] No prior radiotherapy to target lesions or only site of measurable disease\n",
            "- [NCT00024154] No concurrent radiotherapy\n",
            "- [NCT00028405] If patients have received radiotherapy to sites of disease other than the one planned for insertion of the light delivery catheter, then the patient must have no current local or systemic toxicity from the prior radiation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 73\n",
            "- [NCT00007280] Men or women at least 18 years old\n",
            "- [NCT00034918] Females, aged \\>= 18 years;\n",
            "- [NCT00044291] Women age 18 years or older\n",
            "- [NCT00087477] Males and females, age ≥ 18 years.\n",
            "- [NCT00094003] Male and female at least 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 74\n",
            "- [NCT00007280] At least one ulcer (wound) greater than or equal to 2 centimeters\n",
            "- [NCT00007280] Ulcer (wound) present for at least 3 months or greater\n",
            "- [NCT00035958] Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis\n",
            "- [NCT00065663] Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement\n",
            "- [NCT00065663] Ulcer present for \\> 6 weeks prior to study entry\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 75\n",
            "- [NCT00007280] Ankle/brachial index \\> 0.7\n",
            "- [NCT00065663] Affected limb transcutaneous oxygen pressure (TcpO2) \\> 30 mmHg at screening or a palpable dorsal pedal or posterior tibial pulse\n",
            "- [NCT00366132] Palpable pedal pulse in the affected leg OR peripheral vascular disease evaluation demonstrating acceptable blood supply to affected foot;\n",
            "- [NCT00446472] Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.\n",
            "- [NCT00448903] Ankle-brachial index (ABI) \\> or = 0,7\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 76\n",
            "- [NCT00021463] Are at least 13 years old and have signed consent of parent or guardian if under 18 years of age.\n",
            "- [NCT00175344] Age 18 years or older with ability to provide written informed consent.\n",
            "- [NCT00245960] 18 years of age or older at time of consent\n",
            "- [NCT00387062] Age 21 or older at the time of consent.\n",
            "- [NCT00403559] Must be 18 or older and sign written informed consent.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 77\n",
            "- [NCT00001137] Active alcohol or drug abuse that may interfere with the study\n",
            "- [NCT00021463] Abuse drugs or alcohol.\n",
            "- [NCT00424749] History of drug, alcohol, or chemical abuse within 6 months prior to screening\n",
            "- [NCT00438815] Narcotic addiction\n",
            "- [NCT00519246] No alcohol drinking.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 78\n",
            "- [NCT00024154] Male or female\n",
            "- [NCT00025883] All ethnic groups. Males and females.\n",
            "- [NCT00270972] Male or female\n",
            "- [NCT00324259] Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.\n",
            "- [NCT00365599] Both men and women of all races and ethnic groups are eligible for this trial.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 79\n",
            "- [NCT00024154] Granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00074308] Absolute granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00077363] Granulocytes \\> 1500/mm\\^3\n",
            "- [NCT00109005] Granulocyte count greater than 1,500/mm\\^3\n",
            "- [NCT00255762] Absolute granulocyte count ≥ 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 80\n",
            "- [NCT00024154] AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases is present)\n",
            "- [NCT00071981] Alkaline phosphatase no greater than 2 times ULN\n",
            "- [NCT00206492] alkaline phosphatase within 5 x ULN. 7. Performance status (WHO scale) \\<2. 8. Age \\> 18 years.\n",
            "- [NCT00255762] Alkaline phosphatase ≤ 3 times ULN\n",
            "- [NCT00349934] Serum ASAT and ALAT \\< 3 times the upper limit of normal or \\< 5 times upper limit of normal if liver metastases are present.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 81\n",
            "- [NCT00024154] PT and PTT no greater than 1.5 times ULN\n",
            "- [NCT00074308] INR no greater than 1.5\n",
            "- [NCT00074308] APTT normal\n",
            "- [NCT00087373] PT/PTT ≤ 1.25 times upper limit of normal (ULN)\n",
            "- [NCT00094003] PT and PTT \\< 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 82\n",
            "- [NCT00024154] No prior trastuzumab (Herceptin)\n",
            "- [NCT00153218] must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy\n",
            "- [NCT00153218] must not have received trastuzumab in the adjuvant or neoadjuvant setting\n",
            "- [NCT00153218] must have started trastuzumab treatment for metastatic disease any time between January 1996 to June 2003\n",
            "- [NCT00258349] More than 4 weeks since prior lapatinib ditosylate\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 83\n",
            "- [NCT00024154] See Disease Characteristics\n",
            "- [NCT00035958] Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter\n",
            "- [NCT00074308] Histologically or cytologically confirmed diagnosis of 1 of the following:\n",
            "- [NCT00087373] See Disease Characteristics\n",
            "- [NCT00257530] CL diagnosis confirmed\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 84\n",
            "- [NCT00024154] No concurrent topical eye agents\n",
            "- [NCT00121511] Patients must have clinical photoaging judged by rhytides, dyspigmentation, poikiloderma, lentigines, skin thinning, and/or telangiectases.\n",
            "- [NCT00176969] Not be taking any medications including topical medications\n",
            "- [NCT00253331] agree to apply gel as per protocol\n",
            "- [NCT00335179] Discontinuation of moisturizers\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 85\n",
            "- [NCT00024154] Concurrent bisphosphonates allowed for hypercalcemia and/or prophylaxis of bone metastases\n",
            "- [NCT00048633] Patients may receive concomitant bisphosphonate therapy for bone metastasis.\n",
            "- [NCT00051779] Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug\n",
            "- [NCT00258349] Concurrent bisphosphonates allowed provided therapy was initiated prior to study treatment\n",
            "- [NCT00324259] For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 86\n",
            "- [NCT00025883] Age greater than or equal to 6 months.\n",
            "- [NCT00104884] Age greater than or equal to 18\n",
            "- [NCT00133341] Age more or equal to 18 years.\n",
            "- [NCT00204529] ≥ 18 years of age and \\< 75 years of age\n",
            "- [NCT00304460] Age greater than or equal to18 years old.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 87\n",
            "- [NCT00028405] Tumor mass is not immediately adjacent to, or directly invading a major vessel or hollow viscus such that tumor necrosis could result in hemorrhage or perforation.\n",
            "- [NCT00044291] At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques)\n",
            "- [NCT00255762] No tumor invasion of major blood vessels\n",
            "- [NCT00388115] Tumor less than or equal to 2.0 cm in diameter.\n",
            "- [NCT00802932] Pathologic tumor size \\< 5.0 cm (Microscopic multifocality is allowed if total pathologic tumor size is within 5 cm)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 88\n",
            "- [NCT00028405] Patient has an ECOG performance status of 0-3 (Karnofsky 30 or higher).\n",
            "- [NCT00161291] Be ambulatory (outpatient) and have an ECOG PS \\<2 (Appendix F).\n",
            "- [NCT00251472] Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I).\n",
            "- [NCT00323206] Patients must have ECOG performance status 0-2\n",
            "- [NCT00324259] The patient must have an ECOG performance status of 0-2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 89\n",
            "- [NCT00031460] Less than or equal to 28 days of age at the time of initial presentation with CNS disease.\n",
            "- [NCT00031486] Patients who are 12 years of age or older.\n",
            "- [NCT00087620] Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama\n",
            "- [NCT00087776] Patients must be \\>= 18 years of age.\n",
            "- [NCT00155259] Patients must be ≦ 65 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 90\n",
            "- [NCT00031460] Birth weight greater than or equal to 800 grams.\n",
            "- [NCT00031486] Patients who weigh greater than or equal to 45.5kg (100 pounds).\n",
            "- [NCT00123253] For males: waist circumference \\> 95 cm and waist to hip ratio \\> 0.94;\n",
            "- [NCT00123253] For females: waist circumference \\> 94 cm and waist to hip ratio \\> 0.88.\n",
            "- [NCT00211133] Weight \\> = 40 kg (88 lbs)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 91\n",
            "- [NCT00034918] WHO performance status 0, 1 or 2 on the day of registration;\n",
            "- [NCT00048633] Zubrod performance status less than or equal to 2.\n",
            "- [NCT00191243] performance status 0-2 (WHO, Zubrod)\n",
            "- [NCT00197912] WHO-Performance Status 0-1\n",
            "- [NCT00237198] Patients whose performance status (PS) is 0～2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 92\n",
            "- [NCT00035958] Prior treatment with specific TNF-blocking agents\n",
            "- [NCT01511315] Subjects must not have received TNF-α inhibitors (such as infliximab, etanercept, adalimumab) within the 12 week period prior to Week 0 or during the study\n",
            "- [NCT02147600] adalimumab (40mg) subcutaneously every other week\n",
            "- [NCT02147600] at least 24 weeks of adalimumab treatment\n",
            "- [NCT02922192] TNF -α antagonists (including adalimumab, certolizumab, etanercept \\[not included for IBD\\], golimumab, infliximab, and natalizumab \\[IBD only\\])\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 93\n",
            "- [NCT00035958] Any of the following laboratory abnormalities at baseline: platelet count \\< 100,000/cmm, total white cell count of \\< 3000 cells/cmm, neutrophils \\< 1000 cells/cmm, serum bilirubin \\> 2 times upper limit of normal, estimated creatinine clearance of \\< 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to \\<13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)\n",
            "- [NCT00161291] Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \\> 1,500/mm3, hemoglobin \\> 8.0 g/dl, platelets \\> 75,000/mm3, total bilirubin \\< 2 mg/dl, serum creatinine \\< 2 mg/dl, Transaminases (AST, ALT) may be up to 2.0 x institutional upper limit of normal. In addition \\< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \\< 1.0.\n",
            "- [NCT00192517] Prior to randomization (must be within 21 days of the first administration of the study drug), all of the following: WBC less than or equal to 3,800/mm3; hematocrit above 32%, platelet count less than or equal to 140,000/mm3; AST, ALT, BUN, or creatinine\\<1.5 x ULN; and stool negative for occult blood\n",
            "- [NCT00197912] Acceptable CBC and blood chemistry results\n",
            "- [NCT00237185] Performance status ≤3 as defined by the Eastern Cooperative Oncology Group (ECOG) criteria, as well as a life expectancy ≥6 months and adequate end organ function defined as follows: Total bilirubin \\<1.5 times upper limit of normal (ULN), aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) \\<2.5 x ULN (or \\<5 x ULN if hepatic metastases were present), creatinine \\<1.5 x ULN, absolute neutrophil count (ANC) \\>1.5 x 10\\^9/L, platelet count \\>100 x 10\\^9/L\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 94\n",
            "- [NCT00035958] Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)\n",
            "- [NCT00071981] This extremity may still be considered for vaccination\n",
            "- [NCT00106184] Willing to forgo immunization with a live vaccine for the duration of the study\n",
            "- [NCT00356460] Documentation of flu vaccination if enrolled during flu season (as defined by the availability of vaccine). Otherwise, patient should receive the current flu vaccine \\> or = 1 wk before beginning GC1008 therapy.\n",
            "- [NCT00723528] Participants must agree not to receive Bacillus Calmette-Guérin (BCG) vaccination and live vaccine inoculation for 1 year after final treatment with the investigational product\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 95\n",
            "- [NCT00036621] ANC \\> 1500/mm3\n",
            "- [NCT00094003] Afebrile (≤37.5C or 99.5F)\n",
            "- [NCT00146562] ANC \\> 1,500/uL\n",
            "- [NCT00407888] ANC \\>= 1,500\n",
            "- [NCT00470301] FEV1 \\>= 1 L\\\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 96\n",
            "- [NCT00043472] To be considered at increased genetic risk of OC, subjects must have: Age greater than or equal to 30; No prior history of OC, including low malignant potential cancers (LMP), or primary papillary serous carcinoma of the peritoneum; At least one intact ovary: Satisfied one of the following additional criteria: The family of the subject has a documented deleterious BRCA1 or BRCA2 mutation - either:\n",
            "- [NCT00043472] the subject herself has tested positive for a deleterious BRCA1 or BRCA2 mutation; OR\n",
            "- [NCT00494234] Advanced breast cancer with positive BRCA1 or BRCA2 status\n",
            "- [NCT00526617] BRCA deficient tumor status\\\n",
            "- [NCT00526617] Patients must have histologically or cytologically confirmed solid tumors with a positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be considered eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 97\n",
            "- [NCT00043472] the subject has a first- or second-degree relative with a deleterious BRCA1 or BRCA2 mutation OR The family contains at least two ovarian and/or breast cancers among the subject or first- or second-degree relatives of the subject within the same lineage. This condition is satisfied by multiple primary cancers in the same person. Where breast cancer is required to meet this criterion, at least one breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown); OR The subject is of Ashkenazi Jewish ethnicity with one first-degree or two second-degree relatives with breast and/or OC. Where breast cancer is required to meet this criterion, at least one case must have been diagnosed prior to menopause (or at age less than or equal to 50, if age at menopause is unknown). OR The subject is of Ashkenazi ancestry and has had breast cancer herself. To meet this criterion, her breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown). OR The probability of carrying a BRCA1/2 mutation given the family pedigree of breast and OCs exceeds 20% as calculated by BRCAPRO. Note: BRCAPRO does NOT need to be calculated on everyone who enters the study. Patients are eligible based on a family history which meets one of the specific patterns described in this protocol, regardless of BRCAPRO results. BRCAPRO assessment is valuable in families where genetic testing has not been done, and the family history does not fit one of the specific patterns described, but the pattern of cancers leads you to believe that the family might still be considered high-risk. At that point, if the BRCAPRO estimate of being a mutation carrier is greater than 20 percent, then the patient IS eligible. Signed an approved informed consent and authorization permitting release of personal health information.\n",
            "- [NCT00150917] at least one 1st-degree relative with Breast Cancer\n",
            "- [NCT00329017] at high risk of developing breast cancer determined by family or personal history\n",
            "- [NCT00996710] Cancer at any age in 2 or more siblings suggestive of a genetic etiology, such as brothers with testicular germ cell tumor or sisters with breast cancer and ovarian cancer\n",
            "- [NCT01004666] High-risk for breast cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 98\n",
            "- [NCT00044291] ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher\n",
            "- [NCT00262834] ECOG 0-2 OR Karnofsky 60-100%\n",
            "- [NCT00436605] ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%\n",
            "- [NCT00659568] ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%\n",
            "- [NCT00720031] General state with Karnowsky greater than 80, ECOG = 0, 1 or 2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 99\n",
            "- [NCT00044291] Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago\n",
            "- [NCT00050141] Postmenopausal\n",
            "- [NCT00065325] Postmenopausal women defined as a women who has stopped having menstrual periods\n",
            "- [NCT00143052] Regular menses\n",
            "- [NCT00146601] Patients must be premenopausal.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 100\n",
            "- [NCT00048633] Patients much have recovered from acute toxic effects of any prior therapy.\n",
            "- [NCT00306553] All AEs form prior anticancer therapy have resolved to ≤ Grade 1.\n",
            "- [NCT00349934] Resolution of toxicity of prior therapy to grade \\< 2 (except alopecia).\n",
            "- [NCT00356460] At the time of enrollment, patients must be \\>4 wks since major surgery, radiotherapy, chemotherapy (\\> or =6 wks if they were treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab), immunotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to\\< or = Grade 1, exclusive of alopecia. Concurrent cancer therapy is not permitted. (In patients who received long acting agents, a treatment-free interval of 2 half-lives should be considered.)\n",
            "- [NCT00431275] Recovered from all prior surgical or adjuvant treatment-related toxicities\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 101\n",
            "- [NCT00050141] Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n",
            "- [NCT00071981] Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n",
            "- [NCT00087477] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "- [NCT00104884] Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n",
            "- [NCT00281697] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 102\n",
            "- [NCT00051103] Signed informed consent\n",
            "- [NCT00123253] Signed informed consent\n",
            "- [NCT00155259] Signed informed consent\n",
            "- [NCT00202241] signed informed consent\n",
            "- [NCT00211133] Must have signed an informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 103\n",
            "- [NCT00051103] Tumor tissue available for testing.\n",
            "- [NCT00198237] Pre-treatment core or incisional bx w/ adequate tissue for histology \\& genomic/proteomic analysis.\n",
            "- [NCT00235235] Disease amenable to pre-treatment core or incisional biopsy with adequate tissue for histology and genomic/proteomic analysis.\n",
            "- [NCT00293865] Previous conservative surgical biopsy\n",
            "- [NCT00323206] Patients must have a minimum of two eligible tumors and may have up to four eligible tumors treated with electroporation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 104\n",
            "- [NCT00051103] Adequate bone marrow function\n",
            "- [NCT00087776] Patients must have adequate bone marrow function.\n",
            "- [NCT00191243] adequate bone marrow reserve defined\n",
            "- [NCT00430105] red cell casts.\n",
            "- [NCT00650910] Adequate bone marrow function.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 105\n",
            "- [NCT00071981] No disease progression in the brain for the past 3 months\n",
            "- [NCT00257530] \\>4 weeks time disease\n",
            "- [NCT00317980] Disease duration of 2 to 20 weeks\n",
            "- [NCT00321178] Disease duration no longer than six months\n",
            "- [NCT00379431] Disease duration less than 4 years (from the appearance of skin changes (oedema, fibrosis)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 106\n",
            "- [NCT00071981] Adequate organ function measured within 4 weeks before randomization:\n",
            "- [NCT00455312] Requirement for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or erythropoietin, or\n",
            "- [NCT00471887] Adequate bone marrow and hepatic function determined within 30 days prior to enrollment, defined as:\n",
            "- [NCT00483223] Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol\n",
            "- [NCT00618826] Patients must have adequate bone marrow reserve as evidenced by the following: ANC \\> 1500/mcL, platelets \\> 100, 000/mcL, and hemoglobin \\> 9.0 gm/dL. These results must be obtained within 28 days prior to registration.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 107\n",
            "- [NCT00071981] Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) no greater than 2 times upper limit of normal (ULN)\n",
            "- [NCT00206492] liver transaminases within 2.5 x ULN,\n",
            "- [NCT00217672] Alkaline phosphatase (AP) normal AND Angiotensin Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN) or AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN or AP ≤ 5 times ULN AND AST or ALT normal. Exclusion Criteria\n",
            "- [NCT00254592] Patients must have a serum creatinine and bilirubin ≤ the institutional upper limit of normal, and an serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.\n",
            "- [NCT00404066] Aspartate aminotransferase (AST); alanine aminotransferase (ALT); and alkaline phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 108\n",
            "- [NCT00071981] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00074308] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00087373] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n",
            "- [NCT00087477] Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity. Localized palliative radiation therapy to non-target lesions is permitted within the four weeks prior to randomization.\n",
            "- [NCT00109005] Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate aminotransferase (AST) less than 10 x upper limit of normal. 6. Patients must have recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified above. 7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation therapy, or biological therapy, for at least 4 weeks prior to starting study medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy. 8. Patients must not have an acute, critical illness, including a serious untreated infection. 9. Patients must be willing to return to the National Institutes of Health (NIH) for follow-up visits. 10. All patients who are sexually active and able to conceive will be required to use contraception during treatment with lenalidomide. Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women of child bearing potential will be required to use two methods of birth control, one highly effective method and one additional method, at the same time during treatment and for one month after the completion of lenalidomide treatment. These methods must be used for at least four weeks before starting lenalidomide, during treatment, and for at least four weeks following the last dose of lenalidomide. Acceptable forms of birth control include: Intrauterine device (IUD) Latex condom Hormonal (Birth control pills, injections, implants) Diaphragm Tubal Ligation Cervical cap Partner's vasectomy Two barrier methods may be used if the physician agrees that the highly effective methods are medically contraindicated. Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the start of lenalidomide. Men who are sexually active must agree to use latex condoms. Patients must be able to understand and sign informed consent form. Patients must be greater than or equal to 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 109\n",
            "- [NCT00074308] Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)\n",
            "- [NCT00155259] Women with histological proven LABC, without metastasis, and no prior therapy. LABC is defined as follows： 1. Tumor more than 5 cm in diameter 2. Tumor involvement of chest wall (ribs or intercostals or serratus anterior muscles) or skin (ipsilateral cutaneous edema, ulceration, or satellite nodules) 3. Clinical evident inflammatory carcinoma 4. Ipsilateral fixed axillary adenopathy\n",
            "- [NCT00237185] Men and non-pregnant women ≥18 years of age with the histopathologically documented diagnosis of malignant GIST that was unresectable and/or metastatic. Confirmation of KIT (CD117) expression via immunohistochemical analysis of tumor sample was also required\n",
            "- [NCT00240682] Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression.\n",
            "- [NCT00526617] Evaluable disease, histologically confirmed malignancy (metastatic or unresectable) and standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 110\n",
            "- [NCT00074308] No history of bleeding diathesis or coagulopathy\n",
            "- [NCT00074308] No recent or concurrent full-dose anticoagulants (except as required to maintain patency of preexisting permanent indwelling IV catheters) or thrombolytic agent\n",
            "- [NCT00077363] Because of the potential for a drug interaction between warfarin and both tipifarnib and capecitabine, patients taking warfarin adjusted to an elevated INR are not eligible; patients taking prophylactic low-dose warfarin (i.e., 1 mg daily) are eligible, but a PT and INR are required within 2 weeks of registration and must be normal\n",
            "- [NCT00087373] No uncontrolled bleeding disorder that would increase the risk of bleeding from the injected lesion\n",
            "- [NCT00087373] No active thrombotic thrombocytopenic purpura within the past 2 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 111\n",
            "- [NCT00074308] Grade II or greater peripheral vascular disease\n",
            "- [NCT00074308] Other arterial thromboembolic event\n",
            "- [NCT00161291] No history of thrombosis during the previous year.\n",
            "- [NCT00217672] Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (\\> grade 2) peripheral vascular disease\n",
            "- [NCT00255762] No clinically significant peripheral vascular disease\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 112\n",
            "- [NCT00074308] Transient ischemic attack\n",
            "- [NCT00074308] Cerebrovascular accident\n",
            "- [NCT00255762] No clinically significant stroke within the past 6 months\n",
            "- [NCT00369655] Cerebrovascular accident or stroke within the past 6 months\n",
            "- [NCT01005472] Cerebrovascular accident or transient ischemic attack\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 113\n",
            "- [NCT00074308] No seizures not controlled with standard medical therapy\n",
            "- [NCT00087373] No active seizure disorder\n",
            "- [NCT00255762] No uncontrolled seizures\n",
            "- [NCT00436605] Uncontrolled seizure disorder\n",
            "- [NCT01233505] Patients who have active seizures or history of seizures are ineligible\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 114\n",
            "- [NCT00074308] No serious, nonhealing wound, ulcer, or bone fracture\n",
            "- [NCT00087373] No skin disease and/or open unhealing wounds\n",
            "- [NCT00091819] infected burn (see exclusion criteria for important qualifications)\n",
            "- [NCT00091819] wound infections\n",
            "- [NCT00107978] infected burn (see exclusion criteria for important qualifications);\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 115\n",
            "- [NCT00074308] No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)\n",
            "- [NCT00436605] More than 7 days since prior and no concurrent CYP3A4 inhibitors\n",
            "- [NCT00436605] No concurrent CYP3A4 inducers\n",
            "- [NCT00667121] Willing to avoid known inhibitors of the CYP2D6 system for duration of study\n",
            "- [NCT01005472] treatment with potent CYP3A4 inhibitors 7 days before study dosing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 116\n",
            "- [NCT00077363] ECOG performance status 0-2\n",
            "- [NCT00083239] ECOG Performance Status of 0, 1, or 2\n",
            "- [NCT00146562] ECOG performance status 0 or 1\n",
            "- [NCT00146601] ECOG performance status 0-2\n",
            "- [NCT00225056] ECOG of 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 117\n",
            "- [NCT00077363] No prior radiotherapy other than to the conserved breast, to the postmastectomy chest wall or to a limited field involving less than 25% of marrow - containing bone\n",
            "- [NCT00171340] Recent surgery for breast cancer\n",
            "- [NCT00262834] No prior radiotherapy to the ipsilateral breast\n",
            "- [NCT00262834] No prior or concurrent radiotherapy for breast cancer\n",
            "- [NCT00894712] Patients must not have received prior radiation therapy to the breast.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 118\n",
            "- [NCT00083239] Expected survival ≥12 weeks\n",
            "- [NCT00304460] Expected survival greater than three months.\n",
            "- [NCT00306553] Expected survival of at least 6 months.\n",
            "- [NCT00349934] Expected survival longer than three months.\n",
            "- [NCT00356460] Expected survival ≥5 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 119\n",
            "- [NCT00087373] No active autoimmune disorders or disease\n",
            "- [NCT00610857] Patients must not have autoimmune disorders (except vitiligo). Patients with positive titers for autoimmune antibodies are allowed on the study in the absence of history of clinical manifestations of autoimmune disease.\n",
            "- [NCT00753415] Participant has undergone splenectomy or has any history of autoimmune disorder.\n",
            "- [NCT00753415] Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.\n",
            "- [NCT01543126] There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 120\n",
            "- [NCT00087373] Children \\< 3 years of age\n",
            "- [NCT00123253] Ages 18 to 65 years inclusive\n",
            "- [NCT00191815] You are female in the age of 18 to 75 years old.\n",
            "- [NCT00795951] Children and adolescents 6 to 18 years of age, and in general good health.\n",
            "- [NCT00979745] Aged 18 - 70 years (inclusive)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 121\n",
            "- [NCT00087776] Patients must have Eastern Cooperative Oncology Group performance status of 0 - 2.\n",
            "- [NCT00574145] Eastern Cooperative Oncology Group performance status of 0, 1 or 2\n",
            "- [NCT01052142] Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n",
            "- [NCT01220128] Eastern Cooperative Oncology Group (performance status of 0 or 1 at the time of study treatment allocation.\n",
            "- [NCT01344109] Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at initiation of study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 122\n",
            "- [NCT00094003] Life expectancy \\> 3 months\n",
            "- [NCT00240682] Life expectancy \\> 3 months.\n",
            "- [NCT00369655] Life expectancy \\> 3 months\n",
            "- [NCT00431704] Life expectancy \\>3 months\n",
            "- [NCT00436605] Life expectancy \\> 3 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 123\n",
            "- [NCT00094003] ECOG performance status: 0-1\n",
            "- [NCT00121134] ECOG performance status 0-1\n",
            "- [NCT00198237] ECOG performance status 0-1\n",
            "- [NCT00217672] ECOG performance status 0-1\n",
            "- [NCT00369655] ECOG performance status 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 124\n",
            "- [NCT00094003] Serum calcium \\<11 mg/dL\n",
            "- [NCT00324259] Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.\n",
            "- [NCT00526617] Normal sodium, calcium and magnesium levels\n",
            "- [NCT00650910] Potassium and magnesium within the normal range of institutional values. \\[Serum potassium or magnesium values that fall outside the normal range may be repeated once at the discretion of the investigator, provided they are considered to be clinically insignificant.\\]\n",
            "- [NCT00777335] Biochemistry\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 125\n",
            "- [NCT00094003] Amylase and lipase ≤ ULN\n",
            "- [NCT01782508] Amylase and lipase \\< 1.5 x ULN\n",
            "- [NCT02272998] Serum lipase and amylase =\\< 1.5 x ULN\n",
            "- [NCT02303951] Amylase and lipase ≤ 1.5 x ULN\n",
            "- [NCT02519322] Lipase \\< 1.5 X ULN (within 28 days of first study treatment)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 126\n",
            "- [NCT00098358] Moderate to severe facial acne vulgaris\n",
            "- [NCT00098358] 20 to 60 facial inflammatory lesions\n",
            "- [NCT00098358] 10 to 200 facial non-inflammatory lesions\n",
            "- [NCT00098358] No more than 3 facial nodular cystic lesions\n",
            "- [NCT00126399] 10 to 40 papules and pustules and ≤2 nodules\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 127\n",
            "- [NCT00104884] Normal organ and marrow function\n",
            "- [NCT00470301] Normal organ function including:\n",
            "- [NCT00546156] Normal organ function as outlined in the protocol\n",
            "- [NCT00580333] Normal organ function as described in the protocol\n",
            "- [NCT00627978] Patients must have normal organ and marrow function as defined below:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 128\n",
            "- [NCT00106184] Adults with definite or probable dermatomyositis or polymyositis and pediatric patients five years of age and over with definite or probable juvenile dermatomyositis (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e., first symptom of myositis or dermatomyositis rash) is less 18 years of age\n",
            "- [NCT00106184] Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test) score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the following criteria: 1. An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. OR 2. If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at least 3 abnormal core set measures.\n",
            "- [NCT01734369] for myositis subjects are: -Diagnosis of PM, DM or IBM during military service. Subjects may be active duty or no longer active duty personnel. A matrix diagnosis of myositis will be based on ICD-9 codes, laboratory tests and medical records in an attempt to match criteria for probable or definite PM, DM or IBM The inclusion criteria for matched control subjects are: -The same gender, race, age within 10 years, and service in the military within 10 years as the myositis subject. The exclusion criteria for control subjects are: -A matrix diagnosis of autoimmune or chronic muscle disease based on ICD-9 codes and medical records. For Aims 2 and 3 of the study: The inclusion criteria for enrollment of myositis subjects are:\n",
            "- [NCT01734369] Diagnosis of myositis during military service or service as a military contractor or civilian working for the military, based on criteria for probable or definite PM or DM, or clinically or pathologically defined or possible IBM. Subjects may be active duty or no longer active duty personnel. Military contractors or civilians working for the military include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998 and developed myositis will be eligible for this study.\n",
            "- [NCT01734369] Persons with military experience or having served as a military contractor or civilian working for the military attending the same clinic or hospital as the myositis subject to which they are matched, or if not available, volunteers from the general community (such as other participating military or VA hospitals, private HCPs, or the NIH healthy volunteer program), gender- race- and age- (within 10 years) and military service period (within 10 years) matched to the myositis subject. Military contractors include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 129\n",
            "- [NCT00119158] Clinical diagnosis of (Atopic Dermatitis) AD according to the American Academy of Dermatology (AAD) Consensus Conference (2001)\n",
            "- [NCT00257582] Eczema \\& dermatitis group\n",
            "- [NCT00257582] Atopic dermatitis\n",
            "- [NCT00267826] Must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin and Rajka and having active inflammation.\n",
            "- [NCT00346398] Diagnosed with eczema (atopic dermatitis)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 130\n",
            "- [NCT00119158] Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or\n",
            "- [NCT00462280] For women of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she:\n",
            "- [NCT00479674] No reproductive potential:\n",
            "- [NCT00563524] Men and Women of nonchildbearing potential 18 years or older.\n",
            "- [NCT00583739] Women of childbearing potential are eligible for this study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 131\n",
            "- [NCT00119405] Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI\n",
            "- [NCT01033552] UCB\n",
            "- [NCT01889238] Advanced AR+ TNBC;\n",
            "- [NCT01957514] Subjects have metastatic TNBC\n",
            "- [NCT02214381] All TN\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 132\n",
            "- [NCT00121511] Patients must have actinic keratoses\n",
            "- [NCT00308854] Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on head and/or face (hairless areas)\n",
            "- [NCT00335179] Have actinic keratoses on balding scalp\n",
            "- [NCT00601640] No more than 10 actinic keratoses on the left forearm, and no actinic keratoses in the treatment area\n",
            "- [NCT00991861] At least 4-10 clinically assessed actinic keratosis grade I to II (according to Olsen et al, 1991) in the face/forehead and/or on the bald scalp\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 133\n",
            "- [NCT00126399] Healthy patients with rosacea\n",
            "- [NCT00989014] Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea.\n",
            "- [NCT01016782] Clinical diagnosis of rosacea\n",
            "- [NCT01016782] Good health with the exception of rosacea\n",
            "- [NCT01359228] \\> 18 years of age with rosacea defined as:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 134\n",
            "- [NCT00126399] Score of 2 to 4 on the IGA\n",
            "- [NCT00143052] Hirsute score: \\>7\n",
            "- [NCT00143052] Hirsute score: 0 (without razing)\n",
            "- [NCT00177840] Average to above average fatigue\n",
            "- [NCT00192517] PASI score greater than 12\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 135\n",
            "- [NCT00126724] Rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) diagnosed according to established criteria.\n",
            "- [NCT00265096] Psoriatic arthritis (PsA) diagnosed \\> 6months prior\n",
            "- [NCT00265096] Active PsA at the time of screening and at baseline visits, with \\>= 3 swollen joints and \\>= 3 tender joints\n",
            "- [NCT00265096] Have at least 1 of the PsA subsets (DIP joint arthritis, polyarticular arthritis without rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis)\n",
            "- [NCT00456092] Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or asymmetrical peripheral joint involvement for at least 6 months\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 136\n",
            "- [NCT00126724] Persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory arthritis in at least one peripheral joint eligible for injection.\n",
            "- [NCT01169844] The number of tender joints was the same or more than the core study baseline; or,\n",
            "- [NCT01169844] The number of swollen joints was the same or more than the core study baseline; or,\n",
            "- [NCT01877668] Must have 3 or more swollen joints AND 3 or more tender joints\n",
            "- [NCT02047851] Pain from at least two peripheral joints and/or inflammatory back pain\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 137\n",
            "- [NCT00126724] For subjects with RA, an adequate trial of at least one disease-modifying drug (DMARD) prior to screening.\n",
            "- [NCT00126724] For subjects currently on DMARD(s), a stable regimen of inflammatory arthritis for the previous three months, with no changes in doses four weeks prior to screening.\n",
            "- [NCT00265096] Active arthritis despite current disease modifying anti-rheumatic drug (DMARD) or nonsteroidal anti-inflammatory drug (NSAID) therapy\n",
            "- [NCT01877668] Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).\n",
            "- [NCT02181673] Have active PsA despite current or previous disease-modifying antirheumatic drugs (DMARD) and/or nonsteroidal anti-inflammatory drug (NSAID) therapy. DMARD therapy is defined as taking a DMARD for at least 3 months, or evidence of DMARD intolerance. NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of NSAID intolerance\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 138\n",
            "- [NCT00126724] Age greater than 18 years and less than 75 years at the time of screening.\n",
            "- [NCT01026051] 18 years of age or older at screening evaluation\n",
            "- [NCT01220128] The patient is ≥ 18 years of age at the time the informed consent to screening has been obtained.\n",
            "- [NCT01689285] Subject is at least 18 and not older than 55 years of age at screening.\n",
            "- [NCT01971346] At least 18 years of age at screening.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 139\n",
            "- [NCT00133315] Age\\>18 years old\n",
            "- [NCT00197912] Age: \\> 18\n",
            "- [NCT00268125] Age \\> 18 years\n",
            "- [NCT00293865] Age \\> 18 years\n",
            "- [NCT00323206] Age \\> 18 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 140\n",
            "- [NCT00133315] No signs of tuberculosis (TB)\n",
            "- [NCT00134368] Subjects must have a negative tuberculin (TB) skin test at entry into the study\n",
            "- [NCT00307437] Have no history of latent or active tuberculosis (TB)\n",
            "- [NCT00640393] Patient with negative purified protein derivative (PPD) within 3 months of Day 0;\n",
            "- [NCT00687401] Eligible according to tuberculosis (TB) eligibility assessment, screening and early detection of reactivation rules.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 141\n",
            "- [NCT00133341] Signed informed consent.\n",
            "- [NCT00548184] Signed informed consent.\n",
            "- [NCT00691678] Signed informed consent.\n",
            "- [NCT00717015] Signed informed consent.\n",
            "- [NCT00941330] Signed informed consent.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 142\n",
            "- [NCT00134368] Vitiligo patients aged 18 years and older\n",
            "- [NCT00134368] Vitiligo patients with evaluable lesions; duration of 3 months to 10 years.\n",
            "- [NCT00631865] Stable form of vitiligo (no increase in the size of the lesion for at least one year)\n",
            "- [NCT00907062] self selected candidates identifying themselves to suffer with vitiligo vulgaris of any duration\n",
            "- [NCT00907062] stable or progressing vitiligo\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 143\n",
            "- [NCT00134368] Disease interferes significantly with quality of life and/or involving 3% or more body surface area\n",
            "- [NCT00707070] PASI \\> 10 e/o BSA (Body Surface Area) \\> 10\n",
            "- [NCT00927212] Diseased Body surface area (BSA) ≤ 20%.\n",
            "- [NCT01049243] Percentage of overall body surface are of involvement (BSA) must be ≥2%\n",
            "- [NCT01093469] Percentage of overall body surface area of involvement (BSA) must be \\> 1% and may include facial and intertriginous skin.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 144\n",
            "- [NCT00135720] Have a clinical diagnosis of pemphigus vulgaris\n",
            "- [NCT00135720] Have at least 6 active pemphigus lesions (blisters or erosions)\n",
            "- [NCT00135720] Have no adverse effects due to combining etanercept with concurrent pemphigus medications\n",
            "- [NCT00135720] Be on stable dose of current pemphigus medications for at least one month\n",
            "- [NCT00431119] clinical lesions suggestive of bullous pemphigoid\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 145\n",
            "- [NCT00143052] Hirsute subjects:\n",
            "- [NCT00355485] Subjects must be in generally good health.\n",
            "- [NCT00839280] Healthy subjects\n",
            "- [NCT01422538] Subject in good health.\n",
            "- [NCT01519206] Subject in good health\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 146\n",
            "- [NCT00146562] 18 years of age or older\n",
            "- [NCT00202241] 18 years of age or older\n",
            "- [NCT00483223] 18 years of age or older\n",
            "- [NCT00546156] 18 year of age or older\n",
            "- [NCT00580333] 18 years of age or older\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 147\n",
            "- [NCT00150917] live within one hour of downtown Toronto\n",
            "- [NCT00198250] living within 60 miles of Indianapolis\n",
            "- [NCT00286598] Residence within 50 miles of Columbia, MO\n",
            "- [NCT00601640] Resident of Pima or an adjoining Southern Arizona county\n",
            "- [NCT01174875] Singapore citizens or Singapore Permanent Residents\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 148\n",
            "- [NCT00157079] Subjects \\> 24 months of age\n",
            "- [NCT00256230] Subjects must be between the ages of 18 and 80.\n",
            "- [NCT00346606] The subject ≥ 12 years old.\n",
            "- [NCT00366132] Subjects age \\> 18 years;\n",
            "- [NCT00385502] Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 149\n",
            "- [NCT00175344] Patients must be able to provide informed consent and be physically able to perform daily self-administered breast scar massage\n",
            "- [NCT00179634] Skin sparing mastectomy with transverse rectus abdominal muscle (TRAM) or deep inferior epigastric perforator (DIEP) flap reconstruction planned\n",
            "- [NCT00201929] Candidate for breast conserving surgery\n",
            "- [NCT00455533] Unfit for breast and/or axillary surgery\n",
            "- [NCT00499681] Scheduled to undergo surgical treatment with either segmental resection or total mastectomy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 150\n",
            "- [NCT00176969] Must have alopecia totalis or universalis.\n",
            "- [NCT00176969] Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.\n",
            "- [NCT00746980] clinical diagnosis of alopecia totalis, alopecia universalis, or severe ophiasis variant of alopecia areata.\n",
            "- [NCT01008774] Absence of alopecia at inclusion\n",
            "- [NCT01203189] Practice less than or equal to once weekly hair washing\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 151\n",
            "- [NCT00176969] Be in good health.\n",
            "- [NCT00427609] With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.\n",
            "- [NCT00467233] Good health.\n",
            "- [NCT00509977] Good health.\n",
            "- [NCT00540917] apparent good health\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 152\n",
            "- [NCT00178126] Braden score of 18 or less\n",
            "- [NCT00178126] combined activity and mobility Braden sub-score of 5 or less\n",
            "- [NCT01333670] Braden index at baseline\\>=10\n",
            "- [NCT02363842] Deemed at risk for tissue breakdown by clinical staff via an institutional assessment protocol such as the Braden Scale, the Waterlow Scale or the Norton Scale.\n",
            "- [NCT03351049] total Braden Score \\<= 18\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 153\n",
            "- [NCT00190697] Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia).\n",
            "- [NCT00193037] Adequate bone marrow, liver and kidney function\n",
            "- [NCT00378313] Evidence of adequate organ function (liver, bone marrow, kidney)\n",
            "- [NCT00383851] Patients must have adequate organ and marrow function as defined below:\n",
            "- [NCT00704158] Adequate bone marrow, renal and liver function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 154\n",
            "- [NCT00192517] Plaque psoriasis involving at least 10% of body surface area (Appendix A)\n",
            "- [NCT00192517] Currently receiving no therapy for psoriasis except emollients\n",
            "- [NCT00245960] Clinically stable, plaque psoriasis involving more than 10% of the body surface area\n",
            "- [NCT00265096] Active plaque psoriasis with a lesion \\>= 2cm in diameter\n",
            "- [NCT00307437] Plaque-type psoriasis diagnosed \\>= 6 months prior\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 155\n",
            "- [NCT00201929] Female\n",
            "- [NCT00268125] Woman\n",
            "- [NCT00404066] Female\n",
            "- [NCT00513058] Female\n",
            "- [NCT00653718] Female\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 156\n",
            "- [NCT00204529] Informed consent\n",
            "- [NCT00204581] Informed consent\n",
            "- [NCT00257582] Giving informed consent\n",
            "- [NCT00388115] Informed consent given.\n",
            "- [NCT00689832] Informed consent\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 157\n",
            "- [NCT00206492] Hematocrit \\>30%,\n",
            "- [NCT00456092] Hematocrit ≥ 27%\n",
            "- [NCT00544765] Hematology:\n",
            "- [NCT00712621] Not specified Hematopoietic:\n",
            "- [NCT00777335] Hematology\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 158\n",
            "- [NCT00213460] patients with systemic sclerosis, who had an upper intestinal tract manometry 5 years before, with:\n",
            "- [NCT00213525] patients with scleroderma with:\n",
            "- [NCT00251238] Primary Raynaud´s phenomenon\n",
            "- [NCT00251238] Duration of Raynaud´s phenomenon at least 2 years\n",
            "- [NCT00253331] clinical diagnosis of Raynaud's phenomenon\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 159\n",
            "- [NCT00217672] Required laboratory values\n",
            "- [NCT00359190] Clinical labs are within acceptable ranges.\n",
            "- [NCT00442260] Normal laboratory values as explained below.\n",
            "- [NCT00456092] Must meet the following laboratory criteria:\n",
            "- [NCT00650910] Clinical lab results with ranges as stated per protocol.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 160\n",
            "- [NCT00217672] Total bilirubin \\< 1.0 x upper limit of normal (ULN) (patients with documents Gilbert's syndrome are eligible).\n",
            "- [NCT00258349] Bilirubin =\\< 1.5 mg/dL (3 mg/dL in the presence of Gilbert's disease provided direct bilirubin is normal)\n",
            "- [NCT00304460] Serum creatinine less than or equal to 1.4 mg/dl or creatinine clearance greater than or equal to 90 mL/min, and total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.\n",
            "- [NCT00349934] Total bilirubin \\< 20 mmol/L, except for familial cholemia (Gilbert's disease).\n",
            "- [NCT00471887] Total bilirubin \\< 2 x ULN (except patients with documented Gilbert's syndrome)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 161\n",
            "- [NCT00221221] willing to accept random assignment.\n",
            "- [NCT00513136] Willing to be randomized\n",
            "- [NCT00945607] Willingness to complete CSES, PSS-14 and FACIT-F scales\n",
            "- [NCT01275872] Willing to participate\n",
            "- [NCT01751893] Willing to participate\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 162\n",
            "- [NCT00221221] not currently participating in another QoL intervention.\n",
            "- [NCT01613482] Inclusion in an other clinical trial or in the 4 weeks before th inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT02799121] The patient agrees to abstain from enrolment in any other interventional clinical trial for the duration of the study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 163\n",
            "- [NCT00225056] must have adequate organ function\n",
            "- [NCT00237198] Patients with sufficient organ function to evaluate the safety\n",
            "- [NCT00320541] Must have adequate organ function as seen in blood test results. Exclusion Criteria:\n",
            "- [NCT00386685] Adequate organs functions\n",
            "- [NCT00496366] Adequate end organ function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 164\n",
            "- [NCT00225056] must be at least 19 years of age\n",
            "- [NCT00267826] Must be at least 18 years of age.\n",
            "- [NCT00270569] Age must be older than 18 and younger than 75 year-old.\n",
            "- [NCT00673829] Must be 18 years of age or older\n",
            "- [NCT00791557] Must Be ages 18-75\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 165\n",
            "- [NCT00226174] Patients presenting to the UCSF oral medicine clinic with oral lichen planus confirmed by biopsy. Patients with either the atrophic or the erosive form of oral lichen planus were eligible.\n",
            "- [NCT00297037] With a diagnosis of oral lichen planus previously proven on biopsy.\n",
            "- [NCT00455312] A triad of mucocutaneous features: oral leukoplakia, nail dystrophy, abnormal reticular skin hyperpigmentation.\n",
            "- [NCT00542373] Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)\n",
            "- [NCT00542373] Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 166\n",
            "- [NCT00240682] ECOG Performance status \\< 2.\n",
            "- [NCT00277160] ECOG performance status \\</=2\n",
            "- [NCT00304460] ECOG less than 2.\n",
            "- [NCT00518895] ECOG performance status ≤ 1\n",
            "- [NCT00661531] Ecog performance status \\</= 2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 167\n",
            "- [NCT00240682] Age \\> 18 years.\n",
            "- [NCT00284180] Age \\>18 years.\n",
            "- [NCT00544765] Age \\> 18 years.\n",
            "- [NCT00691678] Age \\>21 years.\n",
            "- [NCT00991978] Age \\> 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 168\n",
            "- [NCT00255762] No known esophageal varices\n",
            "- [NCT01522820] Esophageal: resected patients with any nodal (i.e., thoracic or abdominal) disease; and patients with residual disease on imaging after definitive chemoradiation therapy\n",
            "- [NCT03475953] or esophageal or gastric carcinoma (cohort C),\n",
            "- [NCT03924466] adenocarcinoma of the gastric body or gastro-esophageal junction\n",
            "- [NCT04032704] Cohort 5: esophageal-squamous (Parts A and B)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 169\n",
            "- [NCT00006412] Have gall bladder disease or symptoms within 3 months prior to study entry or symptoms of gallstones.\n",
            "- [NCT00091819] major abscess requiring surgical incision and drainage\n",
            "- [NCT00107978] major abscess requiring surgical incision and drainage;\n",
            "- [NCT00217672] Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning therapy\n",
            "- [NCT00255762] No history of abdominal fistula\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 170\n",
            "- [NCT00021463] Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).\n",
            "- [NCT00255762] VEGF Trap\n",
            "- [NCT00255762] Anti-VEGF receptor monoclonal antibody\n",
            "- [NCT00255762] Small molecular tyrosine kinase inhibitors of VEGF receptors\n",
            "- [NCT00369655] No history of lung carcinoma of squamous cell type\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 171\n",
            "- [NCT00257582] Chronic urticaria\n",
            "- [NCT00346606] The subject with documented signs and symptoms of CIU for 6 weeks or more.\n",
            "- [NCT00346606] The subject has to have a CIU flare for 3 weeks or more before screening, with urticarial lesions visible 3 days or more per week.\n",
            "- [NCT00346606] The overall severities of CIU have to be at least mild to moderate at screening and baseline, subjects have to have at least mild to moderate pruritus, hives have to be apparent at screening, and subjects have intention to treatment.\n",
            "- [NCT00385372] chronic urticaria (duration: at least 6 weeks)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 172\n",
            "- [NCT00257582] Prurigo group: Acute prurigo, Prurigo subacuta, Chronic prurigo\n",
            "- [NCT00257582] Pruritus cutaneous: Systemic pruritus cutaneous, Topical pruritus cutaneous\n",
            "- [NCT00257582] Children who have 2 grades or more pruritus score when assessed by the investigator or sub-investigator with the criteria for the diurnal or nocturnal pruritus score in the patient diary.\n",
            "- [NCT00257582] Children with a pruritus severity of \"2.Mild\" or severer on the first day of the treatment period.\n",
            "- [NCT00715260] Patients who have \"mild\", \"moderate\" or \"severe\" pruritus;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 173\n",
            "- [NCT00262301] Clear clinical and laboratory diagnosis of HAE\n",
            "- [NCT00262301] Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack\n",
            "- [NCT00438815] Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or\n",
            "- [NCT00438815] Had a known HAE-causing C1INH mutation, or\n",
            "- [NCT00438815] Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 174\n",
            "- [NCT00268125] Patient affiliated at a welfare or beneficiary from it\n",
            "- [NCT00513058] Patients must be affiliated with a Social Security system\n",
            "- [NCT00555061] French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category\n",
            "- [NCT00905281] Patient affiliated with social security\n",
            "- [NCT01262469] Patients must be affiliated to a Social Security System\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 175\n",
            "- [NCT00277160] \\>/= 65 years old\n",
            "- [NCT00448305] Age \\>= 18 years old\n",
            "- [NCT00713154] is \\>/= 18 years of age\n",
            "- [NCT01344109] Age \\>/= 18 years old\n",
            "- [NCT01583426] Age \\>= 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 176\n",
            "- [NCT00281697] ≥ 18 years of age.\n",
            "- [NCT00450762] Age ≥ 18 years\n",
            "- [NCT00496366] Age ³ 18 years of age\n",
            "- [NCT00683670] Age ≥ 18 years\n",
            "- [NCT00704158] Age ≥ 18 years\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 177\n",
            "- [NCT00286598] Functioning telephone service\n",
            "- [NCT00945607] Access to a CD player\n",
            "- [NCT01108315] Has access to either a phone or the internet\n",
            "- [NCT01450020] Owns an operational vehicle\n",
            "- [NCT01450020] Has access to a personal computer with internet access\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 178\n",
            "- [NCT00121511] Subjects must be willing and able to comply with the requirements of the protocol.\n",
            "- [NCT00306553] Able and willing to complete all protocol requirements.\n",
            "- [NCT00403559] Must be wiling and able to comply with protocol.\n",
            "- [NCT00688272] The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria\n",
            "- [NCT00991978] Able to comply with the protocol.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 179\n",
            "- [NCT00306553] Wash-out period of 4 weeks after chemotherapy\n",
            "- [NCT00356642] 14 day washout of current therapy.\n",
            "- [NCT01375101] two weeks wash out periods after the last treatment\n",
            "- [NCT01511315] Washout Period :\n",
            "- [NCT01941537] A washout period from any systemic investigational therapy of at least 90 days.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 180\n",
            "- [NCT00308204] adults 18 to 70 years of age.\n",
            "- [NCT00815282] And who are in the following age groups:\n",
            "- [NCT01045772] Adult (18 years or older)\n",
            "- [NCT01111695] Adult\n",
            "- [NCT01228656] Adults of both sexes, regardless of color or social class;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 181\n",
            "- [NCT00308854] Selected AK study lesions have clearly defined margins and are mild to moderate\n",
            "- [NCT00603798] Have 5 to 20 AKs on the face or balding scalp.\n",
            "- [NCT00859105] Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp\n",
            "- [NCT00942604] 4 to 8 AK lesions on non-head locations.\n",
            "- [NCT00991861] The diameter of each AK target lesion is not less than 0.5 cm and not greater than 1.5 cm\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 182\n",
            "- [NCT00308854] Skin sun sensitivity type I to IV according to Fitzpatrick\n",
            "- [NCT00523588] Fitzpatrick I-III skin type (very fair, fair, or medium skin)\n",
            "- [NCT00688272] Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).\n",
            "- [NCT00719121] Subjects with a phototype III or IV (according to Fitzpatrick classification)\n",
            "- [NCT00839280] Phototype: I to IV according to Fitzpatrick scale\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 183\n",
            "- [NCT00315393] Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA and MPA.\n",
            "- [NCT00315393] For diagnosis of GPA, meets at least 2 of the following 5 modified American College of Rheumatology (ACR) criteria: 1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood 2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities 3. Urinary sediment with microhematuria or red cell casts 4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy 5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA\n",
            "- [NCT00315393] For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA: 1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles) 2. Necrotizing arteritis involving small- and medium-sized arteries may be present 3. Necrotizing glomerulonephritis is very common 4. Pulmonary capillaritis often occurs\n",
            "- [NCT00430105] A new diagnosis of WG, MP or renal-limited vasculitis (RLV) (appendix 5). Patients not previously treated with cytotoxic drugs will be permitted. 2. Renal involvement attributable to active WG, MP or RLV with at least one of the following:\n",
            "- [NCT00430105] haematuria with \\>30 red blood cells/high powered field and proteinuria \\> 1g/24hr. 3. ANCA positivity or confirmatory histology or both (appendix 5). ANCA positivity requires a typical CANCA pattern by indirect immunofluorescence (IIF), (preferably confirmed by anti-PR3 ELISA), or the presence of PR3-ANCA or MPO-ANCA determined by ELISA, PANCA requires confirmation by anti-MPO ELISA \\[6\\]. (Central review of ANCA serology and histology will be performed). 4. Age 18-80 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 184\n",
            "- [NCT00321178] At least 5 years of age\n",
            "- [NCT00359190] At least 18 years of age.\n",
            "- [NCT00389402] At least 18 years of age.\n",
            "- [NCT00548184] Age at least 18 years.\n",
            "- [NCT00612742] at least 50 years of age\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 185\n",
            "- [NCT00121511] Subjects must be in generally good health and willing to undergo skin biopsies from the face.\n",
            "- [NCT00335179] Discontinuation of tanning bed use\n",
            "- [NCT00420173] photoprovocation-test performed in advance\n",
            "- [NCT00469183] Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits.\n",
            "- [NCT00601640] Visible sun-induced damage to the skin as assessed by the study dermatologists\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 186\n",
            "- [NCT00356460] In Part 1, Dose Escalation: Patients with histologically confirmed, locally advanced \\& surgically inoperable or metastatic renal cell carcinoma or malignant melanoma are eligible.\n",
            "- [NCT01263145] For the dose escalation cohorts, patients must have received front-line, cytotoxic, systemic therapy (combination or single agent, with or without the addition of targeted agents) for advanced cancer\n",
            "- [NCT02857270] Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal adenocarcinoma (dose escalation and dose expansion).\n",
            "- [NCT03475953] Dose escalation part: histologically confirmed non MSI-H or deficient-MMR colorectal cancer, or GIST, or esophageal or gastric carcinoma or hepatobiliary cancers,\n",
            "- [NCT04424641] Dose-escalation part: • Patient with locally advanced or metastatic solid tumor(s) (excluding patients with primary central nervous system \\[CNS\\] tumors), who has experienced disease progression while on standard therapy or is intolerant of, or not eligible for, standard therapy. Expansion part: • Must have an advanced or metastatic, pathologically confirmed diagnosis of one of the following tumors: Uterine Cancer, Prostate Cancer, Esophageal Cancer, TNBC, SCCHN, NSCLC (both adenocarcinoma \\[ACC\\] and squamous cell carcinoma \\[SCC\\], Bladder Cancer. Both parts:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 187\n",
            "- [NCT00359190] Females must meet certain criteria specified in protocol.\n",
            "- [NCT00581256] Both men and women are eligible.\n",
            "- [NCT01081106] Participants must be 18 years old or older\n",
            "- [NCT01081106] Participants must be female\n",
            "- [NCT01120184] Adult participants \\>/=18 years of age\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 188\n",
            "- [NCT00091819] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00107978] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00368537] Clinical diagnosis of complicated skin or skin structure infection\n",
            "- [NCT00463801] Subjects with a diagnosis of complicated skin and skin-structure infections (cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalization and intravenous antimicrobial treatment\n",
            "- [NCT00514527] Complicated skin and skin structure infection, presumed or proven to be caused by gram-positive pathogen(s).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 189\n",
            "- [NCT00379431] Severe disease defined by either one of the following: a modified Rodnan skin score (TSS° \\>= 14 ), disease activity score \\>= 3\n",
            "- [NCT00704665] A baseline modified Rodnan skin score (MRSS) of 20 or greater, or at least 16 if truncal involvement was present.\n",
            "- [NCT00962923] Rapidly progressive disease \\<2 years duration with a modified Rodnan skin score(mRSS) above 20, plus ESR \\>25 mm/first h and/or Hb \\<11 g/dL, not explained by other causes than active SSc\n",
            "- [NCT01532869] \\>/= 15 and \\</= 40 mRSS units at screening\n",
            "- [NCT01538719] Must have a MRSS of ≥ 15.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 190\n",
            "- [NCT00379678] Active AD of any severity will be defined according to Hanifin and Rajka clinical criteria (Hanifin, J.M., Rajka, G. 1980)\n",
            "- [NCT00379678] Chronic AD for more than one year duration\n",
            "- [NCT00546000] Subjects meet protocol specific AD signs and symptom severity score\n",
            "- [NCT00753805] A clear and definite diagnosis of AD\n",
            "- [NCT02031445] History of AD for at least 3 months prior to Baseline\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 191\n",
            "- [NCT00383851] Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥50%; see Appendix A)\n",
            "- [NCT00404066] Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 / Karnofsky ≥ 60% at screening and on the first day of treatment.\n",
            "- [NCT00462280] Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky \\> 70%)\n",
            "- [NCT00576654] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2 (Karnofsky \\>= 60%)\n",
            "- [NCT01042535] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1 (Karnofsky \\>= 70%)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 192\n",
            "- [NCT00383851] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00429299] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00576654] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00802932] Ability to understand and the willingness to sign written informed consent document\n",
            "- [NCT01042535] Ability to understand and the willingness to sign a written informed consent document\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 193\n",
            "- [NCT00385502] Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails (\"target toenails\"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum\n",
            "- [NCT00385502] Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.\n",
            "- [NCT00385502] Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 194\n",
            "- [NCT00388115] Core biopsy proven low or intermediate grade DCIS.\n",
            "- [NCT00402519] For DCIS only: lesions must be classified as low or intermediate risk group (Van Nuys Prognostic Index \\<8).\n",
            "- [NCT00455312] Disease Characteristics for DC (both of the following):\n",
            "- [NCT00455312] Diagnosis of DC:\n",
            "- [NCT00669747] Pathological diagnosis of DCIS requiring surgical resection\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 195\n",
            "- [NCT00388115] Multifocal invasive breast cancer patients are eligible. All tumors that are palpable or visualized by USS can be treated.\n",
            "- [NCT01185145] Multifocal findings (define as 2 or more breast quadrants) on MRI scanning should be further evaluated by ultrasound and, if necessary biopsy, to exclude multiquadrant disease.\n",
            "- [NCT01208441] Multifocal disease allowed provided that ≥ 1 of the tumors is \\> 2 cm\n",
            "- [NCT01417286] Multifocal/multicentric disease is allowed\n",
            "- [NCT01583426] In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 196\n",
            "- [NCT00389636] Patients\n",
            "- [NCT00553618] Patients must fulfill one of the following criteria:\n",
            "- [NCT00758862] Patients suffering from SITL must have:\n",
            "- [NCT01068483] All patients:\n",
            "- [NCT01361035] Physician\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 197\n",
            "- [NCT00424749] Renal involvement (\\>25% dysmorphic red cell, red blood cell casts, or pauci-immune glomerulonephritis on biopsy)\n",
            "- [NCT00430105] biopsy demonstrating necrotizing glomerulonephritis.\n",
            "- [NCT00474604] The protocol nurse will check with the patient that there is no h/o kidney disease\n",
            "- [NCT00544765] Renal function:\n",
            "- [NCT00712621] Protein (Albumin, Globulin) Renal:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 198\n",
            "- [NCT00442260] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00583739] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00627978] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00656019] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT01010854] Ability to understand and the willingness to sign a written informed consent document.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 199\n",
            "- [NCT00448305] Histologically proven triple-receptor-negative metastatic or relapsed breast cancer\n",
            "- [NCT00528567] primary tumor centrally confirmed as triple negative.\n",
            "- [NCT01150513] Triple-negative breast cancer\n",
            "- [NCT01467310] Histologically confirmed TNBC (i.e., ER negative, PR negative (each \\<10% staining by immunohistochemistry) and Her2 negative (0-1+ or FISH non-amplified; by clinical assay on primary tumor)\n",
            "- [NCT01617915] if tumor is triple-negative, treatment with DNA-damaging chemotherapy as per standard of care in the first-line setting for advanced/metastatic disease.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 200\n",
            "- [NCT00455312] Patients with early myelodysplastic features.\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) requiring a 2nd transplant\n",
            "- [NCT02162420] Early myelodysplastic features\n",
            "- [NCT02706392] CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody, or who have failed tyrosine kinase or phosphatidylinositol 3 (PI3) kinase inhibitors, or who were not eligible for or declined such therapy; patients with fludarabine refractory disease are eligible\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 201\n",
            "- [NCT00456092] If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for at least 14 days prior to screening and throughout the study\n",
            "- [NCT00601640] No concurrent NSAIDs for more than 14 days per month for arthritic and other pain conditions\n",
            "- [NCT00944918] Relapsed or progressed during prior treatment with single-agent NSAI, meeting either of the following criteria:\n",
            "- [NCT00944918] NSAI given as adjuvant therapy that lasted ≥ 12 months OR\n",
            "- [NCT01752907] Chronic use of oral non-steroidal anti-inflammatory drugs (NSAIDs) or oral antihistamines with the following exception: \\- Chronic oral aspirin use for cardiovascular-related indications\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 202\n",
            "- [NCT00467233] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00467233] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "- [NCT00469183] Subjects must have a clinical diagnosis of moderate to severe melasma\n",
            "- [NCT00509977] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00509977] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 203\n",
            "- [NCT00470301] \\[Note: \\\n",
            "- [NCT00474604] \\\n",
            "- [NCT00526617] \\\n",
            "- [NCT00630032] NOTE: \\\n",
            "- [NCT01689935] \\\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 204\n",
            "- [NCT00491816] Patients must have a serum albumin ≥ 3.0 g/dL\n",
            "- [NCT00777335] Serum albumin ≥ Lower Limit of Normal(LLN) or 30g/L\n",
            "- [NCT00896298] Serum leptin levels less than the 7th percentile of normal values reported by the 3rd National Health and Nutrition Examination survey (less than 7.0 ng/mL in females and less than 3/0 ng/mL in males)\n",
            "- [NCT00962923] digestive tract involvement: with serum albumin ,25 g/L or weight loss exceeding 10% body weight in the preceding year\n",
            "- [NCT01050322] Albumin \\> 2.5 gr /dl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 205\n",
            "- [NCT00492323] Experienced postherpetic neuralgia pain on a daily basis for the past 3 months\n",
            "- [NCT00540969] Worst pain in the last 24 hours must be ≥ 4 on a 0-10 numeric scale\n",
            "- [NCT00588640] Chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical scale from 0-10 during the 24 hours prior to study entry.\n",
            "- [NCT01375101] having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score\n",
            "- [NCT01720602] Patient is willing to continue on same AI therapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 206\n",
            "- [NCT00496795] \"Limited\" distant metastases allowed, but patients with massive distant metastases should be excluded\n",
            "- [NCT01064635] Patients with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastases.\n",
            "- [NCT01264731] No metastasis greater than 2 cm at the time of protocol entry\n",
            "- [NCT01394575] No evidence of distant metastasis\n",
            "- [NCT01503034] No known metastasis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 207\n",
            "- [NCT00502684] ASA score of 1-2\n",
            "- [NCT00519246] ASA I-II\n",
            "- [NCT01055236] ASA classification 1-2\n",
            "- [NCT01185145] Be a Tis, T1, N0, M0 AJC Classification\n",
            "- [NCT01392248] ASA 1-2.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 208\n",
            "- [NCT00005949] LDH normal\n",
            "- [NCT00518895] Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal\n",
            "- [NCT00610857] Serum LDH less than or equal to 2.0 x ULN\n",
            "- [NCT01005472] LDH ≤ 5 times ULN\n",
            "- [NCT01055522] LDH \\< 2.0 x ULN for Phase IIa patients and normal LDH for the Phase IIb ones.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 209\n",
            "- [NCT00525096] surgical ovariectomy\n",
            "- [NCT00530868] Bilateral oophorectomy\n",
            "- [NCT00650910] Has had a hysterectomy\n",
            "- [NCT00650910] Has had a bilateral oophorectomy (ovariectomy)\n",
            "- [NCT00650910] Has had a bilateral tubal ligation, or\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 210\n",
            "- [NCT00525096] ovarian suppression by radiotherapy\n",
            "- [NCT00982631] Patients with proven advanced breast cancer, endometrial cancer or ovarian cancer, who are refractory to standard therapies or for whom no standard therapy exists.\n",
            "- [NCT01035099] Ovarian stimulation will not affect cancer treatment plan\n",
            "- [NCT01095848] Patients with stage III or IV ovarian cancer who have completed a course of platinin-based cytotoxic therapy after debulking surgery with evidence of a complete or partial response by radiological imaging. Patients with metastatic ovarian cancer who have stable disease for greater than 3 months after completion of first-line therapy.\n",
            "- [NCT01233505] Any-line metastatic mucinous ovarian cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 211\n",
            "- [NCT00542373] Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease\n",
            "- [NCT01727076] Patients must have histological or cytological confirmed malignancy in the following disease groups: melanoma, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which no standard effective or curative options are available\n",
            "- [NCT02069158] Histological or cytological diagnosis of advanced/metastatic breast, NSCLC, ovarian and endometrial, small cell lung cancer (SCLC) and Head and Neck (HNSCC) cancer for which there is an indication to the use of paclitaxel and carboplatin.\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx is allowed, but these participants will not be included as response-evaluable participants for efficacy analysis of HNSCC.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 212\n",
            "- [NCT00555061] Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy: The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion. The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area. Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.\n",
            "- [NCT00646958] Acceptable clinical diagnoses of uSSSI include, but are not limited to: Simple abscess, Impetiginous lesions, Folliculitis, Furunculosis, Carbuncles, Cellulitis\n",
            "- [NCT01789229] Just one current known malignant disease or just one current inflammatory disease\n",
            "- [NCT01815450] Qualifying number of non-inflammatory lesions\n",
            "- [NCT01815450] Qualifying number of inflammatory lesions\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 213\n",
            "- [NCT00555061] Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must demonstrate their willingness to participate in the study and comply with its procedures by signing an informed consent.\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must understand and be able to adhere to the dosing and visit schedule, and agree to report concomitant medications and adverse events to the Investigator or designee.\n",
            "- [NCT01035099] Willingness to provide follow-up information on herself and babies born as part of this study\n",
            "- [NCT01760850] Children may be present with parents, but will not be included in any research activities, unless they are emancipated minors (under 18 and married)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 214\n",
            "- [NCT00576654] Patients must have histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT00576654] Patients enrolled on the dose escalation for intermittent ABT-888 portion of the study must histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT01111201] Age \\>18 years and current or past history of lymphoma\n",
            "- [NCT01188915] treated for Hodgkin disease\n",
            "- [NCT01929941] Aged 18 years or older, with histologically or cytologically confirmed solid tumor, Hodgkin's lymphoma, aggressive or indolent non-Hodgkin's lymphoma. (NOTE: Patients with acute and chronic leukemia, Burkitt's lymphoma, precursor B lymphoblastic leukemia/lymphoma, and myeloma are excluded)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 215\n",
            "- [NCT00588640] Responsible companion living with patient during study. Phase II only:\n",
            "- [NCT00709176] Family caregivers must be 18 years old or older, physically and mentally able to participate, and speak and understand English.\n",
            "- [NCT02954900] Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital\n",
            "- [NCT03130569] Registered at a University of New Mexico primary care clinic for ≥6 months\n",
            "- [NCT03130569] Assigned to a primary care provider\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 216\n",
            "- [NCT00610857] History of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, or any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to CT-scan only.\n",
            "- [NCT02796352] For patients who have received prior anti-CTLA4 monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL-2 therapy. Therefore, for these patients if they have a history of colitis or diarrhea during anti-CTLA4 monoclonal antibody therapy, it is recommended that they have a formal evaluation by a gastroenterologist and a colonoscopy/endoscopy should be considered to demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on this protocol.\n",
            "- [NCT03598790] Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)\n",
            "- [NCT03768219] Moderately to severely active ulcerative colitis as defined by:\n",
            "- [NCT03971643] Personal history of inflammatory bowel disease or inflammatory arthritis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 217\n",
            "- [NCT00612742] with a clinical diagnosis of HSDD.\n",
            "- [NCT00949546] Chronic HS for \\> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS\n",
            "- [NCT02157090] duration of HSL symptoms not more than three days\n",
            "- [NCT03569371] Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.\n",
            "- [NCT03569371] Stable course of HS for at least 90 days before screening, as determined by the investigator.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 218\n",
            "- [NCT00650910] Double-barrier contraception (condom with spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male condom and diaphragm).\n",
            "- [NCT00688272] Diaphragm with spermicide\n",
            "- [NCT00688272] Cervical cap or female condoms.\n",
            "- [NCT00761371] Condoms (with spermicide)\n",
            "- [NCT00761371] Diaphragm/cervical cap (with spermicide)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 219\n",
            "- [NCT00650910] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT00821054] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT01358240] Be willing and able to give informed consent/assent or have their parent/guardian do so, if applicable.\n",
            "- [NCT01386775] Conform to one of the following requirements for providing informed consent/assent:\n",
            "- [NCT01638052] informed consent and assent obtained\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 220\n",
            "- [NCT00665782] Smoking cigarettes for the 24-hour period of saliva-sample collection\n",
            "- [NCT00688272] Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.\n",
            "- [NCT00811824] Non-smoker\n",
            "- [NCT01019603] Nonsmoker or smoker with at least 30 days abstinence from smoking or using nicotine-containing products prior to study entry and willing not to smoke or to use nicotine-containing products throughout the study.\n",
            "- [NCT01140282] Nonsmokers (i.e., not smoking during previous 12 months)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 221\n",
            "- [NCT00688272] Healthy Caucasian male or females with no clinically significant abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead ECG.\n",
            "- [NCT00773734] In good health as judged by the investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), serum chemistry, hematology, immunology, and urinalysis\n",
            "- [NCT01694381] Be without clinical significant abnormalities according to the investigator's judgment, based on a detailed medical history, a complete physical examination (including vital signs), a standard 12-lead electrocardiogram, urinalysis, and routine clinical laboratory tests.\n",
            "- [NCT02505568] Participant must be medically stable on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at Screening. If there are abnormalities, they must be consistent with the underlying illness in the study population, or the participant may be included only if the investigator judge the abnormalities from normal to be not clinically significant or to be appropriate. This determination must be recorded in the participant's source documents by the investigator\n",
            "- [NCT02690142] In good health, as determined by medical history, physical examination, vital signs assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 222\n",
            "- [NCT00688272] Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.\n",
            "- [NCT00761371] Oral, injectable, or implantable contraceptives\n",
            "- [NCT01838655] Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring),\n",
            "- [NCT02231879] Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive,\n",
            "- [NCT02950922] Oral Contraceptive, either combined or progestogen alone \\[Hatcher, 2007a\\] Injectable progestogen \\[Hatcher, 2007a\\]\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 223\n",
            "- [NCT00688272] An intrauterine device (a coil micro-insert).\n",
            "- [NCT00688272] Intrauterine system (IUS) e-g Mirena coil\n",
            "- [NCT00761371] Intrauterine devices (IUDs)\n",
            "- [NCT01300533] Use an intrauterine device (IUD) with a documented failure rate of less than 1% per year.\n",
            "- [NCT01838655] Intrauterine device,\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 224\n",
            "- [NCT00708851] able and willing to attend phototherapy sessions and apply LCD at home\n",
            "- [NCT00773734] Candidate for photo/systemic therapy\n",
            "- [NCT01094717] No systemic or phototherapy in the 4 wks prior to entering the study\n",
            "- [NCT01228409] Stabilized on a phototherapy regimen for 4 weeks.\n",
            "- [NCT01291940] Are receiving phototherapy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 225\n",
            "- [NCT00251472] Patients must have signed an IRB-approved informed consent.\n",
            "- [NCT00713154] Can understand and sign the IRB/IEC approved informed consent, can communicate with the Investigator, and can understand with the requirements of the protocol\n",
            "- [NCT00991978] Signed written informed consent (approved by the Institutional Review Board \\[IRB\\]/ Independent Ethics Committee \\[IEC\\]) obtained prior to any study specific screening procedures.\n",
            "- [NCT01047072] If the donor has reached the age of assent, then they must have completed the local institutional review board (IRB) assent process.\n",
            "- [NCT01450176] Sign and date the informed consent form approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 226\n",
            "- [NCT00735293] Have axillary hyperhidrosis/bromidrosis that does not respond to conventional, non-invasive treatment\n",
            "- [NCT02058264] Primary axillary hyperhidrosis of at least 6 months duration.\n",
            "- [NCT02058264] Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.\n",
            "- [NCT02058264] Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.\n",
            "- [NCT02100072] Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 227\n",
            "- [NCT00741260] PART 1:\n",
            "- [NCT00753415] Part A\n",
            "- [NCT01228656] Clarified (appendix);\n",
            "- [NCT01229085] Clarified (appendix);\n",
            "- [NCT02217891] Part 1:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 228\n",
            "- [NCT00743496] Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.\n",
            "- [NCT01104298] Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.\n",
            "- [NCT01104298] Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)\n",
            "- [NCT01104298] Angiosarcoma\n",
            "- [NCT01104298] Synovial sarcoma\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 229\n",
            "- [NCT00802672] Male or female at least 10 years of age, and otherwise healthy\n",
            "- [NCT00850811] healthy males or females;\n",
            "- [NCT01019603] Male or female 12 years of age or older who is in good general health.\n",
            "- [NCT01208298] Females or males subjects, at least 18 to 70 years of age, in good general health\n",
            "- [NCT01243450] Normal, healthy male and female children and adults.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 230\n",
            "- [NCT00814125] No previous endometrial ablation\n",
            "- [NCT01522820] Uterine cancer: patients with advanced (stages II-IV) or recurrent disease who have completed standard therapy, currently no evidence of disease (NED) or with minimal residual disease; patients with stage I uterine serous carcinomas or sarcomas are also eligible after completion of standard therapy\n",
            "- [NCT02996825] Endometrial \\>= 50% of tumor staining \\>= 2+ intensity\n",
            "- [NCT02996825] Cohort B: Patients with recurrent endometrial cancer may have received up to 2 lines of cytotoxic chemotherapy (adjuvant and one line for recurrent disease, or 2 lines of chemotherapy for recurrent uterine cancer in patients who did not receive adjuvant chemotherapy); patients must have received and failed, or have been intolerant to platinum agents, taxanes, liposomal doxorubicin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigator's opinion, patients would benefit from treatment on current protocol\n",
            "- [NCT03924466] endometrial cancer\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 231\n",
            "- [NCT00824889] Age ≥ 18 years.\n",
            "- [NCT01138384] Age ≥ 18 years of age.\n",
            "- [NCT01191528] Age greater than 18\n",
            "- [NCT01291420] Age: ≥ 18 years old\n",
            "- [NCT01308294] Age ≥ 18 years.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 232\n",
            "- [NCT00087373] Individuals with extensive skin disease\n",
            "- [NCT00574613] Symmetric lesions in forearms. The extension of the selected symmetric lesions must be at least 15 cm2.\n",
            "- [NCT00601640] No inflammation of the skin on the lateral forearms\n",
            "- [NCT00839280] Subjects with dry skin on their forearms\n",
            "- [NCT01051960] Diffuse\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 233\n",
            "- [NCT00996710] In certain clinical situations, parent(s) with cancer may be included at the discretion of the Principal Investigator, if the Principal Investigator deems that the etiology of cancer in the parent(s) and proband are biologically unrelated.\n",
            "- [NCT04514484] Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04704661] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04996823] Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n",
            "- [NCT05111561] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this study\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 234\n",
            "- [NCT01001728] Age ≥18\n",
            "- [NCT01138553] Age ≥18\n",
            "- [NCT01342497] Aged ≥18\n",
            "- [NCT02794324] Age ≥18\n",
            "- [NCT02847728] Age ≥18\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 235\n",
            "- [NCT01010854] Because no dosing or adverse event data are currently available on the use of VPA in combination with FEC100 in patients \\<18 years of age, children are excluded from this study\n",
            "- [NCT01111825] Age ≥ 18, as no dosing or adverse event data are currently available on the use of neratinib or temsirolimus in patients \\<18 years of age, children are excluded from this study.\n",
            "- [NCT01149083] Female, age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of ABT-888 in patients \\< 18 years of age, children are excluded from this study\n",
            "- [NCT01246102] Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of AT13387 in patients \\< 18 years of age, children are excluded from this study.\n",
            "- [NCT01894451] Age ≥ 21 years. Because no dosing or adverse event data are currently available on the use of 89Zr-bevacizumab in participants \\<21 years of age, children are excluded from this study but will be eligible for future pediatric trials.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 236\n",
            "- [NCT01010854] absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01029925] Absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01575522] Absolute neutrophil count \\>= 1,500/mcL\n",
            "- [NCT01705340] Absolute neutrophil count \\>= 1,000/mcL\n",
            "- [NCT01727076] Absolute neutrophil count \\> 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 237\n",
            "- [NCT00324259] Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.\n",
            "- [NCT00526045] Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or lapatinib in combination with other agents) for metastatic disease\n",
            "- [NCT00526045] Patients who develop metastases while receiving adjuvant or neo-adjuvant trastuzumab are eligible. HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on either:\n",
            "- [NCT00704158] Subjects with HER2/neu overexpressing tumors must have been treated with trastuzumab except in situations where the subject was intolerant to or not a candidate for trastuzumab\n",
            "- [NCT01029925] HER-2 positive breast cancer should have received Trastuzumab, in either the adjuvant or metastatic setting.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 238\n",
            "- [NCT01029925] Non-small cell lung cancer patients should have received at least platinum based chemotherapy in the adjuvant, neoadjuvant or metastatic setting.\n",
            "- [NCT01910844] Patient non previously treated by platinum salts,\n",
            "- [NCT02210663] Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; \\\n",
            "- [NCT02365662] Expanded Safety Cohort participants must have confirmed metastatic lung cancer and progressed after receiving prior platinum-containing chemotherapy.\n",
            "- [NCT02561832] Prior use of platinum compound in the advanced or metastatic setting. Previous exposure to platinum compounds is allowed only if they were used in early adjuvant or neoadjuvant setting with relapse occurring \\>6 months after the last platinum administration and if there is no residual toxicity\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 239\n",
            "- [NCT01095848] Patients with prostate cancer who have failed at least 1 course of an accepted hormonal therapy. Specifically prostate cancer patients must have castrate testosterone levels (\\< 50 ng/dl) and 2 PSA values higher than the previously documented baseline at least 3 weeks apart or evidence of increases in measurable disease. These patients may have received previous courses of cytotoxic chemotherapy although chemotherapy naïve patients who are deemed not good candidates or who have refused cytotoxic therapy will be eligible. These patients may remain on anti-androgen therapy during the trial. Patients with evidence of progressive bone or other metastases are acceptable.\n",
            "- [NCT01522820] Prostate cancer: patients with metastatic, castrate refractory prostate cancer; the use of luteinizing hormone-releasing hormone (LHRH) agonist is allowed\n",
            "- [NCT02704832] Prostate cancer : metastatic and refractory to hormonal castration,\n",
            "- [NCT03218826] DISEASE SPECIFIC EXPANSION COHORTS: Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have:\n",
            "- [NCT03310541] Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 240\n",
            "- [NCT01164891] Positive BRAF V600E mutation result (by Roche CoDx test)\n",
            "- [NCT01705392] Known BRAF mutation\n",
            "- [NCT01820364] confirmed BRAF V600 mutation\n",
            "- [NCT01910181] Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test\n",
            "- [NCT02133222] Known genotype BRAF V600\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 241\n",
            "- [NCT01233505] First- or second-line metastatic colorectal cancer\n",
            "- [NCT01291420] Colorectal tumors\n",
            "- [NCT01315990] Histologically-confirmed metastatic colorectal cancer (primary tumor or metastasis)\n",
            "- [NCT01372527] Colorectal cancer: Women and men 52-75 years old\n",
            "- [NCT02704832] Colon and rectum : metastatic (unresectable metastasis),\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 242\n",
            "- [NCT01240213] No menopausal HRT use of any type including vaginal X 6 months and willing to avoid use for study duration\n",
            "- [NCT01381445] A female subject is eligible to participate if she is of: • Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the protocol contraception methods if they wish to continue their HRT during the study.\n",
            "- [NCT01899703] A female subject is eligible to participate if she is not pregnant, as confirmed by a negative serum human chorionic gonadotrophin (hCG) test or at least one of the following conditions applies: Non-reproductive potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \\>40 milli-international units per milliliter and estradiol \\<40 picograms per milliliter (\\<147 picomole per liter) is confirmatory\\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods along with either a second form of highly effective contraception or barrier protection (condoms with spermicide) if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the contraception options methods for the specified duration of time.\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab or dabrafenib + trametinib on the developing human fetus are unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to Step 2 crossover to rule out pregnancy; a female of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\n",
            "- [NCT02466152] A woman is eligible to participate if she is of non-reproductive potential, defined as: 1. Postmenopausal (including all women over 60 years of age). 2. Females with one of the following procedures documented and no plans to utilize assisted reproductive techniques (e.g., in vitro fertilization or donor embryo transfer): Bilateral tubal ligation or salpingectomy; Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Bilateral oophorectomy (surgical menopause) Note: A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile (e.g., age appropriate, \\>45 years, in the absence of hormone replacement therapy \\[HRT\\] or medical suppression of the menstrual cycle). In questionable cases for women \\<60 years of age, a blood sample with simultaneous follicle stimulating hormone and estradiol falling into the central laboratory's postmenopausal reference range is confirmatory. Women \\<60 years of age who are on HRT, wish to continue, and whose menopausal status is in doubt are required to use a highly-effective method to avoid pregnancy. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of postmenopausal status, HRT may be resumed during the study without use of a highly-effective method to avoid pregnancy\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 243\n",
            "- [NCT01256489] Bilateral legal blindness (\\<20/200 in better eye)\n",
            "- [NCT01256489] Able to administer eye medications or have a care giver able and willing to do same\n",
            "- [NCT01467310] History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):\n",
            "- [NCT01838655] Bilateral visual acuity E-ETDRS EVA letter score of less than or equal to 83 (i.e., Snellen equivalent of 20/25 or worse) that is not attributable to any other pathology.\n",
            "- [NCT01838655] Bilateral iris transillumination that can be seen in clinical photographs. 2. Predominant contralateral decussation of ganglion cell axons, as determined by pattern visual evoked potential (VEP). 3. Participant has at least one definitive mutation in the OCA1 gene (tyrosinase). 4. Participant has no definitive mutations in the OCA2 gene.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 244\n",
            "- [NCT01276704] Ki-67 ≥2% positivity (≥500 cells).\n",
            "- [NCT01583426] \\- cT1c and Ki67 \\> 20%\n",
            "- [NCT01669265] Ki67 index\n",
            "- [NCT04065321] proliferation index Ki-67 \\< 20%;\n",
            "- [NCT04134598] Ki67 ≤20% by IHC staining;\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 245\n",
            "- [NCT01419184] Less than 24 hours post hospital admission\n",
            "- [NCT01965444] Subject is admitted to an intensive Care Unit (ICU) and has an anticipated ICU course of 48 hours or greater.\n",
            "- [NCT01965444] Subject is anticipated to be bedridden for ore than 6 hours per day.\n",
            "- [NCT02152358] mechanical ventilation \\> 96 hrs and expected duration of mechanical ventilation of at least 2 days\n",
            "- [NCT02325388] Expected to have a length of stay on the unit of at least three days.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 246\n",
            "- [NCT00802672] Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed.\n",
            "- [NCT01543126] Got ICF before enrollment;\n",
            "- [NCT01679197] If ≥ 18 years of age, is able to read, understand and sign the U of M IRBMED approved informed consent form (ICF), communicate with study physician and study team, understand and comply with protocol requirements.\n",
            "- [NCT02209662] Prior to the first clinical intervention, a signed Informed Consent Form (ICF) and Data Consent Form (DCF) must be obtained from the subject or legal representative\n",
            "- [NCT02363842] Subject, or their legal representative, is able and willing to sign an informed consent form (ICF) and willing to undergo all study related procedures.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 247\n",
            "- [NCT01689519] Adequate hematologic and end organ function\n",
            "- [NCT01765556] Adequate hematologic and end organ function\n",
            "- [NCT01849666] Adequate hematologic and end organ function\n",
            "- [NCT01973309] Adequate hematologic and end-organ function\n",
            "- [NCT02338245] Patients with acceptable organ and hematological function\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 248\n",
            "- [NCT01722812] Age 18 years or above\n",
            "- [NCT02285049] Age 18 years old or above\n",
            "- [NCT02889458] aged 18 or above\n",
            "- [NCT03725722] Age 18 years and above.\n",
            "- [NCT05098821] Age 18 and above\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 249\n",
            "- [NCT01723072] Angioedema at least 4x in the last 6 months\n",
            "- [NCT02966314] Adults or adolescents who are 18 years or older at the time of screening with physician diagnosis of idiopathic angioedema\n",
            "- [NCT02966314] Minimum of two episodes of idiopathic angioedema in the past 6 months at the time of screening\n",
            "- [NCT02966314] Management of idiopathic angioedema with a stable controller treatment plan for the prior 6 months\n",
            "- [NCT03029728] The diagnosis of Hereditary Angioedema is confirmed by CENTOGENE EXCLUSION CRITERIA\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 250\n",
            "- [NCT01727076] At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-programmed cell death 1 (PD1)\n",
            "- [NCT01740297] Subjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.\n",
            "- [NCT01986426] Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment). Arm D:\n",
            "- [NCT02224781] NOTE: Patients should (if possible) be at least 1 week from documented PD on Step 1 of current study. All sites of disease must be evaluated within 4 weeks prior to registration\n",
            "- [NCT02676869] Currently receiving anti-PD-1 therapy with pembrolizumab and after 3 cycles achieved asymptomatic irPD (slowly progressive, not requiring urgent intervention, and stable performance status) or sub-optimal response (irSD, irPR) as demonstrated in imaging assessments performed within 6 weeks prior to study start\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 251\n",
            "- [NCT01820234] Able to provide a brief medical history and have/allow an examination of their skin including photographs.\n",
            "- [NCT02385994] Willing to have digital photographs taken of the treatment area.\n",
            "- [NCT02667288] Have a clinically typical appearance\n",
            "- [NCT03374995] Able and willing to have photographs of the affected area taken regularly\n",
            "- [NCT03910543] Patients must be willing to undergo skin biopsies, blood collection, and total body photography and comply with clinic visits\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 252\n",
            "- [NCT00221221] must be in the post treatment phase of their cancer trajectory.\n",
            "- [NCT01333735] Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)\n",
            "- [NCT01977053] Patient surgically-treated or no for non inflammatory breast cancer or for colon cancer or rectal cancer.\n",
            "- [NCT01999062] Patients with prior treatment such as surgery or chemotherapy for any type of cancer.\n",
            "- [NCT03028584] Patients: Have been treated with curative intent (e.g. surgery, chemotherapy and/or radiation therapy) for a Stage 1-3 cancer diagnosis\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 253\n",
            "- [NCT01984255] absolute neutrophil count ≥ 1,500/mcL\n",
            "- [NCT03007979] Absolute neutrophil count ≥ 1,500/mcl\n",
            "- [NCT03225547] absolute neutrophil count ≥ 1,000/mcL\n",
            "- [NCT03691493] Absolute neutrophil count ≥ 1000/mcl (obtained within 14 days prior to registration on study)\n",
            "- [NCT03709446] Absolute neutrophil count ≥ 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 254\n",
            "- [NCT01984255] platelets ≥ 100,000/mcl\n",
            "- [NCT02318771] Platelets ≥100,000 / mcL\n",
            "- [NCT03007979] Platelets ≥ 100,000/mcl\n",
            "- [NCT03225547] platelets ≥ 80,000/mcL\n",
            "- [NCT03709446] platelets ≥ 100,000/mcl\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 255\n",
            "- [NCT02023008] Participants must be:\n",
            "- [NCT02425306] All participants must have:\n",
            "- [NCT03139513] Participants included in the TAU from 26 February 2015\n",
            "- [NCT05672992] Participants must meet at least one of the following:\n",
            "- [NCT06007677] Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 256\n",
            "- [NCT02035813] Both cohorts:\n",
            "- [NCT02035813] Ribociclib cohort:\n",
            "- [NCT02035813] INR ≤ 1,5 (ribocilclib cohort)\n",
            "- [NCT02279004] Cohort 1B:\n",
            "- [NCT02279004] Cohort 2B:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 257\n",
            "- [NCT02061085] Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n",
            "- [NCT02115204] Eastern Cooperative Oncology Group (ECOG) status \\< 2\n",
            "- [NCT02657889] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03055312] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03423199] Eastern Cooperative Oncology Group (ECOG) PS 0-1\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 258\n",
            "- [NCT02083484] Failed or progressed on standard of care systemic therapy including ipilimumab (with the exception of a participant with progressive disease while on the ipilimumab arm of MK-3475-006, regardless of prior treatment with a BRAF/MEK inhibitor, as long as all other eligibility criteria for this study are met)\n",
            "- [NCT02224781] Malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib, or history of retinal vein occlusion are acceptable for patients crossing over to Arm D (ipilimumab + nivolumab) treatment\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Patients must have recovered from adverse events (toxicities resolved to grade 1 or less) of prior therapy; patients with immune related toxicities from ipilimumab + nivolumab may continue onto Step 2 even if still on steroids to control side effects, so long as toxicity has resolved to grade 1 or less\n",
            "- [NCT02260531] Patients must have normal organ and marrow function and laboratory values as follows within 14 days before the first dose of cabozantinib\n",
            "- [NCT02260531] The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 259\n",
            "- [NCT02127970] Male or female participants 18 - 85 years of age.\n",
            "- [NCT02286583] The perfect sample should be 2000 females or more.\n",
            "- [NCT02694640] Women aged 21 years or over will be eligible if they:\n",
            "- [NCT02836795] Male and Female aged 18 to 70 years are eligible;\n",
            "- [NCT03151447] Female aged 18 to 75 years old are eligible.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 260\n",
            "- [NCT02157090] at least 18 years old\n",
            "- [NCT02205736] At least 18 years old\n",
            "- [NCT02272881] At least 18 years old;\n",
            "- [NCT03398538] At least 18 years old.\n",
            "- [NCT03966924] At least 30 years old\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 261\n",
            "- [NCT02158208] recent onset localised headache\n",
            "- [NCT02531633] Diagnosis of GCA defined by the following Revised GCA Diagnosis Criteria: Age \\>=50 years. History of ESR \\>=50 millimeter/hour (mm/hour) or CRP \\>=2.45 milligram/deciliter(mg/dL). Presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of polymyalgia rheumatic (PMR). Presence of at least one of the following: Temporal artery biopsy revealing features of GCA; Evidence of large-vessel vasculitis by angiography or cross-sectional imaging.\n",
            "- [NCT02531633] Active GCA within 6 weeks of Randomization (Baseline) where active disease is defined by an ESR \\>=30 mm/hr or CRP \\>=1 mg/dL AND the presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of PMR; Other features judged by the clinician investigator to be consistent with GCA or PMR flares.\n",
            "- [NCT02703922] Suspected of GCA according to clinician expertise and / or aortitis arteritis or of one or more arteries from the aorta imaging (CT angiography, magnetic resonance angiography or positron emission tomography TDM18FDG)\n",
            "- [NCT02771483] Rheumatologist, neurologist or ophthalmologist suspect diagnosis of GCA\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 262\n",
            "- [NCT02180412] Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes.\n",
            "- [NCT02180412] Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG).\n",
            "- [NCT02180412] Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples:\n",
            "- [NCT02180412] For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins. Most (\\~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (\\>95 percent) will have a demonstrable disease-causing PBGD mutation.\n",
            "- [NCT02180412] For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins. Almost all (\\>95 percent) will have a demonstrable disease-causing coproporphyrinogen oxidase (CPO) mutation.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 263\n",
            "- [NCT01730833] No prior chemotherapy or trastuzumab for treatment of metastatic breast cancer\n",
            "- [NCT02260531] Discontinued prior therapy (with the exception of trastuzumab for patients with HER2+ breast cancer)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 264\n",
            "- [NCT02362594] Tumor tissue available for evaluation of PD-L1 expression\n",
            "- [NCT02519322] All patients must undergo a baseline tumor biopsy; in Arms A and B, tumor biopsy for PD-L1 testing (PD-L1 positivity is determined by greater than or equal to 1% of cells staining in the membrane by immunohistochemistry) is required for stratification; PD-L1 status is not required for enrollment on Arm C; the 28-8 clone for PD-L1 testing is required for assessment of PD-L1 status; for patients with stage IV disease, site of tumor biopsy will preferably be from non-lymph node disease site; for PD-L1 testing, the biopsy should contain sufficient tumor content (\\> 100 tumor cells/4-micron tissue section); if a sample contains insufficient tumor content, a re-biopsy will be required to obtain a sample with sufficient tumor content prior to treatment\n",
            "- [NCT02523313] Tumor tissue from the resected site of disease must be provided for biomarker analyses. In order to be randomized a subject must have a PD-L 1 expression classification (positive (≥ 5% tumor cells expressing PD-L1) or negative (\\< 5% tumor cells expressing PD-L1)). If an insufficient amount of tumor tissue from the resected site is provided for analysis, acquisition of additional archived tumor tissue (block and/or slides) for the biomarker analyses is required.\n",
            "- [NCT02555657] Central determination of programmed cell death ligand 1 (PD-L1) tumor status\n",
            "- [NCT02836795] Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 265\n",
            "- [NCT02540083] Have signed and dated the informed consent form;\n",
            "- [NCT02671513] Signed and dated informed consent\n",
            "- [NCT03055312] Signed and dated an informed consent form\n",
            "- [NCT03330977] Patient who have dated and signed a consent form\n",
            "- [NCT03893019] Signed and dated informed consent before conduct of any trial-specific procedure.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 266\n",
            "- [NCT01935531] Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel\n",
            "- [NCT02612454] Participated in a prior dupilumab study in pediatric participants with AD and adequately completed the visits and assessments required for both the treatment and follow-up periods, as defined in the prior study protocol\n",
            "- [NCT02612454] Must have received the same dupilumab dose regimen to be used in the PFP sub-study during the previous 12 weeks in the main OLE study using the prefilled syringe, as defined in the protocol Key\n",
            "- [NCT04066998] treated with Dupilumab\n",
            "- [NCT04718870] Participants with moderate to severe AD those were eligible to be treated with dupilumab according to product label.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 267\n",
            "- [NCT00036621] Adriamycin (60 mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery)\n",
            "- [NCT00036621] Adriamycin (60mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses, followed by Taxol (175mg/m2 IV on Day 85) repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery). 3. ECOG performance status 0 or 1. 4. Adequate organ function as evidenced by:\n",
            "- [NCT01306825] Patient under treatment with daptomycin for more than 3 days with dosage at 6 mg/kg\n",
            "- [NCT01986140] Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Doxorubicin 50mg/m2 with 5-Fluroruacil 500mg/m2 and Cyclophosphamide 500mg/m2 - Paclitaxel 80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3 weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2-100mg/m2 with pertuzumab and traztuzumab at standard doses - Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and trastuzumab at standard doses\n",
            "- [NCT02614794] Doxorubicin \\> 360 mg/m\\^2\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 268\n",
            "- [NCT01105884] Patients with or without PVD\n",
            "- [NCT01334125] Can be antibody positive or negative\n",
            "- [NCT02704429] Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:\n",
            "- [NCT04422912] Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n",
            "- [NCT04422912] mPV inadequately managed by at least one standard immunosuppressive therapies\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 269\n",
            "- [NCT00526617] Dose escalation and expanded safety cohorts\n",
            "- [NCT00722293] There must be measurable disease or evaluable disease for subjects to be included in the cohort expansion phase. Measurable disease is not a criterion for subjects enrolling in the dose escalation phase.\n",
            "- [NCT01001728] For all patients, the following absolute dose constraints should be met: ≤5% of heart volume to receive 18Gy and ≤10% of ipsilateral lung volume to receive ≥20Gy\n",
            "- [NCT01138384] During the dose escalation phase patients are not required to have measurable disease, but if they do, it will be recorded and followed. Patients at the expanded RP2D must have measurable disease defined by the RECIST 1.1.\n",
            "- [NCT03170960] Dose-Escalation Stage:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 270\n",
            "- [NCT00508274] Willing to complete all screening assessments as outlined in the protocol;\n",
            "- [NCT02672475] Patients must complete all screening assessments as outlined in the protocol\n",
            "- [NCT03328897] Patients must have documented current use on the day of the initial screening visit Main Exclusion Criteria\n",
            "- [NCT03569371] Total AN count of at least 3 at screening and baseline.\n",
            "- [NCT03607487] Total AN count of at least 3 at screening and baseline.\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 271\n",
            "- [NCT03331003] Always burns, never tans\n",
            "- [NCT03331003] Usually burns, tans minimally\n",
            "- [NCT03331003] Frequently burns and tans (light brown)\n",
            "- [NCT03331003] Rarely burns, tans easily (brown)\n",
            "- [NCT03331003] Very rarely burns, tans very easily (brown)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 272\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Absolute neutrophil count (ANC) \\>= 1500/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Platelet count \\>= 75,000/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Hemoglobin \\>= 9.0 g/dL (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Direct bilirubin \\< 1.5 x upper limit of normal (ULN) (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Aspartate transaminase (AST) =\\< 3 x ULN (obtained =\\< 28 days prior to randomization)\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 273\n",
            "- [NCT00073528] Signed informed consent; 2. Subjects with histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery;\n",
            "- [NCT01050322] Signed informed consent must be obtained according to local ethical committee requirements. 2. Subjects must be older than 18 years old. 3. Histologically confirmed invasive adenocarcinoma of the breast which is stage IIIb, stage IIIc with T4 lesion, or stage IV disease \\[according to AJCC 6th edition\\] 4. Documented progression after taxane based treatment for ErbB2 positive patients for 1st line metastatic breast cancer or documented progression after taxane based regimens as adjuvant or neo-adjuvant therapy. Patients may have had a maximum of one prior treatment with a chemotherapy regimen for metastatic disease. 5. Patients must have at least 1 measurable lesion defined by RECIST as follows:\n",
            "- [NCT01300533] Signed informed consent form. (ICF) 2. At least 18 years old. 3. Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists. 4. Measurable or evaluable disease per RECIST version 1.1. 5. Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1. 6. Life expectancy of greater than 12 weeks. 7. Female subjects are eligible to enter and participate in the study if they are of: 1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who:\n",
            "- [NCT01617915] Women or men \\> age 18. Ability to give informed consent Archived tumor tissue must be available for genetic analysis. Patients with early-stage breast cancer Histologic documentation of invasive breast cancer by core needle or incisional biopsy. The invasive cancer must be either:\n",
            "- [NCT02971748] Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \\>/= 18 years of age 3. Has histological confirmation of breast carcinoma. 4. Has confirmed inflammatory breast cancer by using international consensus criteria:\n",
            "\n",
            "================================================================================\n",
            "DBSCAN+UMAP Cluster = 274\n",
            "- [NCT00601640] No evidence of serious underlying medical conditions as demonstrated by abnormal values on baseline laboratory assessment\n",
            "- [NCT00907062] normal on physical examination at the pre-study intake, and in the case of abnormalities the health care practitioner considers them to be clinically insignificant\n",
            "- [NCT01119313] the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;\n",
            "- [NCT02346760] With no clinically relevant abnormalities in vital signs, and clinical laboratory tests at screening visit judged by investigator.\n",
            "- [NCT02801435] In good health, with no history of diseases of major organs and no abnormality found on physical examination and vital signs\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "NqKQoqyl0K6G"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "lW0fkZPz0K-g"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def inspect_clusters(df: pd.DataFrame,\n",
        "                     label_col: str,\n",
        "                     n_examples: int = 5):\n",
        "    for label in sorted(df[label_col].unique()):\n",
        "        subset = df[df[label_col] == label].head(n_examples)\n",
        "        print(\"=\" * 80)\n",
        "        print(f\"Cluster {label_col} = {label}  (showing {len(subset)} examples)\")\n",
        "        for _, row in subset.iterrows():\n",
        "            print(f\"- [{row['nctid']}] {row['criterion']}\")\n",
        "        print()\n",
        "\n",
        "# Example: quickly look at a few clusters in each method\n",
        "inspect_clusters(criteria_df, \"cluster_tfidf\", n_examples=4)\n",
        "inspect_clusters(criteria_df, \"cluster_emb\", n_examples=4)\n",
        "print(\"DBSCAN AND DIM REDUCTION WITH UMAP\")\n",
        "inspect_clusters(criteria_df, \"cluster_dbscan_umap\", n_examples=5)\n"
      ],
      "metadata": {
        "id": "cjrUSrkJowy_",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "eba77654-1cd5-4f3a-ef78-a83857a10cb8"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "================================================================================\n",
            "Cluster cluster_tfidf = 0  (showing 4 examples)\n",
            "- [NCT00003199] ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,000/cells/mm\\^3 (transfusion independent) for at least 5 days before starting therapy\n",
            "- [NCT00003895] Platelets (Plt) \\>= 100,000/mm\\^3\n",
            "- [NCT00004067] The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or \\<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).\n",
            "- [NCT00004067] Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 1  (showing 4 examples)\n",
            "- [NCT00024154] Male or female\n",
            "- [NCT00201929] Female\n",
            "- [NCT00217672] Female 18 and over\n",
            "- [NCT00270972] Male or female\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 2  (showing 4 examples)\n",
            "- [NCT00005617] Adults over the age of 18 with malignant melanoma.\n",
            "- [NCT00028405] Age 18 or older.\n",
            "- [NCT00044291] Women age 18 years or older\n",
            "- [NCT00071981] Age: 18 and over\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 3  (showing 4 examples)\n",
            "- [NCT00001137] HIV-1 infected\n",
            "- [NCT00001137] Active alcohol or drug abuse that may interfere with the study\n",
            "- [NCT00003199] Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (\\>= 2.5 x 10\\^6 CD34+ cells/kg)\n",
            "- [NCT00003895] White blood cell (WBC) \\>= 3500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 4  (showing 4 examples)\n",
            "- [NCT00003199] Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (\\>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions\n",
            "- [NCT00003199] Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol\n",
            "- [NCT00003199] Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:\n",
            "- [NCT00003895] Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 5  (showing 4 examples)\n",
            "- [NCT00001137] Life expectancy of at least 24 weeks\n",
            "- [NCT00004074] Life expectancy of at least 6 months\n",
            "- [NCT00028405] Minimum life expectancy of 12 weeks.\n",
            "- [NCT00044291] Predicted life expectancy of 12 weeks or more\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 6  (showing 4 examples)\n",
            "- [NCT00001137] Enrolled in an AIDS Clinical Trial Group (ACTG) parent study and has enrolled in this study on or before the Week 16 visit of the parent study, including the visit window of the parent study. More information on this criterion can be found in the protocol.\n",
            "- [NCT00001137] Willing to provide consent for the release and use of clinical data from the parent study\n",
            "- [NCT00003199] Pre-Study tests have been performed as outlined in the Study Calendar\n",
            "- [NCT00005764] Are able to read at a sixth-grade level.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 7  (showing 4 examples)\n",
            "- [NCT00001137] Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria\n",
            "- [NCT00003199] The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines\n",
            "- [NCT00004067] Psychiatric or addictive disorders that would preclude obtaining informed consent.\n",
            "- [NCT00004074] Written signed informed consent; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 8  (showing 4 examples)\n",
            "- [NCT00003895] Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy\n",
            "- [NCT00004067] Prior to randomization, the investigator must designate whether the patients who had a lumpectomy will receive local or locoregional radiation therapy. For patients who had a mastectomy, the investigator must designate whether or not the patient will receive radiation therapy. (Pre-randomization discussion and/or consultation with a radiation oncologist is encouraged.) Note: Irradiation of any internal mammary nodes is prohibited in this trial.\n",
            "- [NCT00004067] Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.\n",
            "- [NCT00004067] Prior anthracycline or taxane therapy for any malignancy.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 9  (showing 4 examples)\n",
            "- [NCT00004074] Patients must have measurable or evaluable disease\n",
            "- [NCT00005949] Measurable disease as defined by the following:\n",
            "- [NCT00024154] Measurable disease\n",
            "- [NCT00024154] Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 10  (showing 4 examples)\n",
            "- [NCT00007280] Patient must read, understand and sign informed consent\n",
            "- [NCT00087776] Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.\n",
            "- [NCT00135720] Understand and sign the written informed consent form and be willing and able to comply with the procedures of the study\n",
            "- [NCT00191815] You must sign this informed consent form\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 11  (showing 4 examples)\n",
            "- [NCT00004067] The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.\n",
            "- [NCT00004067] Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. \"Marginal,\" \"borderline,\" etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.\n",
            "- [NCT00024154] Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)\n",
            "- [NCT00024154] Hormone receptor status:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 12  (showing 4 examples)\n",
            "- [NCT00003895] Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment\n",
            "- [NCT00005617] Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment\n",
            "- [NCT00006412] Have a negative pregnancy test.\n",
            "- [NCT00021463] Have a negative pregnancy test within 14 days of study entry, if a woman able to have children.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 13  (showing 4 examples)\n",
            "- [NCT00050141] Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n",
            "- [NCT00071981] Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n",
            "- [NCT00087477] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "- [NCT00087776] Patients must have Eastern Cooperative Oncology Group performance status of 0 - 2.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 14  (showing 4 examples)\n",
            "- [NCT00004067] Prior history of breast cancer, including DCIS (patients with a history of lobular carcinoma in situ \\[LCIS\\] are eligible).\n",
            "- [NCT00004067] History of cardiac disease:\n",
            "- [NCT00006412] Have a history of heart disease.\n",
            "- [NCT00035958] History of chronic or recurrent infections sufficient to preclude the use of etanercept\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 15  (showing 4 examples)\n",
            "- [NCT00003199] Patient has received Cytoxan 4 gm/m\\^2 x 1 and Taxol 250 mg/m\\^2 x 1 per FHCRC protocol 506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and before transplant\n",
            "- [NCT00003199] Can start therapy 30 to 100 days after transplant\n",
            "- [NCT00004067] At the time of randomization, the patient must have had the following: history and physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam (for women who have a uterus and who will be taking tamoxifen) within the past year.\n",
            "- [NCT00004067] Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is \\> 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 16  (showing 4 examples)\n",
            "- [NCT00004067] myocardial infarction documented as a clinical diagnosis or by EKG or any other tests;\n",
            "- [NCT00035958] Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter\n",
            "- [NCT00035958] Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis\n",
            "- [NCT00035958] JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 17  (showing 4 examples)\n",
            "- [NCT00005764] Are at least 18 years old.\n",
            "- [NCT00006412] Are at least 18 years old.\n",
            "- [NCT00007280] Men or women at least 18 years old\n",
            "- [NCT00021463] Are at least 13 years old and have signed consent of parent or guardian if under 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 18  (showing 4 examples)\n",
            "- [NCT00006290] Are 18 years or older.\n",
            "- [NCT00031486] Patients who are 12 years of age or older.\n",
            "- [NCT00051779] Must be a female at least 18 years of age and be using an effective form of birth control.\n",
            "- [NCT00087373] Children \\< 3 years of age\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 19  (showing 4 examples)\n",
            "- [NCT00134368] Disease interferes significantly with quality of life and/or involving 3% or more body surface area\n",
            "- [NCT00192517] Plaque psoriasis involving at least 10% of body surface area (Appendix A)\n",
            "- [NCT00211133] Weight \\> = 40 kg (88 lbs)\n",
            "- [NCT00245960] Clinically stable, plaque psoriasis involving more than 10% of the body surface area\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 20  (showing 4 examples)\n",
            "- [NCT00003199] Total bilirubin =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003199] SGOT =\\< 2.5 x upper limit of normal\n",
            "- [NCT00004067] There must be postoperative evidence of adequate hepatic function, i.e., total bilirubin must be ≤ ULN for the lab unless the patient has a chronic grade 1 bilirubin elevation (\\>ULN to ≤1.5 x ULN) due to Gilbert's disease or similar syndrome; and alkaline phosphatase must be \\<2.5 times the ULN for the lab; and the serum glutamic-oxaloacetic transaminase (SGOT \\[AST\\]) must be \\<1.5 times the ULN for the lab.\n",
            "- [NCT00005949] Bilirubin normal\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 21  (showing 4 examples)\n",
            "- [NCT00003199] Hepatic function: Bilirubin =\\< 2 mg%; SGOT or SGPT =\\< 2.5 x institutional normal\n",
            "- [NCT00003199] Renal function: Creatinine =\\< 2.0 mg/dl or a creatinine clearance \\>= 50 mg/min\n",
            "- [NCT00003199] Creatinine =\\< 2.0 mg/dl\n",
            "- [NCT00003895] Hemoglobin \\>= 9 gm/100 ml\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 22  (showing 4 examples)\n",
            "- [NCT00004067] Pregnancy or lactation at the time of proposed randomization. This protocol excludes pregnant or lactating women based on the fetal toxicity of both tamoxifen and Taxol which are listed as Pregnancy Category D agents. Pregnant women who received tamoxifen have experienced fetal deaths, birth defects, spontaneous abortions, and vaginal bleeding. Women of reproductive potential must agree to use an effective barrier method of contraception. Hormonal birth control methods are not permitted.\n",
            "- [NCT00004074] Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; a woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant\n",
            "- [NCT00005764] Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.\n",
            "- [NCT00005949] Fertile patients must use effective contraception\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 23  (showing 4 examples)\n",
            "- [NCT00003199] Karnofsky performance status \\> 60\n",
            "- [NCT00003895] Patients must be ambulatory with good performance status (Karnofsky performance status \\[PS\\] 80-100)\n",
            "- [NCT00004074] Karnofsky Performance Status index \\>= 70%\n",
            "- [NCT00005617] Karnofsky Performance Status greater than or equal to 70 percent\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_tfidf = 24  (showing 4 examples)\n",
            "- [NCT00004067] The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)\n",
            "- [NCT00024154] Histologically confirmed metastatic adenocarcinoma of the breast\n",
            "- [NCT00034918] Histological and/or cytological confirmation of metastatic breast cancer which is refractory to anthracycline, taxane, with or without capecitabine therapies;\n",
            "- [NCT00039793] Confirmed tissue diagnosis of cancer of the breast, ovary, prostate or colo-rectum\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 0  (showing 4 examples)\n",
            "- [NCT00003199] Hepatic function: Bilirubin =\\< 2 mg%; SGOT or SGPT =\\< 2.5 x institutional normal\n",
            "- [NCT00003199] Total bilirubin =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003199] SGOT =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003895] Total bilirubin =\\< 2.0 mg/dl\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 1  (showing 4 examples)\n",
            "- [NCT00003199] Karnofsky performance status \\> 60\n",
            "- [NCT00003895] Patients must be ambulatory with good performance status (Karnofsky performance status \\[PS\\] 80-100)\n",
            "- [NCT00004067] M0\n",
            "- [NCT00004074] Karnofsky Performance Status index \\>= 70%\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 2  (showing 4 examples)\n",
            "- [NCT00004067] The tumor must be invasive adenocarcinoma on histologic examination.\n",
            "- [NCT00004067] Patients must have no clinical or radiologic evidence of metastatic disease. Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A patient with skeletal pain is eligible for inclusion in the study if bone scan and/or roentgenological examination fails to disclose metastatic disease.\n",
            "- [NCT00004067] Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.\n",
            "- [NCT00004074] No concurrent malignancy other than non-melanoma skin carcinoma\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 3  (showing 4 examples)\n",
            "- [NCT00003199] Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (\\>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions\n",
            "- [NCT00003199] Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol\n",
            "- [NCT00003199] Patient has received Cytoxan 4 gm/m\\^2 x 1 and Taxol 250 mg/m\\^2 x 1 per FHCRC protocol 506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and before transplant\n",
            "- [NCT00003199] Can start therapy 30 to 100 days after transplant\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 4  (showing 4 examples)\n",
            "- [NCT00001137] Enrolled in an AIDS Clinical Trial Group (ACTG) parent study and has enrolled in this study on or before the Week 16 visit of the parent study, including the visit window of the parent study. More information on this criterion can be found in the protocol.\n",
            "- [NCT00001137] Willing to provide consent for the release and use of clinical data from the parent study\n",
            "- [NCT00001137] Active alcohol or drug abuse that may interfere with the study\n",
            "- [NCT00003199] Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (\\>= 2.5 x 10\\^6 CD34+ cells/kg)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 5  (showing 4 examples)\n",
            "- [NCT00003895] After accrual to the original 26 patient goal, all patients must be enrolled prior to sentinel lymph node dissection; patients with previous lymph node dissection will not be eligible\n",
            "- [NCT00003895] Patients must have recovered from any effects of major surgery and be free of significant systemic infection\n",
            "- [NCT00004067] Ipsilateral nodes must be cN0-1 by clinical evaluation.\n",
            "- [NCT00004067] Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 6  (showing 4 examples)\n",
            "- [NCT00004067] Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is \\> 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)\n",
            "- [NCT00004067] Active cardiac disease:\n",
            "- [NCT00004067] cardiac arrhythmia requiring medication;\n",
            "- [NCT00004067] severe conduction abnormality;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 7  (showing 4 examples)\n",
            "- [NCT00001137] Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria\n",
            "- [NCT00003199] The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines\n",
            "- [NCT00003895] Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy\n",
            "- [NCT00004074] Written signed informed consent; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 8  (showing 4 examples)\n",
            "- [NCT00005764] Are pregnant or breast-feeding.\n",
            "- [NCT00005949] Not pregnant or nursing\n",
            "- [NCT00006290] Are male and either gay or bisexual (if enrolling in the Ohio State University or University of California focus groups).\n",
            "- [NCT00006290] Are pregnant.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 9  (showing 4 examples)\n",
            "- [NCT00004067] Contraindications to corticosteroid use which, in the opinion of the investigator, would preclude participation in this study.\n",
            "- [NCT00005617] Positive skin test to common antigens (tetanus and candida)\n",
            "- [NCT00005764] (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in buttocks area; or\n",
            "- [NCT00005764] Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical steroids) in the last 4 months or plan to take these drugs during the study.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 10  (showing 4 examples)\n",
            "- [NCT00001137] HIV-1 infected\n",
            "- [NCT00003895] Patients must be negative for human immunodeficiency virus (HIV) antibody by enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is positive) if they are considered to be at high risk; others do not require serologic testing if there are no symptoms or risk factors for HIV disease\n",
            "- [NCT00004067] Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude a patient from being subjected to any of the treatment options or would prevent prolonged follow-up.\n",
            "- [NCT00004067] angina pectoris that requires the use of antianginal medication;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 11  (showing 4 examples)\n",
            "- [NCT00003895] Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic techniques, flow cytometry, or molecular techniques\n",
            "- [NCT00004067] The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.\n",
            "- [NCT00004067] Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. \"Marginal,\" \"borderline,\" etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.\n",
            "- [NCT00004074] Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 12  (showing 4 examples)\n",
            "- [NCT00007280] At least one ulcer (wound) greater than or equal to 2 centimeters\n",
            "- [NCT00007280] Ulcer (wound) present for at least 3 months or greater\n",
            "- [NCT00035958] Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis\n",
            "- [NCT00065663] Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 13  (showing 4 examples)\n",
            "- [NCT00031486] Patients who are 12 years of age or older.\n",
            "- [NCT00087620] Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama\n",
            "- [NCT00087776] Patients must be \\>= 18 years of age.\n",
            "- [NCT00155259] Patients must be ≦ 65 years old\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 14  (showing 4 examples)\n",
            "- [NCT00004067] The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins) and randomization must be less than or equal to 84 days.\n",
            "- [NCT00004067] Patients treated by lumpectomy and axillary node dissection to be followed by breast radiation therapy must meet all the eligibility criteria in addition to the following: Generally, lumpectomy should be reserved for tumors \\<5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are eligible. The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients in whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary dissection has been performed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. Whole breast irradiation is required. Irradiation of regional lymph nodes is optional, but partial breast irradiation and irradiation of any internal mammary nodes are prohibited in this trial. Intent to irradiate the axilla or other regional node groups must be declared by the investigator prior to randomization for stratification purposes.\n",
            "- [NCT00004067] Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.\n",
            "- [NCT00005949] Inflammatory breast disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 15  (showing 4 examples)\n",
            "- [NCT00003895] White blood cell (WBC) \\>= 3500/mm\\^3\n",
            "- [NCT00004067] The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or \\<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).\n",
            "- [NCT00005617] Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): 1. Hemoglobin \\>9.0 g/dl 2. Platelets \\> 100000/mm3 3. WBC \\> 3000/mm3 4. Absolute Neutrophil Count \\> 1000/mm3\n",
            "- [NCT00024154] Granulocyte count at least 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 16  (showing 4 examples)\n",
            "- [NCT00004067] Pregnancy or lactation at the time of proposed randomization. This protocol excludes pregnant or lactating women based on the fetal toxicity of both tamoxifen and Taxol which are listed as Pregnancy Category D agents. Pregnant women who received tamoxifen have experienced fetal deaths, birth defects, spontaneous abortions, and vaginal bleeding. Women of reproductive potential must agree to use an effective barrier method of contraception. Hormonal birth control methods are not permitted.\n",
            "- [NCT00004074] Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; a woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant\n",
            "- [NCT00005617] Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment\n",
            "- [NCT00005764] Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 17  (showing 4 examples)\n",
            "- [NCT00003199] ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,000/cells/mm\\^3 (transfusion independent) for at least 5 days before starting therapy\n",
            "- [NCT00003895] Platelets (Plt) \\>= 100,000/mm\\^3\n",
            "- [NCT00004067] Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.\n",
            "- [NCT00005949] Platelet count at least 100,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 18  (showing 4 examples)\n",
            "- [NCT00005764] Are at least 18 years old.\n",
            "- [NCT00006290] Are 18 years or older.\n",
            "- [NCT00006412] Are at least 18 years old.\n",
            "- [NCT00007280] Men or women at least 18 years old\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 19  (showing 4 examples)\n",
            "- [NCT00004074] Patients must have measurable or evaluable disease\n",
            "- [NCT00005949] Measurable disease as defined by the following:\n",
            "- [NCT00005949] At least 1 lesion accurately measured in at least 1 dimension\n",
            "- [NCT00005949] Lesions considered intrinsically nonmeasurable include:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 20  (showing 4 examples)\n",
            "- [NCT00003199] Renal function: Creatinine =\\< 2.0 mg/dl or a creatinine clearance \\>= 50 mg/min\n",
            "- [NCT00003199] Creatinine =\\< 2.0 mg/dl\n",
            "- [NCT00003895] Serum creatinine =\\< 2 mg/dl\n",
            "- [NCT00004067] There must be postoperative evidence of adequate renal function (serum creatinine within or less than the institution's normal range).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 21  (showing 4 examples)\n",
            "- [NCT00003895] Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment\n",
            "- [NCT00006412] Have a negative pregnancy test.\n",
            "- [NCT00021463] Have a negative pregnancy test within 14 days of study entry, if a woman able to have children.\n",
            "- [NCT00024154] Negative pregnancy test\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 22  (showing 4 examples)\n",
            "- [NCT00004074] Adequate hematopoietic, cardiac, renal, and hepatic function\n",
            "- [NCT00051103] Adequate kidney and liver function\n",
            "- [NCT00051103] Adequate bone marrow function\n",
            "- [NCT00087776] Patients must have adequate renal and liver function\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 23  (showing 4 examples)\n",
            "- [NCT00003895] Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision\n",
            "- [NCT00003895] Patients whose melanoma is \\> 4.0 mm thick who have positive or negative regional lymph nodes are also eligible\n",
            "- [NCT00005617] Adults over the age of 18 with malignant melanoma.\n",
            "- [NCT00005617] Tumor stages T3N0M0 or greater are eligible for this trial according to the following: 1. I (\\<.75 to 1.5 mm or Clark level III-T1-2N0M0-)-not eligible 2. II (1.5 to 4 mm or level IV-T3N0M0-)-eligible 3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)-eligible 4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)-eligible 5. Relapsed melanoma-eligible\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 24  (showing 4 examples)\n",
            "- [NCT00005764] Are able to read at a sixth-grade level.\n",
            "- [NCT00006290] Are able to speak and read English.\n",
            "- [NCT00179634] Working knowledge of English\n",
            "- [NCT00198250] able to read, write and speak English\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 25  (showing 4 examples)\n",
            "- [NCT00126724] Rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) diagnosed according to established criteria.\n",
            "- [NCT00192517] Plaque psoriasis involving at least 10% of body surface area (Appendix A)\n",
            "- [NCT00192517] Currently receiving no therapy for psoriasis except emollients\n",
            "- [NCT00245960] Active Psoriatic Arthritis\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 26  (showing 4 examples)\n",
            "- [NCT00001137] Life expectancy of at least 24 weeks\n",
            "- [NCT00004067] The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)\n",
            "- [NCT00004074] Life expectancy of at least 6 months\n",
            "- [NCT00028405] Minimum life expectancy of 12 weeks.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 27  (showing 4 examples)\n",
            "- [NCT00050141] Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n",
            "- [NCT00071981] Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n",
            "- [NCT00087477] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "- [NCT00087776] Patients must have Eastern Cooperative Oncology Group performance status of 0 - 2.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 28  (showing 4 examples)\n",
            "- [NCT00003895] Hemoglobin \\>= 9 gm/100 ml\n",
            "- [NCT00005949] Hemoglobin at least 10 g/dL\n",
            "- [NCT00094003] Hemoglobin ≥9.0 g/dL\n",
            "- [NCT00146562] Hemoglobin \\> 9 g/dL\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_emb = 29  (showing 4 examples)\n",
            "- [NCT00005949] Performance status - ECOG 0-1\n",
            "- [NCT00024154] Performance status - ECOG 0-2\n",
            "- [NCT00028405] Patient has an ECOG performance status of 0-3 (Karnofsky 30 or higher).\n",
            "- [NCT00044291] ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher\n",
            "\n",
            "DBSCAN AND DIM REDUCTION WITH UMAP\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = -1  (showing 5 examples)\n",
            "- [NCT00001137] Enrolled in an AIDS Clinical Trial Group (ACTG) parent study and has enrolled in this study on or before the Week 16 visit of the parent study, including the visit window of the parent study. More information on this criterion can be found in the protocol.\n",
            "- [NCT00003199] Patient has received Cytoxan 4 gm/m\\^2 x 1 and Taxol 250 mg/m\\^2 x 1 per FHCRC protocol 506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and before transplant\n",
            "- [NCT00003199] Can start therapy 30 to 100 days after transplant\n",
            "- [NCT00004067] There must be postoperative evidence of adequate hepatic function, i.e., total bilirubin must be ≤ ULN for the lab unless the patient has a chronic grade 1 bilirubin elevation (\\>ULN to ≤1.5 x ULN) due to Gilbert's disease or similar syndrome; and alkaline phosphatase must be \\<2.5 times the ULN for the lab; and the serum glutamic-oxaloacetic transaminase (SGOT \\[AST\\]) must be \\<1.5 times the ULN for the lab.\n",
            "- [NCT00004067] Prior to randomization, the investigator must designate whether the patients who had a lumpectomy will receive local or locoregional radiation therapy. For patients who had a mastectomy, the investigator must designate whether or not the patient will receive radiation therapy. (Pre-randomization discussion and/or consultation with a radiation oncologist is encouraged.) Note: Irradiation of any internal mammary nodes is prohibited in this trial.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 0  (showing 5 examples)\n",
            "- [NCT00001137] HIV-1 infected\n",
            "- [NCT00003895] Patients must be negative for human immunodeficiency virus (HIV) antibody by enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is positive) if they are considered to be at high risk; others do not require serologic testing if there are no symptoms or risk factors for HIV disease\n",
            "- [NCT00005764] Are HIV-positive.\n",
            "- [NCT00005764] Have had HIV-1 RNA levels less than 400 copies/ml on the 2 most recent measurements.\n",
            "- [NCT00005764] Have had an HIV vaccine within 3 months of the screening visit.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 1  (showing 5 examples)\n",
            "- [NCT00001137] Willing to provide consent for the release and use of clinical data from the parent study\n",
            "- [NCT00003199] The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines\n",
            "- [NCT00003895] Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy\n",
            "- [NCT00004067] Psychiatric or addictive disorders that would preclude obtaining informed consent.\n",
            "- [NCT00004074] Written signed informed consent; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 2  (showing 5 examples)\n",
            "- [NCT00001137] Life expectancy of at least 24 weeks\n",
            "- [NCT00004067] The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)\n",
            "- [NCT00004074] Life expectancy of at least 6 months\n",
            "- [NCT00028405] Minimum life expectancy of 12 weeks.\n",
            "- [NCT00044291] Predicted life expectancy of 12 weeks or more\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 3  (showing 5 examples)\n",
            "- [NCT00001137] Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria\n",
            "- [NCT00035958] Patient and/or parent or legal guardian must be willing to sign consent and assent forms Exclusion criteria at the time of enrollment:\n",
            "- [NCT00106184] Parent willing to provide informed consent, if applicable\n",
            "- [NCT00315393] Parent or guardian willing to provide informed consent, if applicable\n",
            "- [NCT00346398] Parent or guardian willing to provide informed consent\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 4  (showing 5 examples)\n",
            "- [NCT00003199] Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (\\>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions\n",
            "- [NCT00004067] The tumor must be invasive adenocarcinoma on histologic examination.\n",
            "- [NCT00004067] Prior history of breast cancer, including DCIS (patients with a history of lobular carcinoma in situ \\[LCIS\\] are eligible).\n",
            "- [NCT00024154] Histologically confirmed metastatic adenocarcinoma of the breast\n",
            "- [NCT00034918] Histological and/or cytological confirmation of metastatic breast cancer which is refractory to anthracycline, taxane, with or without capecitabine therapies;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 5  (showing 5 examples)\n",
            "- [NCT00003199] Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol\n",
            "- [NCT00004067] Prior anthracycline or taxane therapy for any malignancy.\n",
            "- [NCT00048633] Histologically proven breast cancer with primary resistance to anthracyclines (doxorubicin, epirubicin) or taxane (paclitaxel, docetaxel) or both. Primary chemotherapy resistance is defined for the purpose of this protocol as any of the following: 1. Progression after a minimum of 1 cycles of therapy, or 2. Stable disease after a minimum of 2 cycles of therapy or, 3. Relapse within 6 months after completion of an anthracycline or/and taxane containing chemotherapy regimen.\n",
            "- [NCT00051103] No more than two prior regimens for metastatic breast cancer. Each regimen must have contained Herceptin.\n",
            "- [NCT00063570] Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 6  (showing 5 examples)\n",
            "- [NCT00003199] Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (\\>= 2.5 x 10\\^6 CD34+ cells/kg)\n",
            "- [NCT00003895] Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic techniques, flow cytometry, or molecular techniques\n",
            "- [NCT00005617] HLA-A2.1 positive and express MART-1, as assessed by either RT-PCR or by immunohistochemistry\n",
            "- [NCT00005949] HLA-A2\\\n",
            "- [NCT00024154] No prior organ allograft\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 7  (showing 5 examples)\n",
            "- [NCT00003199] Hepatic function: Bilirubin =\\< 2 mg%; SGOT or SGPT =\\< 2.5 x institutional normal\n",
            "- [NCT00048633] Normal renal function: creatinine less than or equal to 2.0 mg/dl. Adequate liver function: bilirubin less than or equal to 1.5 mg/dl. Transaminase (SGOT) and alkaline phosphatase must be less than or equal to 1.5 x of the upper limit of normal in the absence of bone or liver metastasis, or less than or equal to 2.5 x of the upper limit of normal in the presence of radiologically apparent liver metastasis or bone metastasis, respectively.\n",
            "- [NCT00087477] Adequate liver function with alkaline phosphatase \\<= 2.5 X upper limit of normal, SGOT and SGPT \\<= 1.5 X upper limit of normal and total bilirubin \\<= 1.5 X upper limit of normal.\n",
            "- [NCT00129376] Hepatic function: total bilirubin \\<= 1 x upper normal limit (UNL); Aspartate aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) \\<= 2.5 x UNL; alkaline phosphatase \\<= 5 x UNL.\n",
            "- [NCT00155259] Adequate liver and kidney function: total bilirubin ≦ 2.0 mg/dl, serum alanine transaminases (ALT) and aspartate transaminase (AST) ≦ 3 times upper normal limit, serum creatinine ≦ 1.5 mg/dl\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 8  (showing 5 examples)\n",
            "- [NCT00003199] Renal function: Creatinine =\\< 2.0 mg/dl or a creatinine clearance \\>= 50 mg/min\n",
            "- [NCT00003199] Creatinine =\\< 2.0 mg/dl\n",
            "- [NCT00003895] Serum creatinine =\\< 2 mg/dl\n",
            "- [NCT00004067] There must be postoperative evidence of adequate renal function (serum creatinine within or less than the institution's normal range).\n",
            "- [NCT00004074] Calculated creatinine clearance will be used to assess renal function\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 9  (showing 5 examples)\n",
            "- [NCT00003199] Pre-Study tests have been performed as outlined in the Study Calendar\n",
            "- [NCT00254592] In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28. This allows for efficient patient scheduling without exceeding the guidelines. If Day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day.\n",
            "- [NCT00479674] Laboratory tests performed within 14 days of study entry:\n",
            "- [NCT00491816] Pretreatment lab values must be performed within 14 days of patient registration, and other baseline studies within 30 days\n",
            "- [NCT00544765] Laboratory requirements (within 14 days prior to registration):\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 10  (showing 5 examples)\n",
            "- [NCT00003199] Karnofsky performance status \\> 60\n",
            "- [NCT00003895] Patients must be ambulatory with good performance status (Karnofsky performance status \\[PS\\] 80-100)\n",
            "- [NCT00004074] Karnofsky Performance Status index \\>= 70%\n",
            "- [NCT00005617] Karnofsky Performance Status greater than or equal to 70 percent\n",
            "- [NCT00087373] Performance status - Karnofsky 70-100%\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 11  (showing 5 examples)\n",
            "- [NCT00003199] Total bilirubin =\\< 2.5 x upper limit of normal\n",
            "- [NCT00003895] Total bilirubin =\\< 2.0 mg/dl\n",
            "- [NCT00005949] Bilirubin normal\n",
            "- [NCT00024154] Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
            "- [NCT00036621] Total bilirubin \\< 1.5 x ULN\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 12  (showing 5 examples)\n",
            "- [NCT00003199] SGOT =\\< 2.5 x upper limit of normal\n",
            "- [NCT00005949] AST no greater than 2.5 times upper limit of normal\n",
            "- [NCT00024154] INR no greater than 1.5 times ULN\n",
            "- [NCT00074308] AST and ALT no greater than 2.5 times ULN\n",
            "- [NCT00087373] AST and ALT ≤ 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 13  (showing 5 examples)\n",
            "- [NCT00003895] Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision\n",
            "- [NCT00003895] Patients whose melanoma is \\> 4.0 mm thick who have positive or negative regional lymph nodes are also eligible\n",
            "- [NCT00005617] Adults over the age of 18 with malignant melanoma.\n",
            "- [NCT00005617] Tumor stages T3N0M0 or greater are eligible for this trial according to the following: 1. I (\\<.75 to 1.5 mm or Clark level III-T1-2N0M0-)-not eligible 2. II (1.5 to 4 mm or level IV-T3N0M0-)-eligible 3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)-eligible 4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)-eligible 5. Relapsed melanoma-eligible\n",
            "- [NCT00005617] Patients previously treated with any form of therapy for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous treatment was completed \\>30 days prior to enrollment\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 14  (showing 5 examples)\n",
            "- [NCT00003895] After accrual to the original 26 patient goal, all patients must be enrolled prior to sentinel lymph node dissection; patients with previous lymph node dissection will not be eligible\n",
            "- [NCT00004067] Ipsilateral nodes must be cN0-1 by clinical evaluation.\n",
            "- [NCT00004067] Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.\n",
            "- [NCT00004067] Patients must have undergone either a total mastectomy and an axillary dissection or a lumpectomy and an axillary dissection. Sentinel node biopsy is permitted, but must be followed by an axillary dissection.\n",
            "- [NCT00004067] Patients treated by lumpectomy and axillary node dissection to be followed by breast radiation therapy must meet all the eligibility criteria in addition to the following: Generally, lumpectomy should be reserved for tumors \\<5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are eligible. The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients in whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary dissection has been performed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. Whole breast irradiation is required. Irradiation of regional lymph nodes is optional, but partial breast irradiation and irradiation of any internal mammary nodes are prohibited in this trial. Intent to irradiate the axilla or other regional node groups must be declared by the investigator prior to randomization for stratification purposes.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 15  (showing 5 examples)\n",
            "- [NCT00003895] White blood cell (WBC) \\>= 3500/mm\\^3\n",
            "- [NCT00071981] White blood cell (WBC) at least 4,000/mm\\^3\n",
            "- [NCT00071981] Lymphocyte count at least 700/mm\\^3\n",
            "- [NCT00074308] WBC at least 3,000/mm\\^3\n",
            "- [NCT00087373] WBC ≥ 3,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 16  (showing 5 examples)\n",
            "- [NCT00003199] ANC \\> 1,000 cells/mm\\^3 and platelets \\> 30,000/cells/mm\\^3 (transfusion independent) for at least 5 days before starting therapy\n",
            "- [NCT00003895] Platelets (Plt) \\>= 100,000/mm\\^3\n",
            "- [NCT00004067] Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.\n",
            "- [NCT00005949] Platelet count at least 100,000/mm\\^3\n",
            "- [NCT00024154] Platelet count at least 100,000/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 17  (showing 5 examples)\n",
            "- [NCT00003895] Hemoglobin \\>= 9 gm/100 ml\n",
            "- [NCT00005949] Hemoglobin at least 10 g/dL\n",
            "- [NCT00094003] Hemoglobin ≥9.0 g/dL\n",
            "- [NCT00146562] Hemoglobin \\> 9 g/dL\n",
            "- [NCT00217672] Hemoglobin ≥ 9.0 g/dL\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 18  (showing 5 examples)\n",
            "- [NCT00003895] Patients must have recovered from any effects of major surgery and be free of significant systemic infection\n",
            "- [NCT00006412] Had surgery to remove their gallbladder within 3 months prior to study entry.\n",
            "- [NCT00028405] Patient has recovered from all previous surgery in the judgment of the Principal Investigator.\n",
            "- [NCT00071981] Recovered from prior major surgery\n",
            "- [NCT00087373] More than 2 weeks since prior surgery and recovered\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 19  (showing 5 examples)\n",
            "- [NCT00003895] Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment\n",
            "- [NCT00004074] Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; a woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant\n",
            "- [NCT00005617] Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment\n",
            "- [NCT00005764] Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.\n",
            "- [NCT00005949] Fertile patients must use effective contraception\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 20  (showing 5 examples)\n",
            "- [NCT00004067] The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins) and randomization must be less than or equal to 84 days.\n",
            "- [NCT00004067] Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.\n",
            "- [NCT00513136] At least 3 months since last breast cancer treatment (excluding hormonal therapy or Herceptin).\n",
            "- [NCT00546156] Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer\n",
            "- [NCT01095848] Patients with stage IV breast cancer who have received at least 1 course of hormonal or cytotoxic therapy for metastatic cancer. Patients must be off cytotoxic therapy with stable disease or better for 3 months or greater duration. Patients may have stable disease and still be on hormonal therapy.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 21  (showing 5 examples)\n",
            "- [NCT00004067] All of the following staging criteria must be met:\n",
            "- [NCT00004067] Primary tumor must be T1-3 by clinical and pathologic evaluation.\n",
            "- [NCT00004067] Primary tumor staged as T4 for any reason.\n",
            "- [NCT00087373] Stage IV disease\n",
            "- [NCT00087373] Detectable intratumoral T cells measured in the index lesion that is to be injected with rF-TRICOMTM by immunohistochemistry (IHC) for CD4, CD8 or another T cell marker, or by real time RT-PCR for CD8a, CD4, or other T cell transcripts\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 22  (showing 5 examples)\n",
            "- [NCT00004067] M0\n",
            "- [NCT00394251] T1-3, N1-3, M0, regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.\n",
            "- [NCT00394251] T \\> 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative\n",
            "- [NCT00402519] M0.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 23  (showing 5 examples)\n",
            "- [NCT00004067] The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.\n",
            "- [NCT00004067] Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. \"Marginal,\" \"borderline,\" etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.\n",
            "- [NCT00004074] Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use\n",
            "- [NCT00024154] Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)\n",
            "- [NCT00024154] Hormone receptor status:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 24  (showing 5 examples)\n",
            "- [NCT00004067] At the time of randomization, the patient must have had the following: history and physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam (for women who have a uterus and who will be taking tamoxifen) within the past year.\n",
            "- [NCT00004067] Bilateral malignancy or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant.\n",
            "- [NCT00123253] Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.\n",
            "- [NCT00129376] Negative extension study, including bilateral mammography, thoracic x-ray, computed tomography (CT)-scan or abdominal echography and bone scintigraphy.\n",
            "- [NCT00161291] Patients must have measurable disease by mammogram and/or breast ultrasound. The target lesion must not have been previously irradiated.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 25  (showing 5 examples)\n",
            "- [NCT00004067] Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is \\> 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)\n",
            "- [NCT00004074] Normal cardiac ejection fraction by echocardiogram or MUGA (i.e., greater than OSU lower limit of normal)\n",
            "- [NCT00024154] LVEF ≥ 50% by MUGA scan\n",
            "- [NCT00051103] Cardiac ejection fraction within the institutional range of normal as measured by MUGA (Multiple Gated Acquisition Scan).\n",
            "- [NCT00104884] Left ventricular ejection fraction (LVEF) \\> 40% by Multi Gated Acquisition Scan (MUGA)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 26  (showing 5 examples)\n",
            "- [NCT00004067] At the time of randomization:\n",
            "- [NCT00031486] Patient is expected to be available for follow-up visits of study drug administration and through the 24 month study visit.\n",
            "- [NCT00074308] More than 3 months\n",
            "- [NCT00074308] None of the following within the past 6 months:\n",
            "- [NCT00087373] More than 12 weeks\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 27  (showing 5 examples)\n",
            "- [NCT00004067] The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or \\<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).\n",
            "- [NCT00094003] Absolute neutrophil count (ANC) ≥1,500/mm3, without growth factor support\n",
            "- [NCT00206492] total neutrophil count must be \\>1.5 x 10\\^9/L, and\n",
            "- [NCT00217672] Absolute neutrophil count ≥ 1,500/mm\\^3\n",
            "- [NCT00258349] Absolute neutrophil count \\>= 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 28  (showing 5 examples)\n",
            "- [NCT00004067] Patients must have no clinical or radiologic evidence of metastatic disease. Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A patient with skeletal pain is eligible for inclusion in the study if bone scan and/or roentgenological examination fails to disclose metastatic disease.\n",
            "- [NCT00044291] Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease\n",
            "- [NCT00221221] no known or active metastatic disease.\n",
            "- [NCT00255762] Evidence of metastatic disease\n",
            "- [NCT00258349] Metastatic or chest wall recurrent disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 29  (showing 5 examples)\n",
            "- [NCT00004067] Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible only if this therapy is discontinued prior to randomization.)\n",
            "- [NCT00005617] A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy\n",
            "- [NCT00005764] Have had chemotherapy or radiation therapy within 4 weeks prior to screening visit (except for local treatment for Kaposi's sarcoma) or plan to have such treatment during the study.\n",
            "- [NCT00005764] Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical steroids) in the last 4 months or plan to take these drugs during the study.\n",
            "- [NCT00005949] At least 4 weeks since prior chemotherapy\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 30  (showing 5 examples)\n",
            "- [NCT00004067] Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. (Patients are eligible only if these medications are discontinued prior to randomization. These medications are not permitted while on the study except for the use of tamoxifen as described in the protocol)\n",
            "- [NCT00024154] No concurrent hormonal therapy, including tamoxifen\n",
            "- [NCT00036621] Tamoxifen (20mg) given orally once per day\n",
            "- [NCT00201929] Chemotherapy alone or in addition to tamoxifen as an appropriate treatment option Surgery Group:\n",
            "- [NCT00287534] continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 31  (showing 5 examples)\n",
            "- [NCT00004067] Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude a patient from being subjected to any of the treatment options or would prevent prolonged follow-up.\n",
            "- [NCT00004074] The patient must have failed standard curative and/or palliative therapies for their disease\n",
            "- [NCT00006412] Have failed previous statin or fibrate therapy (after 24 weeks of treatment) or have had side effects from these drugs.\n",
            "- [NCT00021463] Have had treatment with ABC.\n",
            "- [NCT00024154] No prior gefitinib\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 32  (showing 5 examples)\n",
            "- [NCT00004067] Cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin. This includes:\n",
            "- [NCT00004067] Active cardiac disease:\n",
            "- [NCT00004067] angina pectoris that requires the use of antianginal medication;\n",
            "- [NCT00004067] cardiac arrhythmia requiring medication;\n",
            "- [NCT00004067] severe conduction abnormality;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 33  (showing 5 examples)\n",
            "- [NCT00004067] patients with poorly controlled hypertension, i.e., diastolic greater than 100 mm/Hg. (Patients with hypertension who are well controlled on medication are eligible for entry.)\n",
            "- [NCT00005949] No antihypertensive medications from 1 day prior until 2 days after first course\n",
            "- [NCT00006412] Have uncontrolled high blood pressure within 4 weeks of study entry.\n",
            "- [NCT00074308] No uncontrolled hypertension within the past 6 months\n",
            "- [NCT00074308] Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 34  (showing 5 examples)\n",
            "- [NCT00004067] Sensory/motor neuropathy ≥ grade 2, as defined by the NCI's Common Toxicity Criteria version 2.0.\n",
            "- [NCT00077363] Patients with CTC v 3.0 grade 2-4 neuropathy are not eligible\n",
            "- [NCT00217672] Presence of neuropathy \\> grade 2 (NCI- Common Toxicity Criteria (CTC) version 3.0) at baseline\n",
            "- [NCT00225056] peripheral neuropathy less than or equal to grade 1\n",
            "- [NCT00255762] No peripheral neuropathy ≥ grade 2\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 35  (showing 5 examples)\n",
            "- [NCT00004067] Contraindications to corticosteroid use which, in the opinion of the investigator, would preclude participation in this study.\n",
            "- [NCT00006290] Have a mental disability that, in the opinion of the researcher, could interfere with study participation.\n",
            "- [NCT00006412] Abuse drugs or alcohol, and the doctor thinks this may interfere with the study.\n",
            "- [NCT00024154] No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation\n",
            "- [NCT00074308] No psychiatric illness or social situation that would preclude study compliance\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 36  (showing 5 examples)\n",
            "- [NCT00004067] Concurrent treatment with other investigational agents.\n",
            "- [NCT00024154] No other concurrent investigational agents\n",
            "- [NCT00074308] No other concurrent investigational agents\n",
            "- [NCT00087373] No other concurrent investigational agents\n",
            "- [NCT00258349] No other concurrent investigational agents\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 37  (showing 5 examples)\n",
            "- [NCT00004067] Patients in whom the margins of the resected specimen are involved with invasive tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to obtain free margins are allowed. Patients in whom tumor is still present after the additional resection(s) must undergo mastectomy to be eligible.\n",
            "- [NCT00121134] Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.\n",
            "- [NCT00325598] Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.\n",
            "- [NCT00325598] Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.\n",
            "- [NCT00337064] Pathologically negative margins\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 38  (showing 5 examples)\n",
            "- [NCT00004074] Patients must have measurable or evaluable disease\n",
            "- [NCT00048633] Patients must have measurable disease as defined by the RECIST criteria in their breast/nodal regions or at a distant organ site(s).\n",
            "- [NCT00063570] Must have disease that can be measured.\n",
            "- [NCT00191243] measurable and/or non-measurable disease\n",
            "- [NCT00225056] must have measurable or evaluable disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 39  (showing 5 examples)\n",
            "- [NCT00004067] Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.\n",
            "- [NCT00004074] No concurrent malignancy other than non-melanoma skin carcinoma\n",
            "- [NCT00005949] No currently active second malignancy (e.g., patient has completed therapy and is considered unlikely to have recurrence within 1 year) other than nonmelanoma skin cancer\n",
            "- [NCT00024154] No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n",
            "- [NCT00039793] Have a primary oncologist\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 40  (showing 5 examples)\n",
            "- [NCT00004074] Adequate hematopoietic, cardiac, renal, and hepatic function\n",
            "- [NCT00006412] Have liver disease.\n",
            "- [NCT00051103] Adequate kidney and liver function\n",
            "- [NCT00087776] Patients must have adequate renal and liver function\n",
            "- [NCT00191243] adequate liver / renal functions defined\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 41  (showing 5 examples)\n",
            "- [NCT00005617] No previous evidence of opportunistic infection\n",
            "- [NCT00074308] No ongoing or active infection requiring parenteral antibiotics\n",
            "- [NCT00087373] No uncontrolled active or chronic infection\n",
            "- [NCT00091819] Patients must be expected to require at least 7 days of intravenous antibiotic treatment\n",
            "- [NCT00107978] Patients must be expected to require at least 7 days of intravenous antibiotic treatment.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 42  (showing 5 examples)\n",
            "- [NCT00005617] Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): 1. Hemoglobin \\>9.0 g/dl 2. Platelets \\> 100000/mm3 3. WBC \\> 3000/mm3 4. Absolute Neutrophil Count \\> 1000/mm3\n",
            "- [NCT00048633] Adequate bone marrow function: platelets greater than or equal to 100,000/mm3, ANC greater than or equal to 1500 cells/mm3, hemoglobin greater than or equal to 8g/dl.\n",
            "- [NCT00087477] Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and absolute neutrophil count (ANC)≥ 1,500 cells/mm3.\n",
            "- [NCT00129376] Haematology: neutrophils \\>= 2.0 x10\\^9/l; platelets \\>= 100 x10\\^9/l; hemoglobin \\>=10 g/dl.\n",
            "- [NCT00155259] Adequate bone marrow reserve, defined as white blood cell (WBC)≧ 3,500/ mm3, absolute neutrophil count (ANC)≧ 1,500/mm3, platelets ≧ 100,000/mm3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 43  (showing 5 examples)\n",
            "- [NCT00005617] Positive skin test to common antigens (tetanus and candida)\n",
            "- [NCT00317980] Presence of 1 to 9 cutaneous lesions clinically compatible with leishmaniasis\n",
            "- [NCT00317980] Positive leishmanin skin test\n",
            "- [NCT00317980] Parasitological diagnosis confirmed through culture or genus-specific polymerase chain reaction (PCR) for Leishmania spp\n",
            "- [NCT01011309] Must have a clinical diagnosis of cutaneous leishmaniasis confirmed by positive identification of Leishmania parasite and identification of L. peruviana by PCR.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 44  (showing 5 examples)\n",
            "- [NCT00005617] Ability to give informed consent\n",
            "- [NCT00028405] Ability to provide informed consent.\n",
            "- [NCT00044291] Written informed consent obtained\n",
            "- [NCT00048633] Written informed consent.\n",
            "- [NCT00083239] Written informed consent\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 45  (showing 5 examples)\n",
            "- [NCT00005764] Patients may be eligible for this study if they:\n",
            "- [NCT00005764] Have taken d4T consistently for the 6 months before entering study. Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "- [NCT00005764] Are enrolled in other clinical studies.\n",
            "- [NCT00006290] Patients may be eligible for this study if they:\n",
            "- [NCT00006290] Are either female or heterosexual male (if enrolling in the University of Pennsylvania or Johns Hopkins University focus groups). Exclusion Criteria Patients will not be eligible for this study if they:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 46  (showing 5 examples)\n",
            "- [NCT00005764] Are at least 18 years old.\n",
            "- [NCT00006412] Are at least 18 years old.\n",
            "- [NCT00650910] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT00821054] Is at least 18 years of age and not greater than 65 years of age.\n",
            "- [NCT01473680] Is at least 18 years old, but not older than 61 years old;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 47  (showing 5 examples)\n",
            "- [NCT00005764] Have at least 1 of the following situations:\n",
            "- [NCT00006412] (This reflects a change in exclusion requirements.)\n",
            "- [NCT00024154] Not specified\n",
            "- [NCT00087373] Must have 1 of the following criteria:\n",
            "- [NCT00245960] Inclusion Criteria:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 48  (showing 5 examples)\n",
            "- [NCT00005764] (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in buttocks area; or\n",
            "- [NCT00005764] (b) an increase in lactate level greater than 2.2 mmol/L at the screening visit plus at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in the buttocks area; or\n",
            "- [NCT00006290] Are experiencing at least 1 of the following symptoms associated with fat changes due to HIV: 1) increase in belt or waist size; 2) increase in size of back of neck; 3) increase in bra, shirt, or blouse size to fit increasing breast size; 4) fat increase in other areas of the body; 5) loss of facial fat; 6) loss of fat in arms or legs; 7) loss of fat in buttocks.\n",
            "- [NCT00006290] Have diabetes or Cushing's disease or have had surgery that might otherwise explain changes in body fat.\n",
            "- [NCT00006290] Have changes in diet or physical activity that might explain changes in body fat.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 49  (showing 5 examples)\n",
            "- [NCT00005764] (c) an increase in lactate level greater than 2.2 mmol/L at screening visit plus at least 2 of the following: (1) shortness of breath, (2) weakness, (3) fast heartbeat, (4) recent weight loss (10 lbs. within the past 2 months), (5) pain and/or bloating in the abdomen, (6) nausea and/or vomiting and/or lack of appetite; or\n",
            "- [NCT00005764] Have serious medical conditions, such as congestive heart failure or other heart disease, which would affect the safety of the patient.\n",
            "- [NCT00074308] No other concurrent uncontrolled illness\n",
            "- [NCT00077363] Patients must not have any uncontrolled intercurrent illness including, but not limited to, chronic nausea/vomiting, complete or partial bowel obstruction, dysphagia/odynophagia with inability to swallow pills, ongoing or active infection, symptomatic cardiovascular disease, or other chronic medical or psychiatric conditions that would impair compliance or would substantially increase the risk of participating in this study\n",
            "- [NCT00255762] No other uncontrolled illness\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 50  (showing 5 examples)\n",
            "- [NCT00005764] Are able to read at a sixth-grade level.\n",
            "- [NCT00006290] Are able to speak and read English.\n",
            "- [NCT00106184] Able and willing to complete self-report questionnaires. Parents of pediatric participants will be required to complete the questionnaires on behalf of their children.\n",
            "- [NCT00179634] Working knowledge of English\n",
            "- [NCT00198250] able to read, write and speak English\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 51  (showing 5 examples)\n",
            "- [NCT00005764] Have diabetes or kidney failure.\n",
            "- [NCT00006412] Have diabetes requiring drug treatment or diabetes not controlled by diet.\n",
            "- [NCT00024154] Random blood sugar less than 2.5 times ULN\n",
            "- [NCT00025883] Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient. Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period. Presence of at least one of the following metabolic abnormalities: 1. Presence of diabetes as defined by the 2007 ADA criteria 1. Fasting plasma glucose greater than or equal to 126 mg/dL, or 2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or 3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl 2. Fasting insulin greater than 30 micro units/ml. 3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants) -Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.\n",
            "- [NCT00065663] Adequately controlled diabetes mellitus (type I or II) as defined by HbA1c \\< 10.0%\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 52  (showing 5 examples)\n",
            "- [NCT00005764] Are unable to take medications by mouth.\n",
            "- [NCT00034918] No Gastrointestinal pathology which could affect the bioavailability of ZD6474.\n",
            "- [NCT00051103] Able to swallow and retain oral medication\n",
            "- [NCT00359190] Ability to swallow and retain oral medication.\n",
            "- [NCT00383851] History of malabsorption syndromes or other gastrointestinal disorders that may affect ATN-224 or temozolomide absorption, including bowel obstruction, celiac disease, sprue, cystic fibrosis\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 53  (showing 5 examples)\n",
            "- [NCT00005764] Are pregnant or breast-feeding.\n",
            "- [NCT00006290] Are pregnant.\n",
            "- [NCT00006412] Are pregnant or breast-feeding.\n",
            "- [NCT00021463] Are pregnant or breast-feeding.\n",
            "- [NCT00087373] Pregnant women\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 54  (showing 5 examples)\n",
            "- [NCT00005764] Have taken hydroxyurea within the past 3 days or plan to take this drug during the study.\n",
            "- [NCT00005949] At least 1 month since prior systemic corticosteroids\n",
            "- [NCT00005949] No concurrent systemic, inhaled, or topical corticosteroids\n",
            "- [NCT00006290] Have been on glucocorticoid therapy for a long time.\n",
            "- [NCT00006412] Have taken any prescription or non-prescription lipid-lowering drug within 14 days prior to study entry or for over 24 weeks in the past.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 55  (showing 5 examples)\n",
            "- [NCT00005949] 0201 positive by genotyping\n",
            "- [NCT00306553] 0201 haplotype\n",
            "- [NCT00700167] 0201 positive.\n",
            "- [NCT01026051] 0201 as assessed by DNA typing\n",
            "- [NCT01273181] 0201 positive Serology:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 56  (showing 5 examples)\n",
            "- [NCT00005949] Measurable disease as defined by the following:\n",
            "- [NCT00024154] Measurable disease\n",
            "- [NCT00050141] Measurable disease\n",
            "- [NCT00074308] Measurable disease (phase II)\n",
            "- [NCT00087373] Measurable disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 57  (showing 5 examples)\n",
            "- [NCT00005949] At least 1 lesion accurately measured in at least 1 dimension\n",
            "- [NCT00005949] At least 20 mm by conventional techniques\n",
            "- [NCT00005949] Lesions considered intrinsically nonmeasurable include:\n",
            "- [NCT00083239] Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins\n",
            "- [NCT00087373] At least 1 cutaneous or lymph node mass ≥ 1 cm AND amenable to biopsy and percutaneous injection AND can be accurately measured with standard calipers\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 58  (showing 5 examples)\n",
            "- [NCT00005949] Bone lesions\n",
            "- [NCT00005949] Abdominal masses not confirmed and followed by imaging techniques\n",
            "- [NCT00051779] A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases.\n",
            "- [NCT00051779] Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention.\n",
            "- [NCT00077363] Patients must have at least one objective measurable disease parameter as defined by RECIST criteria; tumor measurements and evaluation of non-measurable sites must be performed within 4 weeks prior to registration\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 59  (showing 5 examples)\n",
            "- [NCT00005949] Leptomeningeal disease\n",
            "- [NCT00005949] No prior or concurrent liver or brain metastases\n",
            "- [NCT00024154] No untreated brain metastases or brain metastases undergoing radiotherapy\n",
            "- [NCT00024154] Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease\n",
            "- [NCT00048633] Patients with brain metastases whose disease remained stable for more than 3 months after completing therapy to the brain are eligible.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 60  (showing 5 examples)\n",
            "- [NCT00005949] Ascites\n",
            "- [NCT00369655] Ascites\n",
            "- [NCT01005472] Terfenadine\n",
            "- [NCT01005472] Quinidine\n",
            "- [NCT01005472] Procainamide\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 61  (showing 5 examples)\n",
            "- [NCT00005949] Pleural/pericardial effusion\n",
            "- [NCT00369655] Pleural/pericardial effusion\n",
            "- [NCT00436605] No large pleural effusions\n",
            "- [NCT01283789] Pleural/pericardial effusion\n",
            "- [NCT01543126] Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 62  (showing 5 examples)\n",
            "- [NCT00005949] Lymphangitis cutis/pulmonis\n",
            "- [NCT00194363] Women without lymphedema must be 1-5 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must be 1-15 years post breast cancer diagnosis\n",
            "- [NCT00194363] Women with lymphedema must have stable lymphedema. ONE of the following:\n",
            "- [NCT00194363] A prior clinical diagnosis of lymphedema and having had any prior intensive lymphedema therapy on the affected arm As well as ALL of the following four conditions:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 63  (showing 5 examples)\n",
            "- [NCT00005949] At least 10 mm by spiral CT scan\n",
            "- [NCT00005949] Lesions situated in a previously irradiated area\n",
            "- [NCT00071981] Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST criteria)\n",
            "- [NCT00073528] Subjects with either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).\n",
            "- [NCT00077363] Previously irradiated tumors cannot be used to assess a clinical response; patients will not be eligible for this study if the previously irradiated tumors constitute the only site of measurable disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 64  (showing 5 examples)\n",
            "- [NCT00005949] No severe chronic pulmonary disease\n",
            "- [NCT00035958] JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)\n",
            "- [NCT00333437] Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.\n",
            "- [NCT00377949] Diagnosis of \"pre\" pulmonary arterial hypertension defined as:\n",
            "- [NCT00377949] Pulmonary function test with FVC \\>70% and a DLCO \\<55% of predicted or a FVC/DLco ratio \\>1.6. or\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 65  (showing 5 examples)\n",
            "- [NCT00005949] Not pregnant or nursing\n",
            "- [NCT00024154] Not pregnant or nursing\n",
            "- [NCT00035958] Pregnant or nursing female\n",
            "- [NCT00074308] Not pregnant or nursing\n",
            "- [NCT00087373] Not pregnant or nursing\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 66  (showing 5 examples)\n",
            "- [NCT00003199] Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:\n",
            "- [NCT00005764] Have taken drugs that affect the immune system, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to the screening visit.\n",
            "- [NCT00005949] At least 4 weeks since prior immunotherapy\n",
            "- [NCT00005949] No prior interleukin-2\n",
            "- [NCT00005949] No other concurrent cytokines or growth factors\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 67  (showing 5 examples)\n",
            "- [NCT00006290] Are 18 years or older.\n",
            "- [NCT00028405] Age 18 or older.\n",
            "- [NCT00071981] Age: 18 and over\n",
            "- [NCT00107991] Age 18 or older.\n",
            "- [NCT00119158] Age 2 to 65 years\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 68  (showing 5 examples)\n",
            "- [NCT00006412] Are on a lipid-lowering diet based on the patient's statement and have been exercising for at least 30 days before being screened for the study. Patients will be asked if they were counseled by their health care provider. The lipid-lowering diet and exercise program do not have to be prescribed by a physician.\n",
            "- [NCT00006412] Take prescription lipid-lowering agents, other than those given by the study, and non-prescription lipid-lowering agents such as garlic supplements.\n",
            "- [NCT00178126] use wheelchair \\> 6 hours per day\n",
            "- [NCT00193037] Able to perform activities of daily living with minimal assistance\n",
            "- [NCT00235196] Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 69  (showing 5 examples)\n",
            "- [NCT00006412] Have a triglyceride (TG) level of at least 200 mg/dl and low-density lipoprotein (LDL) level of at least 130 mg/dl after fasting for 8 to 12 hours.\n",
            "- [NCT00811824] LDL cholesterol \\< 150\n",
            "- [NCT01283789] Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, patient may be included after initiation of appropriate lipid lowering medication with approval from the principal investigator.\n",
            "- [NCT01513356] Cholesterol \\< ULN - 7.75 mmol/L and Triglycerides \\< ULN - 2.5 x ULN (with lipid-lowering drugs permitted)\n",
            "- [NCT01997255] Acceptable fasting serum cholesterol and fasting triglycerides levels.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 70  (showing 5 examples)\n",
            "- [NCT00006412] Have hypothyroidism (low thyroid activity).\n",
            "- [NCT00006412] Take or have taken levothyroxine and liothyronine for hypothyroidism.\n",
            "- [NCT00336102] No diagnosis of hypothyroidism or hyperthyroidism.\n",
            "- [NCT00459771] Thyroid stimulating hormone between 0.5-3.9 MU/l\n",
            "- [NCT00777335] Clinically euthyroid function (thyroid-stimulating hormone (TSH) and free T4). (Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 71  (showing 5 examples)\n",
            "- [NCT00006412] Are allergic or sensitive to the study drug(s) or to other lipid-lowering drugs.\n",
            "- [NCT00021463] Are allergic to study drugs or any ingredient in them.\n",
            "- [NCT00074308] No prior allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biological composition to imatinib mesylate\n",
            "- [NCT00087373] No prior significant allergic reaction or hypersensitivity to eggs or egg products\n",
            "- [NCT00217672] A history of a severe hypersensitivity reaction to Bevacizumab, or Docetaxel or other drugs formulated with polysorbate 80.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 72  (showing 5 examples)\n",
            "- [NCT00006412] Were given radiation therapy within 30 days of study entry.\n",
            "- [NCT00024154] At least 2 weeks since prior radiotherapy\n",
            "- [NCT00024154] No prior radiotherapy to target lesions or only site of measurable disease\n",
            "- [NCT00024154] No concurrent radiotherapy\n",
            "- [NCT00028405] If patients have received radiotherapy to sites of disease other than the one planned for insertion of the light delivery catheter, then the patient must have no current local or systemic toxicity from the prior radiation.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 73  (showing 5 examples)\n",
            "- [NCT00007280] Men or women at least 18 years old\n",
            "- [NCT00034918] Females, aged \\>= 18 years;\n",
            "- [NCT00044291] Women age 18 years or older\n",
            "- [NCT00087477] Males and females, age ≥ 18 years.\n",
            "- [NCT00094003] Male and female at least 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 74  (showing 5 examples)\n",
            "- [NCT00007280] At least one ulcer (wound) greater than or equal to 2 centimeters\n",
            "- [NCT00007280] Ulcer (wound) present for at least 3 months or greater\n",
            "- [NCT00035958] Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis\n",
            "- [NCT00065663] Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement\n",
            "- [NCT00065663] Ulcer present for \\> 6 weeks prior to study entry\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 75  (showing 5 examples)\n",
            "- [NCT00007280] Ankle/brachial index \\> 0.7\n",
            "- [NCT00065663] Affected limb transcutaneous oxygen pressure (TcpO2) \\> 30 mmHg at screening or a palpable dorsal pedal or posterior tibial pulse\n",
            "- [NCT00366132] Palpable pedal pulse in the affected leg OR peripheral vascular disease evaluation demonstrating acceptable blood supply to affected foot;\n",
            "- [NCT00446472] Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.\n",
            "- [NCT00448903] Ankle-brachial index (ABI) \\> or = 0,7\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 76  (showing 5 examples)\n",
            "- [NCT00021463] Are at least 13 years old and have signed consent of parent or guardian if under 18 years of age.\n",
            "- [NCT00175344] Age 18 years or older with ability to provide written informed consent.\n",
            "- [NCT00245960] 18 years of age or older at time of consent\n",
            "- [NCT00387062] Age 21 or older at the time of consent.\n",
            "- [NCT00403559] Must be 18 or older and sign written informed consent.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 77  (showing 5 examples)\n",
            "- [NCT00001137] Active alcohol or drug abuse that may interfere with the study\n",
            "- [NCT00021463] Abuse drugs or alcohol.\n",
            "- [NCT00424749] History of drug, alcohol, or chemical abuse within 6 months prior to screening\n",
            "- [NCT00438815] Narcotic addiction\n",
            "- [NCT00519246] No alcohol drinking.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 78  (showing 5 examples)\n",
            "- [NCT00024154] Male or female\n",
            "- [NCT00025883] All ethnic groups. Males and females.\n",
            "- [NCT00270972] Male or female\n",
            "- [NCT00324259] Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.\n",
            "- [NCT00365599] Both men and women of all races and ethnic groups are eligible for this trial.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 79  (showing 5 examples)\n",
            "- [NCT00024154] Granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00074308] Absolute granulocyte count at least 1,500/mm\\^3\n",
            "- [NCT00077363] Granulocytes \\> 1500/mm\\^3\n",
            "- [NCT00109005] Granulocyte count greater than 1,500/mm\\^3\n",
            "- [NCT00255762] Absolute granulocyte count ≥ 1,500/mm\\^3\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 80  (showing 5 examples)\n",
            "- [NCT00024154] AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases is present)\n",
            "- [NCT00071981] Alkaline phosphatase no greater than 2 times ULN\n",
            "- [NCT00206492] alkaline phosphatase within 5 x ULN. 7. Performance status (WHO scale) \\<2. 8. Age \\> 18 years.\n",
            "- [NCT00255762] Alkaline phosphatase ≤ 3 times ULN\n",
            "- [NCT00349934] Serum ASAT and ALAT \\< 3 times the upper limit of normal or \\< 5 times upper limit of normal if liver metastases are present.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 81  (showing 5 examples)\n",
            "- [NCT00024154] PT and PTT no greater than 1.5 times ULN\n",
            "- [NCT00074308] INR no greater than 1.5\n",
            "- [NCT00074308] APTT normal\n",
            "- [NCT00087373] PT/PTT ≤ 1.25 times upper limit of normal (ULN)\n",
            "- [NCT00094003] PT and PTT \\< 1.5 times ULN\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 82  (showing 5 examples)\n",
            "- [NCT00024154] No prior trastuzumab (Herceptin)\n",
            "- [NCT00153218] must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy\n",
            "- [NCT00153218] must not have received trastuzumab in the adjuvant or neoadjuvant setting\n",
            "- [NCT00153218] must have started trastuzumab treatment for metastatic disease any time between January 1996 to June 2003\n",
            "- [NCT00258349] More than 4 weeks since prior lapatinib ditosylate\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 83  (showing 5 examples)\n",
            "- [NCT00024154] See Disease Characteristics\n",
            "- [NCT00035958] Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter\n",
            "- [NCT00074308] Histologically or cytologically confirmed diagnosis of 1 of the following:\n",
            "- [NCT00087373] See Disease Characteristics\n",
            "- [NCT00257530] CL diagnosis confirmed\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 84  (showing 5 examples)\n",
            "- [NCT00024154] No concurrent topical eye agents\n",
            "- [NCT00121511] Patients must have clinical photoaging judged by rhytides, dyspigmentation, poikiloderma, lentigines, skin thinning, and/or telangiectases.\n",
            "- [NCT00176969] Not be taking any medications including topical medications\n",
            "- [NCT00253331] agree to apply gel as per protocol\n",
            "- [NCT00335179] Discontinuation of moisturizers\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 85  (showing 5 examples)\n",
            "- [NCT00024154] Concurrent bisphosphonates allowed for hypercalcemia and/or prophylaxis of bone metastases\n",
            "- [NCT00048633] Patients may receive concomitant bisphosphonate therapy for bone metastasis.\n",
            "- [NCT00051779] Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug\n",
            "- [NCT00258349] Concurrent bisphosphonates allowed provided therapy was initiated prior to study treatment\n",
            "- [NCT00324259] For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 86  (showing 5 examples)\n",
            "- [NCT00025883] Age greater than or equal to 6 months.\n",
            "- [NCT00104884] Age greater than or equal to 18\n",
            "- [NCT00133341] Age more or equal to 18 years.\n",
            "- [NCT00204529] ≥ 18 years of age and \\< 75 years of age\n",
            "- [NCT00304460] Age greater than or equal to18 years old.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 87  (showing 5 examples)\n",
            "- [NCT00028405] Tumor mass is not immediately adjacent to, or directly invading a major vessel or hollow viscus such that tumor necrosis could result in hemorrhage or perforation.\n",
            "- [NCT00044291] At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques)\n",
            "- [NCT00255762] No tumor invasion of major blood vessels\n",
            "- [NCT00388115] Tumor less than or equal to 2.0 cm in diameter.\n",
            "- [NCT00802932] Pathologic tumor size \\< 5.0 cm (Microscopic multifocality is allowed if total pathologic tumor size is within 5 cm)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 88  (showing 5 examples)\n",
            "- [NCT00028405] Patient has an ECOG performance status of 0-3 (Karnofsky 30 or higher).\n",
            "- [NCT00161291] Be ambulatory (outpatient) and have an ECOG PS \\<2 (Appendix F).\n",
            "- [NCT00251472] Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I).\n",
            "- [NCT00323206] Patients must have ECOG performance status 0-2\n",
            "- [NCT00324259] The patient must have an ECOG performance status of 0-2\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 89  (showing 5 examples)\n",
            "- [NCT00031460] Less than or equal to 28 days of age at the time of initial presentation with CNS disease.\n",
            "- [NCT00031486] Patients who are 12 years of age or older.\n",
            "- [NCT00087620] Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama\n",
            "- [NCT00087776] Patients must be \\>= 18 years of age.\n",
            "- [NCT00155259] Patients must be ≦ 65 years old\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 90  (showing 5 examples)\n",
            "- [NCT00031460] Birth weight greater than or equal to 800 grams.\n",
            "- [NCT00031486] Patients who weigh greater than or equal to 45.5kg (100 pounds).\n",
            "- [NCT00123253] For males: waist circumference \\> 95 cm and waist to hip ratio \\> 0.94;\n",
            "- [NCT00123253] For females: waist circumference \\> 94 cm and waist to hip ratio \\> 0.88.\n",
            "- [NCT00211133] Weight \\> = 40 kg (88 lbs)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 91  (showing 5 examples)\n",
            "- [NCT00034918] WHO performance status 0, 1 or 2 on the day of registration;\n",
            "- [NCT00048633] Zubrod performance status less than or equal to 2.\n",
            "- [NCT00191243] performance status 0-2 (WHO, Zubrod)\n",
            "- [NCT00197912] WHO-Performance Status 0-1\n",
            "- [NCT00237198] Patients whose performance status (PS) is 0～2\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 92  (showing 5 examples)\n",
            "- [NCT00035958] Prior treatment with specific TNF-blocking agents\n",
            "- [NCT01511315] Subjects must not have received TNF-α inhibitors (such as infliximab, etanercept, adalimumab) within the 12 week period prior to Week 0 or during the study\n",
            "- [NCT02147600] adalimumab (40mg) subcutaneously every other week\n",
            "- [NCT02147600] at least 24 weeks of adalimumab treatment\n",
            "- [NCT02922192] TNF -α antagonists (including adalimumab, certolizumab, etanercept \\[not included for IBD\\], golimumab, infliximab, and natalizumab \\[IBD only\\])\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 93  (showing 5 examples)\n",
            "- [NCT00035958] Any of the following laboratory abnormalities at baseline: platelet count \\< 100,000/cmm, total white cell count of \\< 3000 cells/cmm, neutrophils \\< 1000 cells/cmm, serum bilirubin \\> 2 times upper limit of normal, estimated creatinine clearance of \\< 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to \\<13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)\n",
            "- [NCT00161291] Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \\> 1,500/mm3, hemoglobin \\> 8.0 g/dl, platelets \\> 75,000/mm3, total bilirubin \\< 2 mg/dl, serum creatinine \\< 2 mg/dl, Transaminases (AST, ALT) may be up to 2.0 x institutional upper limit of normal. In addition \\< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \\< 1.0.\n",
            "- [NCT00192517] Prior to randomization (must be within 21 days of the first administration of the study drug), all of the following: WBC less than or equal to 3,800/mm3; hematocrit above 32%, platelet count less than or equal to 140,000/mm3; AST, ALT, BUN, or creatinine\\<1.5 x ULN; and stool negative for occult blood\n",
            "- [NCT00197912] Acceptable CBC and blood chemistry results\n",
            "- [NCT00237185] Performance status ≤3 as defined by the Eastern Cooperative Oncology Group (ECOG) criteria, as well as a life expectancy ≥6 months and adequate end organ function defined as follows: Total bilirubin \\<1.5 times upper limit of normal (ULN), aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) \\<2.5 x ULN (or \\<5 x ULN if hepatic metastases were present), creatinine \\<1.5 x ULN, absolute neutrophil count (ANC) \\>1.5 x 10\\^9/L, platelet count \\>100 x 10\\^9/L\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 94  (showing 5 examples)\n",
            "- [NCT00035958] Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)\n",
            "- [NCT00071981] This extremity may still be considered for vaccination\n",
            "- [NCT00106184] Willing to forgo immunization with a live vaccine for the duration of the study\n",
            "- [NCT00356460] Documentation of flu vaccination if enrolled during flu season (as defined by the availability of vaccine). Otherwise, patient should receive the current flu vaccine \\> or = 1 wk before beginning GC1008 therapy.\n",
            "- [NCT00723528] Participants must agree not to receive Bacillus Calmette-Guérin (BCG) vaccination and live vaccine inoculation for 1 year after final treatment with the investigational product\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 95  (showing 5 examples)\n",
            "- [NCT00036621] ANC \\> 1500/mm3\n",
            "- [NCT00094003] Afebrile (≤37.5C or 99.5F)\n",
            "- [NCT00146562] ANC \\> 1,500/uL\n",
            "- [NCT00407888] ANC \\>= 1,500\n",
            "- [NCT00470301] FEV1 \\>= 1 L\\\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 96  (showing 5 examples)\n",
            "- [NCT00043472] To be considered at increased genetic risk of OC, subjects must have: Age greater than or equal to 30; No prior history of OC, including low malignant potential cancers (LMP), or primary papillary serous carcinoma of the peritoneum; At least one intact ovary: Satisfied one of the following additional criteria: The family of the subject has a documented deleterious BRCA1 or BRCA2 mutation - either:\n",
            "- [NCT00043472] the subject herself has tested positive for a deleterious BRCA1 or BRCA2 mutation; OR\n",
            "- [NCT00494234] Advanced breast cancer with positive BRCA1 or BRCA2 status\n",
            "- [NCT00526617] BRCA deficient tumor status\\\n",
            "- [NCT00526617] Patients must have histologically or cytologically confirmed solid tumors with a positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be considered eligible.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 97  (showing 5 examples)\n",
            "- [NCT00043472] the subject has a first- or second-degree relative with a deleterious BRCA1 or BRCA2 mutation OR The family contains at least two ovarian and/or breast cancers among the subject or first- or second-degree relatives of the subject within the same lineage. This condition is satisfied by multiple primary cancers in the same person. Where breast cancer is required to meet this criterion, at least one breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown); OR The subject is of Ashkenazi Jewish ethnicity with one first-degree or two second-degree relatives with breast and/or OC. Where breast cancer is required to meet this criterion, at least one case must have been diagnosed prior to menopause (or at age less than or equal to 50, if age at menopause is unknown). OR The subject is of Ashkenazi ancestry and has had breast cancer herself. To meet this criterion, her breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown). OR The probability of carrying a BRCA1/2 mutation given the family pedigree of breast and OCs exceeds 20% as calculated by BRCAPRO. Note: BRCAPRO does NOT need to be calculated on everyone who enters the study. Patients are eligible based on a family history which meets one of the specific patterns described in this protocol, regardless of BRCAPRO results. BRCAPRO assessment is valuable in families where genetic testing has not been done, and the family history does not fit one of the specific patterns described, but the pattern of cancers leads you to believe that the family might still be considered high-risk. At that point, if the BRCAPRO estimate of being a mutation carrier is greater than 20 percent, then the patient IS eligible. Signed an approved informed consent and authorization permitting release of personal health information.\n",
            "- [NCT00150917] at least one 1st-degree relative with Breast Cancer\n",
            "- [NCT00329017] at high risk of developing breast cancer determined by family or personal history\n",
            "- [NCT00996710] Cancer at any age in 2 or more siblings suggestive of a genetic etiology, such as brothers with testicular germ cell tumor or sisters with breast cancer and ovarian cancer\n",
            "- [NCT01004666] High-risk for breast cancer\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 98  (showing 5 examples)\n",
            "- [NCT00044291] ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher\n",
            "- [NCT00262834] ECOG 0-2 OR Karnofsky 60-100%\n",
            "- [NCT00436605] ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%\n",
            "- [NCT00659568] ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%\n",
            "- [NCT00720031] General state with Karnowsky greater than 80, ECOG = 0, 1 or 2.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 99  (showing 5 examples)\n",
            "- [NCT00044291] Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago\n",
            "- [NCT00050141] Postmenopausal\n",
            "- [NCT00065325] Postmenopausal women defined as a women who has stopped having menstrual periods\n",
            "- [NCT00143052] Regular menses\n",
            "- [NCT00146601] Patients must be premenopausal.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 100  (showing 5 examples)\n",
            "- [NCT00048633] Patients much have recovered from acute toxic effects of any prior therapy.\n",
            "- [NCT00306553] All AEs form prior anticancer therapy have resolved to ≤ Grade 1.\n",
            "- [NCT00349934] Resolution of toxicity of prior therapy to grade \\< 2 (except alopecia).\n",
            "- [NCT00356460] At the time of enrollment, patients must be \\>4 wks since major surgery, radiotherapy, chemotherapy (\\> or =6 wks if they were treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab), immunotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to\\< or = Grade 1, exclusive of alopecia. Concurrent cancer therapy is not permitted. (In patients who received long acting agents, a treatment-free interval of 2 half-lives should be considered.)\n",
            "- [NCT00431275] Recovered from all prior surgical or adjuvant treatment-related toxicities\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 101  (showing 5 examples)\n",
            "- [NCT00050141] Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n",
            "- [NCT00071981] Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n",
            "- [NCT00087477] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "- [NCT00104884] Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n",
            "- [NCT00281697] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 102  (showing 5 examples)\n",
            "- [NCT00051103] Signed informed consent\n",
            "- [NCT00123253] Signed informed consent\n",
            "- [NCT00155259] Signed informed consent\n",
            "- [NCT00202241] signed informed consent\n",
            "- [NCT00211133] Must have signed an informed consent\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 103  (showing 5 examples)\n",
            "- [NCT00051103] Tumor tissue available for testing.\n",
            "- [NCT00198237] Pre-treatment core or incisional bx w/ adequate tissue for histology \\& genomic/proteomic analysis.\n",
            "- [NCT00235235] Disease amenable to pre-treatment core or incisional biopsy with adequate tissue for histology and genomic/proteomic analysis.\n",
            "- [NCT00293865] Previous conservative surgical biopsy\n",
            "- [NCT00323206] Patients must have a minimum of two eligible tumors and may have up to four eligible tumors treated with electroporation.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 104  (showing 5 examples)\n",
            "- [NCT00051103] Adequate bone marrow function\n",
            "- [NCT00087776] Patients must have adequate bone marrow function.\n",
            "- [NCT00191243] adequate bone marrow reserve defined\n",
            "- [NCT00430105] red cell casts.\n",
            "- [NCT00650910] Adequate bone marrow function.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 105  (showing 5 examples)\n",
            "- [NCT00071981] No disease progression in the brain for the past 3 months\n",
            "- [NCT00257530] \\>4 weeks time disease\n",
            "- [NCT00317980] Disease duration of 2 to 20 weeks\n",
            "- [NCT00321178] Disease duration no longer than six months\n",
            "- [NCT00379431] Disease duration less than 4 years (from the appearance of skin changes (oedema, fibrosis)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 106  (showing 5 examples)\n",
            "- [NCT00071981] Adequate organ function measured within 4 weeks before randomization:\n",
            "- [NCT00455312] Requirement for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or erythropoietin, or\n",
            "- [NCT00471887] Adequate bone marrow and hepatic function determined within 30 days prior to enrollment, defined as:\n",
            "- [NCT00483223] Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol\n",
            "- [NCT00618826] Patients must have adequate bone marrow reserve as evidenced by the following: ANC \\> 1500/mcL, platelets \\> 100, 000/mcL, and hemoglobin \\> 9.0 gm/dL. These results must be obtained within 28 days prior to registration.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 107  (showing 5 examples)\n",
            "- [NCT00071981] Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) no greater than 2 times upper limit of normal (ULN)\n",
            "- [NCT00206492] liver transaminases within 2.5 x ULN,\n",
            "- [NCT00217672] Alkaline phosphatase (AP) normal AND Angiotensin Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN) or AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN or AP ≤ 5 times ULN AND AST or ALT normal. Exclusion Criteria\n",
            "- [NCT00254592] Patients must have a serum creatinine and bilirubin ≤ the institutional upper limit of normal, and an serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.\n",
            "- [NCT00404066] Aspartate aminotransferase (AST); alanine aminotransferase (ALT); and alkaline phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 108  (showing 5 examples)\n",
            "- [NCT00071981] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00074308] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
            "- [NCT00087373] More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n",
            "- [NCT00087477] Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity. Localized palliative radiation therapy to non-target lesions is permitted within the four weeks prior to randomization.\n",
            "- [NCT00109005] Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate aminotransferase (AST) less than 10 x upper limit of normal. 6. Patients must have recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified above. 7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation therapy, or biological therapy, for at least 4 weeks prior to starting study medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy. 8. Patients must not have an acute, critical illness, including a serious untreated infection. 9. Patients must be willing to return to the National Institutes of Health (NIH) for follow-up visits. 10. All patients who are sexually active and able to conceive will be required to use contraception during treatment with lenalidomide. Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women of child bearing potential will be required to use two methods of birth control, one highly effective method and one additional method, at the same time during treatment and for one month after the completion of lenalidomide treatment. These methods must be used for at least four weeks before starting lenalidomide, during treatment, and for at least four weeks following the last dose of lenalidomide. Acceptable forms of birth control include: Intrauterine device (IUD) Latex condom Hormonal (Birth control pills, injections, implants) Diaphragm Tubal Ligation Cervical cap Partner's vasectomy Two barrier methods may be used if the physician agrees that the highly effective methods are medically contraindicated. Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the start of lenalidomide. Men who are sexually active must agree to use latex condoms. Patients must be able to understand and sign informed consent form. Patients must be greater than or equal to 18 years of age.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 109  (showing 5 examples)\n",
            "- [NCT00074308] Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)\n",
            "- [NCT00155259] Women with histological proven LABC, without metastasis, and no prior therapy. LABC is defined as follows： 1. Tumor more than 5 cm in diameter 2. Tumor involvement of chest wall (ribs or intercostals or serratus anterior muscles) or skin (ipsilateral cutaneous edema, ulceration, or satellite nodules) 3. Clinical evident inflammatory carcinoma 4. Ipsilateral fixed axillary adenopathy\n",
            "- [NCT00237185] Men and non-pregnant women ≥18 years of age with the histopathologically documented diagnosis of malignant GIST that was unresectable and/or metastatic. Confirmation of KIT (CD117) expression via immunohistochemical analysis of tumor sample was also required\n",
            "- [NCT00240682] Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression.\n",
            "- [NCT00526617] Evaluable disease, histologically confirmed malignancy (metastatic or unresectable) and standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 110  (showing 5 examples)\n",
            "- [NCT00074308] No history of bleeding diathesis or coagulopathy\n",
            "- [NCT00074308] No recent or concurrent full-dose anticoagulants (except as required to maintain patency of preexisting permanent indwelling IV catheters) or thrombolytic agent\n",
            "- [NCT00077363] Because of the potential for a drug interaction between warfarin and both tipifarnib and capecitabine, patients taking warfarin adjusted to an elevated INR are not eligible; patients taking prophylactic low-dose warfarin (i.e., 1 mg daily) are eligible, but a PT and INR are required within 2 weeks of registration and must be normal\n",
            "- [NCT00087373] No uncontrolled bleeding disorder that would increase the risk of bleeding from the injected lesion\n",
            "- [NCT00087373] No active thrombotic thrombocytopenic purpura within the past 2 years\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 111  (showing 5 examples)\n",
            "- [NCT00074308] Grade II or greater peripheral vascular disease\n",
            "- [NCT00074308] Other arterial thromboembolic event\n",
            "- [NCT00161291] No history of thrombosis during the previous year.\n",
            "- [NCT00217672] Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (\\> grade 2) peripheral vascular disease\n",
            "- [NCT00255762] No clinically significant peripheral vascular disease\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 112  (showing 5 examples)\n",
            "- [NCT00074308] Transient ischemic attack\n",
            "- [NCT00074308] Cerebrovascular accident\n",
            "- [NCT00255762] No clinically significant stroke within the past 6 months\n",
            "- [NCT00369655] Cerebrovascular accident or stroke within the past 6 months\n",
            "- [NCT01005472] Cerebrovascular accident or transient ischemic attack\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 113  (showing 5 examples)\n",
            "- [NCT00074308] No seizures not controlled with standard medical therapy\n",
            "- [NCT00087373] No active seizure disorder\n",
            "- [NCT00255762] No uncontrolled seizures\n",
            "- [NCT00436605] Uncontrolled seizure disorder\n",
            "- [NCT01233505] Patients who have active seizures or history of seizures are ineligible\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 114  (showing 5 examples)\n",
            "- [NCT00074308] No serious, nonhealing wound, ulcer, or bone fracture\n",
            "- [NCT00087373] No skin disease and/or open unhealing wounds\n",
            "- [NCT00091819] infected burn (see exclusion criteria for important qualifications)\n",
            "- [NCT00091819] wound infections\n",
            "- [NCT00107978] infected burn (see exclusion criteria for important qualifications);\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 115  (showing 5 examples)\n",
            "- [NCT00074308] No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)\n",
            "- [NCT00436605] More than 7 days since prior and no concurrent CYP3A4 inhibitors\n",
            "- [NCT00436605] No concurrent CYP3A4 inducers\n",
            "- [NCT00667121] Willing to avoid known inhibitors of the CYP2D6 system for duration of study\n",
            "- [NCT01005472] treatment with potent CYP3A4 inhibitors 7 days before study dosing\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 116  (showing 5 examples)\n",
            "- [NCT00077363] ECOG performance status 0-2\n",
            "- [NCT00083239] ECOG Performance Status of 0, 1, or 2\n",
            "- [NCT00146562] ECOG performance status 0 or 1\n",
            "- [NCT00146601] ECOG performance status 0-2\n",
            "- [NCT00225056] ECOG of 0-1\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 117  (showing 5 examples)\n",
            "- [NCT00077363] No prior radiotherapy other than to the conserved breast, to the postmastectomy chest wall or to a limited field involving less than 25% of marrow - containing bone\n",
            "- [NCT00171340] Recent surgery for breast cancer\n",
            "- [NCT00262834] No prior radiotherapy to the ipsilateral breast\n",
            "- [NCT00262834] No prior or concurrent radiotherapy for breast cancer\n",
            "- [NCT00894712] Patients must not have received prior radiation therapy to the breast.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 118  (showing 5 examples)\n",
            "- [NCT00083239] Expected survival ≥12 weeks\n",
            "- [NCT00304460] Expected survival greater than three months.\n",
            "- [NCT00306553] Expected survival of at least 6 months.\n",
            "- [NCT00349934] Expected survival longer than three months.\n",
            "- [NCT00356460] Expected survival ≥5 months\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 119  (showing 5 examples)\n",
            "- [NCT00087373] No active autoimmune disorders or disease\n",
            "- [NCT00610857] Patients must not have autoimmune disorders (except vitiligo). Patients with positive titers for autoimmune antibodies are allowed on the study in the absence of history of clinical manifestations of autoimmune disease.\n",
            "- [NCT00753415] Participant has undergone splenectomy or has any history of autoimmune disorder.\n",
            "- [NCT00753415] Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.\n",
            "- [NCT01543126] There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 120  (showing 5 examples)\n",
            "- [NCT00087373] Children \\< 3 years of age\n",
            "- [NCT00123253] Ages 18 to 65 years inclusive\n",
            "- [NCT00191815] You are female in the age of 18 to 75 years old.\n",
            "- [NCT00795951] Children and adolescents 6 to 18 years of age, and in general good health.\n",
            "- [NCT00979745] Aged 18 - 70 years (inclusive)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 121  (showing 5 examples)\n",
            "- [NCT00087776] Patients must have Eastern Cooperative Oncology Group performance status of 0 - 2.\n",
            "- [NCT00574145] Eastern Cooperative Oncology Group performance status of 0, 1 or 2\n",
            "- [NCT01052142] Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n",
            "- [NCT01220128] Eastern Cooperative Oncology Group (performance status of 0 or 1 at the time of study treatment allocation.\n",
            "- [NCT01344109] Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at initiation of study\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 122  (showing 5 examples)\n",
            "- [NCT00094003] Life expectancy \\> 3 months\n",
            "- [NCT00240682] Life expectancy \\> 3 months.\n",
            "- [NCT00369655] Life expectancy \\> 3 months\n",
            "- [NCT00431704] Life expectancy \\>3 months\n",
            "- [NCT00436605] Life expectancy \\> 3 months\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 123  (showing 5 examples)\n",
            "- [NCT00094003] ECOG performance status: 0-1\n",
            "- [NCT00121134] ECOG performance status 0-1\n",
            "- [NCT00198237] ECOG performance status 0-1\n",
            "- [NCT00217672] ECOG performance status 0-1\n",
            "- [NCT00369655] ECOG performance status 0-1\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 124  (showing 5 examples)\n",
            "- [NCT00094003] Serum calcium \\<11 mg/dL\n",
            "- [NCT00324259] Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.\n",
            "- [NCT00526617] Normal sodium, calcium and magnesium levels\n",
            "- [NCT00650910] Potassium and magnesium within the normal range of institutional values. \\[Serum potassium or magnesium values that fall outside the normal range may be repeated once at the discretion of the investigator, provided they are considered to be clinically insignificant.\\]\n",
            "- [NCT00777335] Biochemistry\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 125  (showing 5 examples)\n",
            "- [NCT00094003] Amylase and lipase ≤ ULN\n",
            "- [NCT01782508] Amylase and lipase \\< 1.5 x ULN\n",
            "- [NCT02272998] Serum lipase and amylase =\\< 1.5 x ULN\n",
            "- [NCT02303951] Amylase and lipase ≤ 1.5 x ULN\n",
            "- [NCT02519322] Lipase \\< 1.5 X ULN (within 28 days of first study treatment)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 126  (showing 5 examples)\n",
            "- [NCT00098358] Moderate to severe facial acne vulgaris\n",
            "- [NCT00098358] 20 to 60 facial inflammatory lesions\n",
            "- [NCT00098358] 10 to 200 facial non-inflammatory lesions\n",
            "- [NCT00098358] No more than 3 facial nodular cystic lesions\n",
            "- [NCT00126399] 10 to 40 papules and pustules and ≤2 nodules\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 127  (showing 5 examples)\n",
            "- [NCT00104884] Normal organ and marrow function\n",
            "- [NCT00470301] Normal organ function including:\n",
            "- [NCT00546156] Normal organ function as outlined in the protocol\n",
            "- [NCT00580333] Normal organ function as described in the protocol\n",
            "- [NCT00627978] Patients must have normal organ and marrow function as defined below:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 128  (showing 5 examples)\n",
            "- [NCT00106184] Adults with definite or probable dermatomyositis or polymyositis and pediatric patients five years of age and over with definite or probable juvenile dermatomyositis (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e., first symptom of myositis or dermatomyositis rash) is less 18 years of age\n",
            "- [NCT00106184] Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test) score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the following criteria: 1. An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. OR 2. If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at least 3 abnormal core set measures.\n",
            "- [NCT01734369] for myositis subjects are: -Diagnosis of PM, DM or IBM during military service. Subjects may be active duty or no longer active duty personnel. A matrix diagnosis of myositis will be based on ICD-9 codes, laboratory tests and medical records in an attempt to match criteria for probable or definite PM, DM or IBM The inclusion criteria for matched control subjects are: -The same gender, race, age within 10 years, and service in the military within 10 years as the myositis subject. The exclusion criteria for control subjects are: -A matrix diagnosis of autoimmune or chronic muscle disease based on ICD-9 codes and medical records. For Aims 2 and 3 of the study: The inclusion criteria for enrollment of myositis subjects are:\n",
            "- [NCT01734369] Diagnosis of myositis during military service or service as a military contractor or civilian working for the military, based on criteria for probable or definite PM or DM, or clinically or pathologically defined or possible IBM. Subjects may be active duty or no longer active duty personnel. Military contractors or civilians working for the military include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998 and developed myositis will be eligible for this study.\n",
            "- [NCT01734369] Persons with military experience or having served as a military contractor or civilian working for the military attending the same clinic or hospital as the myositis subject to which they are matched, or if not available, volunteers from the general community (such as other participating military or VA hospitals, private HCPs, or the NIH healthy volunteer program), gender- race- and age- (within 10 years) and military service period (within 10 years) matched to the myositis subject. Military contractors include those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 129  (showing 5 examples)\n",
            "- [NCT00119158] Clinical diagnosis of (Atopic Dermatitis) AD according to the American Academy of Dermatology (AAD) Consensus Conference (2001)\n",
            "- [NCT00257582] Eczema \\& dermatitis group\n",
            "- [NCT00257582] Atopic dermatitis\n",
            "- [NCT00267826] Must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin and Rajka and having active inflammation.\n",
            "- [NCT00346398] Diagnosed with eczema (atopic dermatitis)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 130  (showing 5 examples)\n",
            "- [NCT00119158] Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or\n",
            "- [NCT00462280] For women of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she:\n",
            "- [NCT00479674] No reproductive potential:\n",
            "- [NCT00563524] Men and Women of nonchildbearing potential 18 years or older.\n",
            "- [NCT00583739] Women of childbearing potential are eligible for this study.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 131  (showing 5 examples)\n",
            "- [NCT00119405] Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI\n",
            "- [NCT01033552] UCB\n",
            "- [NCT01889238] Advanced AR+ TNBC;\n",
            "- [NCT01957514] Subjects have metastatic TNBC\n",
            "- [NCT02214381] All TN\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 132  (showing 5 examples)\n",
            "- [NCT00121511] Patients must have actinic keratoses\n",
            "- [NCT00308854] Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on head and/or face (hairless areas)\n",
            "- [NCT00335179] Have actinic keratoses on balding scalp\n",
            "- [NCT00601640] No more than 10 actinic keratoses on the left forearm, and no actinic keratoses in the treatment area\n",
            "- [NCT00991861] At least 4-10 clinically assessed actinic keratosis grade I to II (according to Olsen et al, 1991) in the face/forehead and/or on the bald scalp\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 133  (showing 5 examples)\n",
            "- [NCT00126399] Healthy patients with rosacea\n",
            "- [NCT00989014] Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea.\n",
            "- [NCT01016782] Clinical diagnosis of rosacea\n",
            "- [NCT01016782] Good health with the exception of rosacea\n",
            "- [NCT01359228] \\> 18 years of age with rosacea defined as:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 134  (showing 5 examples)\n",
            "- [NCT00126399] Score of 2 to 4 on the IGA\n",
            "- [NCT00143052] Hirsute score: \\>7\n",
            "- [NCT00143052] Hirsute score: 0 (without razing)\n",
            "- [NCT00177840] Average to above average fatigue\n",
            "- [NCT00192517] PASI score greater than 12\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 135  (showing 5 examples)\n",
            "- [NCT00126724] Rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) diagnosed according to established criteria.\n",
            "- [NCT00265096] Psoriatic arthritis (PsA) diagnosed \\> 6months prior\n",
            "- [NCT00265096] Active PsA at the time of screening and at baseline visits, with \\>= 3 swollen joints and \\>= 3 tender joints\n",
            "- [NCT00265096] Have at least 1 of the PsA subsets (DIP joint arthritis, polyarticular arthritis without rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis)\n",
            "- [NCT00456092] Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or asymmetrical peripheral joint involvement for at least 6 months\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 136  (showing 5 examples)\n",
            "- [NCT00126724] Persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory arthritis in at least one peripheral joint eligible for injection.\n",
            "- [NCT01169844] The number of tender joints was the same or more than the core study baseline; or,\n",
            "- [NCT01169844] The number of swollen joints was the same or more than the core study baseline; or,\n",
            "- [NCT01877668] Must have 3 or more swollen joints AND 3 or more tender joints\n",
            "- [NCT02047851] Pain from at least two peripheral joints and/or inflammatory back pain\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 137  (showing 5 examples)\n",
            "- [NCT00126724] For subjects with RA, an adequate trial of at least one disease-modifying drug (DMARD) prior to screening.\n",
            "- [NCT00126724] For subjects currently on DMARD(s), a stable regimen of inflammatory arthritis for the previous three months, with no changes in doses four weeks prior to screening.\n",
            "- [NCT00265096] Active arthritis despite current disease modifying anti-rheumatic drug (DMARD) or nonsteroidal anti-inflammatory drug (NSAID) therapy\n",
            "- [NCT01877668] Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).\n",
            "- [NCT02181673] Have active PsA despite current or previous disease-modifying antirheumatic drugs (DMARD) and/or nonsteroidal anti-inflammatory drug (NSAID) therapy. DMARD therapy is defined as taking a DMARD for at least 3 months, or evidence of DMARD intolerance. NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of NSAID intolerance\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 138  (showing 5 examples)\n",
            "- [NCT00126724] Age greater than 18 years and less than 75 years at the time of screening.\n",
            "- [NCT01026051] 18 years of age or older at screening evaluation\n",
            "- [NCT01220128] The patient is ≥ 18 years of age at the time the informed consent to screening has been obtained.\n",
            "- [NCT01689285] Subject is at least 18 and not older than 55 years of age at screening.\n",
            "- [NCT01971346] At least 18 years of age at screening.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 139  (showing 5 examples)\n",
            "- [NCT00133315] Age\\>18 years old\n",
            "- [NCT00197912] Age: \\> 18\n",
            "- [NCT00268125] Age \\> 18 years\n",
            "- [NCT00293865] Age \\> 18 years\n",
            "- [NCT00323206] Age \\> 18 years old\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 140  (showing 5 examples)\n",
            "- [NCT00133315] No signs of tuberculosis (TB)\n",
            "- [NCT00134368] Subjects must have a negative tuberculin (TB) skin test at entry into the study\n",
            "- [NCT00307437] Have no history of latent or active tuberculosis (TB)\n",
            "- [NCT00640393] Patient with negative purified protein derivative (PPD) within 3 months of Day 0;\n",
            "- [NCT00687401] Eligible according to tuberculosis (TB) eligibility assessment, screening and early detection of reactivation rules.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 141  (showing 5 examples)\n",
            "- [NCT00133341] Signed informed consent.\n",
            "- [NCT00548184] Signed informed consent.\n",
            "- [NCT00691678] Signed informed consent.\n",
            "- [NCT00717015] Signed informed consent.\n",
            "- [NCT00941330] Signed informed consent.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 142  (showing 5 examples)\n",
            "- [NCT00134368] Vitiligo patients aged 18 years and older\n",
            "- [NCT00134368] Vitiligo patients with evaluable lesions; duration of 3 months to 10 years.\n",
            "- [NCT00631865] Stable form of vitiligo (no increase in the size of the lesion for at least one year)\n",
            "- [NCT00907062] self selected candidates identifying themselves to suffer with vitiligo vulgaris of any duration\n",
            "- [NCT00907062] stable or progressing vitiligo\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 143  (showing 5 examples)\n",
            "- [NCT00134368] Disease interferes significantly with quality of life and/or involving 3% or more body surface area\n",
            "- [NCT00707070] PASI \\> 10 e/o BSA (Body Surface Area) \\> 10\n",
            "- [NCT00927212] Diseased Body surface area (BSA) ≤ 20%.\n",
            "- [NCT01049243] Percentage of overall body surface are of involvement (BSA) must be ≥2%\n",
            "- [NCT01093469] Percentage of overall body surface area of involvement (BSA) must be \\> 1% and may include facial and intertriginous skin.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 144  (showing 5 examples)\n",
            "- [NCT00135720] Have a clinical diagnosis of pemphigus vulgaris\n",
            "- [NCT00135720] Have at least 6 active pemphigus lesions (blisters or erosions)\n",
            "- [NCT00135720] Have no adverse effects due to combining etanercept with concurrent pemphigus medications\n",
            "- [NCT00135720] Be on stable dose of current pemphigus medications for at least one month\n",
            "- [NCT00431119] clinical lesions suggestive of bullous pemphigoid\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 145  (showing 5 examples)\n",
            "- [NCT00143052] Hirsute subjects:\n",
            "- [NCT00355485] Subjects must be in generally good health.\n",
            "- [NCT00839280] Healthy subjects\n",
            "- [NCT01422538] Subject in good health.\n",
            "- [NCT01519206] Subject in good health\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 146  (showing 5 examples)\n",
            "- [NCT00146562] 18 years of age or older\n",
            "- [NCT00202241] 18 years of age or older\n",
            "- [NCT00483223] 18 years of age or older\n",
            "- [NCT00546156] 18 year of age or older\n",
            "- [NCT00580333] 18 years of age or older\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 147  (showing 5 examples)\n",
            "- [NCT00150917] live within one hour of downtown Toronto\n",
            "- [NCT00198250] living within 60 miles of Indianapolis\n",
            "- [NCT00286598] Residence within 50 miles of Columbia, MO\n",
            "- [NCT00601640] Resident of Pima or an adjoining Southern Arizona county\n",
            "- [NCT01174875] Singapore citizens or Singapore Permanent Residents\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 148  (showing 5 examples)\n",
            "- [NCT00157079] Subjects \\> 24 months of age\n",
            "- [NCT00256230] Subjects must be between the ages of 18 and 80.\n",
            "- [NCT00346606] The subject ≥ 12 years old.\n",
            "- [NCT00366132] Subjects age \\> 18 years;\n",
            "- [NCT00385502] Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 149  (showing 5 examples)\n",
            "- [NCT00175344] Patients must be able to provide informed consent and be physically able to perform daily self-administered breast scar massage\n",
            "- [NCT00179634] Skin sparing mastectomy with transverse rectus abdominal muscle (TRAM) or deep inferior epigastric perforator (DIEP) flap reconstruction planned\n",
            "- [NCT00201929] Candidate for breast conserving surgery\n",
            "- [NCT00455533] Unfit for breast and/or axillary surgery\n",
            "- [NCT00499681] Scheduled to undergo surgical treatment with either segmental resection or total mastectomy\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 150  (showing 5 examples)\n",
            "- [NCT00176969] Must have alopecia totalis or universalis.\n",
            "- [NCT00176969] Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.\n",
            "- [NCT00746980] clinical diagnosis of alopecia totalis, alopecia universalis, or severe ophiasis variant of alopecia areata.\n",
            "- [NCT01008774] Absence of alopecia at inclusion\n",
            "- [NCT01203189] Practice less than or equal to once weekly hair washing\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 151  (showing 5 examples)\n",
            "- [NCT00176969] Be in good health.\n",
            "- [NCT00427609] With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.\n",
            "- [NCT00467233] Good health.\n",
            "- [NCT00509977] Good health.\n",
            "- [NCT00540917] apparent good health\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 152  (showing 5 examples)\n",
            "- [NCT00178126] Braden score of 18 or less\n",
            "- [NCT00178126] combined activity and mobility Braden sub-score of 5 or less\n",
            "- [NCT01333670] Braden index at baseline\\>=10\n",
            "- [NCT02363842] Deemed at risk for tissue breakdown by clinical staff via an institutional assessment protocol such as the Braden Scale, the Waterlow Scale or the Norton Scale.\n",
            "- [NCT03351049] total Braden Score \\<= 18\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 153  (showing 5 examples)\n",
            "- [NCT00190697] Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia).\n",
            "- [NCT00193037] Adequate bone marrow, liver and kidney function\n",
            "- [NCT00378313] Evidence of adequate organ function (liver, bone marrow, kidney)\n",
            "- [NCT00383851] Patients must have adequate organ and marrow function as defined below:\n",
            "- [NCT00704158] Adequate bone marrow, renal and liver function\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 154  (showing 5 examples)\n",
            "- [NCT00192517] Plaque psoriasis involving at least 10% of body surface area (Appendix A)\n",
            "- [NCT00192517] Currently receiving no therapy for psoriasis except emollients\n",
            "- [NCT00245960] Clinically stable, plaque psoriasis involving more than 10% of the body surface area\n",
            "- [NCT00265096] Active plaque psoriasis with a lesion \\>= 2cm in diameter\n",
            "- [NCT00307437] Plaque-type psoriasis diagnosed \\>= 6 months prior\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 155  (showing 5 examples)\n",
            "- [NCT00201929] Female\n",
            "- [NCT00268125] Woman\n",
            "- [NCT00404066] Female\n",
            "- [NCT00513058] Female\n",
            "- [NCT00653718] Female\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 156  (showing 5 examples)\n",
            "- [NCT00204529] Informed consent\n",
            "- [NCT00204581] Informed consent\n",
            "- [NCT00257582] Giving informed consent\n",
            "- [NCT00388115] Informed consent given.\n",
            "- [NCT00689832] Informed consent\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 157  (showing 5 examples)\n",
            "- [NCT00206492] Hematocrit \\>30%,\n",
            "- [NCT00456092] Hematocrit ≥ 27%\n",
            "- [NCT00544765] Hematology:\n",
            "- [NCT00712621] Not specified Hematopoietic:\n",
            "- [NCT00777335] Hematology\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 158  (showing 5 examples)\n",
            "- [NCT00213460] patients with systemic sclerosis, who had an upper intestinal tract manometry 5 years before, with:\n",
            "- [NCT00213525] patients with scleroderma with:\n",
            "- [NCT00251238] Primary Raynaud´s phenomenon\n",
            "- [NCT00251238] Duration of Raynaud´s phenomenon at least 2 years\n",
            "- [NCT00253331] clinical diagnosis of Raynaud's phenomenon\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 159  (showing 5 examples)\n",
            "- [NCT00217672] Required laboratory values\n",
            "- [NCT00359190] Clinical labs are within acceptable ranges.\n",
            "- [NCT00442260] Normal laboratory values as explained below.\n",
            "- [NCT00456092] Must meet the following laboratory criteria:\n",
            "- [NCT00650910] Clinical lab results with ranges as stated per protocol.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 160  (showing 5 examples)\n",
            "- [NCT00217672] Total bilirubin \\< 1.0 x upper limit of normal (ULN) (patients with documents Gilbert's syndrome are eligible).\n",
            "- [NCT00258349] Bilirubin =\\< 1.5 mg/dL (3 mg/dL in the presence of Gilbert's disease provided direct bilirubin is normal)\n",
            "- [NCT00304460] Serum creatinine less than or equal to 1.4 mg/dl or creatinine clearance greater than or equal to 90 mL/min, and total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.\n",
            "- [NCT00349934] Total bilirubin \\< 20 mmol/L, except for familial cholemia (Gilbert's disease).\n",
            "- [NCT00471887] Total bilirubin \\< 2 x ULN (except patients with documented Gilbert's syndrome)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 161  (showing 5 examples)\n",
            "- [NCT00221221] willing to accept random assignment.\n",
            "- [NCT00513136] Willing to be randomized\n",
            "- [NCT00945607] Willingness to complete CSES, PSS-14 and FACIT-F scales\n",
            "- [NCT01275872] Willing to participate\n",
            "- [NCT01751893] Willing to participate\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 162  (showing 5 examples)\n",
            "- [NCT00221221] not currently participating in another QoL intervention.\n",
            "- [NCT01613482] Inclusion in an other clinical trial or in the 4 weeks before th inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT01935531] Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion\n",
            "- [NCT02799121] The patient agrees to abstain from enrolment in any other interventional clinical trial for the duration of the study\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 163  (showing 5 examples)\n",
            "- [NCT00225056] must have adequate organ function\n",
            "- [NCT00237198] Patients with sufficient organ function to evaluate the safety\n",
            "- [NCT00320541] Must have adequate organ function as seen in blood test results. Exclusion Criteria:\n",
            "- [NCT00386685] Adequate organs functions\n",
            "- [NCT00496366] Adequate end organ function\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 164  (showing 5 examples)\n",
            "- [NCT00225056] must be at least 19 years of age\n",
            "- [NCT00267826] Must be at least 18 years of age.\n",
            "- [NCT00270569] Age must be older than 18 and younger than 75 year-old.\n",
            "- [NCT00673829] Must be 18 years of age or older\n",
            "- [NCT00791557] Must Be ages 18-75\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 165  (showing 5 examples)\n",
            "- [NCT00226174] Patients presenting to the UCSF oral medicine clinic with oral lichen planus confirmed by biopsy. Patients with either the atrophic or the erosive form of oral lichen planus were eligible.\n",
            "- [NCT00297037] With a diagnosis of oral lichen planus previously proven on biopsy.\n",
            "- [NCT00455312] A triad of mucocutaneous features: oral leukoplakia, nail dystrophy, abnormal reticular skin hyperpigmentation.\n",
            "- [NCT00542373] Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)\n",
            "- [NCT00542373] Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 166  (showing 5 examples)\n",
            "- [NCT00240682] ECOG Performance status \\< 2.\n",
            "- [NCT00277160] ECOG performance status \\</=2\n",
            "- [NCT00304460] ECOG less than 2.\n",
            "- [NCT00518895] ECOG performance status ≤ 1\n",
            "- [NCT00661531] Ecog performance status \\</= 2.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 167  (showing 5 examples)\n",
            "- [NCT00240682] Age \\> 18 years.\n",
            "- [NCT00284180] Age \\>18 years.\n",
            "- [NCT00544765] Age \\> 18 years.\n",
            "- [NCT00691678] Age \\>21 years.\n",
            "- [NCT00991978] Age \\> 18 years.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 168  (showing 5 examples)\n",
            "- [NCT00255762] No known esophageal varices\n",
            "- [NCT01522820] Esophageal: resected patients with any nodal (i.e., thoracic or abdominal) disease; and patients with residual disease on imaging after definitive chemoradiation therapy\n",
            "- [NCT03475953] or esophageal or gastric carcinoma (cohort C),\n",
            "- [NCT03924466] adenocarcinoma of the gastric body or gastro-esophageal junction\n",
            "- [NCT04032704] Cohort 5: esophageal-squamous (Parts A and B)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 169  (showing 5 examples)\n",
            "- [NCT00006412] Have gall bladder disease or symptoms within 3 months prior to study entry or symptoms of gallstones.\n",
            "- [NCT00091819] major abscess requiring surgical incision and drainage\n",
            "- [NCT00107978] major abscess requiring surgical incision and drainage;\n",
            "- [NCT00217672] Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning therapy\n",
            "- [NCT00255762] No history of abdominal fistula\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 170  (showing 5 examples)\n",
            "- [NCT00021463] Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).\n",
            "- [NCT00255762] VEGF Trap\n",
            "- [NCT00255762] Anti-VEGF receptor monoclonal antibody\n",
            "- [NCT00255762] Small molecular tyrosine kinase inhibitors of VEGF receptors\n",
            "- [NCT00369655] No history of lung carcinoma of squamous cell type\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 171  (showing 5 examples)\n",
            "- [NCT00257582] Chronic urticaria\n",
            "- [NCT00346606] The subject with documented signs and symptoms of CIU for 6 weeks or more.\n",
            "- [NCT00346606] The subject has to have a CIU flare for 3 weeks or more before screening, with urticarial lesions visible 3 days or more per week.\n",
            "- [NCT00346606] The overall severities of CIU have to be at least mild to moderate at screening and baseline, subjects have to have at least mild to moderate pruritus, hives have to be apparent at screening, and subjects have intention to treatment.\n",
            "- [NCT00385372] chronic urticaria (duration: at least 6 weeks)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 172  (showing 5 examples)\n",
            "- [NCT00257582] Prurigo group: Acute prurigo, Prurigo subacuta, Chronic prurigo\n",
            "- [NCT00257582] Pruritus cutaneous: Systemic pruritus cutaneous, Topical pruritus cutaneous\n",
            "- [NCT00257582] Children who have 2 grades or more pruritus score when assessed by the investigator or sub-investigator with the criteria for the diurnal or nocturnal pruritus score in the patient diary.\n",
            "- [NCT00257582] Children with a pruritus severity of \"2.Mild\" or severer on the first day of the treatment period.\n",
            "- [NCT00715260] Patients who have \"mild\", \"moderate\" or \"severe\" pruritus;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 173  (showing 5 examples)\n",
            "- [NCT00262301] Clear clinical and laboratory diagnosis of HAE\n",
            "- [NCT00262301] Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack\n",
            "- [NCT00438815] Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or\n",
            "- [NCT00438815] Had a known HAE-causing C1INH mutation, or\n",
            "- [NCT00438815] Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 174  (showing 5 examples)\n",
            "- [NCT00268125] Patient affiliated at a welfare or beneficiary from it\n",
            "- [NCT00513058] Patients must be affiliated with a Social Security system\n",
            "- [NCT00555061] French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category\n",
            "- [NCT00905281] Patient affiliated with social security\n",
            "- [NCT01262469] Patients must be affiliated to a Social Security System\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 175  (showing 5 examples)\n",
            "- [NCT00277160] \\>/= 65 years old\n",
            "- [NCT00448305] Age \\>= 18 years old\n",
            "- [NCT00713154] is \\>/= 18 years of age\n",
            "- [NCT01344109] Age \\>/= 18 years old\n",
            "- [NCT01583426] Age \\>= 18 years.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 176  (showing 5 examples)\n",
            "- [NCT00281697] ≥ 18 years of age.\n",
            "- [NCT00450762] Age ≥ 18 years\n",
            "- [NCT00496366] Age ³ 18 years of age\n",
            "- [NCT00683670] Age ≥ 18 years\n",
            "- [NCT00704158] Age ≥ 18 years\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 177  (showing 5 examples)\n",
            "- [NCT00286598] Functioning telephone service\n",
            "- [NCT00945607] Access to a CD player\n",
            "- [NCT01108315] Has access to either a phone or the internet\n",
            "- [NCT01450020] Owns an operational vehicle\n",
            "- [NCT01450020] Has access to a personal computer with internet access\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 178  (showing 5 examples)\n",
            "- [NCT00121511] Subjects must be willing and able to comply with the requirements of the protocol.\n",
            "- [NCT00306553] Able and willing to complete all protocol requirements.\n",
            "- [NCT00403559] Must be wiling and able to comply with protocol.\n",
            "- [NCT00688272] The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria\n",
            "- [NCT00991978] Able to comply with the protocol.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 179  (showing 5 examples)\n",
            "- [NCT00306553] Wash-out period of 4 weeks after chemotherapy\n",
            "- [NCT00356642] 14 day washout of current therapy.\n",
            "- [NCT01375101] two weeks wash out periods after the last treatment\n",
            "- [NCT01511315] Washout Period :\n",
            "- [NCT01941537] A washout period from any systemic investigational therapy of at least 90 days.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 180  (showing 5 examples)\n",
            "- [NCT00308204] adults 18 to 70 years of age.\n",
            "- [NCT00815282] And who are in the following age groups:\n",
            "- [NCT01045772] Adult (18 years or older)\n",
            "- [NCT01111695] Adult\n",
            "- [NCT01228656] Adults of both sexes, regardless of color or social class;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 181  (showing 5 examples)\n",
            "- [NCT00308854] Selected AK study lesions have clearly defined margins and are mild to moderate\n",
            "- [NCT00603798] Have 5 to 20 AKs on the face or balding scalp.\n",
            "- [NCT00859105] Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp\n",
            "- [NCT00942604] 4 to 8 AK lesions on non-head locations.\n",
            "- [NCT00991861] The diameter of each AK target lesion is not less than 0.5 cm and not greater than 1.5 cm\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 182  (showing 5 examples)\n",
            "- [NCT00308854] Skin sun sensitivity type I to IV according to Fitzpatrick\n",
            "- [NCT00523588] Fitzpatrick I-III skin type (very fair, fair, or medium skin)\n",
            "- [NCT00688272] Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).\n",
            "- [NCT00719121] Subjects with a phototype III or IV (according to Fitzpatrick classification)\n",
            "- [NCT00839280] Phototype: I to IV according to Fitzpatrick scale\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 183  (showing 5 examples)\n",
            "- [NCT00315393] Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA and MPA.\n",
            "- [NCT00315393] For diagnosis of GPA, meets at least 2 of the following 5 modified American College of Rheumatology (ACR) criteria: 1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood 2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities 3. Urinary sediment with microhematuria or red cell casts 4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy 5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA\n",
            "- [NCT00315393] For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA: 1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles) 2. Necrotizing arteritis involving small- and medium-sized arteries may be present 3. Necrotizing glomerulonephritis is very common 4. Pulmonary capillaritis often occurs\n",
            "- [NCT00430105] A new diagnosis of WG, MP or renal-limited vasculitis (RLV) (appendix 5). Patients not previously treated with cytotoxic drugs will be permitted. 2. Renal involvement attributable to active WG, MP or RLV with at least one of the following:\n",
            "- [NCT00430105] haematuria with \\>30 red blood cells/high powered field and proteinuria \\> 1g/24hr. 3. ANCA positivity or confirmatory histology or both (appendix 5). ANCA positivity requires a typical CANCA pattern by indirect immunofluorescence (IIF), (preferably confirmed by anti-PR3 ELISA), or the presence of PR3-ANCA or MPO-ANCA determined by ELISA, PANCA requires confirmation by anti-MPO ELISA \\[6\\]. (Central review of ANCA serology and histology will be performed). 4. Age 18-80 years.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 184  (showing 5 examples)\n",
            "- [NCT00321178] At least 5 years of age\n",
            "- [NCT00359190] At least 18 years of age.\n",
            "- [NCT00389402] At least 18 years of age.\n",
            "- [NCT00548184] Age at least 18 years.\n",
            "- [NCT00612742] at least 50 years of age\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 185  (showing 5 examples)\n",
            "- [NCT00121511] Subjects must be in generally good health and willing to undergo skin biopsies from the face.\n",
            "- [NCT00335179] Discontinuation of tanning bed use\n",
            "- [NCT00420173] photoprovocation-test performed in advance\n",
            "- [NCT00469183] Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits.\n",
            "- [NCT00601640] Visible sun-induced damage to the skin as assessed by the study dermatologists\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 186  (showing 5 examples)\n",
            "- [NCT00356460] In Part 1, Dose Escalation: Patients with histologically confirmed, locally advanced \\& surgically inoperable or metastatic renal cell carcinoma or malignant melanoma are eligible.\n",
            "- [NCT01263145] For the dose escalation cohorts, patients must have received front-line, cytotoxic, systemic therapy (combination or single agent, with or without the addition of targeted agents) for advanced cancer\n",
            "- [NCT02857270] Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal adenocarcinoma (dose escalation and dose expansion).\n",
            "- [NCT03475953] Dose escalation part: histologically confirmed non MSI-H or deficient-MMR colorectal cancer, or GIST, or esophageal or gastric carcinoma or hepatobiliary cancers,\n",
            "- [NCT04424641] Dose-escalation part: • Patient with locally advanced or metastatic solid tumor(s) (excluding patients with primary central nervous system \\[CNS\\] tumors), who has experienced disease progression while on standard therapy or is intolerant of, or not eligible for, standard therapy. Expansion part: • Must have an advanced or metastatic, pathologically confirmed diagnosis of one of the following tumors: Uterine Cancer, Prostate Cancer, Esophageal Cancer, TNBC, SCCHN, NSCLC (both adenocarcinoma \\[ACC\\] and squamous cell carcinoma \\[SCC\\], Bladder Cancer. Both parts:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 187  (showing 5 examples)\n",
            "- [NCT00359190] Females must meet certain criteria specified in protocol.\n",
            "- [NCT00581256] Both men and women are eligible.\n",
            "- [NCT01081106] Participants must be 18 years old or older\n",
            "- [NCT01081106] Participants must be female\n",
            "- [NCT01120184] Adult participants \\>/=18 years of age\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 188  (showing 5 examples)\n",
            "- [NCT00091819] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00107978] Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:\n",
            "- [NCT00368537] Clinical diagnosis of complicated skin or skin structure infection\n",
            "- [NCT00463801] Subjects with a diagnosis of complicated skin and skin-structure infections (cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalization and intravenous antimicrobial treatment\n",
            "- [NCT00514527] Complicated skin and skin structure infection, presumed or proven to be caused by gram-positive pathogen(s).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 189  (showing 5 examples)\n",
            "- [NCT00379431] Severe disease defined by either one of the following: a modified Rodnan skin score (TSS° \\>= 14 ), disease activity score \\>= 3\n",
            "- [NCT00704665] A baseline modified Rodnan skin score (MRSS) of 20 or greater, or at least 16 if truncal involvement was present.\n",
            "- [NCT00962923] Rapidly progressive disease \\<2 years duration with a modified Rodnan skin score(mRSS) above 20, plus ESR \\>25 mm/first h and/or Hb \\<11 g/dL, not explained by other causes than active SSc\n",
            "- [NCT01532869] \\>/= 15 and \\</= 40 mRSS units at screening\n",
            "- [NCT01538719] Must have a MRSS of ≥ 15.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 190  (showing 5 examples)\n",
            "- [NCT00379678] Active AD of any severity will be defined according to Hanifin and Rajka clinical criteria (Hanifin, J.M., Rajka, G. 1980)\n",
            "- [NCT00379678] Chronic AD for more than one year duration\n",
            "- [NCT00546000] Subjects meet protocol specific AD signs and symptom severity score\n",
            "- [NCT00753805] A clear and definite diagnosis of AD\n",
            "- [NCT02031445] History of AD for at least 3 months prior to Baseline\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 191  (showing 5 examples)\n",
            "- [NCT00383851] Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥50%; see Appendix A)\n",
            "- [NCT00404066] Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 / Karnofsky ≥ 60% at screening and on the first day of treatment.\n",
            "- [NCT00462280] Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky \\> 70%)\n",
            "- [NCT00576654] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2 (Karnofsky \\>= 60%)\n",
            "- [NCT01042535] Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1 (Karnofsky \\>= 70%)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 192  (showing 5 examples)\n",
            "- [NCT00383851] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00429299] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00576654] Ability to understand and the willingness to sign a written informed consent document\n",
            "- [NCT00802932] Ability to understand and the willingness to sign written informed consent document\n",
            "- [NCT01042535] Ability to understand and the willingness to sign a written informed consent document\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 193  (showing 5 examples)\n",
            "- [NCT00385502] Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails (\"target toenails\"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum\n",
            "- [NCT00385502] Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.\n",
            "- [NCT00385502] Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.\n",
            "- [NCT00385502] Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 194  (showing 5 examples)\n",
            "- [NCT00388115] Core biopsy proven low or intermediate grade DCIS.\n",
            "- [NCT00402519] For DCIS only: lesions must be classified as low or intermediate risk group (Van Nuys Prognostic Index \\<8).\n",
            "- [NCT00455312] Disease Characteristics for DC (both of the following):\n",
            "- [NCT00455312] Diagnosis of DC:\n",
            "- [NCT00669747] Pathological diagnosis of DCIS requiring surgical resection\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 195  (showing 5 examples)\n",
            "- [NCT00388115] Multifocal invasive breast cancer patients are eligible. All tumors that are palpable or visualized by USS can be treated.\n",
            "- [NCT01185145] Multifocal findings (define as 2 or more breast quadrants) on MRI scanning should be further evaluated by ultrasound and, if necessary biopsy, to exclude multiquadrant disease.\n",
            "- [NCT01208441] Multifocal disease allowed provided that ≥ 1 of the tumors is \\> 2 cm\n",
            "- [NCT01417286] Multifocal/multicentric disease is allowed\n",
            "- [NCT01583426] In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 196  (showing 5 examples)\n",
            "- [NCT00389636] Patients\n",
            "- [NCT00553618] Patients must fulfill one of the following criteria:\n",
            "- [NCT00758862] Patients suffering from SITL must have:\n",
            "- [NCT01068483] All patients:\n",
            "- [NCT01361035] Physician\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 197  (showing 5 examples)\n",
            "- [NCT00424749] Renal involvement (\\>25% dysmorphic red cell, red blood cell casts, or pauci-immune glomerulonephritis on biopsy)\n",
            "- [NCT00430105] biopsy demonstrating necrotizing glomerulonephritis.\n",
            "- [NCT00474604] The protocol nurse will check with the patient that there is no h/o kidney disease\n",
            "- [NCT00544765] Renal function:\n",
            "- [NCT00712621] Protein (Albumin, Globulin) Renal:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 198  (showing 5 examples)\n",
            "- [NCT00442260] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00583739] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00627978] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT00656019] Ability to understand and the willingness to sign a written informed consent document.\n",
            "- [NCT01010854] Ability to understand and the willingness to sign a written informed consent document.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 199  (showing 5 examples)\n",
            "- [NCT00448305] Histologically proven triple-receptor-negative metastatic or relapsed breast cancer\n",
            "- [NCT00528567] primary tumor centrally confirmed as triple negative.\n",
            "- [NCT01150513] Triple-negative breast cancer\n",
            "- [NCT01467310] Histologically confirmed TNBC (i.e., ER negative, PR negative (each \\<10% staining by immunohistochemistry) and Her2 negative (0-1+ or FISH non-amplified; by clinical assay on primary tumor)\n",
            "- [NCT01617915] if tumor is triple-negative, treatment with DNA-damaging chemotherapy as per standard of care in the first-line setting for advanced/metastatic disease.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 200  (showing 5 examples)\n",
            "- [NCT00455312] Patients with early myelodysplastic features.\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:\n",
            "- [NCT02162420] Severe Aplastic Anemia (SAA) requiring a 2nd transplant\n",
            "- [NCT02162420] Early myelodysplastic features\n",
            "- [NCT02706392] CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody, or who have failed tyrosine kinase or phosphatidylinositol 3 (PI3) kinase inhibitors, or who were not eligible for or declined such therapy; patients with fludarabine refractory disease are eligible\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 201  (showing 5 examples)\n",
            "- [NCT00456092] If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for at least 14 days prior to screening and throughout the study\n",
            "- [NCT00601640] No concurrent NSAIDs for more than 14 days per month for arthritic and other pain conditions\n",
            "- [NCT00944918] Relapsed or progressed during prior treatment with single-agent NSAI, meeting either of the following criteria:\n",
            "- [NCT00944918] NSAI given as adjuvant therapy that lasted ≥ 12 months OR\n",
            "- [NCT01752907] Chronic use of oral non-steroidal anti-inflammatory drugs (NSAIDs) or oral antihistamines with the following exception: \\- Chronic oral aspirin use for cardiovascular-related indications\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 202  (showing 5 examples)\n",
            "- [NCT00467233] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00467233] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "- [NCT00469183] Subjects must have a clinical diagnosis of moderate to severe melasma\n",
            "- [NCT00509977] Diagnosis of melasma lesion measuring at least 4 square centimeters.\n",
            "- [NCT00509977] Must be willing to forgo other treatment options for melasma during the course of the study.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 203  (showing 5 examples)\n",
            "- [NCT00470301] \\[Note: \\\n",
            "- [NCT00474604] \\\n",
            "- [NCT00526617] \\\n",
            "- [NCT00630032] NOTE: \\\n",
            "- [NCT01689935] \\\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 204  (showing 5 examples)\n",
            "- [NCT00491816] Patients must have a serum albumin ≥ 3.0 g/dL\n",
            "- [NCT00777335] Serum albumin ≥ Lower Limit of Normal(LLN) or 30g/L\n",
            "- [NCT00896298] Serum leptin levels less than the 7th percentile of normal values reported by the 3rd National Health and Nutrition Examination survey (less than 7.0 ng/mL in females and less than 3/0 ng/mL in males)\n",
            "- [NCT00962923] digestive tract involvement: with serum albumin ,25 g/L or weight loss exceeding 10% body weight in the preceding year\n",
            "- [NCT01050322] Albumin \\> 2.5 gr /dl\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 205  (showing 5 examples)\n",
            "- [NCT00492323] Experienced postherpetic neuralgia pain on a daily basis for the past 3 months\n",
            "- [NCT00540969] Worst pain in the last 24 hours must be ≥ 4 on a 0-10 numeric scale\n",
            "- [NCT00588640] Chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical scale from 0-10 during the 24 hours prior to study entry.\n",
            "- [NCT01375101] having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score\n",
            "- [NCT01720602] Patient is willing to continue on same AI therapy\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 206  (showing 5 examples)\n",
            "- [NCT00496795] \"Limited\" distant metastases allowed, but patients with massive distant metastases should be excluded\n",
            "- [NCT01064635] Patients with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastases.\n",
            "- [NCT01264731] No metastasis greater than 2 cm at the time of protocol entry\n",
            "- [NCT01394575] No evidence of distant metastasis\n",
            "- [NCT01503034] No known metastasis\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 207  (showing 5 examples)\n",
            "- [NCT00502684] ASA score of 1-2\n",
            "- [NCT00519246] ASA I-II\n",
            "- [NCT01055236] ASA classification 1-2\n",
            "- [NCT01185145] Be a Tis, T1, N0, M0 AJC Classification\n",
            "- [NCT01392248] ASA 1-2.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 208  (showing 5 examples)\n",
            "- [NCT00005949] LDH normal\n",
            "- [NCT00518895] Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal\n",
            "- [NCT00610857] Serum LDH less than or equal to 2.0 x ULN\n",
            "- [NCT01005472] LDH ≤ 5 times ULN\n",
            "- [NCT01055522] LDH \\< 2.0 x ULN for Phase IIa patients and normal LDH for the Phase IIb ones.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 209  (showing 5 examples)\n",
            "- [NCT00525096] surgical ovariectomy\n",
            "- [NCT00530868] Bilateral oophorectomy\n",
            "- [NCT00650910] Has had a hysterectomy\n",
            "- [NCT00650910] Has had a bilateral oophorectomy (ovariectomy)\n",
            "- [NCT00650910] Has had a bilateral tubal ligation, or\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 210  (showing 5 examples)\n",
            "- [NCT00525096] ovarian suppression by radiotherapy\n",
            "- [NCT00982631] Patients with proven advanced breast cancer, endometrial cancer or ovarian cancer, who are refractory to standard therapies or for whom no standard therapy exists.\n",
            "- [NCT01035099] Ovarian stimulation will not affect cancer treatment plan\n",
            "- [NCT01095848] Patients with stage III or IV ovarian cancer who have completed a course of platinin-based cytotoxic therapy after debulking surgery with evidence of a complete or partial response by radiological imaging. Patients with metastatic ovarian cancer who have stable disease for greater than 3 months after completion of first-line therapy.\n",
            "- [NCT01233505] Any-line metastatic mucinous ovarian cancer\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 211  (showing 5 examples)\n",
            "- [NCT00542373] Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease\n",
            "- [NCT01727076] Patients must have histological or cytological confirmed malignancy in the following disease groups: melanoma, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which no standard effective or curative options are available\n",
            "- [NCT02069158] Histological or cytological diagnosis of advanced/metastatic breast, NSCLC, ovarian and endometrial, small cell lung cancer (SCLC) and Head and Neck (HNSCC) cancer for which there is an indication to the use of paclitaxel and carboplatin.\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).\n",
            "- [NCT02834247] Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx is allowed, but these participants will not be included as response-evaluable participants for efficacy analysis of HNSCC.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 212  (showing 5 examples)\n",
            "- [NCT00555061] Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy: The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion. The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area. Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.\n",
            "- [NCT00646958] Acceptable clinical diagnoses of uSSSI include, but are not limited to: Simple abscess, Impetiginous lesions, Folliculitis, Furunculosis, Carbuncles, Cellulitis\n",
            "- [NCT01789229] Just one current known malignant disease or just one current inflammatory disease\n",
            "- [NCT01815450] Qualifying number of non-inflammatory lesions\n",
            "- [NCT01815450] Qualifying number of inflammatory lesions\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 213  (showing 5 examples)\n",
            "- [NCT00555061] Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must demonstrate their willingness to participate in the study and comply with its procedures by signing an informed consent.\n",
            "- [NCT00817076] Children's parent(s) or legal representative(s) must understand and be able to adhere to the dosing and visit schedule, and agree to report concomitant medications and adverse events to the Investigator or designee.\n",
            "- [NCT01035099] Willingness to provide follow-up information on herself and babies born as part of this study\n",
            "- [NCT01760850] Children may be present with parents, but will not be included in any research activities, unless they are emancipated minors (under 18 and married)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 214  (showing 5 examples)\n",
            "- [NCT00576654] Patients must have histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT00576654] Patients enrolled on the dose escalation for intermittent ABT-888 portion of the study must histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin's and non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatment\n",
            "- [NCT01111201] Age \\>18 years and current or past history of lymphoma\n",
            "- [NCT01188915] treated for Hodgkin disease\n",
            "- [NCT01929941] Aged 18 years or older, with histologically or cytologically confirmed solid tumor, Hodgkin's lymphoma, aggressive or indolent non-Hodgkin's lymphoma. (NOTE: Patients with acute and chronic leukemia, Burkitt's lymphoma, precursor B lymphoblastic leukemia/lymphoma, and myeloma are excluded)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 215  (showing 5 examples)\n",
            "- [NCT00588640] Responsible companion living with patient during study. Phase II only:\n",
            "- [NCT00709176] Family caregivers must be 18 years old or older, physically and mentally able to participate, and speak and understand English.\n",
            "- [NCT02954900] Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital\n",
            "- [NCT03130569] Registered at a University of New Mexico primary care clinic for ≥6 months\n",
            "- [NCT03130569] Assigned to a primary care provider\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 216  (showing 5 examples)\n",
            "- [NCT00610857] History of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, or any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to CT-scan only.\n",
            "- [NCT02796352] For patients who have received prior anti-CTLA4 monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL-2 therapy. Therefore, for these patients if they have a history of colitis or diarrhea during anti-CTLA4 monoclonal antibody therapy, it is recommended that they have a formal evaluation by a gastroenterologist and a colonoscopy/endoscopy should be considered to demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on this protocol.\n",
            "- [NCT03598790] Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)\n",
            "- [NCT03768219] Moderately to severely active ulcerative colitis as defined by:\n",
            "- [NCT03971643] Personal history of inflammatory bowel disease or inflammatory arthritis\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 217  (showing 5 examples)\n",
            "- [NCT00612742] with a clinical diagnosis of HSDD.\n",
            "- [NCT00949546] Chronic HS for \\> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS\n",
            "- [NCT02157090] duration of HSL symptoms not more than three days\n",
            "- [NCT03569371] Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.\n",
            "- [NCT03569371] Stable course of HS for at least 90 days before screening, as determined by the investigator.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 218  (showing 5 examples)\n",
            "- [NCT00650910] Double-barrier contraception (condom with spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male condom and diaphragm).\n",
            "- [NCT00688272] Diaphragm with spermicide\n",
            "- [NCT00688272] Cervical cap or female condoms.\n",
            "- [NCT00761371] Condoms (with spermicide)\n",
            "- [NCT00761371] Diaphragm/cervical cap (with spermicide)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 219  (showing 5 examples)\n",
            "- [NCT00650910] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT00821054] Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n",
            "- [NCT01358240] Be willing and able to give informed consent/assent or have their parent/guardian do so, if applicable.\n",
            "- [NCT01386775] Conform to one of the following requirements for providing informed consent/assent:\n",
            "- [NCT01638052] informed consent and assent obtained\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 220  (showing 5 examples)\n",
            "- [NCT00665782] Smoking cigarettes for the 24-hour period of saliva-sample collection\n",
            "- [NCT00688272] Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.\n",
            "- [NCT00811824] Non-smoker\n",
            "- [NCT01019603] Nonsmoker or smoker with at least 30 days abstinence from smoking or using nicotine-containing products prior to study entry and willing not to smoke or to use nicotine-containing products throughout the study.\n",
            "- [NCT01140282] Nonsmokers (i.e., not smoking during previous 12 months)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 221  (showing 5 examples)\n",
            "- [NCT00688272] Healthy Caucasian male or females with no clinically significant abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead ECG.\n",
            "- [NCT00773734] In good health as judged by the investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), serum chemistry, hematology, immunology, and urinalysis\n",
            "- [NCT01694381] Be without clinical significant abnormalities according to the investigator's judgment, based on a detailed medical history, a complete physical examination (including vital signs), a standard 12-lead electrocardiogram, urinalysis, and routine clinical laboratory tests.\n",
            "- [NCT02505568] Participant must be medically stable on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at Screening. If there are abnormalities, they must be consistent with the underlying illness in the study population, or the participant may be included only if the investigator judge the abnormalities from normal to be not clinically significant or to be appropriate. This determination must be recorded in the participant's source documents by the investigator\n",
            "- [NCT02690142] In good health, as determined by medical history, physical examination, vital signs assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 222  (showing 5 examples)\n",
            "- [NCT00688272] Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.\n",
            "- [NCT00761371] Oral, injectable, or implantable contraceptives\n",
            "- [NCT01838655] Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring),\n",
            "- [NCT02231879] Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive,\n",
            "- [NCT02950922] Oral Contraceptive, either combined or progestogen alone \\[Hatcher, 2007a\\] Injectable progestogen \\[Hatcher, 2007a\\]\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 223  (showing 5 examples)\n",
            "- [NCT00688272] An intrauterine device (a coil micro-insert).\n",
            "- [NCT00688272] Intrauterine system (IUS) e-g Mirena coil\n",
            "- [NCT00761371] Intrauterine devices (IUDs)\n",
            "- [NCT01300533] Use an intrauterine device (IUD) with a documented failure rate of less than 1% per year.\n",
            "- [NCT01838655] Intrauterine device,\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 224  (showing 5 examples)\n",
            "- [NCT00708851] able and willing to attend phototherapy sessions and apply LCD at home\n",
            "- [NCT00773734] Candidate for photo/systemic therapy\n",
            "- [NCT01094717] No systemic or phototherapy in the 4 wks prior to entering the study\n",
            "- [NCT01228409] Stabilized on a phototherapy regimen for 4 weeks.\n",
            "- [NCT01291940] Are receiving phototherapy\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 225  (showing 5 examples)\n",
            "- [NCT00251472] Patients must have signed an IRB-approved informed consent.\n",
            "- [NCT00713154] Can understand and sign the IRB/IEC approved informed consent, can communicate with the Investigator, and can understand with the requirements of the protocol\n",
            "- [NCT00991978] Signed written informed consent (approved by the Institutional Review Board \\[IRB\\]/ Independent Ethics Committee \\[IEC\\]) obtained prior to any study specific screening procedures.\n",
            "- [NCT01047072] If the donor has reached the age of assent, then they must have completed the local institutional review board (IRB) assent process.\n",
            "- [NCT01450176] Sign and date the informed consent form approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 226  (showing 5 examples)\n",
            "- [NCT00735293] Have axillary hyperhidrosis/bromidrosis that does not respond to conventional, non-invasive treatment\n",
            "- [NCT02058264] Primary axillary hyperhidrosis of at least 6 months duration.\n",
            "- [NCT02058264] Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.\n",
            "- [NCT02058264] Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.\n",
            "- [NCT02100072] Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 227  (showing 5 examples)\n",
            "- [NCT00741260] PART 1:\n",
            "- [NCT00753415] Part A\n",
            "- [NCT01228656] Clarified (appendix);\n",
            "- [NCT01229085] Clarified (appendix);\n",
            "- [NCT02217891] Part 1:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 228  (showing 5 examples)\n",
            "- [NCT00743496] Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.\n",
            "- [NCT01104298] Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.\n",
            "- [NCT01104298] Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)\n",
            "- [NCT01104298] Angiosarcoma\n",
            "- [NCT01104298] Synovial sarcoma\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 229  (showing 5 examples)\n",
            "- [NCT00802672] Male or female at least 10 years of age, and otherwise healthy\n",
            "- [NCT00850811] healthy males or females;\n",
            "- [NCT01019603] Male or female 12 years of age or older who is in good general health.\n",
            "- [NCT01208298] Females or males subjects, at least 18 to 70 years of age, in good general health\n",
            "- [NCT01243450] Normal, healthy male and female children and adults.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 230  (showing 5 examples)\n",
            "- [NCT00814125] No previous endometrial ablation\n",
            "- [NCT01522820] Uterine cancer: patients with advanced (stages II-IV) or recurrent disease who have completed standard therapy, currently no evidence of disease (NED) or with minimal residual disease; patients with stage I uterine serous carcinomas or sarcomas are also eligible after completion of standard therapy\n",
            "- [NCT02996825] Endometrial \\>= 50% of tumor staining \\>= 2+ intensity\n",
            "- [NCT02996825] Cohort B: Patients with recurrent endometrial cancer may have received up to 2 lines of cytotoxic chemotherapy (adjuvant and one line for recurrent disease, or 2 lines of chemotherapy for recurrent uterine cancer in patients who did not receive adjuvant chemotherapy); patients must have received and failed, or have been intolerant to platinum agents, taxanes, liposomal doxorubicin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigator's opinion, patients would benefit from treatment on current protocol\n",
            "- [NCT03924466] endometrial cancer\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 231  (showing 5 examples)\n",
            "- [NCT00824889] Age ≥ 18 years.\n",
            "- [NCT01138384] Age ≥ 18 years of age.\n",
            "- [NCT01191528] Age greater than 18\n",
            "- [NCT01291420] Age: ≥ 18 years old\n",
            "- [NCT01308294] Age ≥ 18 years.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 232  (showing 5 examples)\n",
            "- [NCT00087373] Individuals with extensive skin disease\n",
            "- [NCT00574613] Symmetric lesions in forearms. The extension of the selected symmetric lesions must be at least 15 cm2.\n",
            "- [NCT00601640] No inflammation of the skin on the lateral forearms\n",
            "- [NCT00839280] Subjects with dry skin on their forearms\n",
            "- [NCT01051960] Diffuse\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 233  (showing 5 examples)\n",
            "- [NCT00996710] In certain clinical situations, parent(s) with cancer may be included at the discretion of the Principal Investigator, if the Principal Investigator deems that the etiology of cancer in the parent(s) and proband are biologically unrelated.\n",
            "- [NCT04514484] Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04704661] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n",
            "- [NCT04996823] Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n",
            "- [NCT05111561] Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this study\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 234  (showing 5 examples)\n",
            "- [NCT01001728] Age ≥18\n",
            "- [NCT01138553] Age ≥18\n",
            "- [NCT01342497] Aged ≥18\n",
            "- [NCT02794324] Age ≥18\n",
            "- [NCT02847728] Age ≥18\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 235  (showing 5 examples)\n",
            "- [NCT01010854] Because no dosing or adverse event data are currently available on the use of VPA in combination with FEC100 in patients \\<18 years of age, children are excluded from this study\n",
            "- [NCT01111825] Age ≥ 18, as no dosing or adverse event data are currently available on the use of neratinib or temsirolimus in patients \\<18 years of age, children are excluded from this study.\n",
            "- [NCT01149083] Female, age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of ABT-888 in patients \\< 18 years of age, children are excluded from this study\n",
            "- [NCT01246102] Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of AT13387 in patients \\< 18 years of age, children are excluded from this study.\n",
            "- [NCT01894451] Age ≥ 21 years. Because no dosing or adverse event data are currently available on the use of 89Zr-bevacizumab in participants \\<21 years of age, children are excluded from this study but will be eligible for future pediatric trials.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 236  (showing 5 examples)\n",
            "- [NCT01010854] absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01029925] Absolute neutrophil count \\>1,500/mcL\n",
            "- [NCT01575522] Absolute neutrophil count \\>= 1,500/mcL\n",
            "- [NCT01705340] Absolute neutrophil count \\>= 1,000/mcL\n",
            "- [NCT01727076] Absolute neutrophil count \\> 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 237  (showing 5 examples)\n",
            "- [NCT00324259] Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.\n",
            "- [NCT00526045] Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or lapatinib in combination with other agents) for metastatic disease\n",
            "- [NCT00526045] Patients who develop metastases while receiving adjuvant or neo-adjuvant trastuzumab are eligible. HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on either:\n",
            "- [NCT00704158] Subjects with HER2/neu overexpressing tumors must have been treated with trastuzumab except in situations where the subject was intolerant to or not a candidate for trastuzumab\n",
            "- [NCT01029925] HER-2 positive breast cancer should have received Trastuzumab, in either the adjuvant or metastatic setting.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 238  (showing 5 examples)\n",
            "- [NCT01029925] Non-small cell lung cancer patients should have received at least platinum based chemotherapy in the adjuvant, neoadjuvant or metastatic setting.\n",
            "- [NCT01910844] Patient non previously treated by platinum salts,\n",
            "- [NCT02210663] Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; \\\n",
            "- [NCT02365662] Expanded Safety Cohort participants must have confirmed metastatic lung cancer and progressed after receiving prior platinum-containing chemotherapy.\n",
            "- [NCT02561832] Prior use of platinum compound in the advanced or metastatic setting. Previous exposure to platinum compounds is allowed only if they were used in early adjuvant or neoadjuvant setting with relapse occurring \\>6 months after the last platinum administration and if there is no residual toxicity\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 239  (showing 5 examples)\n",
            "- [NCT01095848] Patients with prostate cancer who have failed at least 1 course of an accepted hormonal therapy. Specifically prostate cancer patients must have castrate testosterone levels (\\< 50 ng/dl) and 2 PSA values higher than the previously documented baseline at least 3 weeks apart or evidence of increases in measurable disease. These patients may have received previous courses of cytotoxic chemotherapy although chemotherapy naïve patients who are deemed not good candidates or who have refused cytotoxic therapy will be eligible. These patients may remain on anti-androgen therapy during the trial. Patients with evidence of progressive bone or other metastases are acceptable.\n",
            "- [NCT01522820] Prostate cancer: patients with metastatic, castrate refractory prostate cancer; the use of luteinizing hormone-releasing hormone (LHRH) agonist is allowed\n",
            "- [NCT02704832] Prostate cancer : metastatic and refractory to hormonal castration,\n",
            "- [NCT03218826] DISEASE SPECIFIC EXPANSION COHORTS: Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have:\n",
            "- [NCT03310541] Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 240  (showing 5 examples)\n",
            "- [NCT01164891] Positive BRAF V600E mutation result (by Roche CoDx test)\n",
            "- [NCT01705392] Known BRAF mutation\n",
            "- [NCT01820364] confirmed BRAF V600 mutation\n",
            "- [NCT01910181] Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test\n",
            "- [NCT02133222] Known genotype BRAF V600\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 241  (showing 5 examples)\n",
            "- [NCT01233505] First- or second-line metastatic colorectal cancer\n",
            "- [NCT01291420] Colorectal tumors\n",
            "- [NCT01315990] Histologically-confirmed metastatic colorectal cancer (primary tumor or metastasis)\n",
            "- [NCT01372527] Colorectal cancer: Women and men 52-75 years old\n",
            "- [NCT02704832] Colon and rectum : metastatic (unresectable metastasis),\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 242  (showing 5 examples)\n",
            "- [NCT01240213] No menopausal HRT use of any type including vaginal X 6 months and willing to avoid use for study duration\n",
            "- [NCT01381445] A female subject is eligible to participate if she is of: • Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the protocol contraception methods if they wish to continue their HRT during the study.\n",
            "- [NCT01899703] A female subject is eligible to participate if she is not pregnant, as confirmed by a negative serum human chorionic gonadotrophin (hCG) test or at least one of the following conditions applies: Non-reproductive potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \\>40 milli-international units per milliliter and estradiol \\<40 picograms per milliliter (\\<147 picomole per liter) is confirmatory\\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods along with either a second form of highly effective contraception or barrier protection (condoms with spermicide) if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the contraception options methods for the specified duration of time.\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab or dabrafenib + trametinib on the developing human fetus are unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to Step 2 crossover to rule out pregnancy; a female of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\n",
            "- [NCT02466152] A woman is eligible to participate if she is of non-reproductive potential, defined as: 1. Postmenopausal (including all women over 60 years of age). 2. Females with one of the following procedures documented and no plans to utilize assisted reproductive techniques (e.g., in vitro fertilization or donor embryo transfer): Bilateral tubal ligation or salpingectomy; Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Bilateral oophorectomy (surgical menopause) Note: A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile (e.g., age appropriate, \\>45 years, in the absence of hormone replacement therapy \\[HRT\\] or medical suppression of the menstrual cycle). In questionable cases for women \\<60 years of age, a blood sample with simultaneous follicle stimulating hormone and estradiol falling into the central laboratory's postmenopausal reference range is confirmatory. Women \\<60 years of age who are on HRT, wish to continue, and whose menopausal status is in doubt are required to use a highly-effective method to avoid pregnancy. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of postmenopausal status, HRT may be resumed during the study without use of a highly-effective method to avoid pregnancy\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 243  (showing 5 examples)\n",
            "- [NCT01256489] Bilateral legal blindness (\\<20/200 in better eye)\n",
            "- [NCT01256489] Able to administer eye medications or have a care giver able and willing to do same\n",
            "- [NCT01467310] History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):\n",
            "- [NCT01838655] Bilateral visual acuity E-ETDRS EVA letter score of less than or equal to 83 (i.e., Snellen equivalent of 20/25 or worse) that is not attributable to any other pathology.\n",
            "- [NCT01838655] Bilateral iris transillumination that can be seen in clinical photographs. 2. Predominant contralateral decussation of ganglion cell axons, as determined by pattern visual evoked potential (VEP). 3. Participant has at least one definitive mutation in the OCA1 gene (tyrosinase). 4. Participant has no definitive mutations in the OCA2 gene.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 244  (showing 5 examples)\n",
            "- [NCT01276704] Ki-67 ≥2% positivity (≥500 cells).\n",
            "- [NCT01583426] \\- cT1c and Ki67 \\> 20%\n",
            "- [NCT01669265] Ki67 index\n",
            "- [NCT04065321] proliferation index Ki-67 \\< 20%;\n",
            "- [NCT04134598] Ki67 ≤20% by IHC staining;\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 245  (showing 5 examples)\n",
            "- [NCT01419184] Less than 24 hours post hospital admission\n",
            "- [NCT01965444] Subject is admitted to an intensive Care Unit (ICU) and has an anticipated ICU course of 48 hours or greater.\n",
            "- [NCT01965444] Subject is anticipated to be bedridden for ore than 6 hours per day.\n",
            "- [NCT02152358] mechanical ventilation \\> 96 hrs and expected duration of mechanical ventilation of at least 2 days\n",
            "- [NCT02325388] Expected to have a length of stay on the unit of at least three days.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 246  (showing 5 examples)\n",
            "- [NCT00802672] Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed.\n",
            "- [NCT01543126] Got ICF before enrollment;\n",
            "- [NCT01679197] If ≥ 18 years of age, is able to read, understand and sign the U of M IRBMED approved informed consent form (ICF), communicate with study physician and study team, understand and comply with protocol requirements.\n",
            "- [NCT02209662] Prior to the first clinical intervention, a signed Informed Consent Form (ICF) and Data Consent Form (DCF) must be obtained from the subject or legal representative\n",
            "- [NCT02363842] Subject, or their legal representative, is able and willing to sign an informed consent form (ICF) and willing to undergo all study related procedures.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 247  (showing 5 examples)\n",
            "- [NCT01689519] Adequate hematologic and end organ function\n",
            "- [NCT01765556] Adequate hematologic and end organ function\n",
            "- [NCT01849666] Adequate hematologic and end organ function\n",
            "- [NCT01973309] Adequate hematologic and end-organ function\n",
            "- [NCT02338245] Patients with acceptable organ and hematological function\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 248  (showing 5 examples)\n",
            "- [NCT01722812] Age 18 years or above\n",
            "- [NCT02285049] Age 18 years old or above\n",
            "- [NCT02889458] aged 18 or above\n",
            "- [NCT03725722] Age 18 years and above.\n",
            "- [NCT05098821] Age 18 and above\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 249  (showing 5 examples)\n",
            "- [NCT01723072] Angioedema at least 4x in the last 6 months\n",
            "- [NCT02966314] Adults or adolescents who are 18 years or older at the time of screening with physician diagnosis of idiopathic angioedema\n",
            "- [NCT02966314] Minimum of two episodes of idiopathic angioedema in the past 6 months at the time of screening\n",
            "- [NCT02966314] Management of idiopathic angioedema with a stable controller treatment plan for the prior 6 months\n",
            "- [NCT03029728] The diagnosis of Hereditary Angioedema is confirmed by CENTOGENE EXCLUSION CRITERIA\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 250  (showing 5 examples)\n",
            "- [NCT01727076] At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-programmed cell death 1 (PD1)\n",
            "- [NCT01740297] Subjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.\n",
            "- [NCT01986426] Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment). Arm D:\n",
            "- [NCT02224781] NOTE: Patients should (if possible) be at least 1 week from documented PD on Step 1 of current study. All sites of disease must be evaluated within 4 weeks prior to registration\n",
            "- [NCT02676869] Currently receiving anti-PD-1 therapy with pembrolizumab and after 3 cycles achieved asymptomatic irPD (slowly progressive, not requiring urgent intervention, and stable performance status) or sub-optimal response (irSD, irPR) as demonstrated in imaging assessments performed within 6 weeks prior to study start\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 251  (showing 5 examples)\n",
            "- [NCT01820234] Able to provide a brief medical history and have/allow an examination of their skin including photographs.\n",
            "- [NCT02385994] Willing to have digital photographs taken of the treatment area.\n",
            "- [NCT02667288] Have a clinically typical appearance\n",
            "- [NCT03374995] Able and willing to have photographs of the affected area taken regularly\n",
            "- [NCT03910543] Patients must be willing to undergo skin biopsies, blood collection, and total body photography and comply with clinic visits\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 252  (showing 5 examples)\n",
            "- [NCT00221221] must be in the post treatment phase of their cancer trajectory.\n",
            "- [NCT01333735] Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)\n",
            "- [NCT01977053] Patient surgically-treated or no for non inflammatory breast cancer or for colon cancer or rectal cancer.\n",
            "- [NCT01999062] Patients with prior treatment such as surgery or chemotherapy for any type of cancer.\n",
            "- [NCT03028584] Patients: Have been treated with curative intent (e.g. surgery, chemotherapy and/or radiation therapy) for a Stage 1-3 cancer diagnosis\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 253  (showing 5 examples)\n",
            "- [NCT01984255] absolute neutrophil count ≥ 1,500/mcL\n",
            "- [NCT03007979] Absolute neutrophil count ≥ 1,500/mcl\n",
            "- [NCT03225547] absolute neutrophil count ≥ 1,000/mcL\n",
            "- [NCT03691493] Absolute neutrophil count ≥ 1000/mcl (obtained within 14 days prior to registration on study)\n",
            "- [NCT03709446] Absolute neutrophil count ≥ 1,000/mcL\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 254  (showing 5 examples)\n",
            "- [NCT01984255] platelets ≥ 100,000/mcl\n",
            "- [NCT02318771] Platelets ≥100,000 / mcL\n",
            "- [NCT03007979] Platelets ≥ 100,000/mcl\n",
            "- [NCT03225547] platelets ≥ 80,000/mcL\n",
            "- [NCT03709446] platelets ≥ 100,000/mcl\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 255  (showing 5 examples)\n",
            "- [NCT02023008] Participants must be:\n",
            "- [NCT02425306] All participants must have:\n",
            "- [NCT03139513] Participants included in the TAU from 26 February 2015\n",
            "- [NCT05672992] Participants must meet at least one of the following:\n",
            "- [NCT06007677] Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 256  (showing 5 examples)\n",
            "- [NCT02035813] Both cohorts:\n",
            "- [NCT02035813] Ribociclib cohort:\n",
            "- [NCT02035813] INR ≤ 1,5 (ribocilclib cohort)\n",
            "- [NCT02279004] Cohort 1B:\n",
            "- [NCT02279004] Cohort 2B:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 257  (showing 5 examples)\n",
            "- [NCT02061085] Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n",
            "- [NCT02115204] Eastern Cooperative Oncology Group (ECOG) status \\< 2\n",
            "- [NCT02657889] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03055312] Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
            "- [NCT03423199] Eastern Cooperative Oncology Group (ECOG) PS 0-1\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 258  (showing 5 examples)\n",
            "- [NCT02083484] Failed or progressed on standard of care systemic therapy including ipilimumab (with the exception of a participant with progressive disease while on the ipilimumab arm of MK-3475-006, regardless of prior treatment with a BRAF/MEK inhibitor, as long as all other eligibility criteria for this study are met)\n",
            "- [NCT02224781] Malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib, or history of retinal vein occlusion are acceptable for patients crossing over to Arm D (ipilimumab + nivolumab) treatment\n",
            "- [NCT02224781] STEP 2 (CROSSOVER ARMS): Patients must have recovered from adverse events (toxicities resolved to grade 1 or less) of prior therapy; patients with immune related toxicities from ipilimumab + nivolumab may continue onto Step 2 even if still on steroids to control side effects, so long as toxicity has resolved to grade 1 or less\n",
            "- [NCT02260531] Patients must have normal organ and marrow function and laboratory values as follows within 14 days before the first dose of cabozantinib\n",
            "- [NCT02260531] The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 259  (showing 5 examples)\n",
            "- [NCT02127970] Male or female participants 18 - 85 years of age.\n",
            "- [NCT02286583] The perfect sample should be 2000 females or more.\n",
            "- [NCT02694640] Women aged 21 years or over will be eligible if they:\n",
            "- [NCT02836795] Male and Female aged 18 to 70 years are eligible;\n",
            "- [NCT03151447] Female aged 18 to 75 years old are eligible.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 260  (showing 5 examples)\n",
            "- [NCT02157090] at least 18 years old\n",
            "- [NCT02205736] At least 18 years old\n",
            "- [NCT02272881] At least 18 years old;\n",
            "- [NCT03398538] At least 18 years old.\n",
            "- [NCT03966924] At least 30 years old\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 261  (showing 5 examples)\n",
            "- [NCT02158208] recent onset localised headache\n",
            "- [NCT02531633] Diagnosis of GCA defined by the following Revised GCA Diagnosis Criteria: Age \\>=50 years. History of ESR \\>=50 millimeter/hour (mm/hour) or CRP \\>=2.45 milligram/deciliter(mg/dL). Presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of polymyalgia rheumatic (PMR). Presence of at least one of the following: Temporal artery biopsy revealing features of GCA; Evidence of large-vessel vasculitis by angiography or cross-sectional imaging.\n",
            "- [NCT02531633] Active GCA within 6 weeks of Randomization (Baseline) where active disease is defined by an ESR \\>=30 mm/hr or CRP \\>=1 mg/dL AND the presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal symptoms of PMR; Other features judged by the clinician investigator to be consistent with GCA or PMR flares.\n",
            "- [NCT02703922] Suspected of GCA according to clinician expertise and / or aortitis arteritis or of one or more arteries from the aorta imaging (CT angiography, magnetic resonance angiography or positron emission tomography TDM18FDG)\n",
            "- [NCT02771483] Rheumatologist, neurologist or ophthalmologist suspect diagnosis of GCA\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 262  (showing 5 examples)\n",
            "- [NCT02180412] Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes.\n",
            "- [NCT02180412] Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG).\n",
            "- [NCT02180412] Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples:\n",
            "- [NCT02180412] For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins. Most (\\~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (\\>95 percent) will have a demonstrable disease-causing PBGD mutation.\n",
            "- [NCT02180412] For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins. Almost all (\\>95 percent) will have a demonstrable disease-causing coproporphyrinogen oxidase (CPO) mutation.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 263  (showing 2 examples)\n",
            "- [NCT01730833] No prior chemotherapy or trastuzumab for treatment of metastatic breast cancer\n",
            "- [NCT02260531] Discontinued prior therapy (with the exception of trastuzumab for patients with HER2+ breast cancer)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 264  (showing 5 examples)\n",
            "- [NCT02362594] Tumor tissue available for evaluation of PD-L1 expression\n",
            "- [NCT02519322] All patients must undergo a baseline tumor biopsy; in Arms A and B, tumor biopsy for PD-L1 testing (PD-L1 positivity is determined by greater than or equal to 1% of cells staining in the membrane by immunohistochemistry) is required for stratification; PD-L1 status is not required for enrollment on Arm C; the 28-8 clone for PD-L1 testing is required for assessment of PD-L1 status; for patients with stage IV disease, site of tumor biopsy will preferably be from non-lymph node disease site; for PD-L1 testing, the biopsy should contain sufficient tumor content (\\> 100 tumor cells/4-micron tissue section); if a sample contains insufficient tumor content, a re-biopsy will be required to obtain a sample with sufficient tumor content prior to treatment\n",
            "- [NCT02523313] Tumor tissue from the resected site of disease must be provided for biomarker analyses. In order to be randomized a subject must have a PD-L 1 expression classification (positive (≥ 5% tumor cells expressing PD-L1) or negative (\\< 5% tumor cells expressing PD-L1)). If an insufficient amount of tumor tissue from the resected site is provided for analysis, acquisition of additional archived tumor tissue (block and/or slides) for the biomarker analyses is required.\n",
            "- [NCT02555657] Central determination of programmed cell death ligand 1 (PD-L1) tumor status\n",
            "- [NCT02836795] Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 265  (showing 5 examples)\n",
            "- [NCT02540083] Have signed and dated the informed consent form;\n",
            "- [NCT02671513] Signed and dated informed consent\n",
            "- [NCT03055312] Signed and dated an informed consent form\n",
            "- [NCT03330977] Patient who have dated and signed a consent form\n",
            "- [NCT03893019] Signed and dated informed consent before conduct of any trial-specific procedure.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 266  (showing 5 examples)\n",
            "- [NCT01935531] Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel\n",
            "- [NCT02612454] Participated in a prior dupilumab study in pediatric participants with AD and adequately completed the visits and assessments required for both the treatment and follow-up periods, as defined in the prior study protocol\n",
            "- [NCT02612454] Must have received the same dupilumab dose regimen to be used in the PFP sub-study during the previous 12 weeks in the main OLE study using the prefilled syringe, as defined in the protocol Key\n",
            "- [NCT04066998] treated with Dupilumab\n",
            "- [NCT04718870] Participants with moderate to severe AD those were eligible to be treated with dupilumab according to product label.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 267  (showing 5 examples)\n",
            "- [NCT00036621] Adriamycin (60 mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery)\n",
            "- [NCT00036621] Adriamycin (60mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses, followed by Taxol (175mg/m2 IV on Day 85) repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery). 3. ECOG performance status 0 or 1. 4. Adequate organ function as evidenced by:\n",
            "- [NCT01306825] Patient under treatment with daptomycin for more than 3 days with dosage at 6 mg/kg\n",
            "- [NCT01986140] Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Doxorubicin 50mg/m2 with 5-Fluroruacil 500mg/m2 and Cyclophosphamide 500mg/m2 - Paclitaxel 80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3 weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2-100mg/m2 with pertuzumab and traztuzumab at standard doses - Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and trastuzumab at standard doses\n",
            "- [NCT02614794] Doxorubicin \\> 360 mg/m\\^2\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 268  (showing 5 examples)\n",
            "- [NCT01105884] Patients with or without PVD\n",
            "- [NCT01334125] Can be antibody positive or negative\n",
            "- [NCT02704429] Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:\n",
            "- [NCT04422912] Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n",
            "- [NCT04422912] mPV inadequately managed by at least one standard immunosuppressive therapies\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 269  (showing 5 examples)\n",
            "- [NCT00526617] Dose escalation and expanded safety cohorts\n",
            "- [NCT00722293] There must be measurable disease or evaluable disease for subjects to be included in the cohort expansion phase. Measurable disease is not a criterion for subjects enrolling in the dose escalation phase.\n",
            "- [NCT01001728] For all patients, the following absolute dose constraints should be met: ≤5% of heart volume to receive 18Gy and ≤10% of ipsilateral lung volume to receive ≥20Gy\n",
            "- [NCT01138384] During the dose escalation phase patients are not required to have measurable disease, but if they do, it will be recorded and followed. Patients at the expanded RP2D must have measurable disease defined by the RECIST 1.1.\n",
            "- [NCT03170960] Dose-Escalation Stage:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 270  (showing 5 examples)\n",
            "- [NCT00508274] Willing to complete all screening assessments as outlined in the protocol;\n",
            "- [NCT02672475] Patients must complete all screening assessments as outlined in the protocol\n",
            "- [NCT03328897] Patients must have documented current use on the day of the initial screening visit Main Exclusion Criteria\n",
            "- [NCT03569371] Total AN count of at least 3 at screening and baseline.\n",
            "- [NCT03607487] Total AN count of at least 3 at screening and baseline.\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 271  (showing 5 examples)\n",
            "- [NCT03331003] Always burns, never tans\n",
            "- [NCT03331003] Usually burns, tans minimally\n",
            "- [NCT03331003] Frequently burns and tans (light brown)\n",
            "- [NCT03331003] Rarely burns, tans easily (brown)\n",
            "- [NCT03331003] Very rarely burns, tans very easily (brown)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 272  (showing 5 examples)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Absolute neutrophil count (ANC) \\>= 1500/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Platelet count \\>= 75,000/mm\\^3 (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Hemoglobin \\>= 9.0 g/dL (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Direct bilirubin \\< 1.5 x upper limit of normal (ULN) (obtained =\\< 28 days prior to randomization)\n",
            "- [NCT04197687] RANDOMIZATION - PATIENTS WITH RESIDUAL DISEASE POST NEOADJUVANT TRATUZUMAB +/- PERTUZUMAB BASED CHEMOTHERAPY (NO pCR) - (PHASE II): Aspartate transaminase (AST) =\\< 3 x ULN (obtained =\\< 28 days prior to randomization)\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 273  (showing 5 examples)\n",
            "- [NCT00073528] Signed informed consent; 2. Subjects with histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery;\n",
            "- [NCT01050322] Signed informed consent must be obtained according to local ethical committee requirements. 2. Subjects must be older than 18 years old. 3. Histologically confirmed invasive adenocarcinoma of the breast which is stage IIIb, stage IIIc with T4 lesion, or stage IV disease \\[according to AJCC 6th edition\\] 4. Documented progression after taxane based treatment for ErbB2 positive patients for 1st line metastatic breast cancer or documented progression after taxane based regimens as adjuvant or neo-adjuvant therapy. Patients may have had a maximum of one prior treatment with a chemotherapy regimen for metastatic disease. 5. Patients must have at least 1 measurable lesion defined by RECIST as follows:\n",
            "- [NCT01300533] Signed informed consent form. (ICF) 2. At least 18 years old. 3. Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists. 4. Measurable or evaluable disease per RECIST version 1.1. 5. Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1. 6. Life expectancy of greater than 12 weeks. 7. Female subjects are eligible to enter and participate in the study if they are of: 1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who:\n",
            "- [NCT01617915] Women or men \\> age 18. Ability to give informed consent Archived tumor tissue must be available for genetic analysis. Patients with early-stage breast cancer Histologic documentation of invasive breast cancer by core needle or incisional biopsy. The invasive cancer must be either:\n",
            "- [NCT02971748] Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \\>/= 18 years of age 3. Has histological confirmation of breast carcinoma. 4. Has confirmed inflammatory breast cancer by using international consensus criteria:\n",
            "\n",
            "================================================================================\n",
            "Cluster cluster_dbscan_umap = 274  (showing 5 examples)\n",
            "- [NCT00601640] No evidence of serious underlying medical conditions as demonstrated by abnormal values on baseline laboratory assessment\n",
            "- [NCT00907062] normal on physical examination at the pre-study intake, and in the case of abnormalities the health care practitioner considers them to be clinically insignificant\n",
            "- [NCT01119313] the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;\n",
            "- [NCT02346760] With no clinically relevant abnormalities in vital signs, and clinical laboratory tests at screening visit judged by investigator.\n",
            "- [NCT02801435] In good health, with no history of diseases of major organs and no abnormality found on physical examination and vital signs\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Map numbers to string labels\n",
        "# Look at all clustering algorithms and see which ones are better\n",
        "\n",
        "\n",
        "def numeric_to_string_labels(int_labels: np.ndarray) -> np.ndarray:\n",
        "    uniq = np.unique(int_labels)\n",
        "    mapping = {c: f\"label{chr(ord('A') + i)}\" for i, c in enumerate(uniq)}\n",
        "    return np.array([mapping[c] for c in int_labels])\n",
        "\n",
        "criteria_df[\"cluster_final\"] = numeric_to_string_labels(criteria_df[\"cluster_emb\"].values)\n",
        "\n",
        "results_df = criteria_df[[\"nctid\", \"criterion\", \"cluster_final\"]].copy()\n",
        "results_df.columns = [\"nctid\", \"criterion\", \"cluster\"]\n",
        "\n",
        "\n",
        "RESULTS_PATH = \"results_sendroff_partner.txt\"\n",
        "\n",
        "results_df.to_csv(\n",
        "    RESULTS_PATH,\n",
        "    sep=\"\\t\",\n",
        "    index=False\n",
        ")\n",
        "\n",
        "print(\"Saved results to\", RESULTS_PATH)\n",
        "results_df.head()\n"
      ],
      "metadata": {
        "id": "dDdATcMOoyA3",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 225
        },
        "outputId": "39409988-e348-41dc-9a85-21133d8a56ae"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Saved results to results_sendroff_partner.txt\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         nctid                                          criterion cluster\n",
              "0  NCT00001137                                     HIV-1 infected  labelK\n",
              "1  NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...  labelE\n",
              "2  NCT00001137  Willing to provide consent for the release and...  labelE\n",
              "3  NCT00001137               Life expectancy of at least 24 weeks  label[\n",
              "4  NCT00001137  Parent or guardian willing to provide informed...  labelH"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ce287d38-d163-4d9e-b7bc-92c827cb0ee0\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>nctid</th>\n",
              "      <th>criterion</th>\n",
              "      <th>cluster</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>HIV-1 infected</td>\n",
              "      <td>labelK</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Enrolled in an AIDS Clinical Trial Group (ACTG...</td>\n",
              "      <td>labelE</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Willing to provide consent for the release and...</td>\n",
              "      <td>labelE</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Life expectancy of at least 24 weeks</td>\n",
              "      <td>label[</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT00001137</td>\n",
              "      <td>Parent or guardian willing to provide informed...</td>\n",
              "      <td>labelH</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ce287d38-d163-4d9e-b7bc-92c827cb0ee0')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ce287d38-d163-4d9e-b7bc-92c827cb0ee0 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ce287d38-d163-4d9e-b7bc-92c827cb0ee0');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-3c834952-b6cd-426e-9422-859e288eb615\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-3c834952-b6cd-426e-9422-859e288eb615')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-3c834952-b6cd-426e-9422-859e288eb615 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "results_df",
              "summary": "{\n  \"name\": \"results_df\",\n  \"rows\": 26369,\n  \"fields\": [\n    {\n      \"column\": \"nctid\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3103,\n        \"samples\": [\n          \"NCT02349828\",\n          \"NCT04265716\",\n          \"NCT00612768\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"criterion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24761,\n        \"samples\": [\n          \"Prior to starting mifepristone subjects must meet the following laboratory criteria; Granulocytes \\\\> 1.5E9/l (grade \\u2264 1); Platelets \\u2265 100E9/l; Hemoglobin \\\\> 10 g/dl (grade \\u2264 1); Creatinine \\\\< 1.5x normal reference range (grade \\u2264 1); SGOT, SGPT, alk phos \\u2264 1x normal reference range; Total bilirubin \\\\< 1x normal reference range; Calcium \\\\< 11.5 mg/dl (grade \\u2264 1); HBsAg = Negative; HCV Ab = Negative; INR \\\\< 1.5;\",\n          \"Part 1F: prostate cancer\",\n          \"Females of childbearing potential must use a reliable method of contraception\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"cluster\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"labelN\",\n          \"labelO\",\n          \"labelY\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "\n",
        "# Helper function to map numbers to strings, handling Noise (-1)\n",
        "def get_string_label(label):\n",
        "    if label == -1:\n",
        "        return \"labelNoise\"\n",
        "    # Maps 0 -> labelA, 1 -> labelB, etc.\n",
        "    # Using modulo 26 to wrap around if you have >26 clusters (labelA...labelZ, labelA...)\n",
        "    letter = chr(ord('A') + (label % 26))\n",
        "    suffix = str(label // 26) if label >= 26 else \"\"\n",
        "    return f\"label{letter}{suffix}\"\n",
        "\n",
        "# Apply to the Optimized DBSCAN column (or KMeans if that score was better!)\n",
        "# Assuming DBSCAN was your best approach:\n",
        "criteria_df[\"final_string_label\"] = criteria_df[\"cluster_dbscan_opt\"].apply(get_string_label)\n",
        "\n",
        "# Create the final dataframe for export\n",
        "final_results = criteria_df[[\"nctid\", \"criterion\", \"final_string_label\"]].copy()\n",
        "final_results.columns = [\"nctid\", \"criterion\", \"cluster\"]\n",
        "\n",
        "# Save to .txt as requested\n",
        "output_filename = \"results_sendroff_partner.txt\"\n",
        "final_results.to_csv(output_filename, sep=\"\\t\", index=False)\n",
        "\n",
        "print(f\"Success! Saved {len(final_results)} rows to {output_filename}\")\n",
        "print(final_results.head())"
      ],
      "metadata": {
        "id": "jAREOTgATC9F",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "outputId": "1b84db55-9f52-40b1-dcae-601a34def043"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Success! Saved 26369 rows to results_sendroff_partner.txt\n",
            "         nctid                                          criterion     cluster\n",
            "0  NCT00001137                                     HIV-1 infected      labelA\n",
            "1  NCT00001137  Enrolled in an AIDS Clinical Trial Group (ACTG...  labelNoise\n",
            "2  NCT00001137  Willing to provide consent for the release and...      labelB\n",
            "3  NCT00001137               Life expectancy of at least 24 weeks      labelC\n",
            "4  NCT00001137  Parent or guardian willing to provide informed...      labelD\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# Analyzation\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "5MsxikV5oyM7"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}